Genetically engineering a new system for the expression of cytochrome P450 enzymes in insect cells using novel P450 reductases by Mahajan, Pravin
1Genetically engineering a new system for
the expression of cytochrome P450
enzymes in insect cells using novel P450
reductases
by
Pravin Mahajan
Thesis submitted to De Montfort University, Leicester in partial fulfillment
of the requirements for the degree of Doctor of Philosophy
April 2010
2Abstract
Human cytochrome P450 enzymes (CYPs) are a superfamily of haem-binding
monooxygenase enzymes involved in the metabolism of xenobiotics such as toxins,
carcinogens and pharmaceutical drugs as well as in the biosynthesis of cholesterol,
vitamins and steroids. In recent years, the area of drug metabolism in the drug
discovery process has become crucial for the final clinical success of a drug candidate.
Use of CYPs early in the drug discovery process can save significant amount of costs
and time required in pre-clinical and clinical studies, thereby greatly facilitating the
process.
The human CYP superfamily of proteins comprises more than 50 enzymes, each
enzyme being able to catalyse multiple reactions. With the exception of some plants, a
single NADPH cytochrome P450 reductase (CPR) of a particular eukaryotic species
interacts with all CYPs of the same species. For CYP catalytic activity, CPR is
absolutely essential, however at the same time CPR is detrimental for the expression of
CYPs. Therefore, understanding the process by which the interaction between CYP and
CPR occurs is an important biological goal.
I have cloned, expressed and studied the interactions of seven CYPs, CYP2D6,
CYP3A4, CYP1A1, CYP1B1, CYP1A2, CYP2E1 and CYP2C8 in conjunction with
different CPR species (the native human CPR, variants of human CPR and the yeast
CPR) using the baculovirus expression system. In my studies I have found that
different CPRs have different coupling efficiencies towards the individual CYP
3isoforms. Use of a high-activity CPR from yeast in this study has allowed us to
improve our understanding on CYP-CPR interactions. I have found that the ability of a
CPR to reduce an artificial substrate like MTT is not directly proportional to its ability
to reduce the physiological substrate, CYP. In other words, the strength of the reductase
does not determine CYP activity but it is the ability of CPR to couple with CYP which
is crucial.  This study has resulted in the identification of ΔhRDM, a genetically 
engineered variant of human CPR, which couples with CYPs far better than the human
native CPR and also offers advantage of better reaction rates for CYPs.  ΔhRDM also 
offers an improvement in the ratio of spectrally active CYP2D6 to spectrally inactive
CYP2D6.  Identification of ΔhRDM has allowed us to devise an insect cell expression 
system that genetically provides an improvement in the levels and activities of the drug
metabolising cytochrome P450 enzymes.
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BSA Bovine Serum Albumin
bp base pair
cDNA Complementary deoxyribonucleic acid
CO Carbon Monoxide
CPR NADPH-P450 reductase
CYP Cytochrome P450
DNA Deoxyribonucleic acid
DMSO Dimethyl sulfoxide
DTT Dithiothreitol
E. coli Escherichia coli
EDTA Ethylene diamine tetra acetic acid
ER Endoplasmic reticulum
G6P Glucose-6-phosphate disodium salt hydrate
G6DPH Glucose-6-phosphate dehydrogenase
H2DCFDA 5-(and-6)-carboxy-2´,7´-dichlorodihydrofluorescein diacetate
hRD Human NADPH P450 reductase
IC50 The half maximal inhibitory concentration
kb kilobase
LB Luria-Bertani (medium)
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NADP
+
β-Nicotinamide adenine dinucleotide phosphate  
NADPH  β-Nicotinamide adenine dinucleotide phosphate (reduced form)  
OD Optical density
6PBS Phosphate buffered saline
PCR Polymerase Chain Reaction
RFU Relative fluorescence units
ROS Reactive oxygen species
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
S. cerevisiae Saccharomyces cerevisiae
SDS Sodium Dodecyl Sulfate
TAE Tris/EDTA/Glacial acetic acid buffer
TE Tris-HCl/EDTA
TEMED N,N,N’,N’,-tetramethylethylenediamine
Tris-HCl Tris(hydroxymethyl)aminomethane-HCl
U Unit
UV Ultraviolet
V Volt
yRD Yeast NADPH P450 reductase
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Chapter 1 Introduction
1.1 The Biotransformation Process
All living organisms are constantly exposed to xenobiotics. A xenobiotic is a
chemical which is not a natural component of the human or animal organism. It is
foreign to these organisms. After absorption via oral, pulmonary or cutaneous route,
water soluble xenobiotics are eliminated from the body easily through body fluids like
urine and faeces. But the xenobiotics that are fat-soluble could accumulate in the lipid-
rich tissues which have no defence system. This could lead to toxicity. The metabolism
of xenobiotics protects the body against their accumulation and eventually any toxicity.
Metabolism involves conversion of xenobiotics into more polar (hydrophilic)
substances and facilitates their removal from the body, a process also referred to as
detoxification (Masters 1998).
The process of detoxification takes place in three phases. It is regulated by the
biotransformation enzymes in Phases I, II and III. The Phase I enzymes catalyse
reactions linked to oxidation, reduction or hydrolysis. These reactions release or
introduce a functional group (–OH, –NH2, –COOH) thus increasing the polarity of the
parent compound. The most common reactions involve mono-oxygenation reactions
(involving introduction of –OH groups) at unreactive carbon atoms. They are
performed by cytochrome P450 (CYP) enzymes. Phase II detoxification involves
conjugation with a small endogenous substance like glutathione, glucuronic acid, or
14
cysteine. Reactions in Phase II make the metabolite (initially formed by a Phase I
reaction) even more hydrophilic and facilitate excretion via bile or urine. Phase II
metabolism also decreases the pharmacological activity of the metabolite. Phase III
reactions further metabolise products derived from Phase II conjugation reactions.
These are catalysed by the same enzymes which are active in Phases I and/ or II
(Danielson 2002).
Chemical Reactions Involved in Different Phases of Xenobiotic Metabolism:
Phase I – Oxidation, reduction and hydrolysis
Phase II – Conjugation
Phase III – Oxidation, hydrolysis and deamination
The most important enzyme system catalysing Phase I metabolic reactions is the
cytochrome P450 system comprising a number of different enzymes. Cytochrome P450
is a generic term for a large number of oxidative enzymes all of which have about 500
amino acids and a single haem group. The cytochrome P450 enzymes are members of a
superfamily of membrane bound haem containing monooxygenases that are responsible
for metabolism of endogenous (e.g. cholesterol biosynthesis and steroidogenesis) and
exogenous (xenobiotics) substrates. CYPs metabolise xenobiotic substrates which
could be pharmaceutical drugs, potential carcinogens, mutagens or environmental
pollutants, through the introduction of oxygen containing functionalities into substrate
molecules (Danielson 2002).
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CYPs are present in many human tissues that include the lung, the mucosa of the
gastrointestinal tract, the brain and the kidneys. However the liver is a major organ of
xenobiotic metabolism and acts as a filter for xenobiotics. In mammalian cells, CYPs
are localized predominantly in the smooth endoplasmic reticulum and are different from
the cytochrome proteins that function in electron transport. In contrast to CYPs,
cytochrome proteins are localized in the mitochondrial membranes and act as electron
carriers for aerobic energy production (Hannemann et al. 2007).
1.2 The History of Cytochrome P450
The name cytochrome P450 originated from the work done by Omura and Sato
(1964). In 1964, they reported that the carbon monoxide adduct of the reduced form of
a microsomal binding pigment shows a single peak at 450 nm which was readily
detected in dithionite treated microsomes by difference spectrophotometry. They also
reported evidence for its haemoprotein nature. Before Omura and Sato’s work, the
presence of a carbon monoxide binding pigment had been reported by Klingenberg and
Garfinkel (1958). Since then, cytochrome P450 research has come a long way,
advancing in many areas such as drug discovery and pathways related to cancer. CYPs
have been characterized in many species (i.e. organisms) that include bacteria, fungi,
plants, fish, and mammalian systems (Nebert and McKinnon 1994).
The fifth iron coordination site of the haem in CYPs is bound to protein through
the thiolate group of a cysteine rather than through a histidine residue (Poulos et al.
16
1986). This structural property gives the cytochrome P450 haem its unique spectral
properties and allows its detection, even in a background of other haemoproteins.
Cytochromes, in a true sense, are proteins which also contain haem as the prosthetic
group but carry out electron transport. Although CYPs do not strictly carry out electron
transport and therefore are not true cytochromes, the name is still being used. However,
the nomenclature committee of the International Union of Biochemistry and Molecular
Biology (NC-IUBMB) prefers the term ‘haem-thiolate’ enzyme instead of ‘cytochrome
P450’ enzyme (Graham and Peterson 1999).
1.3 Cytochrome P450 Nomenclature
The human CYP superfamily of proteins comprises more than 50 enzymes, each
enzyme being able to catalyse multiple reactions. The superfamily has 18 families of
cytochrome P450 genes and 43 subfamilies, out of which 57 are CYP genes and 58
pseudogenes. (http://drnelson.utmem.edu/P450lect.htm, Jan. 2007). Based on sequence
similarities, a standard nomenclature has been adopted that categorizes the individual
CYP into families and subfamilies.
The foundation for the P450 gene superfamily nomenclature system were laid
with the first report by Nebert et al. (1987) and have been extended in subsequent
updates by the same group in 1989 and 1991 and later by Nelson et al. (1993). The
catalogue on the website, http://drnelson.utmem.edu/CytochromeP450.html, maintained
by the P450 gene superfamily nomenclature committee is updated regularly. The
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current P450 nomenclature and classification scheme was most recently reviewed in
1996 (Nelson et al. 1996). This nomenclature is genetically based and has no functional
relevance. The committee recommendations for naming a P450 gene include,
The italicized root symbol ‘CYP’ denotes cytochrome P450, an Arabic number
designates the P450 family, a letter indicates the subfamily when two or more
subfamilies are known to exist within that family, and the Arabic numeral following
the letter represents the individual gene. For example, CYP2D6 implies,
CYP cytochrome P450
2 the P450 family
D the subfamily
6 the individual gene
The same numbers and letters, without any spaces between them, are
recommended for the corresponding gene products like mRNA, cDNA and
enzyme but the product names are not italicized. For example, CYP2D6
(italicised) represents the gene whereas CYP2D6 (non-italicised) could represent
the corresponding mRNA, cDNA or protein.
A P450 protein sequence from one gene family usually is defined as having
≤40% amino acid identity to a P450 protein from any other family.  This means 
18
that the P450 protein sequences within a given gene family are >40% identical.
Mammalian sequences within the same subfamily are always >55% identical.
Table 1.1 highlights some of the important human CYPs with respect to their expression
and xenobiotic metabolism. The information compiled in this Table is gathered from
Omiecinski et al. (1999).
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Table 1.1. The CYP isoforms that stem from different subfamilies.
Family Subfamily Isoforms
CYP1 CYP1A CYP1A1 and CYP1A2
CYP1B CYP1B1
CYP2 CYP2A CYP2A6 and CYP2A7
CYP2B CYP2B6
CYP2C CYP2C8, CYP2C9, CYP2C18, and CYP2C19
CYP2D CYP2D6
CYP2E CYP2E1
CYP3 CYP3A CYP3A4, CYP3A5 and CYP3A7
1.4 Role of CYPs in Human Diseases and Drug Discovery
Hepatic cytochrome P450s are the most widely studied of the P450 enzymes.
As briefly mentioned earlier, CYPs are involved in oxidative metabolism of many xeno-
and endobiotics. Most CYPs metabolise multiple substrates participating in the
catalysis of specific reactions linked to substrate metabolism. This accounts for their
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key role in metabolising an extremely large number of endogenous and exogenous
molecules.
CYPs play important roles in endogenous biochemical pathways linked to
steroid hormone biosynthesis, metabolism of polyunsaturated fatty acids (such as
arachidonic acid and prostaglandins) and activation of vitamin A and D3 to biologically
active hormones. They also participate in the activation and detoxification of a variety
of different types of chemicals, some of which possess medicinal properties and others
which are known to contaminate or pollute the environment (Estabrook 2003).
Mutations in CYP genes that correlate with deficiencies in enzyme activities are
responsible for several human diseases (Watanabe 1998). CYPs can also show great
inter-individual variability mainly due to environmental factors (e.g. CYP2E being
induced in individuals who drink ethanol and CYP1A being induced in individuals who
are exposed to aromatic hydrocarbons), genetic factors (that could result in specific
CYP enzyme deficiencies) and patho-physiological factors (CYP2E being induced in
diabetics).
Moreover, induction of CYP1 family (e.g. which is induced by polycyclic
hydrocarbons found in cigarette smoke and charred food) is a risk factor in several
cancers such as lung and colon cancers because these enzymes can convert pro-
carcinogens to carcinogens. Mutations in the CYP1B1 gene (leading to defects in
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CYP1B1 activity) are linked to congenital glaucoma possibly because of the enzyme’s
major role in steroidogenesis. A metabolite formed from acetaminophen (Paracetamol)
by CYP2E1 can cause severe toxic effects in humans. People who are alcoholic are at
high risk to Paracetamol toxicity because they possess alcohol-induced highlevels of
CYP2E1. CYP2C8 is selectively responsible for inactivation of the anti-cancer drug
paclitaxel (Taxol) through oxidation to 6α-hydroxypaclitaxel.  Specific alleles of 
CYP2C8 are known to have a great influence on the pharmacokinetics of paclitaxel
(Nakajima et al. 2005). CYP2C19 is known to metabolise a proton pump inhibitor,
omeprazole, which is used to treat peptic ulcer. Omeprazole has been used as a
CYP2C19 marker to assess gene-dose effect and its intra-subject variability (Yin et al.
2004).
Some drug molecules can activate or inhibit the CYPs and this can lead to
adverse effects of drugs on the human body. For example if ketoconazole (an
antifungal compound), a CYP3A4 inhibitor, is administered together with Triazolam
(sedative to treat insomnia) which is metabolised by CYP3A4, it will result in an
overdose of Triazolam. This is an example of drug-drug interactions which often can
cause major problems in the clinic. New drug candidates with poor metabolism profile
or which cause drug-drug interactions do not survive the drug development process
which is a very expensive process often leading to expenditures of $1 billion or more.
Therefore, choosing drugs that do not interact with CYPs is very important at an early
stage of drug development. In recent years, the area of drug metabolism has become
crucial to the drug discovery process. Use of drug metabolising enzymes early in the
drug discovery process can save significant amount of costs and time required in pre-
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clinical and clinical studies, thereby greatly facilitating the process. That is the reason
why introduction of drug metabolism screens as early as possible in the drug discovery
process is gaining appeal. Drug metabolism studies have become as important as
primary screening in the drug discovery process.
A relatively small subset of CYPs (CYP1A2, CYP2D6, CYP2C9, CYP2C19,
CYP3A4 and CYP2E1) appears to be responsible for the metabolism of most drugs and
associated drug-drug interactions (Spatzenegger and Jaeger 1995). It appears that these
enzymes have a high affinity towards chemical structures commonly found in
pharmaceutical drugs. CYP2D6 is known to metabolise a quarter of all known
pharmaceutical entities (Werck and Feyereisen 2000). This subset of enzymes is also
considered to be highly important in drug metabolism studies because of their presence
in the human liver – the main organ involved in metabolism. For example, CYP3A4 is
the most abundant CYP at ~30% of the total CYPs present in the human liver, the
others existing in lower yet substantial amounts as indicated in Figure 1.1 (Gonzalez
1992; Beaune 1993).
Figure 1.1 shows relative percentage of CYPs in human liver samples. The information
compiled in this chart is gathered from Shimada et al. (1994).
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31%
Figure 1.1. Relative percentage of CYPs present in the human liver.
Table 1.2 lists substrates, inducers and inhibitors of the important CYPs mentioned
above. The information compiled in this table is gathered from Rendic and DiCarlo
(1997) and Parkinson (1996).
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Table 1.2. Pharmaceutical substrates for different CYPs.
CYP Xenobiotics
Metabolised
Xenobiotics
Activated
Inducers Inhibitors
CYP1A2 Caffeine; 7-
ethoxy-resorufin; 7-
methoxy- resorufin;
imipramine; phenacetin;
theophylline; tacrine
R-warfarin
Acetaminophen
(paracetamol);
aflatoxin B1;
2-aminoacetyl
fluorine;
Omeprazol;
cruciferous
vegetables;
cigarette
smoking
Enoxacin;
fluvoxamine
; isosafrole;
apigenin
CYP2C9 Chloramphenicol;
diclofenac; ibuprofen;
flurbiprofen;
hexabarbital; naproxen;
omeprazole; phenytoin;
retinoids
Rifampin Warfarin;
tolbutamide;
sulfaphenazoe
CYP2C19 Diazepam; hexobarbital;
mephobarbital;
omeprazole; propanolol;
phenytoin
Rifampin Omeprazole;
mephenytoin
(competitive)
CYP2D6 Bufarolol;
dextromethorp-han;
Quinidine;
quinine;
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desipramine;
ethylmorphine;
imipramine; metoprolol;
paroxetine;
fluoxetine;
norfluoxetine
CYP2E1 Acetaminophen;
acrylonitrile; dapsone;
enflurane; ethanol;
halothane; isoflurane;
p-nitrophenol
Acetaminophen
acrylonitrile;
benzene;
chloroform;
nitrosamine;
styrene;
vinylbromide
Alcohol;
acetone;
pyrazole;
isoniazid;
obesity
Disulfiram;
diethyldithio
- carbamate;
4-methyl-
pyrazole
CYP3A4 Alfentanil; antipyrine;
chloropromazine;clarithro
mycin; cyclosporine-A;
dapsone; dexamethasone;
erythromycin
Acetaminophen
aflatoxin B1;
Phenobarbital
;dexa-
methasone;
rifampin;
phenytoin;
carbamazepie
Triacetyl-
oleandomycin;
clarithromycin
erythromycin;
gestodene;
ketoconazole;
clotrimazole
; naringenin
1.5 Mechanism of Action of CYPs
Though different CYPs are able to react with a number of chemically different
substrates, the basic mechanism of substrate oxygenation is the same for all CYPs. The
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CYP reaction is governed by the thermodynamic parameters of the oxygenation process
described below (White 1980),
RH (substrate) + O2 + NADPH + H+ → ROH (product) + H2O + NADP+
Substrate oxygenation by CYPs is a multi-step process as described below (Groves
1995).
In the first step, the substrate binds to CYP to form a CYP-substrate complex.
In the second step, the CYP-substrate complex is reduced by another
endoplasmic reticulum anchored enzyme known as NADPH-cytochrome P450
reductase (CPR) (French et al 1980; Blanck 1984). CPR reduces ferric
cytochrome P450 to ferrous cytochrome P450 by an electron derived from
NADPH.
In the third step, dioxygen binds to the ferrous haem iron of CYP and forms the
ternary CYP-dioxygen-substrate complex.
In the fourth step, a second electron is introduced into the ternary CYP-
dioxygen-substrate complex by CPR or cytochrome b5.
The fifth step includes splitting of the O-O bond with formation of reactive iron-
oxo intermediate and a water molecule.
In the sixth step, transfer of oxygen molecule takes place from the reactive iron-
oxo intermediate to the substrate bound next to the haem.
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(Substrate)
(From CPR)
(From CPR or
cytochrome b5)
(Product)
2
Finally, in the seventh step, product dissociation completes the cycle. Thus the
introduction of oxygen molecule in a substrate makes the substrate more water-
soluble and this process helps in excretion of the substrate from the body
(human or animal).
Under physiological conditions, electron transfer steps are believed to be rate
limiting. The consensus catalytic cycle for oxygen activation and transfer by
cytochrome P450 is shown in Figure 1.2, adapted from John Groves, Models and
Mechanism of Cytochrome P450 Action (Groves 1995).
Figure 1.2. The consensus catalytic cycle for oxygen activation and transfer by
cytochrome P450.
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1.6 Role of NADPH-Cytochrome P450 Reductase (CPR)
in CYP Reaction
CPR is responsible for the transfer of electrons from NADPH to CYPs and also
to cytochrome b5. Cytochrome b5 is another membrane bound protein, which enhances
the activity of some but not all CYPs. Similar to the CYPs, CPR is also membrane
bound and most abundant in the liver. The amino-terminal hydrophobic region of the
CPR anchors the protein in the membrane. Unlike the CYPs which belong to a
superfamily of genes, CPR is encoded by a single gene in most mammalian species
(Simmons 1985; Sutter and Loper 1989; Yamano et al 1989; Shephard 1989). This
single enzyme interacts with all the CYPs. CPR levels are not modulated by inducers of
the cytochrome P450 system.
As described earlier in Section 1.5, “Mechanism of Action of CYPs”, CYPs
cannot metabolise the substrates on their own, they require molecular oxygen and an
electron donor protein for their catalytic activity. The first step of the catalytic cycle
after formation of the CYP-substrate complex is transfer of the first electron. NADPH-
cytochrome P450 reductase (CPR) acts as the electron transfer protein.
In 1950, Horecker (Horecker 1950) reported CPR in liver tissues. He also
reported that the enzyme used NADPH as a source of reducing equivalents and
contained flavin adenine dinucleotide (FAD) as a prosthetic group. After another 12
years, the enzyme was found to be located in the microsomal fraction which essentially
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consist of the endoplasmic reticular membranes (Phillips and Langdon 1962; Wiliams
and Kamin 1962). Direct evidence for the involvement of the reductase in microsomal
hydroxylation reactions was shown by reconstitution of laurate ω-hydroxylase activity 
from a preparation of cytochrome P450, NADPH-cytochrome c reductase and
phosphatidylcholine (Lu and Coon 1968; Lu et al. 1969). Subsequently, the CPR was
reported to contain one molecule of FAD and one molecule of FMN for each molecule
of enzyme (Iyanagi and Mason 1973; Yasukochi and Masters 1976). Kinetic analysis
of reduction of CPR established that NADPH donates electron to FAD, FAD donates
electron to FMN and finally FMN transfers electron to cytochrome P450. CPR is an
electron donor protein not only for CYPs but also for several other oxygenase enzymes
such as squalene monooxygenase and haem oxygenase.
Many scientists (Iyanagi et al. 1978; Vermilion et al. 1981) have suggested that
the mammalian CPR cycles between the 1- and 3-electron containing subforms during
steady state, as shown in Figure 1.3. According to this mechanism, two electrons are
added by NADPH to the air-stable semiquinone of the reductase resulting in a 3-
electron reductase. The two flavin molecules rearrange electrons to yield FMNH2 and
then an electron is transferred to CYP. The 2-electron reductase again undergoes inter-
flavin rearrangement and yields FMNH2, transfers another electron to CYP which is
ready to accept the second electron from NADPH.
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NADPH P450Red P450Red
FMNH FMNH FMNH2 FMNH FMNH2 FMNH
FAD FADH2 FADH FADH FAD FAD
1e- NADP+ 3e- 3e- P450ox 2e- 2e- P450ox 1e-
Figure 1.3. The mammalian CPR cycles between the 1- and 3-electron containing
subforms during steady state
It is important to note that the catalytic activity of a particular CYP in a specific
tissue, sub-cellular fraction, or recombinant expression system is determined not only
by the abundance of the CYP, but also by the amount of its electron transport partner
CPR (Crespi & Miller 1999).
1.7 Role of Cytochrome b5 in CYP Reactions
In 1971, Hildebrandt and Estabrook (Hildebrandt and Estabrook 1971) showed
evidence for the involvement of cytochrome b5 in hepatic CYP reactions. It is a 17-kDa
haemprotein which is also associated with microsomes. Surprisingly, it enhances the
activity of some CYP reactions in vitro, but not all. In early days of research on
cytochrome b5 this perplexing aspect was a subject of much debate. Reports from some
investigators suggested that it is not necessary at all for CYP reactions but others have
shown that it is absolutely essential for particular CYP reactions with specific substrates
(Porter 2002). Cytochrome b5 is reduced by an NADPH-dependent flavoprotein,
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NADPH- b5 reductase (Strittmatter 1967; Takesue and Omura 1970). However, it is
confirmed that cytochrome b5 is also reduced by CPR (Enoch and Strittmatter 1979;
Noshiro et al. 1979). The evidence today indicates that cytochrome b5 enhances the
activities of many CYP reactions (Vergeres and Waskell 1995)[40]. It has been
reported that, in the presence of NADPH, recombinant co-expression of b5 reductase, b5
and CYP3A4 catalyses testosterone and nifidepine oxidation at greater rates than that
obtained with CPR and CYP3A4 (Yamazaki 2002). Similar augmentation in reaction
rates, mediated by b5, has been reported for other CYPs such as CYP2A6, CYP2B6,
CYP2C8, CYP2C9, CYP2C19, and CYP2E1 (Mokashi et al. 2003; Schenkman and
Jansson 2003; Shimada et al. 2005).
Cytochrome b5 also acts as an electron donor protein for fatty acid desaturase
(Holloway and Katz 1975), reduction of haemoglobin (Mauk and Mauk 1982) and
synthesis of methionine (Chen and Banerjee 1988). Figure 1.4 shows the mechanism of
action of cytochrome b5 (Porter 2002).
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Figure 1.4. The mechanism of action of cytochrome b5
1.8 Experimental Systems for CYP mediated drug
metabolism
1.8.1 Human liver tissues
Despite considerable sequence similarity in CYPs across species, even small
differences can cause significant changes in catalytic activity. For example, the 6- and
8-hydroxylation of warfarin is catalysed by rat CYP1A1 but not by the corresponding
enzyme in mice, despite 93% identity in their protein sequences (Kaminsky et al. 1984).
S-mephenytoin is 4-hydroxylated by only human CYP2C19 but this reaction is also
specifically mediated by the rat CYP3A (Shimada and Guengerich 1985; Shimada et al.
1986). Therefore, drug metabolism studies with human liver tissues, containing active
CYP enzymes are considered to be crucial for drug discovery. However, this in turn
raises wider issues of availability and ethics (Bardsley 1994).
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1.8.2 Human liver microsomes
Although the preparation of microsomes (essentially the endoplasmic reticular
membranes) from human liver tissues is not too difficult, microsomal samples on their
own are unable to gauge accurately the degree of inhibition of individual CYPs (present
in the human liver) by specific chemical compounds. Moreover, microsomes (non-
living entities) do not allow assessment of the levels of CYPs that could be induced by a
particular chemical.
1.8.3 Hepatocytes
In contrast to microsomes, hepatocytes are usually used mainly to study
induction of CYPs. Hepatocytes are specialised liver cells which contain 70-80% of the
cytoplasmic mass of the liver. However, primary hepatocytes isolated from the liver
have very limited life span when grown in-vitro.
1.8.4 Heterologous cDNA-Expression Systems for CYPs
Several heterologous expression systems like bacteria (Escherichia coli), yeast
(Saccharomyces cerevisiae), insect cells and mammalian cells have been used
successfully to express CYPs (Gonzalez and Korzekwa 1995). These systems can be
used for expression of CYP alone or together with its redox partners, CPR and/or b5.
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As CYPs require their redox partners, expression of CYP alone in any expression
system does not give optimum catalytic activity. A CYP can be expressed, purified and
later mixed with its redox partners or, alternatively, these redox partners can be co-
expressed with a CYP.
Unfortunately, high level co-expression of a CYP and CPR in heterologous
systems poses some problems to host cells. These are related to the activity of CYP
enzymes that are expressed and their content. Since CYP-CPR complexes are
associated with the endoplasmic reticulum, a vital organelle of eukaryotic cells, their
high level expression cause an increased stress on the cell. Co-expression of CPR with
a specific CYP definitely increases the catalytic activity of the CYP enzyme but also
dramatically reduces the yield of spectrally active CYP enzyme (Pritchard et al. 1998;
Dong and Porter 1996; Chen et al. 1997) which is shown quite emphatically in the
recombinant baculovirus-insect cell system. Although the CYP apoprotein levels
remain unchanged during co-expression of a CYP and a CPR, the amounts of spectrally
active CYP decrease remarkably (Chen et al. 1997; Gonzalez et al. 1991; Tamura et al.
1992).
1.8.4.1 Bacterial Expression System
E. coli has been used for expressing high levels of several CYPs (Gonzalez and
Korzekwa, 1995). The culture media requirements for this expression system are
inexpensive compared to insect and mammalian expression systems. CYPs expressed
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in bacterium have provided valuable information regarding structure-function
relationships. The N-terminal hydrophobic region of mammalian CYPs (Haugen 1997)
is responsible for the insertion of the protein into membrane structures. Truncation or
modification of this hydrophobic region results in change of location of the expressed
enzyme to the cytosol. In order to produce catalytically active CYP and to facilitate
purification, N-terminal modifications of the CYP proteins have been performed (Iwata
et al. 1998; Barnes et al. 1991). Another approach for bacterial expression is insertion
of the outer membrane protein A (ompA) targeting sequence which directs the CYP
protein, devoid of the N-terminal hydrophobic region, to the periplasmic space of the
bacteria, where it is then removed by proteolytic cleavage (Pritchard et al. 1998).
OmpA is a major protein in the E. coli outer membrane. Construction of plasmids that
allow expression of catalytically active CYP-CPR fusion proteins (where the CPR lacks
the N-terminal membrane anchor) has provided some advantages such as convenience
in purification and avoiding the need for reconstitution.
The ability of the bacterium to produce large quantities of an active CYP
enzyme may offer applications of this system in industrial scale biocatalysis and
biosynthesis of metabolites. However, the major drawback of the prokaryotic bacterial
system is that bacterial cells do not contain the endoplasmic reticulum, an intracellular
compartment to which human and mammalian CYPs are naturally associated.
Endoplasmic reticular membrane association is essential for human CYP activity –
human CYPs shorn off the ER membranes are totally inactive. In order to express
CYPs in bacteria, CYP genes must undergo drastic alterations at the genetic level.
36
1.8.4.2 Yeast Expression System
Like bacterial expression systems, a yeast expression system is inexpensive in
terms of culture media requirements and faster doubling time of the cells. Unlike
bacteria, yeast provides a eukaryotic intracellular environment and therefore
mammalian CYPs can be expressed and obtained in their native form, anchored to
yeast’s endoplasmic reticulum. In order to achieve higher catalytic activity, a CYP and
CPR can be co-expressed in yeast. Both CPR and b5 have been successfully co-
expressed with CYPs by stable co-transfection in yeast (Peyronneau et al. 1992).
Studies in our laboratories at De Montfort University (unpublished data) have shown
that high level expression of CYPs with higher catalytic activities can be obtained in
Saccharomyces cerevisiae. The strategies used at De Montfort University allow one to
co-express a human CYP, human CPR and where necessary b5.
1.8.4.3 Mammalian Expression System
Several mammalian host cells have been used for expression of CYPs. Human
lymphoblast cells (Crespi et al. 1990), human hepatic HepG2 cells (Aoyama et al. 1990;
Dai et al. 1993), Chinese hamster ovary cells (Ding et al. 1997), NIH 3T3 cells (Battula
et al. 1987) and V79 cells (Doehmer et al. 1988) have been successfully used for
expression of CYPs. Use of hepatic cell lines provides appropriate electron transport
ability and a host environment in which the CYPs are naturally predominant. There is
some level of natural expression of CYP, CPR and b5 in some hepatic host cells but that
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may be rate limiting and not enough for catalysis. There is an upper limit on the
expression levels of human CYPs that can be achieved in mammalian expression
systems. However the CYP mammalian expression system, if conveniently available,
could be highly relevant for cytotoxicity studies, malignant transformation and
mutagenesis studies (Crespi & Miller 1999).
1.8.4.4 Baculovirus Expression System
Baculoviruses are double stranded DNA viruses which infect insects but are not
pathogenic to mammals. Baculovirus mediated expression of recombinant cDNA
proteins in insect cells is a valuable tool for expressing proteins. The recombinant virus
harbouring a cDNA infects insect cells in-vitro, uses the host cells’ machinery for
multiplication and the protein expression is driven by viral promoters. The baculovirus-
insect cell expression system allows high level expression of recombinant proteins
targeted to the correct cellular compartment (Summers and Smith 1987). It also
provides, like the yeast system, correct folding of recombinant protein, disulfide bond
formation, oligomerization and some of the important post-translational modifications.
The baculovirus-insect cell expression system has gained widespread popularity.
Several recombinant cytoplasmic, secreted and membrane-bound proteins have been
successfully expressed using this system. The recombinant viruses use viral polyhedrin
or p10 gene promoters to drive the expression of proteins (Luckow 1991). The
traditional method of generating recombinant baculoviruses is labour- and time-
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consuming. However, significant progress has been made over the past decade on
methods in recombinant baculovirus generation and insect cells. The time and effort
involved in developing recombinant viruses have been reduced by the use of
commercially available systems. Often multiple baculovirus promoters allow one to
simultaneously express two or more proteins via a single recombinant virus (Weyer and
Possee 1991).
The size of the baculovirus genome is very large (134 kbps) (Ayres 1994), and
therefore no unique restriction site is available for direct subcloning of a gene of interest
into the genome. In view of that, homologous recombination appears to be a convenient
method for generating a recombinant virus. One approach to achieve this is to co-
transfect insect cells with a shuttle plasmid (in which the gene of interest is subcloned)
and the linearized viral genomic DNA. Thus the foreign gene, encoded by a shuttle
plasmid, is introduced into a nonessential region of the viral genome via homologous
recombination. The linearised viral DNA is commercially available from both BD
Pharmingen (BaculoGold, Baculovirus Expression Vector System) and Clontech
(BacPAK6).
Another approach to generate a recombinant baculovirus is newer and developed
by researchers at Monsanto. It is based on site-specific transposition of an expression
cassette from a donor plasmid into a baculovirus shuttle vector (bacmid) which is
propagated in E. coli (Luckow et al. 1993). The system is marketed by Invitrogen (Bac-
to-Bac Baculovirus Expression System). In order to carry a gene of interest on an
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expression cassette, a number of donor plasmids are available for use with this system.
These include pFastBac1 with the polyhedrin promoter (Anderson et al. 1996), N-
terminal 6xHis tag on pFastBacHT together with the polyhedrin promoter (Polayes et al.
1996) and pFastbacDual which contain both the polyhedrin and p10 promoters for
simultaneous expression of two different proteins (Harris and Polayes 1997).
In order to generate recombinant bacmid DNA, the Bac-to-Bac Expression
System takes advantage of the site specific transposition properties of the Tn7
transposon. In the first part of the process, a gene of interest is cloned, for example, in
the pFastBac donor plasmid under the control of viral promoter, polyhedrin (PH) or
p10. The promoters are derived from Autographa californica multiple nuclear
polyhedrosis virus (AcMNPV). The expression cassette is flanked by the left and right
arms of Tn7 transposon. The expression cassette also contains a gentamycin resistance
gene and an SV40 polyadenylation transcription stop signal to form a mini Tn7
transposon.
In the second part of the process the recombinant bacmid is generated. To
achieve this, a DH10Bac E. coli strain is used which contains a bacmid with the mini-
attTn7 target site (i.e. a specific site present in the chromosomes of many bacteria) and
a helper plasmid. The helper plasmid provides the transposase protein required for the
process of transposition and it also contains a tetracycline resistance gene. The
pFastBac donor plasmid transformation into the DH10Bac cells results in transposition
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between the mini-Tn7 element on the pFastBac donor plasmid and the mini-attTn7
target site on the bacmid to generate the recombinant bacmid.
The bacmid in DH10Bac cells also contains a low copy number mini-F replicon,
kanamycin resistance marker and a segment of DNA encoding the LacZα peptide (from 
a pUC-based cloning vector) into which the attachment site for the bacterial transposon,
Tn7 (mini-attTn7) has been inserted.  The reading frame of the LacZα peptide is not 
disrupted by this insertion. However the LacZ gene is deleted from the chromosome of
DH10Bac cells. The LacZ gene present on bacmid complements for the deletion and
produces blue (Lac+) colonies when induced with IPTG in the presence of chromogenic
substrates like Bluo-gal or X-gal. Homologous recombination disrupts the DNA
encoding LacZα peptide on bacmid and the DH10Bac cells harbouring recombinant 
bacmid develop white colour (Lac-) (Bac-to-Bac Baculovirus Expression System,
Invitrogen, Version D, 2004).
High molecular weight recombinant bacmids from white colonies are then
isolated, checked for veracity using PCR and used for transfection into insect cells to
generate recombinant baculovirus. The resulting baculoviruses can be used for
expression of proteins in insect cells. Figure 1.5 shows the schematic representation of
the recombinant baculovirus generation.
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The host cells of insect origin are Sf9, Sf21 and Trichoplusia ni cells (BTI-TN-
5B1-4). The later one has been developed by Boyce Thompson Institute and
commercially available as High Five from Invitrogen Corp. These cells grow as
adherent cultures as well as in suspension. Since the cells also grow in suspension,
large scale biorectors can be used for expression of the recombinant proteins.
Both the CYP and the CPR can be expressed at high levels in insect cells using
the baculovirus expression system (Lee et al. 1995). Amongst different recombinant
expression systems, it appears to offer the best combination of high CYP content and
high catalytic activity per unit CYP enzyme (Crespi and Miller 1999).Tn7Fig
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1.9 Objectives of the Research
The main aim of the investigation was to devise an insect cell expression system
that would allow improvement of the levels and activities of the drug metabolising
cytochrome P450 enzyme (CYPs). With this aim in mind, I embarked on research that
would allow me to answer the following questions:
(1) Is a genetically engineered variant of the human NADPH cytochrome P450
reductase (CPR) less toxic than the native CPR?
(2) Does the genetically engineered CPR variant couple better with CYPs than
the native CPR? and
(3) How does the heterologous yeast CPR, which is so highly active and which in
theory should provide super active CYP enzymes, function when co-
expressed with human CYP genes in insect cells?
It was decided that the four CYPs, CYP3A4, CYP2E1, CYP2D6 and CYP1A2,
which are more prominently expressed in human liver tissues and therefore widely used
for drug metabolism studies, would form the basis of my investigations.
The CYPs cannot metabolise substrates on their own, they require CPR for their
catalytic activity. The catalytic activity of a particular CYP is determined not only by
the abundance of the CYP, but also by the amount of CPR (Crespi and Miller 1999).
Although CPR is essential for CYP activity, paradoxically the mere presence of CPR
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contributes to a dramatic decrease in the levels of active CYP. It can be speculated that
this is possibly the result of production of hydroxyl radicals which are involved in an
uncoupled CYP reaction cycle. The process of transferring electrons from NADPH via
the CPR/CYP complex to oxygen to form reactive oxygen species (ROS) is termed
uncoupling. Some CYPs, such as CYP2E1, have shown a high degree of uncoupling
which results in damage to cellular components, including CYP2E1 itself (Wang et al.
1996). It appears that coupling of the electron transport partner (CPR) to CYPs is a
crucial factor towards high activity of CYP holoenzymes but also an extremely
important element that causes low levels of CYP holoproteins.
There is a pressing need for solving this paradox in view of the widespread
biotechnological applications of recombinant CYP enzymes. It has been reported that
use of radical scavengers (i.e. anti-oxidants) such as dimethyl sulfoxide (DMSO), which
is capable of trapping free radicals, increases the CYP holoenzyme content (Narimatsu
et al. 2005). But this purported to be only a crude attempt in trying to increase levels of
CYP holoenzyme through chemical modulations of the enzymes after their production.
My research hoped to address this paradox through defined genetic means, namely
through
(1) Designing a genetically engineered variant of the human CPR which could be
less toxic and yet could couple better with CYPs than the native enzyme
allowing us to improve upon both CYP levels and activity in an insect cell
expression system, and
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(2) Using a high-activity CPR from a heterologous organism to enable us to monitor
the ability of this particular CPR to couple with a human CYP and compare
results obtained with the native human CPR permitting us to understand better
the phenomenon of CYP activation by a CPR.
We had earlier engineered and cloned a variant of the human CPR (hRD)
(Figure 2.1 Gene Alignment and Protein Alignment) for our yeast expression studies
and surprisingly observed that it was active (see below). I wanted to explore if this
mutant enzyme was less toxic than the native enzyme in the insect cell expression
system.
The native CPR contains binding sites for the essential cofactors FMN and FAD
at its NH2-terminus. The first 165 bps at the 5’-end of the hRD gene code for a 55-
amino acid domain that permit anchoring to microsomal membranes. Within this DNA
sequence lies a 72 bps region which code for a 24-amino acid negatively charged
domain. The FMN binding site spans a sequence that includes the membrane anchor
whereas the region to which FAD binds is positioned beyond this domain. The
complete hRD membrane anchor is essential for coupling to CYPs. The lack of the
NH2-terminal 24-amino acid charged region present in hRD prevents association of the
resultant molecule, ΔhRD, to microsomal membranes.  However, the ΔhRDM protein 
which also lacks the NH2-terminal 24-amino acids of CPR but contains an extra 12-
amino acid sequence (referred to as the c-myc tag) added to ΔhRD’s COOH-terminus 
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has the inexplicable ability to adhere once again to microsomal membranes like the
native CPR.
Figure 1.6. The genetically engineered variant of human CPR, hRDM.
Gene Alignment of hRD and hRDM. Comparison of the coding strand of full length
human P450 reductase gene (hRD) with its genetically engineered variant ΔhRDM. 
10 20 30 40 50 60
hRD GGATCCATGGGAGACTCCCACGTGGACACCAGCTCCACCGTGTCCGAGGCGGTGGCCGAA
ΔhRDM ------------------------------------------------------------
70 80 90 100 110 120
hRD GAAGTATCTCTTTTCAGCATGACGGACATGATTCTGTTTTCGCTCATCGTGGGTCTCCTA
::::::::::::::::::::::::::::::::::::::::::
ΔhRDM ------------------ATGACGGACATGATTCTGTTTTCGCTCATCGTGGGTCTCCTA
10 20 30 40
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130 140 150 160 170 180
hRD ACCTACTGGTTCCTCTTCAGAAAGAAAAAAGAAGAAGTCCCCGAGTTCACCAAAATTCAG
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM ACCTACTGGTTCCTCTTCAGAAAGAAAAAAGAAGAAGTCCCCGAGTTCACCAAAATTCAG
50 60 70 80 90 100
190 200 210 220 230 240
hRD ACATTGACCTCCTCTGTCAGAGAGAGCAGCTTTGTGGAAAAGATGAAGAAAACGGGGAGG
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM ACATTGACCTCCTCTGTCAGAGAGAGCAGCTTTGTGGAAAAGATGAAGAAAACGGGGAGG
110 120 130 140 150 160
250 260 270 280 290 300
hRD AACATCATCGTGTTCTACGGCTCCCAGACGGGGACTGCAGAGGAGTTTGCCAACCGCCTG
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM AACATCATCGTGTTCTACGGCTCCCAGACGGGGACTGCAGAGGAGTTTGCCAACCGCCTG
170 180 190 200 210 220
310 320 330 340 350 360
hRD TCCAAGGACGCCCACCGCTACGGGATGCGAGGCATGTCAGCGGACCCTGAGGAGTATGAC
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM TCCAAGGACGCCCACCGCTACGGGATGCGAGGCATGTCAGCGGACCCTGAGGAGTATGAC
230 240 250 260 270 280
370 380 390 400 410 420
hRD CTGGCCGACCTGAGCAGCCTGCCAGAGATCGACAACGCCCTGGTGGTTTTCTGCATGGCC
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM CTGGCCGACCTGAGCAGCCTGCCAGAGATCGACAACGCCCTGGTGGTTTTCTGCATGGCC
290 300 310 320 330 340
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430 440 450 460 470 480
hRD ACCTACGGTGAGGGAGACCCCACCGACAATGCCCAGGACTTCTACGACTGGCTGCAGGAG
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM ACCTACGGTGAGGGAGACCCCACCGACAATGCCCAGGACTTCTACGACTGGCTGCAGGAG
350 360 370 380 390 400
490 500 510 520 530 540
hRD ACAGACGTGGATCTCTCTGGGGTCAAGTTCGCGGTGTTTGGTCTTGGGAACAAGACCTAC
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM ACAGACGTGGATCTCTCTGGGGTCAAGTTCGCGGTGTTTGGTCTTGGGAACAAGACCTAC
410 420 430 440 450 460
550 560 570 580 590 600
hRD GAGCACTTCAATGCCATGGGCAAGTACGTGGACAAGCGGCTGGAGCAGCTCGGCGCCCAG
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM GAGCACTTCAATGCCATGGGCAAGTACGTGGACAAGCGGCTGGAGCAGCTCGGCGCCCAG
470 480 490 500 510 520
610 620 630 640 650 660
hRD CGCATCTTTGAGCTGGGGTTGGGCGACGACGATGGGAACTTGGAGGAGGACTTCATCACC
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM CGCATCTTTGAGCTGGGGTTGGGCGACGACGATGGGAACTTGGAGGAGGACTTCATCACC
530 540 550 560 570 580
670 680 690 700 710 720
hRD TGGCGAGAGCAGTTCTGGCCGGCCGTGTGTGAACACTTTGGGGTGGAAGCCACTGGCGAG
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM TGGCGAGAGCAGTTCTGGCCGGCCGTGTGTGAACACTTTGGGGTGGAAGCCACTGGCGAG
590 600 610 620 630 640
48
730 740 750 760 770 780
hRD GAGTCCAGCATTCGCCAGTACGAGCTTGTGGTCCACACCGACATAGATGCGGCCAAGGTG
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM GAGTCCAGCATTCGCCAGTACGAGCTTGTGGTCCACACCGACATAGATGCGGCCAAGGTG
650 660 670 680 690 700
790 800 810 820 830 840
hRD TACATGGGGGAGATGGGCCGGCTGAAGAGCTACGAGAACCAGAAGCCCCCCTTTGATGCC
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM TACATGGGGGAGATGGGCCGGCTGAAGAGCTACGAGAACCAGAAGCCCCCCTTTGATGCC
710 720 730 740 750 760
850 860 870 880 890 900
hRD AAGAATCCGTTCCTGGCTGCAGTCACCACCAACCGGAAGCTGAACCAGGGAACCGAGCGC
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM AAGAATCCGTTCCTGGCTGCAGTCACCACCAACCGGAAGCTGAACCAGGGAACCGAGCGC
770 780 790 800 810 820
910 920 930 940 950 960
hRD CACCTCATGCACCTGGAATTGGACATCTCGGACTCCAAAATCAGGTATGAATCTGGGGAC
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM CACCTCATGCACCTGGAATTGGACATCTCGGACTCCAAAATCAGGTATGAATCTGGGGAC
830 840 850 860 870 880
970 980 990 1000 1010 1020
hRD CACGTGGCTGTGTACCCAGCCAACGACTCTGCTCTCGTCAACCAGCTGGGCAAAATCCTG
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM CACGTGGCTGTGTACCCAGCCAACGACTCTGCTCTCGTCAACCAGCTGGGCAAAATCCTG
890 900 910 920 930 940
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1030 1040 1050 1060 1070 1080
hRD GGTGCCGACCTGGACGTCGTCATGTCCCTGAACAACCTGGATGAGGAGTCCAACAAGAAG
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM GGTGCCGACCTGGACGTCGTCATGTCCCTGAACAACCTGGATGAGGAGTCCAACAAGAAG
950 960 970 980 990 1000
1090 1100 1110 1120 1130 1140
hRD CACCCATTCCCGTGCCCTACGTCCTACCGCACGGCCCTCACCTACTACCTGGACATCACC
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM CACCCATTCCCGTGCCCTACGTCCTACCGCACGGCCCTCACCTACTACCTGGACATCACC
1010 1020 1030 1040 1050 1060
1150 1160 1170 1180 1190 1200
hRD AACCCGCCGCGTACCAACGTGCTGTACGAGCTGGCGCAGTACGCCTCGGAGCCCTCGGAG
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM AACCCGCCGCGTACCAACGTGCTGTACGAGCTGGCGCAGTACGCCTCGGAGCCCTCGGAG
1070 1080 1090 1100 1110 1120
1210 1220 1230 1240 1250 1260
hRD CAGGAGCTGCTGCGCAAGCTGGCCTCCTCCTCCGGCGAGGGCAAGGAGCTGTACCTGAGC
:::::::::::::::::: :::::::::::::::::::::::::::::::::::::::::
ΔhRDM CAGGAGCTGCTGCGCAAGATGGCCTCCTCCTCCGGCGAGGGCAAGGAGCTGTACCTGAGC
1130 1140 1150 1160 1170 1180
1270 1280 1290 1300 1310 1320
hRD TGGGTGGTGGAGGCCCGGAGGCACATCCTGGCCATCCTGCAGGACTGCCCGTCCCTGCGG
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM TGGGTGGTGGAGGCCCGGAGGCACATCCTGGCCATCCTGCAGGACTGCCCGTCCCTGCGG
1190 1200 1210 1220 1230 1240
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1330 1340 1350 1360 1370 1380
hRD CCCCCCATCGACCACCTGTGTGAGCTGCTGCCGCGCCTGCAGGCCCGCTACTACTCCATC
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM CCCCCCATCGACCACCTGTGTGAGCTGCTGCCGCGCCTGCAGGCCCGCTACTACTCCATC
1250 1260 1270 1280 1290 1300
1390 1400 1410 1420 1430 1440
hRD GCCTCATCCTCCAAGGTCCACCCCAACTCTGTGCACATCTGTGCGGTGGTTGTGGAGTAC
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM GCCTCATCCTCCAAGGTCCACCCCAACTCTGTGCACATCTGTGCGGTGGTTGTGGAGTAC
1310 1320 1330 1340 1350 1360
1450 1460 1470 1480 1490 1500
hRD GAGACCAAGGCCGGCCGCATCAACAAGGGCGTGGCCACCAACTGGCTGCGGGCCAAGGAG
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM GAGACCAAGGCCGGCCGCATCAACAAGGGCGTGGCCACCAACTGGCTGCGGGCCAAGGAG
1370 1380 1390 1400 1410 1420
1510 1520 1530 1540 1550 1560
hRD CCTGCCGGGGAGAACGGCGGCCGTGCGCTGGTGCCCATGTTCGTGCGCAAGTCCCAGTTA
:::: :::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM CCTGTCGGGGAGAACGGCGGCCGTGCGCTGGTGCCCATGTTCGTGCGCAAGTCCCAGTTA
1430 1440 1450 1460 1470 1480
1570 1580 1590 1600 1610 1620
hRD CGCCTGCCCTTCAAGGCCACCACGCCTGTCATCATGGTGGGCCCCGGCACCGGGGTGGCA
:::::::::::::::::::::::::::::::::::::::::::::::::::::: :::::
ΔhRDM CGCCTGCCCTTCAAGGCCACCACGCCTGTCATCATGGTGGGCCCCGGCACCGGG-TGGCA
1490 1500 1510 1520 1530 1540
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1630 1640 1650 1660 1670
hRD CCCTT-CATAGGCTTCATCCAGGAGCGGGCCTGGCTGCGACAGCAGGGCAAGGAGGTGGG
::::: ::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM CCCTTTCATAGGCTTCATCCAGGAGCGGGCCTGGCTGCGACAGCAGGGCAAGGAGGTGGG
1550 1560 1570 1580 1590 1600
1680 1690 1700 1710 1720 1730
hRD GGAGACGCTGCTGTACTACGGCTGCCGCCGCTCAGATGAGGACTACCTGTACCGGGAGGA
::::::::::::::::::::::::::::::::: ::::::::::::::::::::::::::
ΔhRDM GGAGACGCTGCTGTACTACGGCTGCCGCCGCTCGGATGAGGACTACCTGTACCGGGAGGA
1610 1620 1630 1640 1650 1660
1740 1750 1760 1770 1780 1790
hRD GCTGGCGCAGTTCCACAGGGACGGTGCGCTCACCCAGCTCAACGTGGCCTTCTCCCGGGA
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM GCTGGCGCAGTTCCACAGGGACGGTGCGCTCACCCAGCTCAACGTGGCCTTCTCCCGGGA
1670 1680 1690 1700 1710 1720
1800 1810 1820 1830 1840 1850
hRD GCAGTCCCACAAGGTCTACGTCCAGCACCTGCTAAAGCAAGACCGAGAGCACCTGTGGAA
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM GCAGTCCCACAAGGTCTACGTCCAGCACCTGCTAAAGCAAGACCGAGAGCACCTGTGGAA
1730 1740 1750 1760 1770 1780
1860 1870 1880 1890 1900 1910
hRD GTTGATCGAAGGCGGTGCCCACATCTACGTCTGTGGGGATGCACGGAACATGGCCAGGGA
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM GTTGATCGAAGGCGGTGCCCACATCTACGTCTGTGGGGATGCACGGAACATGGCCAGGGA
1790 1800 1810 1820 1830 1840
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1920 1930 1940 1950 1960 1970
hRD TGTGCAGAACACCTTCTACGACATCGTGGCTGAGCTCGGGGCCATGGAGCACGCGCAGGC
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM TGTGCAGAACACCTTCTACGACATCGTGGCTGAGCTCGGGGCCATGGAGCACGCGCAGGC
1850 1860 1870 1880 1890 1900
1980 1990 2000 2010 2020 2030
hRD GGTGGACTACATCAAGAAACTGATGACCAAGGGCCGCTACTCCCTGGACGTGTGGAGCT-
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ΔhRDM GGTGGACTACATCAAGAAACTGATGACCAAGGGCCGCTACTCCCTGGACGTGTGGAGCTC
1910 1920 1930 1940 1950 1960
2040
hRD -AG-------------------------------------------------
ΔhRDM TAGTGAACAAAAGTTGATCTCTGAAGAAGACTTGAACGGTTCTAGGTTATAA
1970 1980 1990 2000 2010
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10 20 30 40 50 60
* * * * * *
hRD.PRT MGDSHVDTSSTVSEAVAEEVSLFSMTDMILFSLIVGLLTYWFLFRKKKEEVPEFTKIQTL
ΔhRDM.PRT ------------------------MTDMILFSLIVGLLTYWFLFRKKKEEVPEFTKIQTL
70 80 90 100 110 120
* * * * * *
hRD.PRT TSSVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLA
         ΔhRDM.PRT TSSVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLA
130 140 150 160 170 180
* * * * * *
hRD.PRT DLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEH
          ΔhRDM.PRT DLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEH
190 200 210 220 230 240
* * * * * *
hRD.PRT FNAMGKYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEES
          ΔhRDM.PRT FNAMGKYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEES
250 260 270 280 290 300
* * * * * *
hRD.PRT SIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHL
          ΔhRDM.PRT SIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHL
310 320 330 340 350 360
* * * * * *
hRD.PRT MHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHP
          ΔhRDM.PRT MHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHP
370 380 390 400 410 420
* * * * * *
hRD.PRT FPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQELLRKLASSSGEGKELYLSWV
          ΔhRDM.PRT FPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQELLRKLASSSGEGKELYLSWV
430 440 450 460 470 480
* * * * * *
hRD.PRT VEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVVVEYET
          ΔhRDM.PRT VEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVVVEYET
490 500 510 520 530 540
* * * * * *
hRD.PRT KAGRINKGVATNWLRAKEPAGENGGRALVPMFVRKSQLRLPFKATTPVIMVGPGTGVAPF
          ΔhRDM.PRT KAGRINKGVATNWLRAKEPAGENGGRALVPMFVRKSQLRLPFKATTPVIMVGPGTGVAPF
550 560 570 580 590 600
* * * * * *
hRD.PRT IGFIQERAWLRQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQS
          ΔhRDM.PRT IGFIQERAWLRQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQS
610 620 630 640 650 660
* * * * * *
hRD.PRT HKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVD
          ΔhRDM.PRT HKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVD
670
*
hRD.PRT YIKKLMTKGRYSLDVWS------------
          ΔhRDM.PRT YIKKLMTKGRYSLDVWSSSEQKLISEEDL
Protein Alignment of hRD and hRDM. Comparison of the full length human P450
reductase (hRD) and genetically engineered variant ΔhRDM protein sequences. 
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We surmised that it is likely that by deleting an N-terminal domain and
introducing an unusual peptide fragment at the C-terminus, we may have grossly altered
the membrane-binding topology of the engineered molecule, ΔhRDM.  From earlier 
studies in baker’s yeast, we already knew that ΔhRDM was active and membrane-
bound. Hence we thought we could now study the consequence of using this CPR
variant in the context of different human CYPs in insect cells and compare these studies
vis-à-vis the native CPR. We chose to use four CYPs for our studies. Two of them,
CYP3A4 and CYP2E1 require, besides CPR, the additional electron transport partner b5
for expression of activity. The other two CYPS used are CYP2D6 and CYP1A2 which
are able to manifest activity, in the absence of b5, together with only CPR.
We also wished to explore the activity of these four human CYPs in the
presence of the heterologous yeast CPR (yRD) via co-expression in insect cells. The
yRD gene has never been studied in insect cells. We conjectured that the yRD enzyme,
which has extremely high activity, expressed in the context of human CYPs in insect
cells may well provide a better understanding of a CPR’s ability to contribute to the
activity and the levels of different human CYPs.
In addition to the four CYPs enumerated above (CYP2D6, CYP1A2, CYP3A4
and CYP2E1), I have extended my studies and have cloned and expressed CYP1A1,
CYP1B1, CYP2C8 in conjunction with different CPR species (human CPR, variants of
human CPR and yeast CPR) and b5 (where necessary) in order to create functionally
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active enzymes from insect cells. It was envisaged that all protein expression from
insect cells would be mediated by baculoviruses which specifically infect these cells.
With these experiments in mind, we hoped that my results would ultimately
provide a deeper insight into how CPR interactions with CYPs influence the latter’s
activity and correspondingly the levels of synthesis. We were aiming, of course, to find
a set of experimental conditions that probably would be less destructive to CYPs and
also yield higher CYP activity. If successful, the findings could have major
applications in drug metabolism research.
The results that I obtained are presented in the eight chapters of the thesis, as
follows.
In this first chapter, consisting of an Introduction, the literature has been reviewed
focussing on the biotransformation process, history of cytochrome P450, cytochrome
P450 nomenclature, role of CYPs in human diseases and drug discovery, mechanism of
action of CYPs, role of NADPH- cytochrome P450 reductase in CYP reaction, role of
cytochrome b5 in CYP reactions, along with various experimental systems that have
been employed to measure CYP mediated drug metabolism. They include human liver
tissues, human liver microsomes, hepatocytes, and different expression systems,
namely, bacterial, yeast, mammalian and baculoviral. At the end of the introduction,
objectives of the proposed research have been highlighted.
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In the second chapter, Materials and Methods elaborate the source of reagents,
chemicals, cells and instruments used for my research. Together with this, a detailed
account of procedures employed for various experimental designs have been provided.
In the third chapter, results of isolation, expression and catalytic activities of human
NADPH- cytochrome P450 reductase, variants of human NADPH- cytochrome P450
reductase (ΔhRD and ΔhRDM) and yeast NADPH- cytochrome P450 reductase are 
described. The chapter details the cloning and expression of the genes in the
baculovirus expression system. The catalytic activities of all the NADPH- cytochrome
P450 reductases are compared. The results of CYP2D6 which was used as a model
enzyme to study its interactions with various reductases are presented. The results
described in the chapter comprise of isolation, optimisation of protein expression,
identification and biochemical characteristics of proteins after co-expression with the
different reductases in the baculovirus expression system. The chapter also presents
evidence for oxidative damage of CYP2D6 caused by the reductases.
In the fourth chapter, results obtained with CYP3A4 expressed in conjunction with
different CPR species (human CPR, variants of human CPR and yeast CPR) and b5 are
detailed.
In the fifth chapter, results encompassing CYP1A2, CYP3A4, CYP2E1, CYP1A1,
CYP1B1 and CYP2C8 expressed in conjunction with different CPR species (human
CPR, variants of human CPR and yeast CPR) and b5 where necessary are detailed. The
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chapter compares the interactions of the individual reductases with individual CYPs and
provides evidences for poor or stronger interactions. The methodologies used for
improvement of CYP expression levels and CYP catalytic activities are also presented.
In the sixth chapter, CYP inhibition by isoform specific inhibitors is presented. CYP
inhibition assays have been validated for various CYPs whose activities are supported
by different reductase species. The experimental evidence is detailed to show that
inhibition potential of the inhibitors remain unchanged irrespective of reductase species
that is co-expressed to support the CYP activity.
In the seventh chapter, the results obtained with the four reductase species and their
interactions with the seven CYPs are compared and discussed as part of the argument
for destructive nature of the NADPH-cytochrome P450 reductase. The improvement in
CYP-CPR interaction is discussed. Conclusions and unifying summary of the study are
presented.
In the eighth chapter, all the references are provided.
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Chapter 2 Materials and Methods
2.1 Chemicals and Reagents
General reagents and biochemicals were purchased from Sigma-Aldrich
(Gillingham, UK), Fisher Scientific (Loughborough, UK) and Melford Laboratories
Ltd. (Suffolk, UK).
Sf9 insect cells, Grace’s insect cell medium, Express Five SFM, fetal bovine
serum, Cellfectin®, primers, pFastBac-1 cloning vector, DH-5α and DH10Bac E. coli
cells, 4% agarose gel for plaque assays, fluorogenic substrates for CYP assays,
H2DCFDA, Dihydrorhodamine-123 were all purchased from Invitrogen Ltd.
(Paisley,UK).
Molecular biology reagents like Vent DNA polymerase, dNTP mix, restriction
endonucleases and T4 DNA Ligase were purchased from New England Biolabs
(Hitchin, UK).
All electrophoresis and protein blotting reagents and equipments were obtained
from Bio-Rad laboratories (Hemel Hempstead, UK).
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Mouse monoclonal antibody to CYP2D6 (Catalogue Number A246), mouse
polyclonal antibody to CYP3A4 (Catalogue Number 458258), goat polyclonal antibody
to CYP1A1 (Cataloue Number 458124) and goat polyclonal antibody to CYP2E1
(Catalogue Number 458216) were purchased from Gentest. Rabbit polyclonal antibody
to NADPH CYP450 human reductase (Catalogue Number ab13513-50) was purchased
from Abcam. Mouse monoclonal antibody to the c-myc epitope (9E10) (Catalogue
Number SC-40) and the secondary antibody, anti-mouse IgG-HRP conjugate
(Catalogue Number SC-2302), were purchased from Santa Cruz Biotechnology. The
secondary antibody, goat anti-rabbit HRP conjugate (Catalogue Number 1858415) was
purchased from PIERCE.
2.2 Molecular Biology Methods
To study the protein functions and interactions, the baculovirus expression
system was used to express the proteins. In order to express the enzymes in a
heterologous system a range of molecular biology techniques like the polymerase chain
reaction, agarose gel electrophoresis, purification of DNA, gene cloning,
transformations of competent cells, etc were used.
2.2.1 Quantitation of DNA
DNA concentration was determined by measuring absorbance of the sample at
260 nm. If the sample is free from protein and RNA, DNA concentration can be
measured accurately by determining the amount of UV light absorbed by the bases
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present in the DNA sample. For double-stranded DNA quantification, the following
conversion factor was used:
1 OD at 260 nm = 50 mg DNA/ml.
The absorbance, measured at 280 nm, indicates the presence of protein in the
sample. The ratio between the readings between 260 and 280 nm provides an estimate
of the purity of the sample, a value in the range of 1.7 to 1.8 is acceptable.
A 5 µl sample was diluted in 1 ml of molecular biology grade water in a quartz
cuvette and the absorbance was measured at 260 and 280 nm in the spectrophotometer
after blanking with molecular biology grade water.
2.2.2 Polymerase Chain Reaction (PCR)
The polymerase chain reaction (PCR) is a technique that amplifies a target DNA
sequence in vitro rather than in living cells. PCR was developed in the early 1980s by
Dr. Kerry Mullis (Mullis et al. 1986). However, the technique has been greatly
improved since then. PCR can make virtually unlimited copies of a target DNA
sequence even if it is initially present in extremely small amounts in a mixture of many
different DNA sequences.
In order to perform the reaction, sequence of the DNA of interest must be
known. Based on the DNA sequence, short deoxyoligonucleotides, called primers, can
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be chemically synthesised. The primers are precisely complementary to the 3’ end of
each strand of the target DNA sequence. The reaction mixture contains the DNA to be
amplified, the primers, all four deoxynucleotides (dATP, dCTP, dGTP, dTTP) and a
DNA polymerase that is not deactivated by the high temperature needed to separate the
DNA strands.
The technique uses an automated thermal cycler which provides a fast heating
and cooling of the reaction mixture. The reaction mixture is first heated to separate the
DNA strands. If the primers find their complementary sequence in the DNA, they bind
to them. DNA polymerase begins the synthesis of the target DNA molecule from the 5’
to 3’ direction using the four deoxynucleotides. The synthesis continues until each
newly synthesized strand reaches the site recognized by the other primer. This first
cycle of the PCR generates two identical DNA molecules which are again doubled in
the next cycle. After 30 cycles a single DNA molecule is amplified into more than a
billion copies.
The genes of interest were amplified using high-fidelity Vent DNA polymerase
under the following PCR conditions: A 50 µl reaction mixture contained 1X Thermopol
Reaction Buffer (20 mM Tris-HCL, 10 mM (NH4)2 SO4, 10 mM KCl, 2 mM MgSO4,
0.1% Triton X-100, pH8.8 at 25°C), 0.8 mM dNTP mix, 20 ng forward primer, 20 ng
reverse primer, 20 ng template DNA (which often was a cDNA library) and 2.5 units of
Vent DNA polymerase. The final reaction volume was adjusted to 50 µl using
molecular biology grade water. A negative control was set up using the same mixture
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as above but lacking the template DNA. The reaction mixture in PCR tubes was
overlaid with 30 µl mineral oil to prevent the contents of the reaction mixture from
evaporation. The PCR was performed in a Biometra T3 Thermocycler, the reaction was
started with the initial denaturation at 95ºC for 3 min, followed by a cycle of 95ºC
denaturation for 45 sec, annealing for 90 sec at the calculated melting temperature for
the two PCR primers, and finally chain extension was repeated 29 times at 72ºC for 3
min. A final chain extension was performed at 72ºC for 10 min. Products obtained from
the PCR were then analyzed by agarose gel electrophoresis using standard restriction
enzyme(s) digested DNA as markers.
Primer melting temperature (Tm) was calculated according to the following
formula: Tm =61.8ºC + [∑(G+C) x 41ºC -675] / ∑(A+T+G+C) 
2.2.3 Cloning of genes in basic plasmids
For initial cloning of a gene from a cDNA library or a parent plasmid, two basic
plasmids were used, either pBluescript II KS+ (Stratagene, UK, Cat. No. 212207) or
pSP73 (Promega, UK, Cat. No. P2221). The pBluescript II KS+ has an extensive
polylinker with 21 unique restriction enzyme recognition sites which can be used for
cloning most genes of interest. Similarly, pSP73 has a wide range of unique restriction
sites, but different from pBluescript II KS+, for cloning a gene of interest. Both the
plasmid vectors contain a ‘bacterial origin of replication’ that allows extra-chomosomal
DNA replication.  The plasmids also carry the β-lactamase gene which on expression 
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pBlueKS+
2964 bps
500
1000
1500
2000
2500
NaeI 328
NgoMIV 328
FspI 480
PvuI 500
PvuII 530
653
SacI
BstXI
NotI
EagI
XbaI
SpeI
BamHI
SmaI
PstI
EcoRI
EcoRV
HindIII
BspDI
ClaI
HincII
SalI
XhoI
ApaI
Asp718I
KpnI
755
AseI 923
PvuII 975
AseI 982
AflIII 1153
BspHI 1873
DraI 1910
DraI 1929
AseI 2217
FspI 2266
PvuI 2413
ScaI 2524
DraI 2621
BspHI 2881
lacZ
ColE1ori
Amp-r
hydrolyses and inactivates ampicillin. Hence, on ampicillin containing LB agar plates
only those cells grow which harbour the plasmid bearing the ampicillin resistant β-
lactamase gene. These are known as transformants.
The plasmid map and list of features for the pBluescript II KS+ and pSP73 are
shown in Figures 2.1 and 2.2 respectively.
Figure 2.1. Map and abbreviated multiple cloning site region of the plasmid,
pBluescript II KS+.
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pSP73
2464 bps
500
10001500
2000
6
BglII
EcoRV
BspDI
ClaI
EcoRI
SacI
Asp718I
KpnI
SmaI
BamHI
XbaI
HincII
SalI
PstI
SphI
HindIII
PvuII
XhoI
87
AseI 117
HincII 136
HpaI 136
AseI 146
AflIII 317
BspHI 1037
DraI 1074
DraI 1093
AseI 1381
FspI 1430
PvuI 1577
ScaI 1688
DraI 1785
BspHI 2045
BspHI 2150
Esp3I 2194
Esp3I 2248
NdeI 2380
AseI 2414
T7p
ColE1 ori
Amp-R
SP6p
Figure 2.2. Map and abbreviated multiple cloning site region of the plasmid, pSP73.
For directional cloning, vector and insert DNA were first digested using a set of
two compatible restriction enzymes. The digested DNA was fractionated via agarose
gel electrophoresis. DNA was then extracted from the agarose gel. Purified and vector
DNA were ligated and the ligation mixture was transformed in DH5α competent cells 
and plasmids were isolated.
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2.2.4 Restriction enzyme digestion of DNA
Restriction enzymes recognize specific sequences in the DNA molecule and
cleave wherever the particular sequence occurs in the DNA. Restriction enzyme
digestion is either performed for analysis of the DNA or for further treatment such as
ligation and cloning.
A restriction enzyme digestion was usually performed using 10 units of a
restriction enzyme and 1 µg of purified DNA in a final volume of 30 µl of the
appropriate 1X buffer followed by incubation for 2 h at the recommended temperature
(usually 37ºC). The reaction was then terminated by adding 3 µl of 10X loading buffer
(containing 50% glycerol, 0.2mM EDTA, pH 8.0, 0.25 % xylene cyanol and 0.25%
bromophenol blue in molecular biology grade water). After restriction enzyme
digestion, agarose gel electrophoresis was performed to separate the DNA fragments by
size and to visualize the fragments.
2.2.5 Agarose gel electrophoresis
Agarose gel electrophoresis separates DNA fragments according to their size.
An electric current is used to move the DNA molecules across an agarose gel from the
negative to the positive end.
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Agarose gel electrophoresis was performed to analyze and purify products from
PCR and restriction enzyme digestion of DNA. Agarose was added to TAE buffer (40
mM Tris-acetate and 1 mM EDTA) at a concentration of 1% (w/v) and was dissolved
by boiling in a microwave oven. Agarose solution was allowed to cool to about 60°C
and ethidium bromide (10 mg/ml stock) was added to it to give a final concentration of
0.2 µg/ml. The gel was poured into the casting tray with a well-forming comb. The gel
was allowed to solidify for about 30 min. The solidified gel was then placed in an
electrophoresis tank that contained enough TAE buffer to submerge the gel. Along with
the samples, 1 kb DNA ladder was loaded on to the gel so as to analyse the approximate
size of the DNA fragments. The samples were run at 100 V for 45 min. The DNA
bands were then visualised on a UV trans-illuminator and the photograph were captured
to document the results.
2.2.6 DNA purification from agarose gel
In order to purify the PCR products and restriction enzyme digested DNA from
agarose gel, QIAquick gel extraction kit (from Qiagen, UK) was used. QIAquick
column has a silica membrane to which DNA with size ranging from 70 bp to 10 kb can
bind in high salt buffer. The column is then washed to remove primers, nucleotides,
enzymes, mineral oil, salts, agarose and other impurities from DNA samples. After
removing the impurities, the DNA bound on silica membrane is eluted with low-salt
buffer or water.
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PCR products or restriction enzyme digested DNA samples were separated on
1% agarose gel as described above. After analyzing the samples on a UV-trans-
illuminator, the gel slice containing the DNA band of interest was excised with a clean
scalpel. The DNA extraction from agarose gel slice was then performed according to
manufacturer’s recommendations. The gel slice was weighed in a microfuge tube, three
volumes of QG buffer were added and the tube was incubated at 50°C with intermittent
mixing until the gel slice was dissolved. One gel volume of 100% isopropanaol was
then added to the tube and mixed. The sample in the tube was added to the column,
centrifuged at 13,000 rpm for 1 min and the flow-though was discarded. The column
was washed once with 0.5 ml of buffer QC followed by 0.75 ml of buffer PE after
centrifugation at 13,000 rpm for 1 min. After the washing steps, QIAquick column was
centrifuged for one more minute at 13,000 rpm to remove residual ethanol from
previous wash with buffer PE. DNA was eluted from the column by loading 50 µl TE
buffer (10 mM Tris-HCL, 1 mM EDTA, pH 8.0) and by centrifuging the column at
13,000 rpm for 1 min. The eluted DNA was stored at
–20°C until used for further manipulations.
2.2.7 Ligation of DNA and construction of
recombinant DNA molecules
Recombinant DNA is DNA from two or more sources incorporated together to
make a single recombinant molecule. The gene of interest is incorporated into plasmid
that is used as a vector. In order to make the recombinant DNA molecule, both the gene
of interest and plasmid DNA are treated with restriction enzymes followed by ligation
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using T4 DNA ligase. T4 DNA ligase catalyzes the joining of two DNA molecules at
the 5’-phosphate and the 3’- hydroxyl groups of adjacent nucleotides. The molar ratio
of vector DNA to insert DNA is very critical when performing a ligation reaction. The
insert concentration is usually adjusted to a two to four fold molar excess over plasmid
DNA.
The ligation reaction was performed in a total volume of 20 µl in a microfuge
tube. The reaction mixture contained 1 µl of plasmid DNA, 4 µl of insert DNA, 2 µl of
10X T4 DNA ligase reaction buffer (500 mM Tris-HCL, 100 mM MgCl2, 10 mM ATP,
100 mM dithiotheitol, pH 7.5 at 25°C) and the final volume was adjusted to 20 µl with
molecular biology grade water. The reaction mixture was incubated overnight at 4°C
followed by transformation of competent cells.
2.2.8 Preparation of competent E.coli DH5α cells 
Competent cells are bacterial cells that are chemically treated to allow
incorporation of foreign DNA (Hanahan 1983). DH5α is a popular strain of E. coli for
cloning experiments and has the following chomosomal genotype,
F-, φ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, endA1, hdR17(rk-, mk+), phoA,
supE44, λ-, thi-1, gyrA96, relA1
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The endA1 mutation in the strain causes inactivation of the intracellular
endonuclease which is responsible for plasmid DNA degradation in most miniprep
methods. The recA mutation eliminates the possibilities of homologous recombination.
Moreover, as this strain does not carry laclq, it allows selection of recombinant DNA
with X-gal when subcloning a recombinant plasmid.
DH5α cells were streaked out from a glycerol stock on to LB agar plates. The 
plates were incubated overnight at 37°C. Then a single colony was picked up and
inoculated in 5 ml of LB broth. The culture was grown overnight in a 37°C shaking
incubator set at 220 rpm. The overnight culture was diluted 1:100 in LB broth which
was supplemented with 1 mM glucose. The culture was grown in 37°C shaking
incubator to an OD600 of 0.5 -0.6. The cells were spun at 3,500 rpm for 20 min at 4°C.
The cell pellet was gently resuspended in 20 ml of ice-cold 100 mM MgCl2 and
incubated on ice for 20 min. The cells were spun at 3,500 rpm for 20 min at 4°C. The
cell pellet was gently resuspended in 20 ml of ice-cold 100 mM CaCl2 and incubated on
ice for 20 min. The cells were spun down again and gently resuspended in 6 ml of
sterile, ice-cold 100 mM CaCl2 and 13.3% glycerol. The cells were quickly dispensed in
100 µl aliquots and stored at –80°C.
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2.2.9 Transformation of competent cells
After ligation of an insert and vector DNA, the next step is to introduce the
resulting recombinant DNA into competent cells. The process of introducing foreign
DNA into bacterial cells is called transformation.
A 50 µl aliquot of E. coli DH5α competent cells was thawed on ice and 7.5 µl of 
ligation reaction mixture was added directly to the thawed competent cells. The cells
were incubated on ice for 30 min followed by heat-shock at 42°C for 45 sec. After the
short heat-shock, the cells were placed back on ice immediately for 2 min and 900 µl of
pre-warmed LB medium was added to the cells. The cells were incubated in 37°C
shaking incubator set at 220 rpm for 1 h. After the incubation 50 to 100 µl of the cells
were plated on LB agar plates containing 100 µg/ml ampicillin. The plates were then
incubated overnight at 37°C. As the vector DNA contained β-lactamase, the ampicillin-
resistant gene, only the transformed cells could survive and grow on ampicillin
containing LB agar plates. The recombinant DNA was isolated from several
transformants and screened by means of restriction digestion analysis for identification
of transformants bearing the correct size DNA fragments.
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2.2.10 Isolation and identification of recombinant
plasmid DNA
Transformation is followed by identification of correct constructs using
restriction digestion analysis; however before restriction digestion analysis DNA is
isolated from transformants.
Recombinant plasmid DNA was purified using miniprep DNA preparation as
follows:
Six colonies of transformants from the LB agar plates were picked with a disposable
loop and inoculated into 2 ml of LB broth containing 100 µg/ml ampicillin. The
cultures were grown overnight in a 37°C shaking incubator set at 220 rpm. 1.5 ml of
the overnight culture from each transformant was transferred to a microfuge tube and
centrifuged at 8000 rpm for 3 min. The pelleted cells were resuspended in 150 µl buffer
P1 (50 mM glucose, 25 mM Tris-HCl pH 8.0, 10 mM EDTA, 100 µg/ml RNAse A) by
pipetting up and down. After incubating for 5 min at room temperature, 150 µl buffer
P2 (200 mM NaOH, 1% SDS) was added, mixed by inverting the tube 4-6 times and
again incubated at room temperature for 5 min. 150 µl of buffer P3 (3M potassium
acetate, pH 5.5) was then added and mixed by inverting the tube 4-6 times followed by
incubation on ice for 5 min. The tube was centrifuged at 13,000 rpm for 25 min. The
supernatant was transferred to a fresh microfuge tube and 0.7 volume of isopropanol
was added to the supernatant. The tube was then centrifuged at 13,000 rpm for 4 min.
The supernatant was carefully decanted and 500 µl of 70% ethanol was added to the
tube to wash the DNA pellet. The tube was inverted 4-6 times followed by
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centrifugation at 13,000 rpm for 15 min. Ethanol was poured off, the DNA pellet was
air-dried and the DNA was reconstituted in TE buffer (10 mM Tris-HCl, 1 mM EDTA,
pH 8.0). The purified DNA was then used for restriction digestion analysis for
identification of correct recombinants. The restriction digestion analysis was performed
using different sets of restriction enzymes as described before (see Section 2.2.4).
2.2.11 Purification of Plasmid DNA using QIAGEN
mini prep column
After identifying the correct recombinant plasmids, one of the recombinant
plasmids was purified using a mini prep column. The QIAprep spin miniprep kit,
commercially available from QIAGEN was used which is based on alkaline lysis of
bacterial cells followed by adsorption of DNA onto a silica column in the presence of
high salt. The column is then washed with a buffer to remove impurities followed by
elution of DNA in elution buffer or molecular biology grade water.
The culture from a correct transformant, grown in the previous step, was used as
pre-culture to inoculate 10 ml of LB broth containing 100 µg/ml ampicillin. The
cultures were grown overnight in 37°C shaking incubator set at 220 rpm. 6 ml of the
overnight culture from each transformant was transferred to six microfuge tubes, 1 ml in
each and centrifuged at 8000 rpm for 3 min. The pelleted cells in each tube were
resuspended in 150 µl buffer P1 (50 mM glucose, 25 mM Tris-HCl pH 8.0, 10 mM
EDTA, 100 µg/ml RNAse A) by pipetting up and down. After incubating for 5 min at
room temperature, to each tube 150 µl buffer P2 (200 mM NaOH, 1% SDS) was added,
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mixed by inverting the tube 4-6 times and again incubated at room temperature for 5
min. 200 µl of buffer P3 (3M potassium acetate, pH 5.5) was then added and mixed by
inverting the tubes 4-6 times followed by incubation on ice for 5 min. The tubes were
centrifuged at 13,000 rpm for 10 min. The supernatant was applied to the QIAprep mini
columns by pipetting, centrifuged at 13,000 rpm for 1 min and flow though was
discarded. The columns were then washed by adding 0.75 ml of PE buffer and then by
centrifuging at 13,000 rpm for 1 min. The flow through was discarded and the columns
were centrifuged for an additional 1 min to remove residual wash buffer. The columns
were placed in clean microfuge tubes. To elute DNA, 50 µl of buffer EB (10 mM Tris-
HCl, pH 8.5) was added to the centre of the columns, incubated for 1 min and then
centrifuged at 13,000 rpm for 1 min.
2.2.12 Automated fluorescent sequencing
High copy number plasmids containing genes of interest were purified using
QIAGEN plasmid Midi preparation kits before sequencing. The plasmids were diluted
to a concentration of 10 ng/µl and sent to PNACL DNA sequencing service, Protein and
Nucleic Acid Characterisation Laboratory, Leicester University or DNA sequencing
service of Yorkshire Bioscience Ltd. Sequencing was performed using the T7 or SP6
universal primers or primers designed on the basis of the position of the insert.
The sequencing method was based on the one developed by Frederick Sanger
(commonly called the Sanger or dideoxychain-termination method) (Sanger, 1997)
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which utilises a mixture of deoxynucleotide triphosphates (dNTPs) and
dideoxynucleotide triphosphates (ddNTPs). The ddNTPs differ from dNTPs by having
a hydrogen atom attached to the 3’ carbon instead of an –OH group and as such these
molecules terminate DNA chain elongation because they cannot form a phosphodiester
bond with the next deoxynucleotide. Four reactions consisting of the DNA template,
primers, DNA polymerase, and the four dNTPs are set up, with each reaction also
containing a different ddNTP. Polymerisation takes place until a ddNTP is
incorporated, resulting in the synthesis of DNA sequences with varying length in each
tube. These are then sorted according to size by gel electrophoresis and the sequence
read from the bottom of the gel to the top to give the 5’ to 3’ DNA sequence. The DNA
sequencing results were then compared with sequences published in current NCBI
databases.
2.2.13 Cloning of the genes in donor plasmid,
pFastBac1
The genes cloned into cloning vectors (pBluescript KS+ and pSP73) were
isolated by means of restriction digestion and further sub-cloned into the donor plasmid,
pFastBac1. A donor plasmid allows transposition of the sub-cloned gene along with the
expression cassette onto the baculovirus shuttle vector (bacmid). Insect cells are then
transfected with the recombinant bacmid DNA to generate a recombinant baculovirus.
Thus the protein can be expressed as part of the baculoviral genome. pFastBac1
contains Autographa californica multiple nuclear polyhedrosis virus (AcMNPV)
ployhedrin (PH) promoter for protein expression in insect cells. The expression cassette
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pFastBac1
4776 bps
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2000
3000
4000
NaeI 127
NgoMIV 127
SspI 438
BspHI 536
SspI 569
XmnI 772
ScaI 893
PvuI 1004
BspHI 1544
AlwNI 1850
AflIII 2264
BglII 2547
BstXI 2710
SacII 2765
EagI 2768
EcoRV 2823
BsaBI 3012
BglII 3017
Tth111I 3225
AflIII 3246
BbsI 3750
EagI 3758
XmnI 3797
SnaBI 3879
SspI 3893
BsaBI 3924
SspI 3993
BamHI 4032
4047
BssHII
EcoRI
StuI
SalI
SacI
SpeI
NotI
EagI
XbaI
PstI
XhoI
SphI
KpnI
HindIII
4137
ScaI 4150
BsaBI 4160
MunI 4252
HpaI 4263
BclI 4401
f1_ori
Amp-r
ColE1Tn7R
Gm-r
polHp
SV40_polyA
Tn7L
is flanked by the left and right arms of Tn7 and also contains a gentamicin resistance
gene and an SV40 polyadenylation signal to form a mini Tn7 cassette.
The pFastBac1 vector has a multiple cloning site for cloning a gene of interest.
The vector contains the ‘origin of replication’ for plasmid DNA replication that occurs
independent of chomosomal DNA replication of bacteria. It also contains the
ampicillin-resistance gene which helps in the identification of plasmid-bearing
transformants on ampicillin containing LB agar plates. The circular map and list of
features for the pFastBac1 are shown in Figure 2.3.
Figure 2.3. Map and abbreviated multiple cloning site region of the plasmid,
pFastBac1.
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For directional cloning, pFastBac1 and insert DNA from cloning vectors were
cut using a set of two restriction enzymes followed by agarose gel electrophoresis, DNA
extraction from the agarose gel, ligation, transformation in DH5α competent cells and 
plasmid isolation as described above.
2.2.14 Generation of recombinant bacmid by
transforming DH10Bac E.coli
An E.coli host strain, DH10Bac, contains a baculovirus shuttle vector (bacmid)
and a helper plasmid, and allows generation of a recombinant bacmid following
transposition of the pFastBac expression construct.
E. coli DH10Bac competent cells were prepared exactly as described before for
the preparation of competent cells from E. coli strain, DH5α.  
The transformation was performed according to manufacturer’s
recommendations. A vial containing 100 µl of the DH10Bac competent cells was
thawed on ice for 10 min and distributed in 25 µl aliquots in sterile microfuge tubes
which had been kept on ice. For each transformation, 1 ng of pFastBac1 construct in 5
µl of sterile water was added to the 25 µl aliquot of competent cells and mixed gently.
Cells were incubated on ice for 30 min followed by heat-shock at 42°C for 45 secs. The
tubes were immediately transferred on ice for 2 min and 900 µl of LB broth, at room
temperature, was added. The tubes were incubated at 37°C shaking at 225 rpm for 4 h.
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Then the cells were diluted 10-fold (10-1, 10-2, 10-3) with LB broth and 100 µl from each
dilution was plated on LB agar plates containing 50µg/ml kanamycin, 7 µg/ml
gentamicin, 10 µg/ml tetracycline, 100 µg/ml Bluo-gal and 40 µg/ml IPTG. The plates
were incubated at 37°C for 48 h.
Transposition of the mini-Tn7 into the mini-attTn7 attachment site on the
bacmid disrupts the expression of the LacZα peptide.  Therefore, colonies containing 
the recombinant bacmid are white in a background of blue colonies that harbour the
unaltered bacmid.
After 48 h of incubation, six white colonies were picked and re-streaked on fresh
LB agar plates containing 50µg/ml kanamycin, 7 µg/ml gentamicin, 10 µg/ml
tetracycline, 100 µg/ml Bluo-gal and 40 µg/ml IPTG. The plates were incubated
overnight at 37°C. After confirming a white phenotype of re-streaked colonies, a loop-
full of culture was inoculated into 2 ml of LB broth containing 50µg/ml kanamycin, 7
µg/ml gentamicin, 10 µg/ml tetracycline and grown overnight at 37°C with shaking at
225 rpm. The bacmid was then isolated as described below.
2.2.15 Isolation of recombinant bacmid DNA
Six colonies of transformants from the LB agar plates were picked with a
disposable loop and inoculated into 2 ml of LB broth containing 50µg/ml kanamycin, 7
µg/ml gentamicin and 10 µg/ml tetracycline. The cultures were grown overnight in
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37°C shaking incubator set at 220 rpm. 1.5 ml of the overnight culture from each
transformant was transferred to a microfuge tube and centrifuged at 8,000 rpm for 3
min. The pelleted cells were resuspended in 150 µl buffer P1 (50 mM glucose, 25 mM
Tris-HCl pH 8.0, 10 mM EDTA, 100 µg/ml RNAse A) by pipetting up and down. After
incubating for 5 min at room temperature, 150 µl buffer P2 (200 mM NaOH, 1% SDS)
was added, mixed by inverting the tube 4-6 times and again incubated at room
temperature for 5 min. 150 µl of buffer P3 (3M potassium acetate, pH 5.5) was then
added and mixed by inverting the tube 4-6 times followed by incubation on ice for 5
min. The tube was centrifuged at 13,000 rpm for 25 min. The supernatant was
transferred to a fresh microfuge tube and 0.7 volume of isopropanol was added to the
supernatant. The tube was then centrifuged at 13,000 rpm for 4 min. The supernatant
was carefully decanted and 500 µl of 70% ethanol was added to the tube to wash the
DNA pellet. The tube was inverted 4-6 times followed by centrifugation at 13,000 rpm
for 15 min. Ethanol was poured off, the DNA pellet was air-dried and the DNA was
reconstituted in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). The purified DNA
was then used for confirming the transposition of the gene of interest on the bacmid
DNA.
2.2.16 PCR analysis of recombinant bacmid DNA
Recombinant bacmid DNA is over 135 kb in size. Restriction analysis of this
large DNA is difficult and so the transposition of the gene of interest on the bacmid
DNA was verified by PCR analysis. The PCR was performed on all six bacmids
(isolated in the previous step) by using the pUC/M13 forward primer (5’-
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CCCAGTCACGACGTTGTAAAACG-3’) and the reverse primer (5’-
AGCGGATAACAATTTCACACAGG-3’) or a combination of either M13 forward or
reverse primer together with a gene specific primer. The PCR was set up as follows:
A 50 µl reaction mixture contained 1X Taq DNA polymerase Buffer (75 mM
Tris-HCL, 20 mM (NH4)2 SO4, 1.5 mM MgCl2, 0.1% Triton X-100, pH8.8 at 25°C), 0.8
mM dNTP mix, 20 ng M13 forward primer, 20 ng M13 reverse primer, 20 ng bacmid
DNA and 2.5 units of Taq DNA polymerase (purchased from Cancer Research, UK).
The final reaction volume was adjusted to 50 µl using molecular biology grade water.
A negative control was set up using the same mixture as above except template bacmid
DNA was replaced by water. The reaction mixture in PCR tubes was overlaid with 30
µl of mineral oil to prevent the reaction from evaporation. The PCR was performed in
Biometra T3 Thermocycler. The reaction was started with the initial denaturation at
95ºC for 3 min, followed by a cycle of 95ºC denaturation for 45 sec, annealing at 50°C
for 90 sec, chain extension at 72ºC for 3 min which was repeated 29 times. A final
chain extension was performed at 72ºC for 10 min. PCR products were then analyzed
by agarose gel electrophoresis along with standard DNA markers.
pUC/M13 forward and reverse primers hybridize to sites flanking the mini-
attTn7 site within the lacZα-complementation region. If transposition took place and
pUC/M13 forward and reverse primers were used, PCR product of ‘2300 bp + insert
size’ would be observed on the agarose gel. Alternatively, a smaller fragment would be
observed using either a pUC/M13 forward or a reverse primer together with a gene
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specific primer. After the presence of gene of interest on bacmid DNA was verified,
recombinant baculoviruses were generated in Sf9 insect cells as described below
(Section number: 2.3.7).
2.3 Cell Biology Methods
2.3.1 Insect cell culture
The use of insect cell culture for heterologous protein expression is gaining
popularity for basic research as well as for commercial applications. Insect cell
expression systems produce relatively large quantities of post-translationally modified
heterologous proteins.
All cell culture techniques were performed under aseptic conditions using class-
II biological safety cabinet. Two insect cells lines were used viz, Sf9 and Tni and they
were routinely maintained in Grace’s insect cell culture medium supplemented with
10% FBS and Express Five serum free medium respectively. The Grace’s medium was
supplemented with 10% FBS and Express five medium was supplemented with 10 mM
L-glutamine. To both the media, penicillin-streptomycin-neomycin antibiotic mixture
was added at the final concentration of 50 µg/ml penicillin, 50 µg/ml streptomycin and
100 µg/ml neomycin. A new culture was started from a cryopreserved vial after every
one and a half months and the cells were always maintained in mid-log phase.
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2.3.2 Sf9 Insect Cell Culture
Sf9 cells are derived from the pupal ovarian tissue of the fall army worm,
Spodoptera frugiperda. Sf9 cells grow in monolayer as well as in suspension culture.
The small regular size of Sf9 makes it an ideal cell line for plaque formation (i.e. the
plaques formed after infection with the baculovirus of an insect cell line). The cell line
is suitable for generating high titre baculovirus stocks. Sf9 cells were cultured in
Grace’s insect cell culture medium supplemented with L-glutamine, yeastolate and
lactalbumin and 10% FBS. The cells were maintained in spinner flasks with continuous
stirring at 90 RPM in a 270C humidified incubator. Suspension cultures were passaged
before they reached a density of 3×106 cells/ml and diluted back to 0.5 to 1.0×106
cells/ml. Cell count and viability were determined using the trypan blue exclusion
method.
2.3.3 T.ni insect cell culture
The T.ni insect cell line, derived from ovarian cells of the cabbage looper,
Trichoplusia ni, is capable of expressing significantly higher levels of recombinant
proteins compared to other insect cell lines like Sf9 and Sf21. This cell line can grow in
a monolayer as well as in suspension culture. T.ni cells also offer faster doubling time.
The cells were cultured in Express Five SFM serum free medium (Invitrogen, Catalogue
number- 10486), supplemented with 10 mM L-Glutamine (Invitrogen, Catalogue
Number-10486) and 1X Antibiotic: Penicillin-Streptomycin-Neomycin (Invitrogen,
Catalogue Number-15640-055) prior to use. Express Five SFM contains surfactant,
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Pluronic F-68 to minimize damage to cells caused by the shearing force of stirring. The
cells were maintained in spinner flasks with continuous stirring at 95 rpm in a
humidified 27ºC incubator. Suspension cultures were passaged before they reached a
density of 3×106 cells/ml and diluted back to 0.5 to 1.0×106 cells/ml. Cell count and
viability was determined using trypan blue exclusion method.
2.3.4 Setting up a Monolayer culture
A cryovial of insect cells, previously cryo-preserved in liquid nitrogen, was
removed and thawed rapidly in 37°C water-bath. The cells were transferred to 25 cm2
tissue culture grade flask (T25) already containing room-temperature insect cell
medium. Viability of the cells was checked using the trypan blue exclusion method
under phase contrast microscope as described below (section: 2.3.5). The cells were
allowed to attach to the substratum of the flask for 30 min at 27°C humidified incubator.
After 30 min medium was replaced with fresh insect cell medium, this step is necessary
to remove DMSO used during cryopreservation of cells. The T25 flask was returned to
the incubator until the cells reached about 80% confluency. For subculturing, the cells
were detached from T25 by repetitively streaming the medium over the monolayer. The
cells were then transferred to 75 cm2 tissue culture grade flask (T75) to which 20 ml of
fresh room-temperature Grace’s medium was added. The flask was returned to 27°C
humidified incubator, cells were routinely monitored under phase contrast microscope
for viability, morphology and confluency. When the flask was 80% confluent, the cells
were again sub-cultured in a 1:3 ratio by detaching them from the T75 flask and equally
distributing the detached cells into three fresh T75 flasks containing 20 ml of fresh
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Grace’s medium. The flasks were returned to the incubator until the cells reached 80%
confluency. The cells were then detached from all the flasks and suspension culture
was initiated by seeding these cells in 500 ml spinner flask.
2.3.5 Cell counting and trypan blue exclusion
viability assay using haemocytometer
The haemocytometer (Figure 2.4) is a specially designed glass slide with a 0.1
mm3 chamber and a counting grid. It is commonly used in cell culture to determine cell
density of cells in suspension. Estimation of the number of dead cells in a cell
suspension is required before they can be used for cell-based assays or protein
expression studies. Trypan blue dye exclusion viability test in conjunction with
haemocytometer estimates are commonly used for this purpose. Viable cells exclude
trypan blue dye whereas non-viable cells stain due to damage in their cell membrane.
The haemocytometer and the glass cover-slip were thoroughly cleaned with 70%
ethanol and the cover-slip was placed over the grooves and counting area. A 50 µl of
cell suspension was mixed with trypan blue solution (0.4% in PBS) in 1:1 ratio. Using a
pipette, the cell suspension was loaded to the edge of the haemocytometer and the
suspension was allowed to spread evenly by capillary action without under-filling or
overfilling the area within the chamber. The haemocytometer was placed under the
microscope and the 10X objective focus was adjusted on grid lines in the chamber.
Unstained (viable) and blue (dead) cells were counted in all four 16-square grid areas
and the average was calculated from the cells counted in four 16-square areas.
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Figure 2.4. Appearance of haemocytometer grid visualised under the microscope.
Each 16-square area is 1 mm2 and the depth of the chamber after placing the
cover-slip is 0.1 mm, therefore the volume taken up by this area is 0.1 mm x 1.0 mm2=
0.1 mm3, that is 10-4 ml. Therefore,
Cell density (cells/ml) = number of viable cells counted∕ 10-4 ml
or
Cell density (cells∕ ml) = number of viable cells counted X 104∕ ml 
The concentration of the total number of viable cells was determined by viable
cell concentration multiplied by the dilution factor, 2. (1:1 of cell suspension and trypan
blue). The percentage cell viability was calculated using the following equation:
% cell viability = [total viable cells (unstained) ∕ total cells (stained + unstained)] X 100 
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2.3.6 Initiating suspension culture
The cells were detached and removed from the T75 flasks. They were seeded in
a sterile 250 ml spinner flask at a density of 1X 106 cells/ ml. The spinner flask was
placed on a stirrer set with constant stirring of 90 rpm in a 27ºC humidified incubator.
When the cells reached a density of 3X 106 cells/ ml, cells were diluted to a density of
1X 106 cells/ml by adding fresh medium. Once in every two weeks, the cells were
centrifuged at 1,000 rpm for 10 min and resuspended in complete fresh medium to
minimize cell debris and metabolic by-product accumulation.
2.3.7 Generation of recombinant baculovirus
After isolation (see Section 2.2.15) and confirmation (see Section 2.2.16) of the
recombinant bacmid DNA, Sf9 cells were transfected to generate recombinant
baculovirus. All baculoviruses were generated in Sf9 cells.
For generation of baculoviruses, Sf9 cells were transfected with recombinant
bacmids in 6-well tissue culture grade plates. The Sf9 cells in log phase were adjusted
to a cell density of 4.5X 105 cells/ml in Grace’s medium supplemented with 10% FBS
and 2 ml of this cell suspension was seeded into each well of the 6-well plates. The
cells were allowed to attach to the plates over a period of 2 h. Whilst cells were
attaching, 1 µg of purified bacmid DNA was diluted in 200 µl un-supplemented Grace’s
medium already containing 6 µl of the transfection reagent, Cellfectin. Bacmid DNA –
Cellfectin complexes were allowed to form over 45 min at room temperature. During
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this incubation, cells were washed once in the plate with un-supplemented Grace’s
medium. The bacmid DNA-Cellfectin complexes were diluted to 1 ml with un-
supplemented Grace’s medium and this mixture was added to the cell monolayer in the
6-well plate. Cells were incubated in a 27ºC humidified incubator for 5 h and DNA-
Cellfectin complexes were then placed in 2 ml of complete Grace’s medium
supplemented with 10% FBS. Cells were incubated in a 27ºC incubator for 72 h. When
signs of viral infection were observed under the microscope, primary baculovirus stocks
were isolated by separating the supernatant containing baculoviruses from cell pellet by
centrifugation at 800X g for 10 min. The clarified baculovirus stocks were transferred
into fresh sterile tubes and stored at 4°C, protected from light.
2.3.8 Amplification of baculoviruses
The baculoviruses were amplified in Sf9 cells by infecting the cells with primary
baculovirus stocks. Sf9 cells were adjusted to a cell density of 1X 106 cells/ml in
Grace’s medium supplemented with 10% FBS and 2 ml of this cell suspension was
seeded in each well of the 6-well plate. The cells were allowed to attach for 1 h and
then 40 µl of the primary baculovirus stock was added per well. The infected cells were
incubated at 27ºC in a humidified incubator for 96 h. After 96 h, signs of late infection
like detachment of cells, increased cell diameter and granular appearance of cells were
observed and the amplified stock of baculoviruses was isolated as a suspension by
centrifugation at 800X g for 10 min. The supernatant was transferred to a fresh sterile
tube covered with aluminium foil to avoid exposure to light. The amplified stock was
stored at +4ºC, protected from light. For long term storage an aliquot was stored at –
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80ºC which could be used for re-amplification at a later date, if required.
2.3.9 Viral plaque assay
The viral plaque assay was performed to plaque purify the baculoviruses or to
titrate baculovirus stocks. Sf9 cells, grown in Grace’s medium supplemented with 10%
FBS, were seeded in 6-well tissue culture grade plates at a density of 1×106 cells/well in
2 ml volume and were allowed to attach for 1 h. Baculovirus stocks were serially
diluted in Grace’s medium to achieve 10-1 to 10-8 dilutions. The medium was removed
from the plates and replaced with 1 ml of baculovirus dilutions from 10-3 to 10-8
duplicate. Cells were incubated with virus for 1 h; after 1 h, the virus was removed
from the plates and replaced with 2 ml plaquing medium. To prepare plaquing medium,
4% low melting point agarose was melted and kept at 40ºC. The melted agarose was
diluted in 2X Grace’s medium and sterile distilled water to achieve a final agarose
concentrations of 1% and 1X Grace’s medium. Plates were incubated at 27ºC for 7-10
days until plaques were visible with the naked eye or under low-power magnification of
the microscope. The plaques were stained for 1 h with 0.5 ml of 1 mg/ml neutral red
prepared in cell culture grade sterile distilled water. The excess stain was gently
removed with pipette. Plaques were counted and viral titre was determined using the
following formula:
Titer (pfu/ml) = number of plaques × dilution factor X (1 ∕ ml of inoculum per well)  
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2.3.10 Plaque purification of baculoviruses
The viral plaque assay was performed as described above. The plaques were
picked with a pipette tip before staining with neutral red and inoculated in 500 µl of
Grace’s medium in a microfuge tube. The tube was vortexed to homogenize the
agarose. The plaque-purified baculovirus suspension was then used for amplification of
the baculovirus as described before (see Section 2.3.8).
2.3.11 Optimization of protein expression
conditions
Optimal expression conditions are dependent on many factors such as nature of
the gene of interest, multiplicity of infection (MOI), the number of hours of infection
(i.e. the time course) and the cell line. Therefore, determining the optimal expression
conditions of each of these factors is vital for the expression of an active recombinant
protein of interest.
2.3.11.1 Multiplicity of infection (MOI) of
baculoviruses and time course of
recombinant protein expression
MOI is defined as ratio of infectious virus particles to cells. Inoculum required
to achieve a particular MOI is calculated based on titre of a viral stock and the number
of cells as follows:
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Inoculum required (ml) = [MOI (pfu/cell) X number of cells]/ [titre of viral stock
(pfu/ml)]
For determining optimal MOI, Sf9 cells were seeded in T75 flask at a density of 12 X
106 cells in 20 ml of Grace’s medium supplemented with 10% FBS and were allowed to
attach for 1 h. The cells were then infected with baculoviruses using a range of MOI
from 0.03 to 3 0 (0.03, 0.1, 0.3, 1.0 and 3.0). The cells were harvested at 48, 63 and 72
h post-infection by centrifugation at 800X g for 15 min at 4°C. The microsomes were
isolated (see Section 2.4.1), assayed for protein concentration (see Section 2.4.2) and
CYP concentrations were determined spectrophotometrically (see Section 2.4.3).
Afterwards, specific activities of the expressed reductase were measured (see Section
2.4.7) followed by determination of individual CYP activities (see Section 2.4.9). A
particular MOI and time of harvest that resulted in both optimal protein production and
enzyme activity were selected for further protein expression.
2.3.11.2 Choice of cell line for expression of
recombinant proteins from baculoviruses
To determine which of the cell lines, Sf9 or T.ni., was optimal for expression
further experiments were performed. Based on the results obtained from the above MOI
and time-course optimisation experiment, both Sf9 and Tni cells were infected with a
particular MOI and harvested at a single time point. Microsomes were prepared, were
assayed for protein concentration (Section 2.4.2), CYP concentrations were
spectrophotometrically analysed (Section 2.4.3), CYP assays were performed (Section
2.4.10) and reductase activities were determined (Section 2.4.7). The T.ni cell line was
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chosen for large scale protein production in spinner flasks and was based on parallel
studies performed with Sf9 and T.ni.
2.3.12 Recombinant protein expression in T75
flasks
For protein expression, the cells were seeded in T75 flasks at a density of 12 X
106 cells/T75 flask in 20 ml of medium and allowed to attach to the plates for 1 h. The
cells were infected with virus at the indicated multiplicity of infection and incubated in
a humidified 27ºC incubator.  24 h post-infection, haemin (2 µg/ml) and δ-amino 
levulinic acid (100µM) were added to the cells to compensate for low endogenous
levels of haeme in insect cells. Cells were harvested at the indicated time point by
scraping with a cell rake and were washed twice with ice cold PBS. The microsomes
were then prepared as described below.
2.3.13 Recombinant protein expression in spinner
flasks
For protein expression in spinner flasks, the cells were seeded at a density of 1.5
× 106 cells/ml in a volume of medium that was half that of the spinner flask capacity.
The cells were infected with recombinant baculovirus at indicated multiplicity of
infection (MOI) and incubated in a humidified 27ºC incubator. The cells were stirred
continuously on a stirrer set at 95 rpm.  24 h post-infection, haemin (2 µg/ml) and δ-
amino levulinic acid (100µM) were added to the cells to compensate for low
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endogenous levels of haeme in insect cells. Cells were harvested at indicated time
points by pouring the cells into centrifuge bottles and centrifuging them at 800X g for
25 min. The cell pellets were washed twice with ice cold PBS. The microsomes were
then prepared as described below.
2.4 Biochemical Methods
2.4.1 Preparation of Microsomes
The harvested cells were resuspended in five volumes of ice cold 100 mM
potassium phosphate buffer, pH 7.4, 20% (v/v) glycerol, 1mM DTT, 1mM EDTA, and
1mM AEBSF (a protease inhibitor). Cells were lysed by sonication: amplitude 30%,
pulse-1 with 6 bursts of 6 sec duration. Cellular debris was removed by centrifugation
at 9,000 rpm at 4ºC for 30 min. and microsomes were pelleted by centrifugation at
45,000 rpm for 70 min at 4ºC in a Beckman Coulter Optima L100 XP ultracentrifuge
using the Ti70.1 rotor. Microsome pellets were resuspended in 100 mM potassium
phosphate buffer, pH 7.4, 20% (v/v) glycerol, 1mM EDTA and homogenized using a
Glass-Teflon homogenizer to make a uniform microsome suspension. The microsomes
were aliquoted and frozen at –80ºC until further use. All steps of the procedure were
carried out at 4ºC.
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2.4.2 Protein estimation by Bradford assay
Protein concentrations in cell lysates were determined via a modified Bradford
analysis (Bradford 1976) using a kit available from Bio-Rad. The Bradford assay is a
method for determining protein concentrations in solutions and involves the binding of
the dye, Coomassie brilliant blue G-250, to proteins. The protein-dye complex is
spectrophotometrically detected at 595 nm.
The standard curve was prepared using a range of concentrations of bovine
serum albumin (40, 20, 15, 10, 7.5, 5, 2.5 and 1 µg/ml in PBS). Test samples were
diluted 40X in PBS. The total reaction volume was 200 µl which contained 1X
Bradford reagent, indicated concentration of BSA or 40X diluted test sample and PBS.
The assay for standard, as well as sample, was performed in triplicate in 96-well flat
bottomed microtitre plates. Wells containing only PBS were used as blanks.
Absorbance was measured at 595 nm using a spectrophotometer (Bio-Tek, Synergy
HT). Standard curve of BSA was plotted and protein concentrations in test samples
were measured using the equation from the standard curve. A representative standard
curve is shown in Figure 2.5.
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Figure 2.5. A representative protein standard curve for calculations of protein
concentrations in cell lysates.
2.4.3 Reduced CO difference spectra for calculation of
cytochome P450 enzyme concentrations in
microsomes
The carbon monoxide (CO) binding assay (Omura and Sato 1964) is a method
for quantifying the amounts of CYP holoproteins (i.e. active proteins) in microsome
preparations. The CO-binding assay gave the enzyme family its name. The reduced
haeme moiety of CYP binds to carbon monoxide and exhibits maximum absorbance at
450 nm. The method detects only the active haeme-bound CYP holoprotein.
Into two cuvettes (one ml capacity), 800 μl of 100 mM phosphate buffer, pH7.4, 
containing 20% glycerol were added. The microsomal fractions were diluted to a
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protein concentration of about 1 mg/ml and were added to one of these cuvettes
(referred to as the sample cuvette). A few grains (3-5 mg) of sodium dithionite powder
from the tip of a small spatula were added to both the sample and the reference cuvette
and the contents were gently mixed by inverting the cuvettes. The sample cuvette and
the reference cuvette were placed in the respective sample and reference holders of a
dual beam spectrophotometer (Shimadzu UV-2401PC). A baseline was recorded for
the sample verses the reference cuvette. CO was then slowly bubbled through the
sample cuvette for approximately 30 sec in a chemical extraction hood. The difference
spectrum was recorded between 400 and 500 nm and the CYP holoprotein content was
quantified by measuring the change in absorption between wavelengths 450 nm and 490
nm using the extinction coefficient of 91 mM-1cm-1. The CYP content was measured
using the following formula:
CYP content (nmole/ml) = [(A450nm – A490 nm) X dilution factor X 1000]/ 91
Specific CYP content (nmole/ mg protein) = CYP content/ total protein in the reaction
2.4.4 Sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE)
SDS-PAGE electrophoresis separates or resolves proteins according to their
electrophoretic mobility which is a function of size and charge. Proteins are exposed to
SDS before and during electrophoresis which binds and denatures proteins giving them
uniform negative charge along the length of the polypeptide. The similar charge to
mass ratio on all polypeptide chains results in protein mass being the sole determinant
of the migration rate of proteins in SDS-PAGE. A tracking dye like bromophenol blue
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is added to the protein solution to allow tracking of the protein through the gel
(Schägger and von Jagow 1987).
The mini-Protean 3 system from Bio-Rad which includes a casting stand, glass
plates with permanently bonded gel spacers and the mini tank was used for protein gel
electrophoresis. The polyacrylamide gels were prepared by mixing 10% of
acrylamide/bis-acrylamide solution, 375 mM Tris-HCl pH 8.8, 0.1% SDS, 0.066%
N,N,N’,N’-Tetramethylethylenediamine (TEMED) and 0.05% ammonium persulfate
(APS) in distilled water. The mixture was poured in the assembled gel cassette, up to
the level of about 1 cm below the comb teeth and overlayed with 0.5 ml of water-
saturated butanol. The resolving gel was allowed to polymerise for 1 h followed by
washing of the gel surface with distilled water to remove butanol. The stacking gel was
prepared by mixing 4% acrylamide/bis-acrylamide (from a 30% stock solution), 125
mM Tris-HCl pH 6.8, 0.1% SDS, 0.066% TEMED and 0.05% ammonium persulfate in
distilled water. The multi-teeth comb was inserted in the gel cassette and the stacking
gel mixture was slowly poured up to the top of the cassette taking care not to introduce
the bubbles. The stacking gel was allowed to polymerise for 45 min. The comb was
gently removed and the wells were rinsed with the running buffer (25 mM Tris-HCl pH
8.6, 192 mM glycine and 0.1 SDS). The gel cassettes were clamped on the clamping
frame of the electrode assembly to form the inner chamber. The inner chamber was
placed in the mini tank and filled with about 125 ml of running buffer. The lower
chamber of the mini tank was filled with about 200 ml of running buffer before use.
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The protein samples were prepared by mixing with the protein loading buffer
(50 mM Tris-HCl pH 6.8, 12.5 mM EDTA, 2% SDS, 10% gylcerol, 1% β-
mercaptoethanol and 0.02% Bromophenol blue) and boiling for 5 min. The samples
were allowed to cool on ice and then loaded into the wells with a pipette. A 7.5 µl of
pre-stained protein molecular weight marker was also loaded into the first well. The lid
was placed on the mini tank, the correct orientation was made by matching the black
and red colour on the lid and electrode assembly. The electrical leads were inserted into
a power supply with the proper polarity and power was applied at constant 125 volts for
1 h. The gels from the gel cassettes were removed and washed with distilled water
followed by visualization of protein bands with Coomassie staining or Western blotting
as described below (see Sections 2.4.5 and 2.4.6).
2.4.5 Coomassie staining of Sodium dodecyl sulphate
polyacrylamide gels
Coomassie blue staining is based on the binding of the dye Comassie brilliant
blue to virtually all proteins. After separating the proteins on SDS-PAGE, the gel is
stained by soaking in the dye solution followed by de-staining step (see below) in which
the unbound dye diffuses out of the gel.
For Coomassie staining, microsomal samples (25 μg/lane) were separated on 
10% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) at a constant 125 volts
for about 1h. The gel was fixed in fixing solution (50% methanol and 10% glacial
acetic acid in water) for 2 h with gentle agitation. The gel was stained in staining
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solution (0.1% Coomassie Brilliant Blue G-250, 50% methanol and 10% glacial acetic
acid) for 30 min with gentle agitation. De-staining of the gel was performed in de-
staining solution (40% methanol and 10% glacial acetic acid in water) until background
of the gel was fully de-stained. The image of stained protein bands on the gel was
captured on Gel Doc™ workstation (Bio-Rad).
2.4.6 Western Blotting for Immunodetection of Proteins
SDS-PAGE coupled with Western blotting is commonly used to determine the
presence and abundance of a target protein. After separating the proteins on SDS-
PAGE, they are transferred to a polyvinylidene fluoride (PVDF) or nitrocellulose
membranes by applying electric current. The electric current forces the protein
molecules to migrate out of the gel onto the membrane. After transferring the proteins
onto the membrane, a target protein can be subsequently identified through its reaction
with an antigen-specific antibody.
For Western blot analysis, the microsomal samples (1.5µg/lane) were separated
on 10% SDS-PAGE. The gel was washed twice with distilled water and was
equilibrated in cathode buffer (25 mM Tris, 40 mM 6-aminohexanoic acid and 20%
methanol). Three 3 mm Whatman papers, cut to double the size of the gel, and three cut
to the size of the gel were pre-soaked in the cathode buffer. A piece of Immobilon-P
PVDF membrane (Millipore) was cut to the size of the gel and rinsed in methanol for 1
min before equilibrating it in anode buffer II (25 mM Tris, 20% methanol, pH 10.4).
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Three more 3 mm Whatman papers, cut to the size of the gel were pre-soaked in anode
buffer II and three Whatman papers, cut to double the size of the gel were soaked in
Anode buffer I (300 mM Tris, 20% methanol, pH 10.4). The transfer sandwich was
assembled in the following order,
1. Three 3 mm Whatman papers cut to double the size of the gel and pre-soaked in
cathode buffer were placed onto cathode (–ve) plate of the semi-dry transfer
unit.
2. Three 3 mm Whatman papers, cut to the size of the gel and pre-soaked in
cathode buffer were placed on the previous layer of the Whatman papers.
3. The gel equilibrated in cathode buffer was placed on top.
4. A piece of Immobilon-P membrane, cut to the size of the gel and equilibrated in
anode buffer II was placed on the gel; all the air bubbles trapped in the layers
were removed by rolling a pipette over the membrane.
5. Three 3 mm Whatman papers, cut to the size of the gel and pre-soaked in the
Anode buffer II, were placed on the membrane.
6. Three more 3 mm Whatman papers, cut to double the size of the gel and pre-
soaked in anode buffer I, were placed on top.
7. Anode (+ve) plate of the semi-dry transfer unit was placed on top and secured in
position.
The electrical leads were inserted into a power supply with the proper polarity and
power was applied at 0.8 mA per 1 cm2 of gel for 1 h. When the transfer was complete,
the membrane was removed with a pair of forceps and rinsed in sterile distilled water.
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The unoccupied membrane binding sites on the blot were blocked by incubating
the membrane with blocking solution (5% non-fat dry milk in PBS) overnight at 4°C.
The primary antibody was diluted to the indicated concentration in freshly prepared
blocking solution (1% non-fat dry milk in PBS). The membrane was incubated in the
primary antibody solution for 1 h at room temperature with gentle agitation. The
membrane was washed three times for 5 min each with PBS containing 0.05% Tween-
20. The membrane was subsequently incubated with secondary antibody diluted at
indicated concentrations in freshly prepared blocking solution (1% non-fat dry milk in
PBS). The membrane was incubated in the HRP-conjugated secondary antibody
solution for 1 h at room temperature with gentle agitation. The membrane was washed
five times for 5 min each with PBS containing 0.05% Tween-20. Finally the blot was
washed with sterile distilled water. Equal quantities of Luminol reagent solution A and
solution B (Santa Cruz Biotechnology, Catalogue number: sc-2048) were mixed by
inversion, the water was poured off from the blot and the mixed Luminol reagent
solution was added to the membrane with protein side facing up for 2 min at room
temperature. The excess Luminol reagent was poured off and the membrane was lifted
with a pair of forceps to drain excess reagent. The membrane was tightly covered,
protein side facing up, with a single layer of plastic wrap. The chemiluminescence was
detected with the Gel Doc™ system (Bio-Rad) with multiple exposures of 15 seconds,
up to a period of 10 min.
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2.4.7 Measurement of Enzymatic Activity of NADPH
cytochome P450 Reductase (CPR)
Physiologically, CPR is an electron donor protein for CYPs. However,
quantitative measurement of the reduction of CYP by CPR is relatively difficult to
assay. Therefore, non-physiological substrates like 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) or cytochome c, which act as artificial electron
acceptors are widely used for determining CPR activity (Yim et al. 2005). The
reduction of these substrates mirrors the reduction of CYP. Both MTT and cytochome
C were used for assaying the CPR activity as described below.
2.4.7.1 Reductase assay using cytochrome c as a
substrate
Stock solutions for cytochrome c reductase assay
0.6 M Potassium Phosphate (KPO4), pH 7.4 (Kpi buffer)
19.8 ml of buffer A and 80.2 ml of buffer B was made up to 167 ml with sterile water
and adjusted to pH 7.4 (using 0.5 M HCl and 0.5 M NaOH).
Buffer A = 136.1 g KH2PO4/L (1 M) (potassium dihydrogen phosphate) from Sigma-
Aldrich Cat No P2222, MW 136.09.
Buffer B = 174.2 g K2HPO4/L (1 M) (dipotassium hydrogen phosphate) from Sigma-
Aldrich Cat No P5655, MW 174.18.
Buffer A and buffer B were autoclaved before use.
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Solution A: 10 ml stock in deionised water contained 200 mg NADP+, a final
concentration of 26.13 mM (Sigma-Aldrich Cat No N0505, MW 765.4); 200 mg D-
glucose-6-phosphate disodium salt hydrate, a final concentration of 65.77 mM (Sigma-
Aldrich Cat No F7250, MW 304.1); 1 M MgCl2, a final concentration of 65.42 mM
(Sigma-Aldrich Cat No M1028). The solution was stored in aliquots at
–20°C.
Solution B: 6.25 ml stock in 5 mM sodium citrate contained 250U glucose-6-phosphate
dehydrogenase (Sigma-Aldrich Cat No G6378) in a 6.25 ml solution of 5 mM trisbasic
sodium citrate (Sigma-Aldrich Cat No S46410). The resultant solution was stored in
aliquots at –20°C.
0.4 mM cytochrome c contained 50 mg cytochrome c (from bovine heart; Sigma-
Aldrich Cat No C3131, MW 12 327) in 10 ml of deionised water. The solution was
stored in aliquots at –20ºC.
The principle behind the reductase assay is that the oxidized ferric form of
cytochrome c has a characteristic absorption spectrum, as does the reduced (ferrous
form). The reduced ferrous form has a characteristic absorption band at 550 nm, a band
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that is absent in the oxidized form. Therefore, the enzyme activity can be conveniently
assayed by measuring the increase in absorbance at 550 nm as a function of time.
The assay was carried out in a 1 ml cuvette. 860 µl of Kpi buffer was added into
a cuvette together with 100 µg of microsomes (~20 µl), 10 µl of solution B and 100 µl
of 0.4 mM cytochrome c. The contents were mixed gently. 10 µl of solution A was
quickly added to the cuvette, and all contents were mixed by inverting a few times. The
addition of all reagents gave a reaction mixture which contained 40 micromoles of
cytochrome c, 100 μg of microsomal proteins and an NADPH generating system (1.3 
mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl2 and 0.4U/ml glucose-6-
phosphate dehydrogenase). The increase in absorbance at 550 nm was measured for
about 10 min. An extinction coefficient of 19.6 mM−1 cm−1 was used to calculate the
moles of cytochrome c reduced per minute per mg of protein (Fukushima et al. 1984).
2.4.7.2 Reductase assay using MTT as a substrate
Stock solutions for MTT reductase assay
10 mM potassium phosphate buffer, pH 7.4
It was prepared by mixing 8 ml of 1 M K2HPO4 and 2 ml of 1 M KH2PO4, the volume
being adjusted to 1 litre with deionised water.
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10 mM MTT
It was prepared by dissolving 41.4 mg of MTT (Sigma-Aldrich Cat No M2128) was
dissolved into 10 ml of 10 mM potassium phosphate buffer pH 7.4 to give 10 mM
MTT.
100 mM potassium phosphate buffer, pH 7.6
86.6 ml of 1 M K2HPO4 and 13.4 ml of 1 M KH2PO4 were mixed and the volume was
adjusted to 1 litre with deionised water.
Solution A: 131 µl of 1M magnesium chloride solution (Sigma-Aldrich Cat No
M1028) was diluted to 1 ml in deionised water to achieve final concentration of 66 mM.
To this solution, the following reagents were added and dissolved: 43.5 mg of NADP+
at a final concentration of 50 mM (Sigma-Aldrich Cat No N0505, MW 765.4), 172 mg
of D-glucose-6-phosphate disodium salt hydrate at a final concentration of 500 mM
(Sigma-Aldrich Cat No F7250, MW 304.1). The solution was stored in aliquots at
–20°C.
Solution B: 17U glucose-6-phosphate dehydrogenase (Sigma-Aldrich Cat No G6378)
was dissolved in 340 µl of 5 mM trisbasic sodium citrate (14.7 mg/ml; Sigma-Aldrich
Cat No S46410). The solution was stored in aliquots at –20°C.
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MTT, a tetrazolium salt, is reduced by various reductases to a blue formazan
product which shows maximum absorption at 610 nm. Therefore, NADPH-cytochome
P450 reductase activity can be measured by the reduction of MTT (Yim, 2005).
The assay was carried out in a 1 ml cuvette. 950 µl of 100 mM potassium
phosphate buffer, pH 7.6, was added to a cuvette together with 100 µg of microsomes,
10 µl of solution B and 10 µl of 10 mM MTT. Then 10 µl of solution A was quickly
added to the cuvette and the contents were mixed by inverting a few times. The
resulting reaction mixture contained 100 μM MTT (Sigma Cat No M5655), 100 μg 
microsomal protein in 100 mM potassium phosphate buffer, pH 7.4, and the NADPH
generating system (final concentrations of 0.5 mM NADP+, 5 mM glucose 6-phosphate,
1.3 mM MgCl2 and 0.5 unit of glucose 6-phosphate dehydrogenase/ ml). The increase
in absorbance at 610 nm was measured for about 10 min. An extinction coefficient of
11.3 mM−1 cm−1 was used to calculate the moles of MTT reduced per min per mg of
protein as follows:
ΔA610 / min/ 11.3 X 0.1 mg/ ml= µmole MTT reduced/ min/ mg protein.
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2.4.9 CYP assays
Stock solutions for the CYP assays
Solution A: 200 mg NADP+ (Sigma-Aldrich Cat No N0505, MW 765.4), 200 mg D-
glucose-6-phosphate disodium salt hydrate (Sigma-Aldrich Cat No F7250, MW 304.1),
1M MgCl2 solution (Sigma-Aldrich Cat No M1028) were used to make a 10 ml solution
in deionised water which gave final concentrations of 26.13 mM, 65.77 mM, and 65.42
mM of the three constituents. The solution was stored in aliquots at –20°C.
Solution B: 250 U glucose-6-phosphate dehydrogenase (Sigma-Aldrich Cat No G6378)
was dissolved in 6.25 ml solution of 5 mM trisbasic sodium citrate (Sigma-Aldrich Cat
No S46410) and stored in aliquots at –20°C.
Solution C: Solution C was freshly prepared just before the assay by mixing 1.5 ml of
0.5 M KPO4 pH 7.4, 1.5 ml of solution A and 0.3 ml of solution B. The final volume
was made up to 15 ml with deionised water.
0.5 M Potassium Phosphate (KPO4) buffer pH 7.4 (Kpi buffer)
19.8 ml of buffer A and 80.2 ml of buffer B (see below) were mixed and the final
volume was made up to 200 ml with deionised water and pH was adjusted to 7.4 (using
0.5 M HCl and 0.5 M NaOH).
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Buffer A = 136.1 g KH2PO4/L (1 M), autoclaved.
Buffer B = 174.2 g K2HPO4/L (1 M), autoclaved.
0.1 M Potassium Phosphate (KPO4) buffer pH 7.4
1.98 ml of buffer A and 8.02 ml of buffer B were mixed and the final volume was made
up to 100 ml with deionised water and the pH was adjusted (using 0.5 M HCl and 0.5 M
NaOH).
Buffer A = 136.1 g KH2PO4/L (1 M), autoclaved.
Buffer B = 174.2 g K2HPO4/L (1 M), autoclaved.
50 mM tribasic Sodium Citrate
147 mg of tribasic sodium citrate (Sigma-Aldrich Cat No S4641) was dissolved in
deionised water and the final volume was made up to 10 ml.
Assay procedures
The substrates for enzymes assays used in this study are CYP isozyme-specific
fluorogenic substrates which upon oxidative cleavage yield fluorescence at specific
excitation-emission wavelength. The substrates are light sensitive. Therefore, all
assays were set up in the laboratory with yellow lights switched on.
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The reactions were preformed in black 96-well plates with clear flat bottom
(Fisher Cat No FB86083). The assay plate and the solutions were pre-warmed at 37ºC
before initiation of the assay. The plate layout, reaction temperature (37°C), reaction
time (20 to 40 min), fluorescence sensitivity, the wavelength parameters and other
kinetic assay parameters (i.e. excitation-emission wavelengths) were set as is indicated
in the following chapters. Each reaction was performed in triplicate. Each 100 µl
reaction contained a specific concentration of Kpi buffer (as indicated in respective
chapters), solution C, CYP isozyme and an isozyme-specific fluorogenic substrate.
Blank values were measured in reactions where CYP isozyme was not added. The
known concentrations of metabolites were used to plot standard curves. The
fluorescence was measured in terms of relative fluorescence unit (RFU) in kinetic
reactions over a period of 20 to 40 min. Finally, the CYP activities were calculated as
product formed/ min/ pmole of CYP or product formed/min/ ml.
2.4.10 Measurement of reactive oxygen species
2.4.10.1 H2DCFDA Assay
2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) is a cell-permeable
indicator for reactive oxygen species that is non-fluorescent until the acetate groups are
removed by intracellular esterases and oxidation occurs within the cell. The reactive
oxygen species measurement (ROS) assay (Bondza-Kibangou et al. 2004) was
performed using the fluorescent dye H2DCFDA with some modifications as follows.
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Sf9 cells were seeded at a density of 20,000 cells/ well in a 96-well tissue
culture grade black plate. Cells were allowed to attach for 2 h at 27ºC in a humidified
incubator. Sf9 cells were then infected with a range of MOIs (0.2 to 4.0 pfu/ ml) of
different CPR species, as indicated, for 72 h when the medium was removed from the
plate and 100 μl of 10 µM H2DCFDA, diluted in PBS was added to each well. The
plate was incubated in a 27ºC humidified incubator for 30 min. The oxidation of
intracellular non-fluorescent 2',7'-dichlorodihydrofluorescein (H2DCF) to highly
fluorescent 2′,7′-dichlorofluorescein (DCF) was measured on a fluorometer (Bio-Tek 
Synegy HT) using an excitation 485/20 nm and emission 528/20 nm filter set. Blank
values indicating the fluorescence of the dye in PBS were subtracted from all samples.
Percentage induction over control was calculated in baculovirus infected cells.
2.4.10.2 Dihydrorhodamine-123 Assay
ROS was also measured by using dihydrorhodamine-123 dye. Briefly, Sf9 cells
were seeded at a density of 20,000 cells/well in a 96-well tissue culture grade black
plate. Cells were allowed to attach for 2 h at 27ºC in a humidified incubator. Sf9 cells
were then infected with a range of MOIs (0.2 to 4.0 pfu/ ml) of different CPR species,
as indicated, for 72 h. At 72 h, the dihydrorhodamine-123 dye assay was performed.
Medium was removed from the plate and 100 μl of 10 µM dihydrorhodamine-
123, diluted in PBS, was added to each well. The plate was incubated in a 27ºC
humidified incubator for 60 min. The oxidation of dihydrorhodamine-123 to highly
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fluorescent rhodamine was measured on a fluorometer at an excitation wavelength of
500 nm and emission wavelength of 536 nm. Blank values, indicating the fluorescence
of the dye, in PBS were subtracted from all samples. Percentage induction over control
was calculated in baculovirus infected cells.
2.4.11 CYP Inhibition assay
IC50 Determinations
The assay method was adapted from Gentest CYP inhibition protocols (BD
Biosciences, www.bd.com ). The CYP inhibition assays were performed in a 96-well
microtitre plates (Figure 2.6). The assays were performed for IC50 determination in
duplicate rows of 12 wells. A test compound was added to the wells in column 1 and
serially diluted to the wells in column 8. Wells 9 and 10, which were used as control
wells, contained no test compound or positive controls (therefore no inhibition – full
signal is detected). The wells in columns 11 and 12 were used as blanks (STOP
solution was added prior to the addition of the enzyme/ substrate mix to the NADPH
regenerating system in columns 11 and 12) – the only signal present in these wells was
background noise). The assays were conducted in a final volume of 0.2 ml per well.
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Figure 2.6. Typical plate set up for a
high through-put assay.
Columns 1-8 are serial dilutions (3-fold)
of the test compound or positive control.
Columns 9 and 10 contain no test
compound.
Columns 11 and 12 are blank controls
(STOP solution added prior to initiation
of the reaction).
Rows A/B, C/D, E/F and G/H are
replicates.
The detailed methodology of inhibition assays, using CYP isoform-specific inhibitors,
is described in the fifth chapter.
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Chapter 3 Cloning, expression, catalytic activities of
CPR species and CYP2D6 when
expressed alone and together
3.1 Introduction
Human cytochrome P450 enzymes (CYPs) are a superfamily of haem-binding
monooxygenase enzymes involved in the metabolism of xenobiotics such as toxins,
carcinogens and drugs as well as in the biosynthesis of cholesterol, vitamins and
steroids (Wolf et al 1986; Shou et al. 2001). Biotransformation of these xenobiotics and
endobiotics by CYPs requires molecular oxygen and supply of reducing equivalents
from its redox partner NADPH cytochrome P450 reductase (CPR). CPR is responsible
for the transfer of electrons from NADPH to CYPs and is essential for CYP activity.
Similar to the CYPs, human CPR is also endoplasmic reticular (ER) membrane
(microsome) bound and most abundant in the liver. However unlike the CYP
superfamily of genes, CPR is encoded by a single gene (Simmons, 1985; Shephard et al.
1989). This single enzyme couples with all the known human CYPs to make them
active.
The CPR contains FMN, FAD and NADPH binding domains and electrons are
transferred from NADPH to FAD to FMN and finally to CYP. The interaction between
CYP and CPR occurs on the surface of the endoplasmic reticulum. Electrostatic (Shen
and Kasper 1995), hydrophobic and van der Waals forces (Voznesensky and
Schenkman 1994) have been implicated as determinants of this interaction. However
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the mode of CYP-CPR interaction and the formation of a productive monooxygenase
complex are still not clearly understood (Deeni et al. 2001). Both CYP and CPR have
NH2 (N)-terminus hydrophobic domains which anchor on the microsomes and are
important for correct spatial orientation of the redox centres for effective electron
transfer.
The catalytic activity of a particular CYP in a specific tissue, sub-cellular
fraction, or recombinant expression systems is determined not only by the abundance of
the CYP, but also by the amount of its electron transport partner CPR (Crespi and
Miller, 1999). However when a CYP is co-expressed with the CPR, there are some
problems posed by high level heterologous expression of the CYP-CPR complex to host
cells as well as to the activity and content of CYP enzymes. As CYPs are associated
with the endoplasmic reticulum, high level expression causes an increased stress on the
cell (Szczesna-skorupa et al. 2004). Co-expression of CPR with CYP increases the
catalytic activity of the CYP enzyme but unfortunately reduces the yield of spectrally
active CYP enzyme (Pritchard et al., 1998; Chen et al., 1997). Although the CYP
apoprotein levels remain unchanged during co-expression of CYP and CPR, the
amounts of spectrally active CYP holoprotein decreases remarkably (Tamura et al.,
1992), which is possibly the result of an uncoupled CYP reaction cycle. Some CYPs,
such as CYP2E1, have shown a high degree of uncoupling which results in damage to
cellular components, including CYP itself (Wang et al. 1996).
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In order to investigate the interactions of CPR with CYPs and to find out
whether we could improve upon both CYP levels and activity in an insect cell
expression system, we studied human native (wild-type) CPR, two of its genetically
engineered variants and the yeast CPR (yRD) in the context of various human CYPs.
In order to do so, we have cloned full-length human native CPR (hRD) gene together
with its two engineered variants (Figure 3.2).
The N-terminus of the wild-type human hRD protein contains the binding sites
for the essential cofactors FMN and FAD. However, the first 55-amino acids of the
hRD protein (165 bp of the hRD gene) constitute a domain that allows anchoring to
microsomal membranes. Within this sequence lies a 24-amino acid negatively charged
domain. The FMN binding site spans a sequence that includes the membrane anchor
whereas the region to which FAD binds is positioned beyond this domain. It has been
suggested that the complete hRD membrane anchor (the 55-amino acid domain) may be
essential for coupling to CYPs (Bonina et al. 2005). In this chapter we show that
deletion of a 24-amino acid N-terminal charged region present in the hRD’s membrane
anchoring domain prevents association of the resultant molecule, ΔhRD, to microsomal 
membranes.  However, the ΔhRDM protein which also lacks the N-terminal 24-amino 
acids of CPR but contains an extra 17-amino acid sequence (SSEQKLISEEDLNGSRL)
linked to ΔhRD’s COOH (C)-terminus has the ability to adhere once again to 
microsomal membranes like the native CPR. This C-terminal 17-amino acid sequence
includes a 12-amino acid motif (EQKLISEEDLN) which is often referred to as the c-
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myc tag and belongs to an exposed epitope in the oncogenic protein c-myc (Evan et al.
1985).
Comparison of the wild type hRD and ΔhRDM protein sequences is shown 
below in Figure 3.1.
10 20 30 40 50
* * * * *
hRD MGDSHVDTSSTVSEAVAEEVSLFSMTDMILFSLIVGLLTYWFLFRKKKEE
ΔhRDM ------------------------MTDMILFSLIVGLLTYWFLFRKKKEE
60 70 80 90 100
* * * * *
hRD VPEFTKIQTLTSSVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSK
ΔhRDM VPEFTKIQTLTSSVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSK
110 120 130 140 150
* * * * *
hRD DAHRYGMRGMSADPEEYDLADLSSLPEIDNALVVFCMATYGEGDPTDNAQ
ΔhRDM DAHRYGMRGMSADPEEYDLADLSSLPEIDNALVVFCMATYGEGDPTDNAQ
160 170 180 190 200
* * * * *
hRD DFYDWLQETDVDLSGVKFAVFGLGNKTYEHFNAMGKYVDKRLEQLGAQRI
ΔhRDM DFYDWLQETDVDLSGVKFAVFGLGNKTYEHFNAMGKYVDKRLEQLGAQRI
210 220 230 240 250
* * * * *
hRD FELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEESSIRQYELVVH
ΔhRDM FELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEESSIRQYELVVH
115
260 270 280 290 300
* * * * *
hRD TDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHL
ΔhRDM TDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHL
310 320 330 340 350
* * * * *
hRD MHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNN
ΔhRDM MHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNN
360 370 380 390 400
* * * * *
hRD LDEESNKKHPFPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQE
ΔhRDM LDEESNKKHPFPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQE
410 420 430 440 450
* * * * *
hRD LLRKLASSSGEGKELYLSWVVEARRHILAILQDCPSLRPPIDHLCELLPR
ΔhRDM LLRKLASSSGEGKELYLSWVVEARRHILAILQDCPSLRPPIDHLCELLPR
460 470 480 490 500
* * * * *
hRD LQARYYSIASSSKVHPNSVHICAVVVEYETKAGRINKGVATNWLRAKEPA
ΔhRDM LQARYYSIASSSKVHPNSVHICAVVVEYETKAGRINKGVATNWLRAKEPV
510 520 530 540 550
* * * * *
hRD GENGGRALVPMFVRKSQLRLPFKATTPVIMVGPGTGVAPFIGFIQERAWL
ΔhRDM GENGGRALVPMFVRKSQLRLPFKATTPVIMVGPGTGVAPFIGFIQERAWL
560 570 580 590 600
* * * * *
hRD RQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQS
ΔhRDM RQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQS
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610 620 630 640 650
* * * * *
hRD HKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAEL
ΔhRDM HKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAEL
660 670
* *
hRD GAMEHAQAVDYIKKLMTKGRYSLDVWS-----------------
ΔhRDM GAMEHAQAVDYIKKLMTKGRYSLDVWSSSEQKLISEEDLNGSRL
Figure 3.1. Comparison of the two protein sequences, wild-type hRD and the mutant
hRDM.
We have cloned and expressed human wild-type CPR (hRD) and its two
variants (Figure 3.2) in insect cells in order to study their interactions with human
CYPs.
Figure 3.2. Human wild-type (i.e. native) hRD and its two engineered variants.
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The yeast CPR (yRD) has been studied extensively in conjunction with human
CYPs in our yeast expression systems. In fact, human CPR functions extremely poorly
in yeast (unpublished results from our lab) and has rarely been used in the published
literature for expression of human CYPs in yeast. However, although yeast CPR has
been successfully used for heterologous expression of human CYPs in yeast, it has
never been used for expression studies in any other eukaryotic cell system. Therefore,
we considered that we should explore the possible interactions of yeast CPR with
human CYPs in microsomes (ER membranes) derived from insect cells. Hence, we
decided to clone and express yeast CPR (yRD) for co-expression with human CYPs in
insect cells.
At the outset, we envisaged that it would be important to confirm initially the
validity of the insect cell-based baculovirus system by studying the expression of a
prototypic CYP so that the results obtained could be used later as a generic system for
expression of all CYPs. In this chapter, we have studied CYP2D6 in conjunction with
different CPR species with the aim of producing functionally active CYP2D6 enzymes.
CYP2D6 was chosen as a model to study CPR-CYP interactions because it is a very
important isozyme in terms of drug metabolism studies. It is known to metabolise a
quarter of all marketed pharmaceutical entities (Werck-Reichhart and Feyereisen,
2000).
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Hence we embarked on comparing in some detail the known coupling of hRD
and CYP2D6 in insect cells with the possible interactions with CYP2D6 in insect cells
of two novel genetically engineered variants of hRD (which may or may not possess
CPR activities) and the very highly active yeast CPR (yRD) which has never been
studied in any other organism besides yeast. The aim was to find out whether we could
improve upon levels of recombinant CYP2D6 produced and its activity using an insect
cell expression system.
In the following sections of this chapter, a comparative analysis of CYP2D6
activities obtained after coupling with hRD, ΔhRD, ΔhRDM and yRD is presented.  
Results suggesting the probable localisation of the two novel human CPRs, ΔhRD and 
ΔhRDM, are also included.   
3.2 Gene Cloning in Basic Vectors
Cytochrome P450 2D6 (CYP2D6) and human full length human NADPH-
cytochrome P450 reductase (hRD) genes were isolated from a human liver cDNA
library obtained from BD-Clontech. Human delta-N24-NADPH-cytochrome P450
reductase with a stop codon at its 3’-end (ΔhRD-stop) and human delta-N24-NADPH-
cytochrome P450 reductase without a stop codon (ΔhRD-w/ostop) were also isolated
from the same human liver cDNA library. The yeast NADPH-cytochrome P450
reductase (yRD) gene was isolated from a S. cerevisiae genomic library (which was
available in the lab). All four genes had previously been cloned in basic vectors
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(pBlueScript KS+ or pSP73) for expression in yeast cells (unpublished results from our
lab). The CYP2D6 gene was re-cloned for insertion of a Kozak consensus translation
initiation sequence (GCCACC) for expression in insect cells.
The genes were amplified via PCR using the primers mentioned below. The
process of amplification has been described in ‘Materials and Methods’ (Section
Number 2.2.2). The PCR products were run on an agarose gel containing ethidium
bromide. DNA fragments of expected size were isolated and purified using Qiagen gel
extraction kit according to the manufacturer’s protocol. The purified DNA fragments
were digested with the indicated restriction enzymes and after digestion run again on an
agarose gel containing ethidium bromide. The digested DNA fragments were purified
using Qiagen gel extraction kit. CYP2D6, hRD, ΔhRD-stop, ΔhRD-w/ostop and
ΔhRDM genes were then directionally ligated using T4 DNA ligase into linearised
pBluescript KS+ (already digested with appropriate restriction enzymes). The yRD
gene was directionally ligated into pSP73 (BglII-XbaI digested and purified) using T4
DNA ligase. The ligation mixture was used to transform E .coli DH5α competent cells, 
and colonies containing the correct recombinant constructs were identified with
restriction analysis. Plasmids were extracted from positive clones. The experimental
methods employed are detailed in ‘Materials and Methods’ (Section Number 2.2.11).
The gene sequences were confirmed by DNA sequencing and their alignment with
reference sequences in the NCBI database.
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pBluKS+/Bam-Sal/CYP2D6
4425 bps
1000
2000
3000
4000
NaeI 328
NgoMIV 328
FspI 480
PvuI 500
PvuII 530 653
SacI
BstXI
NotI
EagI
XbaI
SpeI
BamHI
NcoI
699
EgeI 774
NarI 774
SrfI 820
SmaI 821
EgeI 885
NarI 885
AflIII 900
PstI 911
PvuII 914
EagI 954
BstEII 973
ApaI 1073
FspI 1116
BstEII 1156
EgeI 1275
NarI 1275
PvuII 1448
StuI 1518
FspI 1584
BstEII 1621
BspHI 1659 ++
BspHI 1780
Tth111I 1802
NdeI 1826
StuI 1992
SphI 2024
SacI 2054
PstI 2081
NcoI 2131
SalI 2195
XhoI 2201
ApaI 2210
Asp718I 2216
KpnI 2216
AseI 2384
PvuII 2436
AseI 2443
AflIII 2614
BspHI 3334
DraI 3371
DraI 3390
AseI 3678
FspI 3727
PvuI 3874
ScaI 3985
DraI 4082
BspHI 4342
''lacZ
h_CYP2D6
lacZ'
ColE1ori
Amp-r
3.2.1 Cloning of the CYP2D6 gene in pBluescript KS+
CYP2D6 was isolated with forward primer (5’-ATGGATCCGC
CACCATGGGG CTAGAAGCAC TGGTGCCCCT GGCCGTG-3’, the BamHI site
and the Kozak sequence are underlined and bold letters respectively), and reverse
primer (5’-ATGTCGACCT AGCGGGGCAC AGCACAAAGC-3’, the SalI site
underlined). The CYP2D6 gene was then cloned into a pBluescriptKS+ vector at the
BamHI, SalI sites to obtain the plasmid, pBluKS+/Bam-Sal/CYP2D6 (Figure 3.3).
Figure 3.3. The plasmid map of pBluKS+/Bam-Sal/CYP2D6.
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pBluKS+/Bam-Xba/hRD_fl
4992 bps
1000
20003000
4000
NaeI 328
NgoMIV 328
FspI 480
PvuI 500
PvuII 530
SacI 653
BstXI 658
NotI 669
EagI 670
XbaI 677
AflIII 691
NcoI 757
SacI 767
SmaI 925
Esp3I 1037
ApaI 1119
FspI 1174
EagI 1200
EagI 1266
NaeI 1268
NgoMIV 1268
PstI 1361
PstI 1421
FspI 1507
Tth111I 1682
PvuII 1715
HincII 1721
PstI 1861
NaeI 1921
NgoMIV 1921
BsrGI 1939
EagI 2038
NaeI 2040
NgoMIV 2040
EgeI 2126
NarI 2126
NcoI 2164
PstI 2246
PstI 2443
2713
NcoI
BamHI
SmaI
PstI
EcoRI
EcoRV
HindIII
BspDI
ClaI
HincII
SalI
XhoI
ApaI
Asp718I
KpnI
2783
AseI 2951
PvuII 3003
AseI 3010
AflIII 3181
BspHI 3901
DraI 3938
DraI 3957
AseI 4245
FspI 4294
PvuI 4441
ScaI 4552
DraI 4649
BspHI 4909
''lacZ
hRD_fl
lacZ'
ColE1ori
Amp-r
3.2.2 Cloning of the hRD gene in pBluescript KS+
The hRD gene was isolated with the forward primer (5’- CGCGGATCCA
TGGGAGACTC CCACGTGGAC ACCAGCTCCA CCG -3’, the BamHI site is
underlined) and the reverse primer (5’- CTAGTCTAGA CTAGCTCCAC
ACGTCCAGGG AGTAGCGGCC C -3’, the XbaI site is underlined). The hRD gene
was then cloned into a pBluescriptKS+ vector at the BamHI, XbaI sites to construct the
plasmid, pBluKS+/Bam-Xba/hRD (Figure 3.4).
Figure 3.4. The plasmid map of pBluKS+/Bam-Xba/hRD.
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pBluKS+/Bam-Xba/DeltahRDStop
4917 bps
1000
20003000
4000
NaeI 328
NgoMIV 328
FspI 480
PvuI 500
PvuII 530
653
SacI
BstXI
NotI
EagI
XbaI
SacI
AflIII
688
NcoI 754
SacI 764
BalI 805
SmaI 922
Esp3I 1034
ApaI 1116
FspI 1171
EagI 1197
BalI 1243 ++
NaeI 1265 ++
SbfI 1357 ++
SbfI 1417 ++
BalI 1426
FspI 1504
Tth111I 1679
PvuII 1712
HincII 1718 ++
NaeI 1918 ++
EagI 2035
NaeI 2037
NgoMIV 2037
EgeI 2123
NarI 2123
NcoI 2161
PstI 2243
BalI 2299
AxyI 2368
Eco81I 2368
PstI 24402642
BamHI
SmaI
PstI
EcoRI
EcoRV
HindIII
BspDI
ClaI
HincII
SalI
StrI
XhoI
ApaI
Asp718I
KpnI
2708
AseI 2876
PvuII 2928
AseI 2935
AflIII 3106
BspHI 3826
DraI 3863
DraI 3882
AseI 4170
FspI 4219
PvuI 4366
ScaI 4477
DraI 4574
BspHI 4834
''lacZ
deltaN24hRDStop
lacZ'
ColE1ori
Amp-r
3.2.3 Cloning of the ΔhRD gene with a stop codon at its 5’-end
in pBluescript KS+
The ΔhRD gene with a stop codon at its 5’-end (i.e. ΔhRD-stop) was isolated
with the forward primer (5’-CGCGGATCCA TGACGGACAT GATTCTGTTT TCGC-
3’, the BamHI site is underlined) and the reverse primer (5’- CTAGTCTAGA
CTAGCTCCAC ACGTCCAGGG AGTAGCGGCC C -3’, the XbaI site is underlined).
The ΔhRD-stop gene was then cloned into the basic pBluescriptKS+ vector at the
BamHI, XbaI sites to construct the plasmid, pBluKS+/Bam-Xba/ΔhRD-stop (Figure
3.5).
Figure 3.5.  The plasmid map of pBluKS+/Bam-Xba/ΔhRD-stop. 
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3.2.4 Cloning of the ΔhRD gene without a stop codon at its 5’-
end in pBluescript KS+
The ΔhRD-w/ostop gene was isolated with the forward primer (5’-
CGCGGATCCA TGACGGACAT GATTCTGTTT TCGC-3’, the BamHI site is
underlined) and the reverse primer (5’- CTAGTCTAGA GCTCCAC ACGTCCAGGG
AGTAGCGGCC C -3’, the XbaI site is underlined). The ΔhRD-w/ostop gene was then
cloned into a pBluescriptKS+ vector at the BamHI, XbaI sites to construct the plasmid,
pBluKS+/ΔhRD-w/ostop.  
3.2.5 Cloning of the ΔhRDM gene in pBluescript KS+
The plasmid pSYIGal1MS, which contains the yeast GAL1 promoter (GAL1p)
and encodes the c-myc tag linked to the transcription terminator from the yeast SUC2
gene (SUC2t), was previously constructed in our laboratory. The plasmid pSYIGal1MS
was constructed utilizing the pRS305 vector (ATCC 77140). The yeast GAL1p gene
was first cloned into the pBluescriptKS+ plasmid at the EcoRI-BamHI sites. The
resultant plasmid was named pBluscriptKS/Gal1. The c-myc tagged SUC2t was
introduced into this plasmid at the XbaI, SacI sites to generate the plasmid pBGal1MS.
The fragment containing the GAL1p―c-myc-SUC2t fusion was isolated from the
plasmid pBGal1MS using the NgoMIV and HindIII restriction enzymes and the isolated
fragment was cloned into pRS305 at the NgoMIV-HindIII sites to create the plasmid
pSYIGal1MS. This plasmid was utilized for sub-cloning of ΔhRD w/ostop as a BamHI-
XbaI gene fragment, isolated from pBluKS+/ΔhRD w/ostop.  The new plasmid was 
named pSYI/ΔhRDM.  The ΔhRDM (ΔhRDw/ostop-c.myc) fragment was isolated from 
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pBluKS+/Bam-Xba/DelN24hRDM
4971 bps
1000
20003000
4000
NaeI 328
NgoMIV 328
FspI 480
PvuI 500
PvuII 530
SacI 653
BstXI 658
NotI 669
EagI 670
XbaI 677
BbsI 704
SacI 735
AflIII 742
NcoI 808
SacI 818
BalI 859
SmaI 976
Esp3I 1088
ApaI 1170
FspI 1225
EagI 1251 ++
EagI 1317 ++
SbfI 1411 ++
SbfI 1471 ++
BalI 1480
FspI 1558
Tth111I 1733
PvuII 1766
HincII 1772 ++
NaeI 1972 ++
BsrGI 1990
EagI 2089
NaeI 2091
NgoMIV 2091
EgeI 2177
NarI 2177
NcoI 2215
PstI 2297
BalI 2353
AxyI 2422
Eco81I 2422
PstI 2494
2696
BamHI
SmaI
PstI
EcoRI
EcoRV
HindIII
BspDI
ClaI
HincII
SalI
StrI
XhoI
ApaI
Asp718I
KpnI
2762
AseI 2930
PvuII 2982
AseI 2989
AflIII 3160
BspHI 3880
DraI 3917
DraI 3936
AseI 4224
FspI 4273
PvuI 4420
ScaI 4531
DraI 4628
BspHI 4888
''lacZ
DelN24hRD-cmyc
lacZ'
ColE1ori
Amp-r
pSYI/ΔhRDM with the forward primer (5’-CGCGGATCCA TGACGGACAT
GATTCTGTTT TCGC-3’, the BamHI site is underlined) and the reverse primer for c-
myc (5’- CCGTCTAGAT CAACCGTTCA AGTCTTCTTC AGAGATCAAC -3’, the
XbaI site is underlined). The ΔhRDM gene was then cloned into pBluescriptKS+ at the
BamHI, XbaI sites to construct the plasmid, pBluKS+/Bam-Xba/ΔhRDM (Figure 3.6).
Figure 3.6.  The plasmid map of pBluKS+/Bam-Xba/ΔhRDM.  
125
pSP73/BglII-XbaI/yRD
4519 bps
1000
2000
3000
4000
BglII 6
SnaBI 78
EcoRV 126
PvuII 133
BstEII 170
BstXI 250
BalI 262
FspI 288
BsaBI 347
NdeI 361 ++
BbsI 402 ++
EcoRI 483
MunI 786
ScaI 910
BstEII 921
BstXI 946
BamHI 1025
MunI 1116
EgeI 1263
NarI 1263
MunI 1467 ++
HpaI 1485
SwaI 1522
DraI 1523
BspHI 1621
Asp718I 1635
KpnI 1635
BamHI 1746
BalI 1785
BstXI 1798
BbsI 1893
BalI 1960
HincII 1973
2085
SacI
Asp718I
KpnI
SmaI
BamHI
XbaI
HincII
SalI
SbfI
PstI
SphI
HindIII
PvuII
StrI
XhoI
2142
AseI 2172
HincII 2191
HpaI 2191
AseI 2201
AflIII 2372
BspHI 3092
DraI 3129
DraI 3148
AseI 3436
FspI 3485
PvuI 3632
ScaI 3743
DraI 3840
BspHI 4100
BspHI 4205
Esp3I 4249
Esp3I 4303
NdeI 4435
AseI 4469
yRD
T7pColE1ori
Amp-r
SP6p
3.2.6 Cloning of the yRD gene in pSP73
The yRD gene was isolated from a S. cerevisiae genomic library with the
forward primer (5’-GGAATTC AGATCT ATG CCG TTT GGA ATA GAC AAC AC-
3’, the BglII site is underlined) and the reverse primer (5’-CTAG TCTAGA TTA CCA
GAC ATC TTC TTG GTA TC-3’, the XbaI site is underlined). The yRD gene was then
cloned into the pSP73 basic vector at the BglII, XbaI sites to construct the plasmid,
pSP73/BglII-XbaI/yRD (Figure 3.7). The experimental methods employed are detailed
in ‘Materials and Methods’.
Figure 3.7. The plasmid map of pSP73/BglII-XbaI/yRD.
126
3.3 Sub-cloning of genes in a transfer vector for
construction of bacmids
The genes were isolated from the basic vectors by means of restriction enzyme
digestions as follows:
 To isolate the CYP2D6 gene, the pBluKS+/Bam-Sal/CYP2D6 plasmid was
digested with BamHI, SalI.
 To isolate the hRD gene, the pBluKS+/Bam-Xba/hRD plasmid was digested
with BamHI, XbaI.
 To isolate the ΔhRD-stop gene, the pBluKS+/Bam-Xba/ΔhRD-stop plasmid was
digested with BamHI, XbaI.
 To isolate the ΔhRDM gene, the pBluKS+/Bam-Xba/ΔhRDM plasmid was
digested with BamHI, XbaI.
 To isolate the yRD gene, the pSP73/BglII-XbaI/yRD plasmid was digested with
BglII, XbaI.
The isolated genes were then sub-cloned into the transfer vector, pFastBac1,
under the control of the polyhedrin promoter (polHp) as follows. The pFastBac1 vector
was digested with
 BamHI, SalI for cloning of CYP2D6 gene,
 BamHI, XbaI for cloning of hRD, ΔhRD-stop, ΔhRDM and yRD genes.
The digested fragments of all genes and the linearised pFastBac1 vectors were run on
agarose gels and purified. The digested gene fragments were directionally ligated into
linearised pFastBac1 using T4 DNA ligase. The ligation mixture was then used to
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transform DH5α E. coli competent cells, and colonies containing the correct
recombinant constructs were identified via restriction enzyme analyses. Plasmids were
extracted from positive clones and named as follows:
 pFastBac1/Bam-Sal/CYP2D6 (Figure 3.8),
 pFastBac1/Bam-Xba/hRD (Figure 3.9),
 pFastBac1/Bam-Xba/ΔhRD-stop (Figure 3.10),  
 pFastBac1/Bam-Xba/∆hRDM (Figure 3.11) and
 pFastBac1/yRD (Figure 3.12).
The experimental methods employed are detailed in ‘Materials and Methods’, Chapter
2.
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pFastBac1/Bam-Sal/CYP2D6
6244 bps
1000
2000
3000
4000
5000
6000
NaeI 127
NgoMIV 127
BspHI 536
DraI 796
ScaI 893
PvuI 1004
FspI 1151
AseI 1200
DraI 1488
DraI 1507
BspHI 1544
AflIII 2264
BglII 2547
BalI 2707
BstXI 2710
EagI 2768
EcoRV 2823
BsaBI 3012
BglII 3017
Esp3I 3176
Tth111I 3225
AflIII 3246
BsrGI 3410
HincII 3548
BbsI 3750
EagI 3758
SnaBI 3879
AseI 3896
BsaBI 3924
BamHI 4032
NcoI 4042
BalI 4081
EgeI 4117
NarI 4117
SrfI 4163
SmaI 4164++
AflIII 4243++
BstEII 4316
ApaI 4416
FspI 4459++
EgeI 4618
NarI 4618++
Eco81I 4649
PvuII 4791
StuI 4861
FspI 4927
BstEII 4964
BspHI 5002
BstEII 5085
BspHI 5123
Tth111I 5145
NdeI 5169
AxyI 5211
Eco81I 5211
StuI 5335
SphI 5367
SacI 5397
PstI 5424
NcoI 5474
5538
HincII
SalI
SacI
SpeI
NotI
EagI
XbaI
PstI
StrI
XhoI
SphI
Asp718I
KpnI
HindIII
ScaI
BsaBI
5628
DraI 5670
MunI 5720
HincII 5731
HpaI 5731
BclI 5869
AseI 6187
f1_ori
Amp-r
ColE1
Tn7R
Gm-r
polHp
h_CYP2D6
SV40_polyA
Tn7L
Figure 3.8. The plasmid map of pFastBac1/Bam-Sal/CYP2D6.
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pFastBac/Bam-Xba/hRD
6744 bps
1000
2000
3000
4000
5000
6000
NaeI 127
NgoMIV 127
BspHI 536
DraI 796
ScaI 893
PvuI 1004
FspI 1151
AseI 1200
DraI 1488
DraI 1507
BspHI 1544
AflIII 2264
BglII 2547
BalI 2707
BstXI 2710
EagI 2768
EcoRV 2823
BsaBI 3012
BglII 3017
Esp3I 3176
Tth111I 3225
AflIII 3246
BsrGI 3410
HincII 3548
BbsI 3750
EagI 3758
SnaBI 3879
AseI 3896
BsaBI 3924
BamHI 4032
NcoI 4036
PstI 4306
AxyI 4377
Eco81I 4377
BalI 4447
PstI 4503
NcoI 4585
EgeI 4623
NarI 4623
NaeI 4709
NgoMIV 4709
EagI 4711++
NaeI 4828++
PstI 4888
HincII 5028
PvuII 5034
Tth111I 5064
FspI 5242
BalI 5320++
SbfI 5387
PstI 5388
NaeI 5481
NgoMIV 5481
EagI 5483
BalI 5503
EagI 5549
FspI 5575
ApaI 5630
Esp3I 5712
SmaI 5824
BalI 5941
SacI 5982
NcoI 5992
6058
AflIII
XbaI
PstI
StrI
XhoI
SphI
Asp718I
KpnI
HindIII
ScaI
BsaBI
6128 DraI 6170
MunI 6220
HincII 6231
HpaI 6231
BclI 6369
AseI 6687
f1_ori
Amp-r
ColE1
Tn7R
Gm-r
polHp
hRD_fl
SV40_polyA
Tn7L
Figure 3.9. The plasmid map of pFastBac1/Bam-Xba/hRD.
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pFastBac1/Bam-Xba/DeltahRDStop
6669 bps
1000
2000
3000
4000
5000
6000
NaeI 127
NgoMIV 127
BspHI 536
DraI 796
ScaI 893
PvuI 1004
FspI 1151
AseI 1200
DraI 1488
DraI 1507
BspHI 1544
AflIII 2264
BglII 2547
BalI 2707
BstXI 2710
EagI 2768
EcoRV 2823
BsaBI 3012
BglII 3017
Esp3I 3176
Tth111I 3225
AflIII 3246
BsrGI 3410
HincII 3548
BbsI 3750
EagI 3758
SnaBI 3879
AseI 3896
BsaBI 3924
BamHI 4032
PstI 4234
AxyI 4305
Eco81I 4305
BalI 4375
PstI 4431
NcoI 4513
EgeI 4551
NarI 4551
NaeI 4637
NgoMIV 4637
EagI 4639
BsrGI 4738++
NgoMIV 4756++
HincII 4956
PvuII 4962
Tth111I 4992
FspI 5170
BalI 5248++
SbfI 5315
PstI 5316
NaeI 5409
NgoMIV 5409
EagI 5411
BalI 5431
EagI 5477
FspI 5503
ApaI 5558
Esp3I 5640
SmaI 5752
BalI 5869
SacI 5910
NcoI 5920
5986
AflIII
SacI
XbaI
PstI
StrI
XhoI
SphI
Asp718I
KpnI
HindIII
ScaI
BsaBI
6053
DraI 6095
MunI 6145
HincII 6156
HpaI 6156
BclI 6294
AseI 6612
f1_ori
Amp-r
ColE1
Tn7R
Gm-r
polHp
deltaN24hRDStop
SV40_polyA
Tn7L
Figure 3.10.  The plasmid map of pFastBac1/Bam-Xba/ΔhRD-stop.  
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pFastBac1/Bam-Xba/DeltahRDM
6723 bps
1000
2000
3000
4000
5000
6000
NaeI 127
NgoMIV 127
BspHI 536
DraI 796
ScaI 893
PvuI 1004
FspI 1151
AseI 1200
DraI 1488
DraI 1507
BspHI 1544
AflIII 2264
BglII 2547
BalI 2707
BstXI 2710
EagI 2768
EcoRV 2823
BsaBI 3012
BglII 3017
Esp3I 3176
Tth111I 3225
AflIII 3246
BsrGI 3410
HincII 3548
BbsI 3750
EagI 3758
SnaBI 3879
AseI 3896
BsaBI 3924
BamHI 4032
PstI 4234
AxyI 4305
Eco81I 4305
BalI 4375
PstI 4431
NcoI 4513
EgeI 4551
NarI 4551
NaeI 4637
NgoMIV 4637
EagI 4639
BsrGI 4738++
NgoMIV 4756++
HincII 4956
PvuII 4962
Tth111I 4992
FspI 5170
BalI 5248++
SbfI 5315++
NaeI 5409++
BalI 5431
EagI 5477
FspI 5503
ApaI 5558
Esp3I 5640
SmaI 5752
BalI 5869
SacI 5910
NcoI 5920
AflIII 5986
SacI 5993
BbsI 6024
6051
XbaI
PstI
StrI
XhoI
SphI
Asp718I
KpnI
HindIII
ScaI
BsaBI
6107 DraI 6149
MunI 6199
HincII 6210
HpaI 6210
BclI 6348
AseI 6666
f1_ori
Amp-r
ColE1
Tn7R
Gm-r
polHp
DeltaN24hRD-cmyc
SV40_polyA
Tn7L
Figure 3.11.  The plasmid map of pFastBac1/Bam-Xba/ΔhRDM.  
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pFastBac1/yRD
6783 bps
1000
2000
3000
4000
5000
6000
NaeI 127
NgoMIV 127
BspHI 536
DraI 796
ScaI 893
PvuI 1004
FspI 1151
AseI 1200
DraI 1488
DraI 1507
BspHI 1544
AflIII 2264
BglII 2547
BalI 2707
BstXI 2710
EagI 2768
EcoRV 2823
BsaBI 3012
BglII 3017
Esp3I 3176
Tth111I 3225
AflIII 3246
BsrGI 3410
HincII 3548
BbsI 3750
EagI 3758
SnaBI 3879
AseI 3896
BsaBI 3924
SnaBI 4104
EcoRV 4152
PvuII 4159
BstEII 4196
BstXI 4276
BalI 4288
FspI 4314++
BbsI 4428++
EcoRI 4509
MunI 4812
ScaI 4936
BstEII 4947
BstXI 4972
BamHI 5051
MunI 5142
EgeI 5289
NarI 5289
MunI 5493++
HpaI 5511
SwaI 5548
DraI 5549
BspHI 5647
Asp718I 5661
KpnI 5661
BamHI 5772
BalI 5811
BstXI 5824
BbsI 5919
BalI 5986
HincII 5999
6111
XbaI
PstI
StrI
XhoI
SphI
Asp718I
KpnI
HindIII
ScaI
BsaBI
6167 DraI 6209
MunI 6259
HincII 6270
HpaI 6270
BclI 6408
AseI 6726
f1_ori
Amp-r
ColE1
Tn7R
Gm-r
polHp
yRD
SV40_polyA
Tn7L
Figure 3.12. The plasmid map of pFastBac1/yRD – a BglII-XbaI fragment of the yRD
gene was cloned in pFastBac1 digested with BamHI, XbaI.
3.4 Generation of bacmid constructs and baculoviruses
The recombinant donor vectors- pFastBac1/Bam-Sal/CYP2D6, pFastBac1/
Bam-Xba/hRD, pFastBac1/Bam-Xba/ΔhRD-stop, pFastBac1/Bam-Xba/ΔhRDM and 
pFastBac1/yRD were used for transformation of E. coli DH10Bac competent cells as
described in Chapter 2 (‘Materials and Methods’). The propagation of recombinant
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bacmid in DH10Bac cells was identified by the white colour of colonies in the presence
of the chromogenic substrate-Bluo-gal and the inducer IPTG. The white colonies were
streaked out for a second time on Bluo-gal containing plates and after confirming the
phenotype of white colonies, recombinant bacmids were isolated and their veracities
were confirmed by PCR (Figure 3.13). PCR was performed using the M13 forward
primer (5’GTTTTCCCAGTCACGAC 3’) and gene specific reverse primers. The
experimental methods employed are detailed in ‘Materials and Methods’.
(A) (B)
Figure 3.13. Confirmation of recombinant bacmid formation by PCR. The
recombinant bacmids were confirmed as described in ‘Materials and Methods’ by PCR
using M13 forward primer and gene specific reverse primers. (A) Lane 1, 1 Kb DNA
ladder; Lane 2, confirmation of CYP2D6 gene transposition on the bacmid, expected
size is about 3200 bp. (B) Lane 1, 1 Kb DNA ladder; Lane 2, confirmation of yRD
gene transposition on the bacmid, expected size is about 3700 bp; Lane 3, confirmation
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of hRD gene transposition on the bacmid, expected size is about 3700 bp; Lane 4,
confirmation of ΔhRD gene transposition on the bacmid, expected size is about 3700 
bp; Lane 5, confirmation of ΔhRDM gene transposition on the bacmid, expected size is 
about 3700 bp.
For generation of baculoviruses, the transfection of Sf9 cells with recombinant
bacmids was performed in 6-well plates and the initial baculovirus stocks were
amplified. The baculoviruses were titrated using plaque assays (Figure 3.14) as
described in Materials and Methods (Section Number 2.3.9).
Figure 3.14. Viral plaque assay for determining baculovirus titres. The plaque assays
were performed as described in ‘Materials and Methods’ (Section Number 2.3.9) using
baculovirus stock dilutions from 10-3 to 10-8. The plaques were stained with neutral red
and viral titres were determined.
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3.5  Expression of hRD, ΔhRD, ΔhRDM and yRD in insect cells  
Following amplification and titration of recombinant baculoviruses, Sf9 cells
were infected with baculoviruses that encode the different species of CPRs (i.e. BV-
CPRs). Hereafter, the specific recombinant baculoviruses would be referred to as BV-
hRD, BV-ΔhRD, BV-ΔhRDM and BV-yRD.  All baculoviruses were used at an MOI of 
1 for infection of Sf9 cells. The microsomes prepared after 63 h of infection with BV-
CPRs were subjected to sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE)
electrophoresis as described in ‘Materials and Methods’ (Section Number 2.4.4).
Twenty-five μg of microsomal protein samples were separated on SDS-PAGE and 
protein bands were visualized by staining with Coomassie blue staining (Figure 3.15) as
described in ‘Materials and Methods’ (Section Number 2.4.25). Coomassie blue
staining detected the hRD, ΔhRDM and yRD proteins, but the ΔhRD protein band was 
not observed on the gel which could mean that either that the protein is not expressed or
that ΔhRD does not anchor to microsomal membranes.  From experiments in yeast, it 
was shown that indeed the ΔhRD protein is cytosolic (unpublished observations).  
However, it is quite clear from the gel that the addition of a 17-amino acid sequence,
which includes the classical c-myc tag, to the C-terminal end of ΔhRD allows ΔhRDM 
to be anchored to the microsomal membranes. The image of stained protein bands on
the gel was captured on Gel Doc™ (Bio-Rad). The experimental methods employed are
described in ‘Materials and Methods’.
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Figure 3.15 (A). Analysis of human CPRs expressed from insect cells on Coomassie-
stained SDS-PAGE. 25 µg of microsomal proteins were loaded per lane on 10% SDS-
PAGE. Gels were stained with Coomassie blue G-250. Lane 1, protein marker; Lane 2,
ΔhRDM (expected MW, 76.257 kD); Lane 3, hRD (expected MW, 76.637 kD); Lane 4, 
ΔhRD (expected MW, 74.370 kD); Lane 5, negative control (proteins from cells 
infected with baculovirus encoding no foreign gene).
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1 2 3
Figure 3.15 (B). Analysis of yRD protein expressed from insect cells on Coomassie-
stained SDS-PAGE. 25 µg of microsomal proteins were loaded per lane on 10% SDS-
PAGE. Gels were stained with Coomassie blue G-250. Lane 1, yRD (expected MW,
80.388 kD); Lane 2, negative control (proteins from cells infected with baculovirus
encoding no foreign gene). Lane 3, protein marker
All the microsomal protein samples except yRD were further subjected to
immunoblotting (antibodies to yRD are not commercially available). For Western blot
analysis, microsomal samples (1.5µg/lane) were separated on 10% SDS-PAGE. The
proteins were electro-transferred to Immobilon-P-membranes (Millipore) by the semi-
dry transfer method. The membranes were blocked with 5% non-fat dry milk in PBS.
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The blots were probed with 1:2000 dilution of mouse monoclonal antibody to CYP2D6
(BD-Gentest, Catalogue No A246), rabbit polyclonal antibody to human NADPH
CYP450 reductase (Abcam, Catalogue No ab13513-50), and mouse monoclonal
antibody to the c-myc epitope (9E10) (Santa Cruz Biotechnology, Catalogue No SC-
40). The immune complexes were detected and visualized with 1:10,000 dilutions of
secondary antibodies, anti-mouse IgG-HRP conjugate and goat anti-rabbit HRP
conjugate. Bound horseradish peroxidase was detected by chemiluminescence with the
luminol chemiluminescent substrate. Chemiluminescence was detected with Gel Doc™
(Bio-Rad). The complete experimental methods employed have been described in
‘Materials and Methods’.
Immunoblotting for CPRs detected hRD and ΔhRDM but did not detect ΔhRD 
(Figure 3.16 A). Immunoblotting confirmed the findings of Coomassie staining which
had shown that ΔhRD was also not present in the microsomes.  In the Western blot 
performed with the c-myc antibody only ΔhRDM was detected since it is the only CPR 
species that contains the c-myc tag (Figure 3.16 B).
Figure 3.16. Western blot analyses of different CPR species expressed in insect cells.
1.5 μg of microsomal proteins were loaded per lane on 10% SDS-PAGE and immuno-
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blotting was performed as described in ‘Materials and Methods’ (Section Number 2.4.6)
by using antibodies to human CPR (A) and c-myc tag (B). Lane 1, Negative control;
Lane 2, ΔhRD; Lane 3, ΔhRDM; Lane 4, hRD.   
3.6  Localisation of ΔhRDM by confocal laser microscopy 
In order to confirm the initial observation that ΔhRDM associates with 
microsomal (i.e. endoplasmic reticular, ER) membranes, its intracellular localisation
was studied using confocal microscopy. Insect cells were infected either with BV-
ΔhRDM alone or co-infected with BV-ΔhRDM and BV-CYP2D6.  24 h after infection, 
cells were prepared for confocal microscopy as described before (Atkins 1999) but with
no lysozyme treatment. The cells were fixed using methanol and acetone treatment.
Subsequently the cells were incubated with
(1) 1:200 dilution of a rabbit polyclonal IgG antibody to the c-myc epitope (9E10)
which is conjugated to Alexafluor 647 (Santa Cruz sc789AF647) and
(2) 1:200 dilution of a monoclonal antibody (Santa Cruz sc-57963) to protein
disulphide isomerase (PDI1) which is an ubiquitous ER membrane protein. A
1:1000 dilution of goat anti mouse IgG secondary antibody against PDI1
protein, conjugated to FITC (Santa Cruz sc2010) was used to demonstrate
localisation of the house-keeping protein, PDI1, to the ER.
Confocal microscopy was performed on a Leica DMIRE2 microscope (Leica TCS SP2)
with a 63X plan-apochromat objective (1.2 water). To detect Alexaflour and FITC
fluorochromes Ar/HeN2 lasers were used at 488 and 543 nm respectively. No signal
from one flourochrome could be detected on the other filter set under standard imaging
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PDI (FITC) c-myc (Alexa 647) merged
CYP2D6 +
∆hRDM
∆hRDM
conditions (no cross-talk). Conditions were also standardized for the pinhole size, for
gain and offset (contrast and brightness) and these were used for image capture. Each
image was an average of 12 scans. For direct comparisons, image capture and
background subtractions were done uniformly on all images. The confocal microscopic
images of ∆hRDM, which co-localises with PDI1, to the microsomal (i.e. ER)
membranes are portrayed in Figure 3.17.
Figure 3.17. Confocal microscopy images confirming localization of hRDM in
recombinant baculovirus infected Sf9 cells. The cells were treated with primary
antibodies for protein disulphide isomerase (PDI), an ER membrane protein, and c-myc
antibody tagged with the fluorochrome, Alexafluor 647. The primary antibody to the
PDI1 protein was counter-stained with a secondary antibody that is conjugated to the
fluorochrome, FITC.
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3.7  Reductase activities of hRD, ΔhRD and ΔhRDM in insect 
cell microsomes
CPR is an electron donor protein for CYP but the direct reduction of CYP is
relatively difficult to assay. Therefore substrates like MTT or cytochrome c, which act
as artificial electron acceptors, are widely used for determining CPR activity. The
reduction of these substrates mirrors the reduction of CYPs.
In order to find out the reductase activities in microsomal samples, reductase
assays were performed.  Sf9 cells were infected with BV-hRD, BV-ΔhRD, BV-ΔhRDM 
and BV-yRD at an MOI of 1. The microsomes prepared after 63 h of infection with
BV-CPRs were assayed for reductase activities using MTT as described in ‘Materials
and Methods’ (Section Number 2.4.7). Reductase activity of yRD was highest among
all the CPRs.  ΔhRD reductase activity was equal to the cell control which was expected 
as the ΔhRD product does not anchor to (at least not present in) the microsomal 
membranes as revealed by Coomassie staining and Western blotting (see Section 3.5).
The reductase activity of wild-type, native hRD was higher than ΔhRDM (Table 3.1). 
142
Table 3.1. CPR activities as exhibited by different CPR species. Sf9 cells were
infected with CPR baculoviruses and microsomes were prepared at 63 h. Reductase
activity was measured by using MTT as described in ‘Materials and Methods’ (Section
Number 2.4.7). The moles of MTT reduced per minute per mg of protein were
calculated. Data are presented as mean values ± STDEV.
CPR Species Reductase activity
(nmole MTT reduced/min/mg protein)
Control
ΔhRD 
ΔhRDM 
hRD
yRD
10.6 ± 2.1
15.5 ± 1.7
1550.4 ± 187.2
2325.7 ± 154.7
2643.7 ± 251.2
3.8 CYP2D6 expression in insect cells
Following amplification and titration of CYP2D6 recombinant baculovirus
(hereafter referred as BV-2D6), Sf9 cells were infected with BV-2D6 at an MOI of 1.
Haemin and δ-amino laevulinic acid were added 24 h post-infection to compensate for 
low levels of haem in insect cells. The microsomes prepared after 63 h of infection with
BV-2D6 were subjected to sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE)
143
electrophoresis.  Twenty-five μg of the microsomal protein sample was separated on 
SDS-PAGE and the protein band was visualised by staining with Coomassie blue dye
(Figure 3.18). Coomassie blue staining detected the expressed CYP2D6 protein. The
image of the stained protein band on the gel was captured on Gel Doc™ (Bio-Rad).
The detailed experimental method employed is provided in ‘Materials and Methods’.
Figure 3.18. Coomassie staining of SDS-PAGE for CYP2D6 expressed in Sf9 cells.
25 μg of microsomal protein was separated on 10% SDS-PAGE.  Gel was stained with 
Coomassie G-250 as described in ‘Materials and Methods’ (Section Number 2.4.5).
Lane 1, Protein Marker; Lane 2, CYP2D6 expressed in Sf9 cells.
3.9 Optimization of CYP2D6 expression
In order to find out an optimum MOI for producing spectrally active CYP2D6,
Sf9 cells were infected with BV-2D6 using a range of MOIs (from 1 x 10-1 pfu/cell to 4
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pfu/cell). The microsomes were prepared after 63 h of infection and were subjected to
CO-binding assay. The carbon monoxide (CO) binding assay is a method for
quantifying the amount of CYP holoprotein in a microsomal preparation. The CO-assay
gives the P450 enzyme family its name. The reduced haem moiety of CYP binds to
carbon monoxide and exhibits maximum absorbance at 450 nm. The method detects
the active haem-bound CYP holoprotein.
After determining protein concentrations using a modified Bradford method
(Bio-Rad kit; Bradford 1976), CYP content in the microsomes was measured using a
dual wavelength spectrophotometer as described in ‘Materials and Methods’ (Section
Number 2.4.3). The spectral analysis was typical of P450 proteins. It was observed that
infection with the lowest MOI of 0.1 pfu/cell resulted in a major peak at 450 nm and a
very small peak at 420 nm (Figure 3.19). The peak at 420 nm is an indication of
spectrally inactive CYP. Our results clearly indicate that using higher MOIs of BV-2D6
result in a gradual increase in the formation of inactive CYP2D6.
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MOI: 0.1 pfu/cell
MOI: 1 pfu/cell
MOI: 3 pfu/cell
MOI: 4 pfu/cell
Figure 3.19. Optimization of CYP2D6 expression using different MOIs. Sf9 cells
were infected with BV-2D6 using a range of MOIs (from 0.1 pfu/cell to 4 pfu/cell).
The microsomes were prepared after 63 h of infection and were subjected to CO-
binding assay as described in ‘Materials and Methods’ (Section Number 2.4.3).
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3.10 Co-expression of CYP2D6 with the CPRs
After optimization of a particular BV-2D6 MOI that would allow a relatively
high level of expression of spectrally active CYP2D6, the ability of different CPR
species to transfer electrons to CYP2D6 and produce active enzymes was studied. Sf9
cells were infected with recombinant BV-2D6 alone at an MOI of 1 pfu/cell. In a
second set of experiments, the cells were also co-infected with various BV-CPRs at an
MOI that was 10-fold less (1×10-1 pfu/ cell) than the MOI used for BV-2D6 (MOI of 1
pfu/cell). The ratio of BV-2D6 to BV-CPR was maintained 10:1 in accordance with the
published literature values (Chen et al. 1997).  Haemin and δ-amino laevulinic acid 
were added 24 h post-infection to compensate for low levels of haem in insect cells as
described in ‘Materials and Methods’. Microsomes were prepared 63 h after infection
and the total microsomal proteins were estimated by the Bradford method.
To confirm expression of recombinant proteins, microsomes obtained after
infecting Sf9 cells with different baculovuruses were subjected to SDS-PAGE. Twenty-
five μg of microsomal protein samples were separated on SDS-PAGE and protein bands 
were visualized by staining with Coomassie blue as described in ‘Materials and
Methods’ (Section Number 2.4.5).  Coomassie blue staining detected hRD, ΔhRDM and 
yRD proteins as well as the CYP2D6 protein (Figure 3.20).
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Figure 3.20. Coomassie staining of SDS-PAGE gels after subjecting Sf9 microsomal
proteins that contain CYP2D6 and different CPRs to SDS-PAGE.  25 μg of microsomal 
proteins were separated per lane on 10% SDS-PAGE. Gels were stained with
Coomassie G-250 as described in ‘Materials and Methods’ (Section Number 2.4.5).
Lane 1, protein marker; Lane 2, control (microsomes that do not contain any
recombinant proteins); Lane 3, CYP2D6 expressed alone; Lane 4, CYP2D6 co-
expressed with ΔhRD; Lane 5, CYP2D6 co-expressed with hRD; Lane 6, CYP2D6 co-
expressed with ΔhRDM; Lane 7, CYP2D6 co-expressed with yRD.  
3.10.1 Amounts of CYP2D6 in microsomes where
CPRs are co-expressed
The CYP2D6 holoprotein content was measured using CO-difference
spectrophotometric analysis. The spectra were typical of spectrally active P450 proteins
with a large peak at 450 nm and a very small peak at 420 nm (Figure 3.21). The
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CYP2D6 spectral content was highest when it was expressed alone. A decrease in
CYP2D6 content was observed when CYP2D6 was co-expressed with different CPRs.
It appeared that the decrease in the content of spectrally active CYP2D6 is not of the
same magnitude – the decrease seemed to depend on the specific CPR that is co-
expressed (Table 3.2). It was observed from the spectral content that co-expression of
yRD resulted in the lowest yield of CYP2D6. In comparison with native human CPR
and its variants, yRD is found to be most destructive to the CYP.  ΔhRD co-expression 
with CYP2D6 yielded the highest CYP content amongst all co-expressions. It is
noteworthy that ΔhRD is absent in microsomal membranes and therefore may not 
contribute at all to the destruction of the microsome-bound CYP. Surprisingly, the CYP
content in hRD co-expressed microsomes was ~20% lower than the CYP2D6 content in
ΔhRDM co-expressed microsomes indicating that the variant human CPR, ΔhRDM, is 
less toxic to the CYP than wild-type hRD.
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Figure 3.21. Reduced carbon monoxide difference spectra of CYP2D6 co-expressed
with different CPRs. Sf9 cells were infected with BV-2D6 at an MOI of 1 pfu/cell and
with BV-CPRs at an MOI of 0.1 pfu/cell. The cells were harvested at 63 h, microsomes
were prepared and CYP content was measured using CO-difference spectra.
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Table 3.2: Specific CYP2D6 content in microsomal samples where CYP2D6 was co-
expressed with CPRs. CYP2D6 content was determined using CO-difference
spectroscopy as described in ‘Materials and Methods’ (Section Number 2.4.3) and as
depicted in Figure 3.21. Sf9 cells were co-infected with BV-2D6 at an MOI of 1
pfu/cell and with BV-CPRs at an MOI of 0.1, and microsomes were prepared at 63 h
post-infection.
Microsome Samples CYP Content (pmol/mg protein)
CYP2D6 513.6 ± 16.9
CYP2D6  ΔhRD                          479.0 ± 13.7 
CYP2D6  ΔhRDM                          361.4 ± 15.0 
CYP2D6  hRD 300.4 ± 11.5
CYP2D6  yRD 107.5 ± 7.9
Western blotting was performed to confirm the presence of the CYP isozyme,
CYP2D6, in microsomal samples that co-express CYP2D6 and CPR.  1.5 μg of 
microsomal protein was separated on 10% SDS-PAGE and immuno-blotting was
performed as described in ‘Materials and Methods’ (Section Number 2.4.6) by using
antibodies specific to human CYP2D6. The blots were probed overnight with 1:2,000
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dilution of mouse monoclonal antibody to CYP2D6 (BD-Gentest, Catalogue No A246)
followed by incubation with 1:10,000 dilution of secondary antibody-Anti-mouse IgG-
HRP conjugate. The blots were developed using luminol chemiluminescent substrate.
The Western blot detected the CYP2D6 protein bands in all the microsomes that co-
express CYP2D6 and a CPR (Figure 3.22). The band intensities were measured by
means of densitometry on Bio-Rad’s Quantity One software. The sharp decrease in
spectrally active CYP2D6 in CPR co-expressed microsomes observed in reduced CO
difference spectra is not observed on the Western blot where band intensities, as
measured by densitometry, were not significantly different (Table 3.3). This means that
apoprotein levels are not drastically affected. There is a slight difference between the
CYP2D6 alone expressed band and the co-expressed CYP2D6 band intensities but this
was not mirrored in the reduced CO-difference spectra. These results indicate that
CPRs generally do not down-regulate or modulate CYP expression levels but are
responsible specifically for the destruction of CYP2D6 holoenzyme (spectrally active
enzyme). The destruction of CYP2D6 could be a result of CPR-initiated oxidative
damage of microsomal proteins.
Figure 3.22. Comparison of the levels of CYP2D6 co-expressed with different CPR
species in Sf9 insect cells, via Western blotting.  1.5 μg of microsomal proteins were 
loaded per lane on 10% SDS-PAGE and immuno-blotting was performed as described
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in ‘Materials and Methods’ (Section Number 2.4.6) using antibody specific to human
CYP2D6. Lane 1, control (microsomes from uninfected Sf9 cells); Lane 2, CYP2D6
co-expressed with yRD; Lane 3, CYP2D6 co-expressed with ΔhRDM; Lane 4, 
CYP2D6 co-expressed with hRD; Lane 5, CYP2D6 co-expressed with ΔhRD; Lane 6, 
CYP2D6 expressed alone without any CPR.
Table 3.3 The intensities of the CYP2D6 protein bands in the image shown in Figure
3.22 were measured by means of densitometry using Bio-Rad’s Quantity One software.
The densities were measured at 6 different points on each protein band and the average
values are presented as mean values ± STDEV.
Samples Average intensities % of CYP2D6 alone
CYP2D6 887 ± 116 100%
CYP2D6  ΔhRD            853 ± 81                                      97%  
CYP2D6  ΔhRDM            738 ± 29                                      85% 
CYP2D6  hRD 773 ± 78 88%
CYP2D6  yRD 805 ± 73 91%
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3.10.2 CPR activities in microsomal samples which
co-express CYP2D6
In order to find out the reductase activities in microsomal samples that co-
express CYP2D6, reductase assays were performed as described in ‘Materials and
Methods’ (Section Number 2.4.7) using both MTT and cytochrome c, as substrates.
Reductase activity of yRD was highest amongst all the CPRs (Table 3.4).  ΔhRD 
reductase activity was equal to control which was expected as the ΔhRD product does 
not anchor to microsomal membranes as revealed by Coomassie staining and Western
blotting (see Section 3.5).  The reductase activity of hRD is higher than ΔhRDM.  
However as seen earlier in the CO-difference spectra (Section 3.10.1), the strongest
CPR, (yRD), results in the lowest yield of spectrally active CYP2D6. The second
strongest CPR, (hRD), also results in a lower yield of spectrally active CYP2D6.
Amongst all the CPRs studied, ΔhRDM appears to yield the highest content of 
spectrally active CYP2D6.
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Table 3.4. Activities of NADPH-Cytochrome P450 reductase (CPR) exhibited by
different CPR species when co-expressed with CYP2D6. Sf9 cells were co-infected
with BV-2D6 and BV-CPRs and microsomes were prepared at 63 h. Reductase
activities were measured by using MTT and cytochrome c as described in ‘Materials
and Methods’ (Section Number 2.4.7). The moles of MTT and cytochrome c reduced
per minute per mg of protein were calculated. Uninfected Sf9 cells were used
as‘Control’.
CPR CPR Activity CPR Activity
(nmol MTT reduced/min/mg protein) (nmol cyt-c reduced/min/mg protein)
ΔhRD    21.2 ± 2.4                                             26.0 ± 1.6 
ΔhRDM    308 ± 23.8           383.7 ± 27.2 
hRD 425 ± 31.1 579.6 ± 51.7
yRD 584 ± 45.3 608.2 ± 68
Control 21.2 ± 1.1 24.1 ± 1.3
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3.11 Measurement of reactive oxygen species
We speculated that the destruction of CYP2D6 holoenzyme by CPR could be a
result of oxidative damage triggered by CPR. Therefore, to further investigate the
reason behind this destruction, two parallel assays were set up to measure reactive
oxygen species (ROS) in cells infected with BV-CPRs. ROS was measured using
H2DCFDA and Dihydrorhodamine-123 as substrates.  As ΔhRD does not anchor to 
microsomal membranes, it was not studied any further.
Sf9 cells were infected with a range of MOIs (0.2 to 4.0 pfu/ml) of different BV-
CPRs species for 72 h. At 72 h, the assay was performed as described in ‘Materials and
Methods’ (Section Number 2.4.10). Percentage induction of ROS over control was
calculated in baculovirus infected cells. The results obtained were in line with the
results presented in Tables 3.2 and 3.4. The reductases, hRD and yRD, which are
stronger than ΔhRDM (in terms of MTT and cytochrome c reduction) exhibited stronger
induction of ROS in comparison with ΔhRDM (Figures 3.23 and 3.24).   
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Figure 3.23. The ROS produced by different CPR species, as measured via the
H2DCFDA assay. ROS was measured using the H2DCFDA dye as substrate. Sf9 cells
were infected with a range of MOIs (0.2 to 4.0 pfu/ml) of different CPR species for 72
h. At 72 h, the H2DCFDA assay was performed as described in ‘Materials and
Methods’ (Section Number 2.4.10). The oxidation of intracellular non-fluorescent
H2DCF to highly fluorescent DCF was measured on a fluorometer. Blank values,
indicating the fluorescence of the dye in PBS were subtracted from all the samples.
Percentage induction over control was calculated in baculovirus infected cells.
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Figure 3.24. The ROS produced by different CPR species, as measured via the
Dihydrorhodamine-123 assay. Sf9 cells were infected with a range of MOIs (0.2 to 4.0
pfu/ml) of different reductase species for 72 h. At 72 h, the Dihydrorhodamine-123
assay was performed as described in ‘Materials and Methods’ (Section Number 2.4.10).
The oxidation of Dihydrorhodamine-123 to highly fluorescent rhodamine was measured
on a fluorometer. Blank values, indicating the fluorescence of the dye in PBS were
subtracted from all the samples. Percentage induction over control was calculated in
baculovirus infected cells.
3.12 CYP2D6 enzymatic activities in the presence of CPRs
To compare the catalytic activity of recombinant CYP2D6 in microsomes that
co-express CPRs, enzyme assays were performed using fluorogenic substrates. These
involved kinetic analyses of CYP2D6 microsomes and were performed using three
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different substrates, EOMCC, AMMC and CEC, as described below. 1.5 pmol of
CYP2D6 was used per reaction and each reaction was performed in replicates. Kinetic
progression of reactions was measured up to a period of 30 min.
3.12.1 EOMCC Assay
Kinetic studies with CYP2D6 microsomes (i.e. measurement of activities) were
performed using the Vivid® fluorogenic substrate EOMCC (3-cyano-7-(ethoxymethoxy)
coumarin) as per the standard Invitrogen Screening Kit protocol (Marks et al. 2002 and
2003). EOMCC is demethylated by human CYP2D6 to the fluorescent product 3-
cyano-7-hydroxycoumarin (CHC). The reactions were carried out in a reaction volume
of 100 μl/ well in 96-well black plates (Fisher Scientific, Catalogue No FB85083).  The 
reaction was carried out at 37ºC in 100 mM potassium phosphate buffer pH 8.0,
containing 10 μM EOMCC, 1.5 pmol CYP2D6 and the NADPH regenerating system 
(1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl2, 0.4U/ml glucose-6-
phosphate dehydrogenase). The fluorescent values were recorded on the Biotek
Synergy HT plate reader using an excitation wavelength of 400 nm (20 nm) and
emission wavelength of 460 nm (40 nm). Changes in fluorescence were measured as
relative fluorescence units (RFU). Kinetic progression of reactions was measured for
30 min (Figure 3.25 (B) and Table 3.5). Concentration of product formed was
determined using CHC as a standard.
The standard curve of CHC was prepared using a range of concentrations of
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CHC (0, 39.1, 78.1, 156.3, 312.5, 625, 1250 pmol/ ml). The assay for the standard was
performed in 96-well black plates. The fluorescent values (RFU) were recorded on the
Biotek Synergy HT plate reader using an excitation wavelength of 400 nm (20 nm) and
emission wavelength of 460 nm (40 nm). Standard curve was plotted and used to
convert the RFU measured with test samples to CHC concentrations. The standard
curve is shown in Figure 3.25 (A).
Figure 3.25 (A). CHC standard curve. The curve was plotted as described in Section
3.12.1.
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Figure 3.25 (B). Comparative kinetic analyses of CYP2D6 co-expressed with different
CPRs, using EOMCC as a substrate. Sf9 cells were co-infected with CYP2D6 and
different CPR species at an MOI of 1 and 0.1 pfu/ cells respectively. The activity of
CYP2D6 co-expressed with various CPR species was measured using microsomes
prepared at 63 h after baculovirus infection. EOMCC assay was performed as described
in Section 3.12.1.
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Table 3.5. CYP2D6 enzyme reaction rates in co-expressed microsomes, as tabulated
from Figure 3.25 (B). Sf9 cells were co-infected with CYP2D6 and the CPR
baculoviruses at an MOI of 1 and 0.1 pfu/ cell, respectively. The reaction rates were
measured in microsomes prepared at 63h post-infection. EOMCC assay was performed
as described in Section 3.12.1.
Microsomes CYP2D6 reaction rates
(pmole CHC formed/ min/ pmole of CYP2D6)
CYP2D6
CYP2D6+hRD
CYP2D6+ΔhRDM 
CYP2D6+yRD
0.08568
0.16388
0.21359
0.18182
3.12.2 AMMC Assay
CYP2D6 microsomal activity was also measured using the 3-[2-(N,N-diethyl-N-
methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) fluorogenic substrate
(Chauret et al, 2001). AMMC is demethylated by human CYP2D6 to the fluorescent
product 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-hydroxy-4-methylcoumarin
(AHMC).  The reactions were carried out in a reaction volume of 100 μl/ well in 96-
well black plates (Fisher Scientific, Catalogue No FB85083). The reaction was carried
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out at 37ºC in 100 mM potassium phosphate buffer pH 8.0, containing 1.5 μM AMMC, 
1.5 pmol CYP2D6 and the NADPH regenerating system (1.3 mM NADP+, 3.3 mM
glucose-6-phosphate, 3.3 mM MgCl2, 0.4U/ml glucose-6-phosphate dehydrogenase).
The fluorescent values were recorded on the Biotek Synergy HT plate reader using an
excitation wavelength of 400 nm (20 nm) and emission wavelength of 460 nm (40 nm).
Changes in fluorescence were measured as relative fluorescence units (RFU). Kinetic
progression of reactions was measured for 30 min (Figure 3.26 (B) and Table 3.6).
The standard curve of AHMC was prepared using a range of concentrations of
AHMC (0, 0.914, 8.222, 24.667, 74.0, 222.0, 666.0 pmol/ ml). The assay for the
standard was performed in 96-well black plates. The fluorescent values (RFU) were
recorded on the Biotek Synergy HT plate reader using an excitation wavelength of 400
nm (20 nm) and emission wavelength of 460 nm (40 nm). Standard curve was plotted
and AHMC concentrations in test samples were measured using the equation from the
standard curve. The standard curve is shown in Figure 3.26 (A).
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Figure 3.26 (A). AHMC standard curve. The curve was plotted as described in Section
3.12.2.
Figure 3.26 (B). Comparative kinetic analyses of CYP2D6 co-expressed with different
CPRs, using AMMC as a substrate. Sf9 cells were co-infected with CYP2D6 and
different CPR species at an MOI of 1 and 0.1 pfu/cell, respectively. The activity of
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CYP2D6 expressed with various CPR species was measured using microsomes from
cells infected with baculoviruses for 63 h. AMMC assay was performed as described in
Section 3.12.2.
Table 3.6. CYP2D6 enzyme reaction rates in co-expressed microsomes, as tabulated
from Figure 3.26 (B). Sf9 cells were co-infected with CYP2D6 and the CPR
baculoviruses at an MOI of 1 and 0.1 pfu/ cell, respectively. The reaction rates were
measured in microsomes prepared at 63h post-infection. AMMC assay was performed
as described in Section 3.12.2.
Microsomes CYP2D6 reaction rates
(pmole AHMC formed/ min/ pmole of CYP2D6)
CYP2D6
CYP2D6+hRD
CYP2D6+ΔhRDM 
CYP2D6+yRD
0.09648
0.32711
0.35025
0.30078
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3.12.3 CEC Assay
CYP2D6 activity was measured using one more fluorogenic substrate, 3-cyano-
7-ethoxycoumarin (CEC). CEC is metabolised mainly by CYP2C19 and CYP1A2 to a
fluorescent product 3-cyano-7-hydroxycoumarin (CHC) (Yamamoto et al. 2003).
However CEC is also metabolised by CYP2D6, though not specific for this CYP
isozyme.  The reactions were carried out in a reaction volume of 100 μl/ well in 96-well 
black plates (Fisher Scientific, Catalogue No FB85083). The reaction was carried out at
37ºC in 100 mM potassium phosphate buffer pH 7.4, containing 50 μM CEC, 1.5 pmol 
CYP2D6 and the NADPH regenerating system (1.3 mM NADP+, 3.3 mM glucose-6-
phosphate, 3.3 mM MgCl2, 0.4U/ml glucose-6-phosphate dehydrogenase). The
fluorescent values were recorded on the Biotek Synergy HT plate reader using an
excitation wavelength of 400 nm (20 nm) and emission wavelength of 460 nm (40 nm).
Changes in fluorescence were measured as relative fluorescence units (RFU). Kinetic
progression of reactions was measured for 30 min (Figure 3.27 and Table 3.7).
Standard curve was plotted and CHC concentrations in test samples were
measured using the equation from the standard curve. The standard curve is shown in
Figure 3.25 (A).
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Figure 3.27: Comparative kinetic analyses of CYP2D6 co-expressed with different
CPRs using CEC as a substrate. Sf9 cells were co-infected with CYP2D6 and different
CPRs. The activity of CYP2D6 expressed with various CPR species was measured
using microsomes from cells infected with baculoviruses for 63 h. CEC assay was
performed as described in Section 3.12.3.
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Table 3.7. CYP2D6 enzyme reaction rates in co-expressed microsomes, as tabulated
from Figure 3.27. Sf9 cells were co-infected with CYP2D6 and the CPR baculoviruses
at an MOI of 1 and 0.1 pfu/ cell, respectively. The reaction rates were measured in
microsomes prepared at 63h post-infection. CEC assay was performed as described in
Section 3.12.3.
Microsomes CYP2D6 reaction rates
(pmole CHC formed/ min/ pmole of CYP2D6)
CYP2D6
CYP2D6+hRD
CYP2D6+ΔhRDM 
CYP2D6+yRD
0.50897
1.2472
1.38
1.3998
3.12.4 LC MS analysis of dextromethorphan O-demethylase
activity of CYP2D6
The ability of the CYP2D6 co-expressed with hRD, hRD and hRDM to
metabolise dextromethorphan, via its dextromethorphan O-demethylase activity, was
studied using the assay described below.
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Dextromethorphan O-demethylase activity was studied according to the method
of Walsky and Obach (2004) with minor modifications. Dextromethorphan O-
demethylase activity was measured in a 100 μl reaction mixture which contained 3.0 
pmole of CYP2D6 co-expressed with various reductases, NADPH regenerating system
(3.6 mM NADP+, 6.6 mM glucose-6-phosphate, 6.6 mM magnesium chloride, 0.8U of
glucose-6-phosphate dehydrogenase) and a range of concentrations of
dextromethorphan (0.25 μM to 4.0 μM).  This mixture was incubated at 37ºC for 20 
min. At the end of this time point, the reaction was stopped by vigorous mixing with
100 µl of 0.05% formic acid in acetonitrile and incubation on ice for 10 min. The
precipitated proteins were removed by centrifugation at 13,000X g.
Analysis of the resulting supernatants was carried out on an Agilent LC/MS
single Quadrupole mass spectrophotometer equipped with an APCI/ESI multimode
ionisation source.  20 μl of the supernatant was loaded for each run on an Agilent 
Eclipse XDB Zorbax C18 column. A 17 min linear gradient elution at a flow rate of 1.0
ml/min, using solvent A (0.05% formic acid) and solvent B (0.05% formic acid in
acetonitrile), was used to detect dextrorphan (the metabolite) and dextromethorphan (the
substrate). All assays were carried out in triplicate. The parameters of enzyme kinetics
(Km, Vmax and efficiency of catalysis) were calculated using Graphpad Prism version
3.02 (2000).
CYP2D6 alone and CYP2D6 + hRD co-expressed microsomes showed lack of
ability to metabolise detromethorphan. This is justified as the presence of the electron
169
donor protein, CPR, is essential for CYP catalytic activity. The absence of hRD on
the microsomes could explain the results observed. In comparison to CYP2D6 + hRD
co-expressed microsomes, the CYP2D6+ hRDM has increased enzyme activity as
seen by increased Vmax and thereby overall efficiency of catalysis (Table 3.8). No
significant changes were observed in the Km values stating that the affinity for the
substrate towards CYP2D6 holoenzyme has not changed but the higher coupling
efficiency of ΔhRDM has resulted in increased Vmax thereby the quadrupling of the 
efficiency of catalysis.
Table 3.8. Efficiency of CYP2D6 enzyme mediated catalysis of dextromethorphan.
CYP2D6 was co-expressed with hRD and ΔhRDM in Sf9 cells and the ability of the 
respective microsomes to metabolise dextromethorphan to dextrorphan was determined
using procedures described in Section 3.12.4. Efficiency of catalysis was calculated
using the ratio, Vmax/Km.
Microsome Vmax (pmol/min/
pmol CYP2D6)
Km (μM) Vmax/Km(μl/min/p
mol CYP2D6)
CYP2D6 0 0 0
CYP2D6+ΔhRD 0 0 0 
CYP2D6+hRD 0.764 + 0.017 1.303 + 0.489 0.586
CYP2D6+ΔhRDM 4.026 + 0.279 1.436 + 0.239 2.803
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The enzyme assays in this Section clearly show that CYP2D6 activity is
significantly higher in microsomes where CPR is co-expressed as compared to the
microsomes where CYP2D6 is expressed alone. However there is a great deal of
difference amongst samples that co-express the CYP and the different CPRs, as
enumerated below.
1. Since the holoprotein content of CYP2D6 is very low when co-expressed with
yRD, significantly more protein is needed to achieve 1.5 pmol enzyme
concentrations in the reactions that are used for enzyme activities.
2. The reductase activity of the yeast CPR, yRD, is very strong but unfortunately it
does not couple well with the human CYP2D6 (i.e. it provides poor CYP2D6
activity).
3. Although the reductase activity of the human CPR variant, ΔhRDM, is much 
lower than the human CPR (hRD) and the yeast CPR (yRD) as determined by
MTT and cytochrome c assays, the reaction rates of CYP2D6 are supported
better by ΔhRDM than the two more powerful reductases, hRD and yRD 
(Figures 3.25, 3.26, 3.27 and Table 3.8).
The only explanation for these results is that ΔhRDM is far more efficient in activating 
CYP2D6 than hRD and yRD.
3.13  Coupling efficiency of hRD, ΔhRDM and yRD with CYP2D6  
The CPR activity of ΔhRDM, as measured by the MTT assay, in microsomes 
that co-express CYP2D6 and ΔhRDM is lower than the CPR activity in microsomes 
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that co-express CYP2D6 and hRD or yRD.  Yet, our results indicate that ΔhRDM has a 
higher potential to activate CYP2D6 enzymatic reactions. To further highlight the
property of this variant human CPR molecule, the coupling ability of ΔhRDM was 
determined in terms of percentage relative coupling efficiency.
Percentage coupling efficiency was calculated by dividing CYP activity in the
EOMCC assay by CPR activity in the MTT assay. The coupling efficiency of the
different CPRs was tabulated in comparison with ΔhRDM (ΔhRDM activity being 
considered as 100%; Figure 3.28). The coupling efficiency values clearly show that
ΔhRDM couples better with CYP2D6 than the native, wild-type form of hRD.  The 
lower levels of ROS induction by ΔhRDM (Figures 3.23 and 3.24) provide a valid 
reason for its higher coupling efficiency.
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Figure 3.28. Percentage relative coupling efficiencies of different CPRs with CYP2D6
were calculated in comparison with ΔhRDM using microsomes that were prepared from 
Sf9 cells after 63 h of baculovirus infection. The product formed (CHC) from the
EOMCC assay and CPR activity measured in the MTT assay were used for the
calculations. CYP2D6 activity was divided by CPR activity and percentage relative
coupling efficiency was determined.
3.14 Augmentation of CYP2D6 activity by changing the reductase
ratios
Since ΔhRDM shows clear superiority over the two reductases hRD and yRD 
(being less destructive to the CYP2D6 holoprotein and having better reaction rates), we
thought of increasing the ΔhRDM amounts during co-expression with CYP2D6.   
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Sf9 cells were seeded and infected in T75 flasks with BV-CYP2D6 and BV-
ΔhRDM as described in ‘Materials and Methods’.  For co-infection, Sf9 cells were 
infected with BV-CYP2D6 with an MOI of 1.0 pfu/cell and with BV-CPR at two
different MOIs of 1×10-1 pfu/cell (CYP2D6 to CPR ratio: 10:1) and 2×10-1 pfu/cell
(CYP2D6 to CPR ratio: 5:1). Microsomes were prepared after 63 h and 1.5 pmol of
CYP2D6 was used per reaction for the enzyme assays which were performed using
CEC as a substrate.  By doubling the MOI of BV-ΔhRDM during co-expression, 
substantial increase in rates of reaction were observed (Figure 3.29). A similar
experiment was performed with CYP2D6 and hRD and again an increase in the reaction
rates were observed (Figure 3.30).  With doubling of MOIs of both BV-ΔhRDM and 
hRD, decrease in spectrally active CYP2D6 was observed. However, the spectrally
active CYP2D6 at 5:1 ratio of CYP2D6 : ΔhRDM was much higher than the CYP2D6 
obtained when the CYP2D6 : hRD ratio was 5:1 (Table 3.9).
Thus ΔhRDM clearly provides more room for improvement.  It would definitely 
allow for further optimisation of experimental routes towards higher levels of CYP2D6
production on insect cell derived microsomal membranes together with much improved
activity.
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Figure 3.29. Kinetic analysis of CYP2D6 co-expressed with two different ratios of
CYP to ΔhRDM, as shown in legend.  CEC assay was performed using microsomes that 
were prepared from Sf9 cells after 63 h of baculovirus infection. Standard curve was
plotted and CHC concentrations in test samples were measured using the equation from
the standard curve. The standard curve is shown in Figure 3.24 (A).
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Figure 3.30. Kinetic analysis of CYP2D6 co-expressed with two different ratios of
CYP to hRD, as shown in legend. CEC assay was performed using microsomes that
were prepared from Sf9 cells at 63 h of baculovirus infection. Standard curve was
plotted and CHC concentrations in test samples were measured using the equation from
the standard curve. The standard curve is shown in Figure 3.24 (A).
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Table 3.9. Comparison of the levels of CYP2D6 produced and CPR activities when
CYP2D6 is co-expressed with hRD and ΔhRDM in two different ratios of CYP to CPR 
(10:1 and 5:1). Spectral analysis for the quantification of CYP and the assay for CPR
were performed using microsomes that were prepared from Sf9 cells after 63 h of
baculovirus infection.
Sample CYP2D6 Content CPR Activity
(nmol/mg protein) (nmol MTT reduced/min/mg protein)
CYP2D6hRD(10:1) 0.2027 ± 0.016 407 ± 29.3
CYP2D6hRD(5:1) 0.0724 ± 0.009 620 ± 42.1
CYP2D6ΔhRDM(10:1)         0.2710 ± 0.011 283 ± 18.0 
CYP2D6ΔhRDM(5:1)            0.1628 ± 0.008 550 ± 28.6 
Insect cells can be grown in bioreactors and thus are able to produce large
quantities of recombinant proteins. Bioreactors can be used for the expression of active
CYPs and have application in large-scale bio-catalysis. Hence, higher CYP reaction
rates are highly sought after not only in drug metabolism studies but also in the area of
bio-transformations.
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3.15 Augmentation of CYP2D6 activity by blending the reductase
microsomes with CYP2D6 microsomes
In order to see if the activity of CYP2D6 could be augmented, we performed
further experiments. Since Tni cells are capable of expressing significantly higher
levels of recombinant proteins compared to other insect cell lines, we used this cell line
for co-expression of the CYP and CPRs. The co-expression of CPR with a CYP results
in CYP destruction, yet co-expression is essential for high catalytic activity of CYPs.
We wanted to find out the consequence of blending additional CPR microsomes, during
the process of microsomal preparations, to the microsomes that co-express the CYP,
CPR enzymes.
Therefore, we co-infected Tni cells with BV-CYP2D6 (MOI of 1.0 pfu/ cell)
and BV-ΔhRDM (MOI of 1×10-1 pfu/ cell). In a separate set of flasks, Tni cells were
infected only with BV-hRD with an MOI of 1.0 pfu/ cell. The cells were processed and
harvested as described in ‘Materials and Methods’. At 63 h post-infection, cells were
lysed and centrifuged to remove cell debris. The cell lysate from the co-expression
experiment was blended with the lysate from cells infected only with hRD in 3:1 ratio
(three parts of co-expression lysate and one part of hRD-expressed cell lysate). The
blended mixture was then processed as described in ‘Materials and Methods’ and
microsomes were prepared. Enzyme activity was assayed using 1.5 pmol of enzyme per
reaction and AMMC as a substrate (Figure 3.31). By blending the enzymes in this way,
it is likely that the organization of CYP and ΔhRDM on microsomal membranes is not 
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altered but that some extra reductase activity is provided to the system. Surprisingly,
blending further increased the enzyme activity by about 40%.
Figure 3.31.  Comparative kinetic analysis of CYP2D6 co-expressed with ΔhRDM and 
blended with hRD as shown in legend. AMMC assay was performed using microsomes
that were prepared from Tni insect cells after 63 h of baculovirus infection. CYP to
CPR ratio for blending was 3:1. Standard curve was plotted and AHMC concentrations
in test samples were measured using the equation from the standard curve. The
standard curve is shown in Figure 3.25 (A).
3.16  Spinner culture for co-expression of CYP2D6 and ΔhRDM in  
Tni cells
Expression level of heterologous proteins in Tni cells is known to be higher than
Sf9 and Sf21 cells.  As ΔhRDM couples better with CYP2D6, a scale-up experiment 
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using spinner culture was set up for co-expression of CYP2D6 with ΔhRDM in Tni 
cells. Spinner cultures were set up as described in ‘Materials and Methods’ (Section
Number 2.3.6). The cells were seeded at a density of 1.25 x 106 cells/ ml in Express
Five™ medium. Total culture volume was 250 ml in 500 ml spinner flask with a
vertical impeller.
It has been reported that cells in suspension require lower MOI for expression of
spectrally active CYPs than that is required for adherent cultures (Crespi and Miller,
1999). In line with this, the cells were co-infected with BV-CYP2D6 at an MOI of 0.3
pfu/ml and with BV-ΔhRDM at an MOI of 0.03 (10 times less).  In previous 
experiments, the adherent cells were infected with BV-CYP2D6 at an MOI of 1 pfu/cell
but in this experiment the cells in suspension were infected with lower MOI (0.3
pfu/cells). The spinner flask was incubated at 27°C with constant stirring at 90 rpm. 24
h post-infection haemin was added to a final concentration of 2.5 µg/ml. Microsomes
were prepared 63 h post-infection and after measuring protein concentrations and CYP
content, EOMCC assay was performed to measure CYP2D6 catalytic activity (as
described in Section 3.12.1). Results from this scale-up experiment were similar to that
obtained from earlier small scale co-expression studies with CYP2D6 and ΔhRDM 
(Figure 3.32). It shows that CYP expression can efficiently be scaled up using lower
MOIs to produce enzymatically active protein.
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Figure 3.32.  Kinetic analysis of CYP2D6 co-expressed with ΔhRDM, in a spinner 
flask, using EOMCC as a substrate. Tni cells in a spinner flask were co-infected with
CYP2D6 and ΔhRDM at an MOI of 0.3 and 0.03 pfu/ cells, respectively.  The activity 
of CYP2D6 co-expressed with ΔhRDM was measured using microsomes prepared at 
63h after baculovirus infection. EOMCC assay was performed as described in Section
3.12.1.
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3.17 Conclusion
With the exception of some plants, a single CPR of a particular eukaryotic
species interacts with all other cytochrome P450s enzymes of the same species
(Benveniste, 1991). Therefore, understanding the process by which this interaction
occurs is an important biological goal.
In this study we have cloned and expressed CYP2D6 with native human CPR
(hRD), two variants of native human CPR (ΔhRD and ΔhRDM) and yeast CPR (yRD) 
in Sf9 insect cells.  The human CPR-variant, ΔhRD from which the N-terminal 24 
amino acids have been removed do not anchor to microsomal membranes. Interestingly
however, the other variant, ΔhRDM (which also lacks the N-terminal 24 amino acids 
but has a 17-amino acid sequence which includes the 12-amino acid c-myc tag epitope
attached at the C-terminal end of ΔhRD) regains the ability to anchor to microsomal 
membranes. The c-myc tag at the C-terminal of the fusion protein, ΔhRDM must be 
somehow involved in the tertiary structure of the protein and helping the protein to
anchor to the microsomal membranes. It is possible that the C-terminal tag is the source
of the ΔhRDM’s activity.  Our experiments have consistently failed to show any 
reductase activity for ΔhRD even in the soluble cytosolic fraction of the cell lysate 
(results not shown).
The c-myc tag is generally used as an epitope tag and can be added to either the
N-terminus or C-terminus of a known protein coding sequence. The tag is recognised
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by antibodies raised against the 12-amino acid c-myc peptide epitope (9E10) and can be
used to localize tagged proteins in cells. Although the tagged protein is merely a fusion
protein between the expressed protein and the tag, its expression may not be regulated
in the same way as would occur in vivo since the fusion protein is usually expressed
under the control of a heterologous promoter. This could result in the abnormal
expression of the tagged protein. Some previous studies have shown that an epitope tag
may or may not affect a target protein activity or its folding and topology (Sells and
Chernoff, 1995; Jarvik and Telmer, 1998; Chavand et al., 2001). In this study we have
demonstrated that the C-terminal c-myc tag in ΔhRDM exhibits an unusual 
phenomenon, that is, allows the N-terminally truncated reductase ΔhRD to bind again to 
microsomal membranes.
The insect cell-baculovirus expression system has been used for expression of a
range of recombinant proteins. But expression of CYPs in the baculovirus expression
system provides some unique advantages. Insect cells can be co-infected with two or
more recombinant baculoviruses, and so CYP to CPR ratio can be changed by altering
the MOI for each virus (Tamura, 1992). In this study we have expressed CYP2D6 with
human CPR and its engineered variants (Figure 3.2) and also with yeast NADPH
cytochrome P450 reductase (yRD). All the CPRs have different reduction potentials as
measured by the MTT assay. However when these CPRs were co-expressed with the
CYP2D6 and the CYP activity was measured using enzyme assays, we found that the
strength of the reductase does not determine CYP activity – it is the ability of CPR to
couple with CYP which is crucial.
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The yeast CPR (yRD) appears to have the strongest reduction potential but it is
extremely destructive to CYP2D6. It also does not offer a better reaction rate in
CYP2D6 assays implying that it fails to couple well with CYP2D6. The destruction of
the CYP2D6 by yeast and human CPRs is significant which is reflected in the decrease
in CYP2D6 spectral content when CYP, CPR proteins are co-expressed. This is in
comparison with the spectral content obtained when CYP2D6 is expressed alone.
Based on the CYP2D6 enzyme assays, percentage relative coupling efficiency
and efficiency of catalysis it can be concluded that the ΔhRDM, which has the weakest 
reduction potential, surprisingly provides the best CYP2D6 reaction rates in comparison
with the two wild-type CPRs – hRD and yRD.  We find that ΔhRDM not only couples 
far better to CYP2D6 than the native human CPR, hRD. But also yields higher levels of
CYP2D6 with far less destruction of the CYP.
All the CPRs studied did decrease the CYP holoenzyme but the apoprotein
levels were found to be unaffected (Figure 3.22). We were able to show the possible
cause of CYP2D6 destruction by CPRs. The reactive oxygen species (ROS) assays
clearly indicated that the cause of CYP2D6 destruction is likely to be oxidative damage
caused by CPRs. Based on the results obtained, this chapter clearly illustrates that peak
enzymatic activity cannot just be obtained by increasing the MOI of the CPR
baculovirus. Coupling efficiency of a CPR is extremely important to achieve the best
enzymatic activity of the CYP.
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In conclusion ΔhRDM, a genetically engineered variant of human CPR offers 
advantages of high-level expression of CYP2D6 with better reaction rates.  ΔhRDM 
also offers an improvement in the ratio of spectrally active CYP2D6 to spectrally
inactive CYP2D6.
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Chapter 4 Interaction of human and yeast NADPH cytochrome
P450 reductases with human CYP3A4 on ER
membranes of insect cells
4.1 Introduction
Cytochrome P450 enzymes (CYPs) belong to a superfamily of haem binding
monooxygenase enzymes involved in metabloism of xenobiotics such as toxins,
carcinogens and drugs as well as in the biosynthesis of cholesterol, vitamins and
steroids (Wolf et al 1986; Shou et al. 2001). Biotransformation of these xenobiotics and
endobiotics by CYPs requires supply of reducing equivalents from its redox partner
NADPH cytochrome P450 reductase (CPR). The CPR contains FMN, FAD and
NADPH binding domains and electrons are transferred from NADPH to FAD to FMN
and finally to CYP. The interaction between CYP and CPR occurs on the surface of the
endoplasmic reticulum (ER). Electrostatic (Shen and Kasper 1995), hydrophobic and
van der Waals forces (Voznesensky and Schenkman 1994) have been implicated as
determinants of this interaction. However CYP-CPR interaction and the formation of a
productive monooxygenase complex remain poorly understood (Deeni et al. 2001).
Both CYP and CPR contain N-terminal hydrophobic domains that allow anchoring to
the microsomes (ER membranes) which appears to be important for correct spatial
orientation of the redox centres for effective electron transfer.
In comparison with other CYPs, human CYP3A4 exhibits negligible catalytic
activity when co-expressed alone in the presence of yeast’s endogenous CPR in yeast
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cells. This was explained by the possibility that CYP3A4 forms two dimensional
aggregates on yeast microsomal membranes, thereby inhibiting interaction with the
endogenous yeast CPR (Hayashi et al 2000). It was observed that only a fusion
between human CYP3A4 and yeast CPR permitted measurable catalytic activity. In the
presence of human cytochrome b5, the catalytic efficiency of CYP3A4 (in the
CYP3A4–yeast CPR fusion) towards its substrates was appreciably enhanced (Hayashi
et al 2000) which corroborated earlier findings that human cytochrome b5 plays a major
role in the catalytic activity of CYP3A4 (Truan et al 1993; Voice et al 1999).
It seems that in all CYP–CPR fusion constructs, the CYP domain is anchored to
the microsomes and the C-terminal reductase (shorn off its own N-terminal membrane
anchor) moves flexibly lying on the cytoplasmic side (Yabusaki 1995). Since the fused
enzyme is expressed as a single polypeptide chain, the reductase domain of CPR and the
haem domain of CYP are probably forced to remain in close proximity rather than
associating with each other via natural interactions on ER membranes which happens
when the two enzymes, CYP and CPR, are expressed as separate entities.
There are a number of reports on the co-expression of the yeast CPR and a
human CYP on yeast microsomes and their resultant activities (Eugster and Sengstag
1993; Ellis et al 1992; Renaud et al 1990; Brian et al 1990) – they vary from being quite
good to extremely poor (our own unpublished observations). To the best of our
knowledge, the possible interaction of the yeast CPR with a human CYP on insect cell
microsomes has never been studied before although a variety of different eukaryotic
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(mainly mammalian) CPRs have been co-expressed with human CYPs in insect cells
(Wang et al. 1996; Lee et al. 1995; Paine et al 1996; Schwarz et al. 2001).
We specifically chose to further understand the interaction of yeast CPR with
human CYP3A4 in insect cells with the knowledge that there have been some
inexplicable hurdles towards the co-expression of these two enzymes, as separate
entities, in baker’s yeast. Hence, human CYP3A4 and cytochrome b5 were co-
expressed in an insect cell system and a comparative study was performed between their
interactions with human and yeast CPR. Cytochrome b5 is known to stimulate CYP3A4
activity towards its substrates (Voice et al 1999).
The CYP3A4 enzyme is the most abundant drug-metabolizing CYP in human
liver, consisting of about 30-40% of the total hepatic CYP content (Shimada et al, 1994;
Imaoka et al. 1996). Apart from the liver, CYP3A4 is also an intestinal phase I enzyme
(Kolars et al. 1992) that metabolises approximately 50% of currently marketed drugs
(Bertz and Granneman 1997). A number of important drugs have been identified as
substrates, inducers and/or inhibitors of CYP3A4. The substrates of CYP3A4 include
drugs, such as quinidine, nifedipine, diltiazem, lidocaine, lovastatin, erythromycin,
cyclosporin, triazolam, and midazolam, and endogenous substances that include
testosterone, progesterone, and androstenedione (Pelkonen et al. 1998, Guengerich
1999). It also activates procarcinogens, including aflatoxin B1 (Aoyama et al. 1990),
polycyclic aromatic hydrocarbons (PAHs) (Kapucuoglu et al. 2003), 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (Hecht 1999), and 6-
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aminochrysene (Yamazaki et al. 1995). CYP3A4 is induced in human hepatocytes by
rifampicin (Morel et al. 1990, Schuetz et al. 1993), dexamethasone (Pichard et al. 1992,
Schuetz et al. 1993, Kocarek et al. 1995), and phenobarbital (Schuetz et al. 1993,
Kocarek et al. 1995). CYP3A4 is also induced in vivo by rifampicin and barbiturates in
the liver (Perrot et al. 1989, Ged et al. 1989) and by rifampicin in the small intestine
(Kolars et al. 1992).
As CYP3A4 is the most abundant and most important CYP in the human liver,
the inhibition or induction of CYP3A4 by drugs often causes unfavourable drug-drug
interactions and can lead to fatal toxicity. Detection of possible CYP3A4 inhibitors and
inducers during the early stages of drug development is critical in preventing potential
drug-drug interactions and side effects. Clinicians are encouraged to have a sound
knowledge of the drugs that behave as substrates, inhibitors or inducers of CYP3A4.
They ought to be prescribed judiciously with close monitoring so as to avoid possible
interactions between drugs that are inhibitors and inducers of CYP3A4. It is often
necessary to use such drugs simultaneously (Zhou 2008).
In this Chapter, we show the interactions of both yeast and human CPR with
human CYP3A4 using the baculovirus expression system. We have explored the ability
of the two CPRs to transfer electrons to an artificial substrate MTT and then extended
the observations to a physiological substrate, CYP3A4. Previously it has been reported
that human CYP levels are drastically reduced when it is co-expressed with CPR in the
baculovirus expression system (Chen et al 1997; Wang et al 1996; Paine et al 1996).
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We have also found in our studies in Chapter 3 that oxidative damage caused by CPRs
is responsible for reduction in CYP holoprotein content. We find here a similar effect
when a human CYP and the human CPR are co-expressed together. However in the
case of yeast CPR, we find that oxidative damage is not the complete reason behind it
being unable to support CYP3A4’s catalytic activity.
4.2 Gene cloning in basic vectors
The cytochrome P450 3A4 (CYP3A4) and cytochrome b5 genes were isolated
by PCR from a human liver cDNA library (Life Technology, Catalogue No 10422-012).
The CYP3A4 gene was isolated with the forward primer (5’- GCAGATCTGC
CACCATGGCT CTCATCCCAG ACTTGGCC -3’, the BglII site and the Kozak
sequence are marked with an underline and bold letters, respectively), and the reverse
primer (5’-ATGTCGACTC AGGCTCCACT TACGGTGCC -3’, the SalI site is
underlined). The cytochrome b5 gene was isolated with the forward primer (5'-
CGGGATCCGC CACCATGGCA GAGCAGTCGG ACGAGG -3', the BamHI site
and the Kozak sequence are marked with an underline and bold letters, respectively) and
the reverse primer (5'-GCTCTAGATC AGTCCTCTGC CATGTATAGG CGATAC -
3', the XbaI site is underlined). The genes coding for human NADPH P450 reductase
(hRD), its variants (ΔhRD and ΔhRDM) and the yeast NADPH P450 reductase (yRD) 
were cloned earlier and are described in Chapter 3.
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The genes were amplified using the above mentioned primers, as described in
‘Materials and Methods’ (Section Number 2.2.2). The PCR products were run on an
agarose gel containing ethidium bromide, and DNA fragments of expected size were
isolated and purified using Qiagen gel extraction kit according to the manufacturer’s
protocol. The purified DNA fragments were digested with the corresponding restriction
enzymes and after digestion run again on an agarose gel containing ethidium bromide.
The digested DNA fragments were purified using the Qiagen gel extraction kit. The
CYP3A4 and cytochrome b5 genes were then directionally ligated using T4 DNA ligase
into pSP73 and pBluescript KS+, respectively (digested with the same restriction
enzymes with which the corresponding genes were digested). The ligation mixture was
used for transforming E. coli DH5α competent cells, and colonies containing the correct 
recombinant constructs were identified via restriction analysis. Plasmids were extracted
from positive clones. The experimental methods employed are described in ‘Materials
and Methods’. The gene sequences were confirmed by DNA sequencing and further
alignment of sequences obtained with reference sequences in the NCBI database. The
resultant plasmids were named pSP73/BglII-Sal/CYP3A4 (Figure 4.1) and
pBluKS+/Bam-Xba/b5 (Figure 4.2).
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Figure 4.1. The plasmid map of pSP73/BglII-Sal/CYP3A4.
pSP73/BglII-SalI/CYP3A4
3937 bps
500
1000
1500
2000
2500
3000
3500
BglII 6
NcoI 16
BalI 37
NcoI 40
HindIII 120
EcoRI 127
ApaI 135
HincII 247
BclI 283
BbsI 318
StuI 333
BsaBI 400
BclI 565
HindIII 642
BamHI 665
PvuII 834
EcoRI 854
SacI 897
BalI 979
PstI 1008
MunI 1120
BstXI 1183
BstXI 1230
ScaI 1234
BspHI 1363
HindIII 1448
1530
HincII
SalI
SbfI
PstI
SphI
HindIII
PvuII
StrI
XhoI
1560
AseI 1590
HincII 1609
HpaI 1609
AseI 1619
AflIII 1790
BspHI 2510
DraI 2547
DraI 2566
AseI 2854
FspI 2903
PvuI 3050
ScaI 3161
DraI 3258
BspHI 3518
BspHI 3623
Esp3I 3667
Esp3I 3721
NdeI 3853
AseI 3887
h_CYP3A4
T7p
ColE1 ori
Amp-R
SP6p
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Figure 4.2. The plasmid map of pBluKS+/Bam-Xba/b5.
4.3 Sub-cloning of genes in baculovirus transfer vector
The CYP3A4 and cytochrome b5 genes were isolated from pSP73/BglII-
Sal/CYP3A4 and pBluKS+/Bam-Xba/b5 using sets of BglII, SalI and BamHI, XbaI
restriction enzymes, respectively. The pFastBac1 vector was digested with BamHI, SalI
for CYP3A4 cloning and with BamHI, XbaI for human cytochrome b5 cloning. The
digested fragments of CYP3A4 and cytochrome b5 genes were gel purified and used for
ligation into linearised pFastBac1 (digested with the appropriate restriction enzymes).
The ligation mixture was used for transforming E. coli DH5α competent cells and 
transformants were screened by restriction analysis. The cDNAs in the pFastBac1
pBluKS+/Bam-Xba/b5
3363 bps
500
1000
1500
2000
2500
3000
NaeI 328
NgoMIV 328
FspI 480
PvuI 500
PvuII 530
SacI 653
BstXI 658
NotI 669
EagI 670
XbaI 677
PstI 727
SacI 836
BstXI 964
ScaI 1054
1084
NcoI
BamHI
SmaI
PstI
EcoRI
EcoRV
HindIII
BspDI
ClaI
HincII
SalI
StrI
XhoI
ApaI
Asp718I
KpnI
1154
AseI 1322
PvuII 1374
AseI 1381
AflIII 1552
BspHI 2272
DraI 2309
DraI 2328
AseI 2616
FspI 2665
PvuI 2812
ScaI 2923
DraI 3020
BspHI 3280
''lacZ
h_cytochrome b5
lacZ'
ColE1ori
Amp-r
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vector were cloned under the control of a polyhedrin promoter. The resultant
recombinant donor vectors were named pFastBac1/CYP3A4 (Figure 4.3) and
pFastBac1/Bam-Xba/b5 (Figure 4.4).
Figure 4.3. The plasmid map of pFastBac1/CYP3A4, the BglII-SalI human CYP3A4
fragment being cloned in BamHI-SalI digested pFastBacI.
pFastBac1/CYP3A4
6262 bps
1000
2000
3000
4000
5000
6000
NaeI 127
NgoMIV 127
BspHI 536
DraI 796
ScaI 893
PvuI 1004
FspI 1151
AseI 1200
DraI 1488
DraI 1507
BspHI 1544
AflIII 2264
BglII 2547
BalI 2707
BstXI 2710
EagI 2768
EcoRV 2823
BsaBI 3012
BglII 3017
Esp3I 3176
Tth111I 3225
AflIII 3246
BsrGI 3410
HincII 3548
BbsI 3750
EagI 3758
SnaBI 3879
AseI 3896
BsaBI 3924
NcoI 4042
BalI 4063
NcoI 4066
HindIII 4146
EcoRI 4153
ApaI 4161
HincII 4273
BclI 4309++
StuI 4359
BsaBI 4426
BclI 4591
HindIII 4668
BamHI 4691
PvuII 4860
EcoRI 4880
SacI 4923
BalI 5005
PstI 5034
MunI 5146
BstXI 5209
BstXI 5256
ScaI 5260
BspHI 5389
HindIII 5474
5556
HincII
SalI
SacI
SpeI
NotI
EagI
XbaI
PstI
StrI
XhoI
SphI
Asp718I
KpnI
HindIII
ScaI
BsaBI
5646
DraI 5688
MunI 5738
HincII 5749
HpaI 5749
BclI 5887
AseI 6205
f1_ori
Amp-r
ColE1
Tn7R
Gm-r
polHp
h_CYP3A4
SV40_polyA
Tn7L
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Figure 4.4. The plasmid map of pFastbac1/Bam-Xba/b5, the BamHI-XbaI human b5
fragment being cloned in BamHI-XbaI digested pFastBacI
4.4 Generation of bacmid constructs and baculoviruses
The recombinant donor vectors, named pFastBac1/CYP3A4 and
pFastBac1/Bam-Xba/b5 were transposed on to E. coli DH10Bac competent cells.
DH10Bac cells contain a baculovirus shuttle vector (bacmid DNA) and a helper
plasmid, and allow generation of a recombinant bacmid by site-specific transposition.
The propagation of recombinant bacmid in DH10Bac was identified by white colour in
the presence of a chromogenic substrate Bluo-gal and the inducer IPTG. The white
pFastBaci/Bam-Xba/b5
5115 bps
1000
2000
3000
4000
5000
NaeI 127
NgoMIV 127
BspHI 536
DraI 796
ScaI 893
PvuI 1004
FspI 1151
AseI 1200
DraI 1488
DraI 1507
BspHI 1544
AflIII 2264
BglII 2547
BalI 2707
BstXI 2710
EagI 2768
EcoRV 2823
BsaBI 3012
BglII 3017
Esp3I 3176
Tth111I 3225
AflIII 3246
BsrGI 3410
HincII 3548
BbsI 3750
EagI 3758
SnaBI 3879
AseI 3896
BsaBI 3924
BamHI 4032
NcoI 4036
ScaI 4066
BstXI 4150
SacI 4284
PstI 4393
4443
XbaI
PstI
StrI
XhoI
SphI
Asp718I
KpnI
HindIII
ScaI
BsaBI
4499
DraI 4541
MunI 4591
HincII 4602
HpaI 4602
BclI 4740
AseI 5058
f1_ori
Amp-r
ColE1
Tn7R
Gm-r
polHp
h_cytochrome b5
SV40_polyA
Tn7L
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colonies were streaked a second time on Bluo-gal plates and after confirming the
phenotype, recombinant bacmids were isolated and confirmed by PCR analysis. PCR
was performed using M13 forward primer (5’ -GTTTTCCCAGTCACGAC- 3’) and
gene-specific reverse primers (Figure 4.5).
(A) (B)
Figure 4.5. Confirmation of CYP3A4 and cytochrome b5 gene transposition on bacmids
via PCR. PCR was performed using a set of M13 forward and gene-specific reverse
primers. PCR was performed as described in ‘Materials and Methods’ (Section Number
2.2.2). After transposition on bacmids, the expected DNA fragment size for CYP3A4
gene is ~3000 bp and for cytochrome b5, ~2000 bp. (A): Lane 1, 1 kb DNA ladder;
Lane 2, clone No 1 of CYP3A4 bacmid; Lane 3, clone No 2 of CYP3A4 bacmid. (B):
Lane 1, 1 kb DNA ladder; Lane 2, clone No 1 of cytochrome b5 bacmid; Lane 3, clone
No 2 of cytochrome b5 bacmid.
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In order to generate baculoviruses, Sf9 cells were transfected with recombinant
bacmids as described in ‘Materials and Methods’ (Section Number 2.2.14). Hereafter,
CYP3A4 baculovirus is referred to as BV-CYP3A4 and cytochrome b5 baculovirus is
referred as BV-cyt-b5. The baculoviruses produced in Sf9 cells were subjected to two
more rounds of amplification by infecting the cells with baculoviruses for 96 h. The
baculovirus titration was performed using plaque assay and titres of the baculovirus
stocks were determined. The experimental methods employed are detailed in ‘Materials
and Methods’.
4.5 Expression of CYP3A4 and cytochrome b5 in Sf9 cells
Following amplification and titration of recombinant baculoviruses, Sf9 cells
were infected with BV-CYP3A4 at an MOI of 1.0 pfu/cell. In a separate experiment,
Sf9 cells were infected with BV-cyt-b5 at an MOI of 1.0 pfu/cell. To compensate for
low endogenous levels of haem in insect cells, haemin (2 µg/ ml) and δ-amino levulinic 
acid (100µM) were added 24 hour post-infection to the cells for expression of CYP3A4.
Cells were harvested 63 h post-infection and the microsomes were prepared.
Coomassie staining was performed to confirm expression of CYP3A4 and
cytochrome b5 proteins. Microsomes (20 µg microsomal protein/ lane) were separated
on 10% sodium dodecyl sulfate-polyacrylamide gel and protein bands were visualized
(Figure 4.6) by staining with Coomassie G-250 and several de-staining steps, as
described in ‘Materials and Methods’ (Section Number 2.4.5). Commassie staining of
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microsomal protein fractions prepared from recombinant baculovirus infected insect
cells detected CYP3A4 and cytochrome b5 protein bands. The size of the protein bands
was consistent with the molecular weight predicted from the cDNA sequence.
Figure 4.6. SDS-PAGE gel analysis of CYP3A4 and cytochrome b5 proteins. 25 µg
microsomal fractions of the proteins expressed in Sf9 cells were loaded per lane on 10%
SDS-PAGE. Gels were stained with Coomassie blue G-250 as described in ‘Materials
and Methods’ (Section Number 2.4.5). Lane 1, protein marker; Lane 2, CYP3A4; Lane
3, negative control; Lane 4, protein marker; Lane 5, cytochrome b5.
4.6 Co-expression of CYP3A4 with the CPRs and cytochrome b5 in
Sf9 cells
In human liver microsomes CYP levels far exceed the levels of NADPH
198
cytochrome P450 reductase (CPR) by a 10:1 to 20:1 ratio (Estabrook et al 1971). In
line with this, while co-infecting Sf9 cells with BV-CYP3A4 and BV-CPR (hRD,
ΔhRD, ΔhRDM and yRD), multiplicity of infection (MOI) for BV-CPR was kept 10 
times less (0.1 pfu/cell) than that of CYP3A4 (1 pfu/cell). For co-expression of the
third protein cytochrome b5, the baculovirus BV-cyt-b5 was used at an MOI of 0.1 pfu/
cell. To compensate for low endogenous levels of haem in insect cells, haemin (2 µg/
ml) and δ-amino levulinic acid (100µM) were added 24 hour post-infection to the cells 
for expression of CYP3A4. Cells were harvested after 63 h and microsomes were
prepared. The experimental methods employed are detailed in ‘Materials and Methods’.
Experiments related to Western blotting and Coomassie staining for expression of the
individual proteins hRD, ΔhRD, ΔhRDM and yRD were presented in Chapter 3. 
Western blotting was performed for CYP3A4 using the co-expressed
microsomes. For Western blotting, the microsomes prepared from the baculovirus
infected Sf9 cells as described above were separated on 10% sodium dodecyl sulfate-
polyacrylamide gel (1.5 µg microsomal protein/ lane). The proteins were transferred to
Immobilon P membrane (Millipore) by the semi-dry transfer method. The membrane
was blocked overnight at 4ºC with 5% non-fat dry milk in PBS. The blot was then
probed with 1:2,500 dilution of mouse polyclonal antibody to CYP3A (Gentest,
Catalogue No 458258). Then the blot was incubated with 1:7,500 dilution of secondary
antibody – anti-mouse IgG-HRP conjugate (Santa Cruz Biotechnology, Catalogue No
SC-2302). The blot was incubated with luminol chemiluminescent substrate for a short
time. Chemiluminescence was captured (Figure 4.7) on Gel Doc™ (Bio-Rad). Human
CYP3A4 protein bands reacted with the CYP3A-specific antibodies in Western blot
199
analysis. The protein band intensities were measured by densitometry using Quantity-
one software from Bio-Rad.
Figure 4.7. Immunoblot analysis of CYP3A4 co-expressed with different CPR species
in Sf9 insect cells. Sf9 cells were infected with CYP and CPR baculoviruses at an MOI
of 1 pfu/cell and 0.1 pfu/cell respectively. The cells were also co-infected with a third
virus, encoding cytochrome b5, at an MOI of 0.1 pfu/cell. 63 h post-infection
microsomes were prepared.  1.5 μg of microsomal fractions were loaded per lane on 
10% SDS-PAGE and immunoblotting was performed as described in ‘Materials and
Methods’ (Section Number 2.4.6) by using antibodies that recognise human CYP3A4.
The numbers below the bands show band intensities in arbitrary units. Lane 1, negative
control; Lane 2, CYP3A4 expressed with cytochrome b5; Lane 3, CYP3A4 and
cytochrome b5 co-expressed with hRD; Lane 4, CYP3A4 and cytochrome b5 co-
expressed with ΔhRDM; Lane 5, CYP3A4 and cytochrome b5 co-expressed with yRD.
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4.7 Amounts of CYP3A4 in microsomes that co-express
different CPRs
The insect cells were infected with recombinant baculovirus encoding CYP3A4
alone (MOI 1.0) and were also co-infected with baculoviruses encoding cytochrome b5
(MOI 0.1) and human CPR or yeast CPR (MOI 0.1). Microsomes were prepared 63-h
post-infection and the protein concentrations were determined by a modified Bradford
method (Bradford 1976). The microsomes were diluted to a protein concentration of 1
mg/ml with 100 mM potassium phosphate buffer (pH 7.4), 20% (vol/vol) glycerol.
Then a few grains of sodium dithionite were added and a baseline recorded on dual
wavelength spectrophotometer (Shimadzu UV-2401PC). CYP3A4 holoprotein contents
were spectrophotometrically measured as reduced carbon monoxide (CO) spectra
(Omura & Sato 1964) using 91 mM-1 cm -1 as extinction coefficient. The experimental
methods employed are detailed in ‘Materials and Methods’ (Section Number 2.4.3).
Figure 4.8 and Table 4.1 summarise CYP3A4 content when co-expressed only
with cytochrome b5 and when co-expressed with human or yeast CPRs. The co-
expression of CYP3A4 with CPRs results in decrease in spectrally active CYP3A4
levels (holoprotein levels). CYP3A4 content is highest when co-expressed only with
cytochrome b5.  CYP3A4 content was higher when co-expressed with ΔhRDM in 
comparison to CYP3A4 content when co-expressed with hRD or yRD. However it is
interesting to note that similar to CYP2D6 (results presented in Chapter-3), CYP3A4
apoprotein levels as measured by densitometry from the immunoblot (Figure 4.7) do not
change irrespective of the CPR (human or yeast) that is co-expressed with CYP3A4.
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These results suggest that CPR does not regulate the CYP expression levels in any way
but is responsible for decrease in spectrally active enzyme i.e. holoprotein. CYP3A4
holoprotein destruction by ΔhRDM is found to be much less than that caused by hRD 
and yRD.  Although ΔhRD does not anchor on the microsomal membranes, it has some 
destructive effect on CYP3A4 holoenzyme as compared to cells that produce CYP3A4
in the absence of any CPR (i.e. CYP3A4 + b5). Experimental evidence, presented in
Chapter 3, correlates reactive oxygen species induced by CPRs as being responsible for
their destructive effects.
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Figure 4.8. Reduced carbon monoxide difference spectra of CYP3A4. Sf9 cells
infected with CYP3A4, cytochrome b5 and CPR baculoviruses at an MOI of 1, 0.1 and
0.1 pfu/ cell, respectively. The cells were harvested 63 h post-infection and microsomes
were prepared. CYP content was measured by reduced carbon monoxide difference
spectra as described in ‘Materials and Methods’ (Section Number 2.4.3).
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Table 4.1. CYP3A4 content in microsomal samples as determined by reduced CO-
difference spectroscopy. Sf9 cells were co-infected with CYP3A4, cytochrome b5 and
CPR baculoviruses at an MOI of 1.0 pfu/cell, 0.1 pfu/cell and 0.1 pfu/cell, respectively.
Microsomes were prepared 63 h post-infection as described in ‘Materials and Methods’
(Section Number 2.4.1). Data are presented as mean values ± STDEV.
Microsomes CYP content
(pmole/mg protein)
CYP3A4+ b5
CYP3A4+hRD+ b5
CYP3A4+ΔhRD+ b5
CYP3A4+ΔhRDM+ b5
CYP3A4+yRD+ b5
512.10 ± 18.3
251.01 ± 21.7
455.83 ± 31.1
339.00 ± 26.9
247.61 ± 19.2
4.8 Measurement of cytochrome b5 in microsomes that co-
express CYP3A4 and CPRs
Cytochrome b5 content in microsomes that co-express CYP3A4 and different
CPRs was measured spectrophotometrically according to procedures published before
(Strittmatter and Velick 1956; Holmans et al. 1994, Shet et al. 1994). Reduced
cytochrome b5 absorbs at 424 nm. The microsomes were diluted to a protein
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concentration of 1 mg/ml in 100 mM potassium phosphate buffer (pH 7.4), 20%
glycerol. The diluted suspension was divided equally in two cuvettes (reference and
sample cuvette). The cuvettes were placed in the dual wavelength spectrophotometer.
The baseline was recorded by scanning samples from 400 nm to 500 nm. A few grains
of sodium dithionite were then added to the sample cuvette in order to reduce
cytochrome b5. The difference spectrum between the two cuvettes was scanned again
from 400 nm to 500 nm and recorded. The absorbance difference between 424 nm and
408 nm was calculated and b5 content in microsomal suspension was measured using
112 mM-1 cm-1 as extinction coefficient.
205
Figure 4.9. A typical difference spectra of cytochrome b5. Sf9 cells were infected with
CYP3A4 and cytochrome b5 baculoviruses at an MOI of 1 and 0.1 pfu/ cell,
respectively. The cells were harvested 63 h post-infection and microsomes were
prepared. Cytochrome b5 content was measured by reduced difference spectra as
described in Section 4.8.
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Table 4.2. Cytochrome b5 content in microsomal samples as determined by
spectroscopy. Sf9 cells were co-infected with CYP3A4, CPR and cytochrome b5
baculoviruses at an MOI of 1.0 pfu/cell 0.1 pfu/cell and 0.1 pfu/cell, respectively.
Microsomes were prepared 63 h post-infection and cytochrome b5 content was
measured as described in ‘Materials and Methods’ (Section Number 2.4.1). Data are
presented as mean values ± STDEV.
Microsomes Cytochrome b5 content
(pmole/mg protein)
CYP3A4+ b5
CYP3A4+hRD+ b5
CYP3A4+ΔhRDM+ b5
CYP3A4+yRD+ b5
289.0 ± 11.3
275.7 ± 16.8
278.6 ± 16.1
288.9 ± 14. 5
4.9 Stimulation of CYP3A4 activity by cytochrome b5
Cytochrome b5 has been shown to stimulate CYP3A4 activity towards its
substrates (Voice et al 1999). We have co-expressed cytochrome b5 with CYP3A4 and
have observed augmentation of CYP3A4 activity towards demethylation of DBOMF.
The Sf9 cells were infected with recombinant baculovirus encoding CYP3A4 alone
(MOI 1.0 pfu/cell). In the second set of experiments, Sf9 cells were co-infected with
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CYP3A4 baculovirus (MOI 1.0 pfu/cell) and ΔhRDM baculovirus (MOI 0.1 pfu/cell).  
In the third set of experiments, Sf9 cells were co-infected with CYP3A4 baculovirus
(MOI 1.0 pfu/cell), ΔhRDM baculovirus (MOI 0.1 pfu/cell) and cytochrome b5
baculovirus (MOI 0.1 pfu/cell). Microsomes were prepared 63-h post-infection, CYP
content was measured and the microsomes were used for measuring CYP3A4 catalytic
activity in DBOMF assay.
The production of the metabolite fluorescein, by dealkylation of Vivid®
fluorogenic substrate dibenzyl-oxymethyl-fluorescein (DBOMF) was measured for 10
min at 37ºC. The assay was performed as per the standard Invitrogen Screening Kit
protocol. The reactions were carried out at 37ºC in a reaction volume of 0.1 ml/well in
96-well black plates. The assay mixture contained 100 mM Potassium phosphate buffer
pH 8.0, containing 10 µM DBOMF, 1.0 pmole CYP3A4 and the NADPH regenerating
system (1.3 mM NADP+, 3.3 mM G6P, 3.3 mM Mg Cl2, 0.4U/ml G6PDH).
Fluorescein formation was measured fluorometrically on the Biotek Synegy HT plate
reader (excitation wavelength of 485/20 nm and emission wavelength of 528/20 nm).
Changes in fluorescence were recorded for 10 min as relative fluorescence units (RFU).
Fluorescein, the metabolite of DBOMF, was used to generate a standard curve.
The standard curve of fluorescein was prepared using a range of concentrations
of fluorescein (0, 39.1, 78.1, 156.3, 312.5, 625, 1250 pmol/ ml). The assay for
generation of the standard was performed in 96-well black plates. The fluorescent
values (RFU) were recorded on the Biotek Synegy HT plate reader using an excitation
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wavelength of 485/20 nm and emission wavelength of 528/20 nm. Standard curve was
plotted and fluorescein concentrations in test samples were measured using the equation
from the standard curve. The standard curve is shown in Figure 4.10 (A).
Co-expression of cytochrome b5 with CYP3A4 and ΔhRDM significantly 
improved the CYP3A4 catalytic activity which is in agreement with the reports that
cytochrome b5 stimulates CYP3A4 catalytic activity towards its substrates (Figure 4.10
(B); Table 4.3).
Figure 4.10 (A). The fluorescein standard curve. The curve was generated as described
in Section 4.9.
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Figure 4.10 (B). Increase in CYP3A4 catalytic activity by co-expression of the third
protein cytochrome b5 in Sf9 cells. Sf9 cells were infected with CYP3A4 alone, co-
infected with ΔhRDM and also co-infected with cytochrome b5 as described in Section
4.9. The catalytic activity of CYP3A4 was measured in microsomes prepared at 63h
post-infection. DBOMF assay was performed as described in Section 4.9.
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Table 4.3. CYP3A4 enzyme reaction rates in co-expressed microsomes, as tabulated
from Figure 4.10 (B). Sf9 cells were infected with CYP3A4 alone, co-infected with
ΔhRDM and also co-infected with cytochrome b5 as described in Section 4.9. The
enzyme reaction rates were measured in DBOMF assay. DBOMF assay was performed
as described in Section 4.9.
Microsomes CYP3A4 reaction rates
(pmole fluorescein formed/ min/ pmole of CYP3A4)
CYP3A4
CYP3A4+ ΔhRDM 
CYP3A4+ΔhRDM+ b5
1.351
1.973
3.5508
4.10 NADPH-cytochrome P450 reductase (CPR) activity assay
NADPH-cytochrome P450 reductase (CPR) activities of human and yeast CPRs
in co-expressed microsomes were measured by the reduction of the tetrazolium salt,
MTT as described in ‘Materials and Methods’ (Section Number 2.4.7). In CYP3A4 and
CPR co-expressed microsomes, reduction potential of yRD is higher than that of hRD
(Table 4.4), which means yRD can reduce MTT more efficiently than hRD. However,
the amount of CYP3A4 holoprotein in cells co-producing yRD is the same as in cells
that co-express hRD (Table 4.1). Both the CPRs, hRD and yRD reduce holoprotein
content with equal magnitude without decreasing the apoprotein levels (Figure 4.7).
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Both the CPRs must be causing oxidative damage to microsomal proteins which results
in decrease in holoprotein levels.  Reduction potential of ΔhRDM towards MTT is 
lower than hRD and yRD. Concomitantly, the amount of CYP3A4 holoprotein in cells
co-producing ΔhRDM is higher than that in cells that co-express hRD or yRD (Table 
4.1).  As ΔhRD does not anchor to the microsomal membranes, the microsomes 
prepared from cells co-expressing ΔhRD do not show any microsomal reductase 
activity.
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Table 4.4. NADPH cytochrome P450 reductase (CPR) activities exhibited by yeast and
human CPRs in CYP3A4 co-expressed microsomes. Sf9 cells were co-infected with
CYP3A4 baculoviruses (MOI 1.0 pfu/cell), cytochrome b5 baculoviruses (MOI 0.1
pfu/cell), CPR baculoviruses (MOI 0.1 pfu/cell) and microsomes were prepared 63 h
post-infection. CPR activity was measured using MTT as described in ‘Materials and
Methods’ (Section Number 2.4.7). The moles of MTT reduced per minute per mg of
protein were calculated.
CPR Species Reductase activity
(nmole MTT reduced/min/mg protein)
CYP3A4+ b5
CYP3A4+hRD+ b5
CYP3A4+ΔhRD+ b5
CYP3A4+ΔhRDM+ b5
CYP3A4+yRD+ b5
21.2 ± 1.3
238.9 ± 31.7
19.7 ± 1.9
169.9 ± 18.3
295.8 ± 29.9
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4.11 CYP3A4 enzymatic activities in the presence of CPRs and
cytochrome b5 – DBOMF dealkylation activity
DBOMF dealkylation activities were determined in microsomal fractions
prepared from Sf9 cells co-infected for 63 h with CYP3A4+b5, CYP3A4+b5+hRD,
CYP3A4+b5+ΔhRD, CYP3A4+b5+ΔhRDM and CYP3A4+b5+yRD baculoviruses. The
production of the metabolite fluorescein from Vivid® fluorogenic substrate dibenzyl-
oxymethyl-fluorescein (DBOMF) was measured for 15 min at 37ºC. The assay was
performed as per the standard Invitrogen Screening Kit protocol. The reactions were
carried out at 37ºC in a reaction volume of 100 µl/well in 96-well black plates. The
assay mixture contained 100 mM Potassium phosphate buffer pH 8.0, containing 10 µM
DBOMF , 1.0 pmole CYP3A4 and the NADPH regenerating system (1.3 mM NADP+,
3.3 mM G6P, 3.3 mM MgCl2, 0.4U/ml G6PDH). Fluorescein formation was measured
fluorometrically on the Biotek Synergy HT plate reader (excitation wavelength of
485/20 nm and emission wavelength of 528/20 nm). Changes in fluorescence were
recorded for 10 min as relative fluorescence units (RFU). Metabolite of DBOMF,
fluorescein, was used to generate a standard curve (Figure 4.10 (A)).
CYP3A4+b5 showed minimal activity whereas both CYP3A4+b5+hRD and
CYP3A4+b5+ΔhRDM exhibited much higher DBOMF dealkylation activity.  However, 
the catalytic activity of CYP3A4+b5, in the presence of hRD and ΔhRDM, is 
significantly higher than that in the presence of yRD (Figure 4.11 and Table 4.5), which
is not consistent with the fact that yRD shows higher MTT reduction potential than hRD
(Table 4.4). This observation indicates that the cause of poor CYP3A4 activity in the
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presence of yRD cannot be due only to oxidative damage since yRD and hRD show
similar ROS induction potential, as shown in Chapter 3 (therefore, one would expect the
same magnitude of oxidative damage to the CYP). It is more likely that, in the specific
intracellular environment of insect cells, co-expressed CYP3A4 and yRD do not form
the correct spatial orientation that would support human CYP catalytic activity.
Figure 4.11. Kinetic analysis of CYP3A4 catalytic activity towards dealkylation of
DBOMF. Sf9 cells were co-infected with CYP3A4, cytochrome b5 and the CPR
baculoviruses at an MOI of 1, 0.1 and 0.1 pfu/ cell, respectively. The catalytic activity
of CYP3A4 was measured in microsomes prepared at 63h post-infection. DBOMF
assay was performed as described in Section 4.11.
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Table 4.5. CYP3A4 enzyme reaction rates in co-expressed microsomes, as tabulated
from Figure 4.11. Sf9 cells were co-infected with CYP3A4, cytochrome b5 and the
CPR baculoviruses at an MOI of 1, 0.1 and 0.1 pfu/ cell, respectively. The reaction
rates were measured in microsomes prepared at 63h post-infection. DBOMF assay was
performed as described in Section 4.9.
Microsomes CYP3A4 reaction rates
(pmole fluorescein formed/ min/ pmole of CYP3A4)
CYP3A4+ b5
CYP3A4+hRD+ b5
CYP3A4+ΔhRD+ b5
CYP3A4+ΔhRDM+ b5
CYP3A4+yRD+ b5
1.653
3.536
1.353
3.851
1.955
4.12 Measurement of reactive oxygen species (ROS)
induction by CPR in presence of cytochrome b5
The experiments presented in Chapter 3 show that ROS induced by CPRs are
responsible for CYP holoenzyme destruction. The results presented in Chapter 3 also
show that ROS induced by yRD and hRD was higher than ROS induced by ΔhRDM.  
Like CYP2D6, as described in Chapter 3, CYP3A4 holoenzyme levels changed
216
depending on which reductase species was co-expressed (Table 4.1). yRD and hRD co-
expression resulted in lower CYP3A4 holoenzymes content than with ΔhRDM co-
expression. CYP3A4 holoenzyme content was not significantly different when co-
expressed with yRD or hRD. Despite this, CYP3A4 catalytic activity supported by
yRD was minimal (Figure 4.11).
To determine whether the oxidative damage to CYP3A4 by CPRs is accelerated
by co-expressing the third protein cytochrome b5, reactive oxygen species (ROS) in
cells infected with CPR and cytochrome b5 baculoviruses were measured. The
fluorescent dye 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) was used for
measuring reactive oxygen species induction in Sf9 cells. Sf9 cells were seeded in 96-
well tissue culture grade black plates at a density of 20,000 cells/well. After cell
attachment on the substratum, they were infected with hRD, ΔhRDM and yRD 
baculoviruses (at an MOI of 2 pfu/cell) and also co-infected with cytochrome b5
baculovirus (at an MOI of 0.2 pfu/ml) for 72 h. At 72 h, medium was removed from the
wells and 100 µl of 10 µM H2DCFDA in PBS was added to each well. The plate was
again incubated for 30 min to allow the dye to enter the cells. The oxidation of
intracellular non-fluorescent H2DCF to highly fluorescent DCF was measured on a
fluorometer (Bio-Tek). Excitation 485/20 nM and emission 528/20 nM filter sets were
used to measure the fluorescence. Blank values, indicating the fluorescence of the dye
in PBS (blank without cells), were subtracted from all samples. Percentage inductions
of ROS in baculovirus-infected cells over control cells (without baculovirus infection)
were calculated.
217
yRD and hRD exhibited stronger induction of ROS than ΔhRDM.  However, co-
expression of b5 with CPRs did not noticeably alter the ROS levels induced by CPRs in
insect cells (Table 4.6).
Table 4.6.  Measurement of ROS induction by hRD, ΔhRDM and yRD.  ROS was 
measured by using H2DCFDA dye. Sf9 cells were infected with CPR baculoviruses (at
an MOI of 2 pfu/ml) and also co-infected with cytochrome b5 baculoviruses (at an MOI
of 0.2 pfu/ml) for 72 h. At 72 h, H2DCFDA assay was performed as described in
Materials and Methods (Section Number 2.4.10). The oxidation of intracellular non-
fluorescent H2DCF to highly DCF was measured on a fluorometer as described in
Section 4.12.
Microsomes Percentage ROS Induction
hRD
hRD+b5
ΔhRDM 
ΔhRDM+b5
yRD
yRD+b5
34.45 ± 4.6
31.95 ± 1.6
16.395 ± 0.56
17.56 ± 3.9
44.45 ± 1.3
46.35 ± 4.45
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4.13 Coupling efficiency of the two CPRs, hRD and
ΔhRDM, with CYP3A4 
Although activities supported by hRD and ΔhRDM of CYP3A4 as measured by 
DBOMF dealkylation assays are similar, the reduction potential of both the reductases
towards MTT is different.  Reduction potential of ΔhRDM towards MTT is much lower 
than that of hRD and yRD which indicates that CYP3A4 activity supported by per unit
of ΔhRDM is better than that supported by hRD or yRD.  This observation is presented 
in terms of coupling efficiencies of hRD, ΔhRDM and yRD with CYP3A4.  
To calculate the percent coupling efficiency, the CYP3A4 activity in DBOMF
assay was divided by CPR activity in the MTT assay. The percent relative coupling
efficiency for hRD and yRD was calculated in comparison with ΔhRDM, considering 
ΔhRDM activity as 100% (Table 4.7).  The percent coupling efficiency values show 
that ΔhRDM couples better with CYP3A4 than its native form hRD.  The percent 
coupling efficiency of yRD with CYP3A4 is extremely poor in comparison to ΔhRDM.  
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Table 4.7. Percentage relative coupling efficiency of hRD and yRD with CYP3A4 was
calculated in comparison with ΔhRDM using microsomes that were prepared from Sf9 
cells after 63 h of baculovirus infection. The product formed (fluorescein) from the
DBOMF assay and CPR activity measured in the MTT assay were used for the
calculations. CYP3A4 activity was divided by CPR activity and percent relative
coupling efficiency was calculated.
Microsomal samples Percentage Relative coupling
efficiency
CYP3A4+ ΔhRDM+ b5
CYP3A4+ hRD+ b5
CYP3A4+ yRD+ b5
100
65.31
29.17
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4.14 Conclusions
Cytochrome P450 enzymes (CYPs) require an electron donor enzyme, a
NADPH cytochrome P450 reductase (CPR), to support their catalytic activities. The
baker’s yeast, Saccharomyces cerevisiae, has been widely used for many years for
expression of human CYPs because it contains intracellular compartments like the
endoplasmic reticulum that are similar to those in human cells. Yeast also contains a
CPR, the electron donor enzyme, which is quite similar to that present in humans.
In the past three decades, many scientific papers have been published on the
expression of human and mammalian cytochrome P450 enzymes in yeast. Most of
these studies have used the yeast CPR as an electron donor to activate human CYPs
(Yabusaki et al 1995; Ellis et al 1992). There are a number of reports on the co-
expression of the yeast CPR and a human CYP so as to obtain active CYPs on yeast
microsomes (Eugster et al 1993; Ellis et al 1992; Renaud et al 1990; Brian et al 1990).
These activities vary from being quite good to extremely poor (also our own
unpublished observations).
Our results in Chapter 3 indicated that the yeast CPR, yRD, could act as an
efficient alternative electronic donor to the human CPR, hRD, for the general activation
of human CYPs. We wanted to explore if the results obtained from co-expression
studies of yRD and CYP2D6, which express optimal activity in the absence of
cytochrome b5, are applicable in the context of another CYP where the presence of
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cytochrome b5 is essential. We chose CYP3A4, which is also widely used for drug
metabolism studies, for these studies. We therefore co-expressed the yeast CPR and
human CYP3A4 enzymes in insect cells along with cytochrome b5.
The beauty of insect cell expression systems using baculoviruses is that one can
vary the CYP to CPR ratio by infecting the cells with baculoviruses at different MOIs.
In this Chapter we have co-expressed different human CPRs (hRD, ΔhRD and ΔhRDM) 
with human CYP3A4 at optimal MOIs and have compared our results with experiments
that allow co-expression of the yeast CPR (yRD) and CYP3A4 using similar MOIs. All
co-expression studies were performed in the presence of human cytochrome b5.
Reduction in human CYP levels has been reported when CYPs are co-expressed
with CPR in baculovirus expression systems (Chen et al 1997; Wang et al 1996; Paine
et al 1996). Our results are in agreement with these reports. We have linked this effect
to the increased production of hydroxyl radicals. However in the case of yRD, we find
that oxidative damage to CYP3A4 may not be the complete reason behind yRD’s
inability to support CYP3A4 activity. The yRD enzyme activity towards its artificial
substrate MTT was higher than hRD and ΔhRDM, which shows that yeast CPR is 
expressed in insect cells with very good reduction potential.
CYP3A4, when co-expressed with hRD or ΔhRDM, on insect cell microsomes 
exhibits strong catalytic activity towards de-alkylation of DBOMF (Figure 4.11)
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whereas CYP3A4 co-expressed with yRD manifests extremely poor activity. This
observation would indicate that yRD is unable to couple efficiently with human
CYP3A4. The CYP3A4 activity in presence of cytochrome b5 and yeast CPR is nearly
as low as the activities observed in the microsomes that co-express CYP3A4 and b5.
Our results from the H2DCFDA assay show that both yRD and hRD induce
higher amounts of reactive oxygen species than ΔhRDM (Table 4.4).  In spite of similar 
amounts of CYP3A4 holoprotein content in microsomes co-expressing yRD and hRD
(Table 4.1), CYP3A4 catalytic activity in the presence of yRD is unusually poor as
compared to CYP3A4 activity in the presence of hRD (Figure 4.11). Therefore, it is
very likely that oxidative damage is not the complete reason for the poor CYP3A4
catalytic activity in the presence of yRD. It is possible that the specific intracellular
environment in insect cells may not support the interaction of yRD with human
CYP3A4 in the presence of human cytochrome b5.
This may suggest the importance for a CYP and the CPR to have correct spatial
orientation of their redox centres for effective electron transfer. Possibly, the human
CYP3A4 and the yeast CPR do not form the correct spatial orientation on the surface of
the insect cell microsomes, in the presence of human cytochrome b5, that would allow
effective electron transfer to the CYP3A4 active site. Recently, protein crystal structure
of yeast CPR has been solved which reveals that it has a second FMN binding site at the
interface of the connecting and FMN binding domains. The two FMN binding domains
have different accessibilities to the bulk solvent and different amino acid environments
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(Lamb et al 2006). Electrostatic forces have been shown experimentally to limit
accessibility of electron transfer sites on CPR for its charged redox partners
(Voznesensky and Schenkman 1994). One could speculate that the human cytochrome
b5, bound to CYP3A4, plays a major role in hindering the transfer of electrons from the
yeast CPR, yRD, to the CYP3A4 active site.
In conclusion, our findings demonstrate that (1) yRD perceptibly lacks the
ability to support human CYP3A4 catalytic activity on insect cell ER membranes, in the
presence of cytochrome b5; (2) oxidative damage cannot be the only reason behind yeast
CPR being unable to support CYP3A4 activity; (3) in comparison with yRD, hRD and
ΔhRDM are probably the best redox partners for a human CYP which demands 
cytochrome b5 for manifestation of optimal activity – this could be due to the inability
of CYP3A4 and yRD to form a mutually correct spatial orientation in the intracellular
endoplasmic reticular environment afforded by insect cells; (4) the variant hRD enzyme,
ΔhRDM, appears to be far superior to the wild-type hRD in terms of its ability to couple 
with CYP3A4 and to produce higher amounts of a spectrally-active, catalytically-useful
CYP enzyme.
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Chapter-5 Interaction of CYP1A1, CYP1B1, CYP1A2, CYP2C8
and CYP2E1 with the CPRs in Sf9 cells
5.1 Introduction
The multiple isoforms of cytochrome P450 enzymes metabolise a wide variety
of xenobiotic compounds such as drugs and carcinogens, as well as endobiotics such as
prostaglandins and steroids. Microsomal P450-mediated monooxygenase activity
supported by NADPH requires an interaction between flavoprotein NADPH-
cytochrome P450 reductase (CPR) and cytochrome P450 (CYP). These proteins have
been identified as the simplest system that possesses monooxygenase function;
however, little is known about the organisation of these proteins on microsomal
membranes (Backes and Kelley 2003).
The results presented in Chapters 3 and 4 show that CPRs are responsible for
reduction in spectrally active CYP enzymes and they also modulate CYP catalytic
activity. In the case of CYP2D6 and CYP3A4 we have observed different magnitudes
of decrease in the CYP holoprotein levels depending on which CPR species is co-
expressed. It has been shown in protein binding assays, where affinities of various
human CYPs for human CPR were studied, that there are differences in the interactions
of CYP enzymes with the accessory proteins, CPR and cytochrome b5 (Shimada et al.
2005).
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Our objective was to perform a comparative study of the interactions of
individual CYPs with diverse CPRs so as to determine if there are any subtle
differences in the affinity of a specific CYP for a CPR. In order to conduct this type of
study, we have taken the approach of ascertaining a particular CYP’s ability to couple
with a CPR via measurement of CYP enzyme catalytic activities. By studying CYP
coupling efficiencies, it would be possible to investigate the comparative ability of
CPRs to support individual CYP catalytic activities. This will possibly aid in our aim to
develop an improved cytochrome P450 expression system by defining a superior CPR
that would generally allow improved CYP catalytic activities.
In order to elucidate the ability of CPRs to couple with individual CYPs, we
studied the CPRs viz. hRD, ∆hRDM and yRD in the context of three other CYPs – 
CYP1B1, CYP1A2 and CYP2E1.  As ΔhRD does not anchor on the microsomal 
membranes, it was not pursued any further. After having obtained indications that
∆hRDM indeed could be a superior CPR, we went on to study enzyme activities of 
CYP1A1 and CYP2C8 in the context of ∆hRDM only.  In the case of CYP2E1 and 
CYP2C8, apart from CPR, a third protein cytochrome b5 was also co-expressed.
Cytochrome b5 is known to augment CYP2C8 and CYP2E1 mediated monooxygenase
reactions (Porter, 2002).
About half of the 57 human CYP isoforms belong to the families 1, 2 and 3
(Nelson, 1999). The majority of CYP isoforms in these families are involved in
xenobiotic metabolism (Gonzalez 1992; Capdevila et al. 2000). Most of the CYPs are
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expressed in the human liver, but some are also expressed in extra-hepatic tissues
(Raunio et al. 1995). The expression is predominant in the liver, probably due to its
major role in the utilisation of all ingested substances by the human organism.
Expression of CYPs in extra-hepatic tissues, such as lung and skin possibly act as the
first line of defence against exogenous compounds.
5.1.1 CYP1 family
CYP1A1, CYP1A2 and CYP1B1, together form the CYP1 family (Nelson et al.
1996). The CYP1 family members are induced by polycyclic aromatic hydrocarbons
(PAH), 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) (Schmidt and Bradfield 1996),
and cigarette smoking (Willey et al. 1997; Zevin and Benowitz 1999). All the three
isoforms are transcriptionally regulated by the aryl hydrocarbon receptor-aryl
hydrocarbon receptor nuclear translocator pathway (AHR-ARNT pathway) (Schmidt
and Bradfield 1996). They can metabolise PAHs into carcinogenic intermediates
(Shimada et al. 1996) and thus they are implicated in the formation of chemically
caused cancers (Nebert et al. 1996). From the CYP1 family we have studied CYP1A1,
CYP1A2 and CYP1B1 in conjunction with the different CPRs; the results of their
affinities towards the CPRs are presented in this chapter.
5.1.1.1 CYP1A1
Constitutive expression of CYP1A1 in the human liver and in extra-hepatic
tissues is very low (Edwards et al. 1998). However it is highly inducible by PAHs and
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also by cigarette smoke (Anttila et al. 1991). It is inducible by AHR ligands in many
tissues including lung, lymphocytes, mammary gland, and placenta (Raunio et al. 1995).
In human primary hepatocytes, CYP1A1 is induced by the AHR agonists, PAH, 3-
methylcholanthrene and omeprazole (Rodríguez-Antona et al. 2000; Bowen et al. 2000).
CYP1A1 is responsible for the activation of pro-carcinogens, and have been linked with
chemical-induced cancers such as lung cancer (Raunio et al. 1995).
5.1.1.2 CYP1A2
CYP1A2 is one of the main drug metabolising enzymes and is responsible for
metabolism of several drugs (Landi et al. 1999). It is known to be expressed only in
liver (Raunio et al. 1995) and constitutes quite a substantial amount (about 13%) of the
total hepatic CYP content (Shimada et al. 1994, Imaoka et al. 1996). It activates PAHs,
nitrosamines, aflatoxin B1, and especially aryl amines into forms that can bind to DNA
and produce mutations (Aoyama et al. 1990; Shimada et al. 1996; Macé et al. 1997;
Hammons et al. 1997; Hecht 1998). The regulation of CYP1A2 is observed to be both
AHR-ARNT–dependent and independent and is induced by cigarette smoke,
charbroiled meat, indole-3-carbinol (contained in cruciferous vegetables), phenytoin,
rifampicin, and omeprazole (Landi et al. 1999).
5.1.1.3 CYP1B1
The expression of CYP1B1 in human liver is nonexistent (Sutter et al. 1994;
Shimada et al. 1996; Hakkola et al. 1997; Edwards et al. 1998; Tang et al. 1999).
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However it expresses in many other tissues such as kidney, prostate, mammary gland,
and ovary (Sutter et al. 1994; Shimada et al. 1996; Tang et al. 1999). CYP1B1 is also
responsible for the metabolism of PAHs and aryl amines (Shimada et al. 1996). It is
known to overexpress in cancer tumours (Murray et al. 1997). The induction of
CYP1B1 is regulated by the AHR-ARNT pathway (Sutter et al. 1994; Savas and
Jefcoate 1994), although the responses of CYP1B1 to AHR ligands differ from those of
CYP1A1 (Hakkola et al. 1997).
5.1.2 CYP2 family
The human CYP2 family is a heterogeneous group of enzymes and contains the
subfamilies CYP2A, CYP2B, CYP2C, CYP2D, CYP2E, CYP2F, and CYP2J (Nelson et
al. 1996) and accounts for about 20% of the human total liver CYP content (Shimada et
al. 1994, Imaoka et al. 1996). CYP2B6, CYP2D6, CYP2E1, CYP2F1, and CYP2J2 are
the only functional members in their respective subfamilies, whereas the CYP2A
subfamily contains two functional enzymes (CYP2A6 and CYP2A13) and CYP2C
subfamily contains four functional enzymes (CYP2C8, CYP2C9, CYP2C18 and
CYP2C19). Unlike the CYP1 family, the members of the CYP2 family do not share
similar features of regulation. The substrate and tissue specificities of these enzymes
also differ markedly (Nelson et al. 1996).
From the CYP2 family we have studied the expression of CYP2D6 and CYP2E1
in conjunction with the CPRs, hRD, ΔhRDM and yRD, whereas CYP2C8 has been 
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expressed only in conjunction with ΔhRDM.  The results from CYP2D6 have already 
been presented in Chapter 3 but the results from CYP2C8 and CYP2E1 are presented in
this chapter.
5.1.2.1 CYP2C
CYP2C8 is known to catalyse 6-alpha hydroxylation of taxol, a drug used in
treating breast cancer. CYP2C9 is the main CYP2C present in the human liver,
followed by CYP2C8 and CYP2C19 (Edwards et al. 1998). The CYP2C18 protein is
not expressed in the liver (Richardson et al. 1997). CYP2C mRNA and protein are
induced in primary hepatocytes by phenobarbital and rifampicin (Morel et al. 1990;
Chang et al. 1997). Pharmaceutical substrates for CYP2C include diazepam,
omeprazole, mephenytoin, tolbutamide, and warfarin (Guengerich 1995) as well as
many non-steroidal anti-inflammatory drugs (Pelkonen et al. 1998). Selective
substrates include taxol for CYP2C8, tolbutamide for CYP2C9, and mephenytoin for
CYP2C19 (Pelkonen et al. 1998).
5.1.2.2 CYP2E1
CYP2E1 is the only isoform in this subfamily (Nelson et al. 1996). About 7% of
the liver CYP content consists of CYP2E1 (Shimada et al. 1994; Imaoka et al. 1996). It
is also expressed in lung and brain (Raunio et al. 1995). The CYP2E1 enzyme has been
studied extensively due to its role in the metabolism of ethanol and also as an activator
of chemical carcinogens (Lieber 1997). Most of the over 70 substrates demonstrated are
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small and hydrophobic compounds (Ronis et al. 1996) that include a few
pharmaceuticals such as paracetamol, chlorzoxazone, enflurane, and halothane
(Guengerich 1995). Disulfiram is a clinically used inhibitor of CYP2E1 (Guengerich
and Shimada 1991).
Many substrates of CYP2E1 are also CYP2E1-inducing agents – they include
acetone, ethanol, pyridine, pyrazole, and isoniazid (Ronis et al. 1996). Ethanol intake
increases the human CYP2E1 content in the liver (Perrot et al. 1989), and it is also
induced in lymphocytes of insulin-dependent diabetics (Song et al. 1990).
5.2 Outline of the chapter
The results obtained with CYP2D6 and CYP3A4 and their interactions with the
CPRs have been presented in Chapters 3 and 4. The findings presented in those
chapters show that ROS induced by CPRs is responsible for decrease in CYP
holoprotein content and ΔhRDM is relatively superior in terms of its ability to produce 
high levels of a spectrally active CYP as well as in terms of its ability to support
CYP2D6 and CYP3A4 catalytic activities. We have also shown that co-expression of
cytochrome b5 does not increase or decrease the CPR’s potential to induce ROS and
thus may not have any role in causing damage to CYP holoprotein.
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The ability of the CPRs to couple with individual CYPs was studied by co-
expressing CPRs viz. hRD, ∆hRDM and yRD in the context of the three more CYPs – 
CYP1B1, CYP1A2 and CYP2E1. We also studied CYP1A1 and CYP2C8 but only in
the context of ∆hRDM.  The experiments that describe gene cloning and protein 
expression, measurement of CYP holoprotein contents and enzyme activities, and
determination of coupling efficiencies are presented in this chapter. General
experimental methodologies have already been highlighted in the ‘Materials and
Methods’ chapter. However, methods which pertain to the specific CYPs in this chapter
are also described here.
5.3 Gene cloning into pBluescript KS+ and pFastBac1
5.3.1 CYP1A1 cloning
Cytochrome P450 1A1 (CYP1A1) cDNA was isolated in our laboratory
previously by PCR from a human liver cDNA library (Life Technology, Catalogue No
10422-012). CYP1A1 was isolated with the forward primer (5’- ATGGATCCGC
CACCATGCTT TTCCCAATCT CCATGTCGGC -3’, the BamHI site and the Kozak
sequence are marked with an underline and bold letters, respectively), and the reverse
primer (5’-ATGTCGACCT AAGAGCGCAG CTGCATTTGG AAGTGC -3’, the SalI
site is underlined).
The cDNA was further amplified using the above mentioned primers as
described in ‘Materials and Methods’ (Section Number 2.2.2). The PCR product was
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run on an agarose gel containing ethidium bromide and the DNA fragment of expected
size was isolated and purified using Qiagen gel extraction kit according to the
manufacturer’s protocol. The purified DNA fragment was digested with BamHI and
SalI restriction enzymes and after digestion run again on an agarose gel that contained
ethidium bromide. The digested DNA fragment was purified using a Qiagen gel
extraction kit. CYP1A1 cDNA was then directionally ligated using T4 DNA ligase into
pBluescript KS+ (digested with BamHI, SalI). The ligation mixture was used for
transforming E. coli DH5α competent cells, and colonies containing the correct 
recombinant constructs were identified with restriction analysis. Plasmids were
extracted from positive clones. The experimental methods employed are detailed in
‘Materials and Methods’. The cDNA sequence was confirmed by DNA sequencing and
its alignment with reference sequence in the NCBI database. The resultant plasmid was
named pBluKS+/Bam-Sal/CYP1A1 (Figure 5.1).
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Figure 5.1. The plasmid map of pBluKS+/Bam-Sal/CYP1A1.
For subcloning CYP1A1 into the transfer vector, the CYP1A1 gene was isolated
from pBluKS+/Bam-Sal/CYP1A1 using the restriction enzymes, BamHI and SalI. The
digested fragment of CYP1A1 was gel purified and used for ligation into pFastBac1
(cut with BamHI, SalI). The ligation mixture was used for transforming E. coli DH5α 
competent cells, and transformants were screened via restriction analysis (Figure
5.2(A)). The cDNA in the pFastBac1 vector was cloned under the control of polyhedrin
promoter. The resultant recombinant transfer vector was named pFastBac1/Bam-
Sal/CYP1A1 (Figure 5.2(B)).
pBluKS+/Bam-Sal/CYP1A1
4470 bps
1000
2000
3000
4000
NaeI 328
NgoMIV 328
FspI 480
PvuI 500
PvuII 530
653
SacI
BstXI
NotI
EagI
XbaI
SpeI
BamHI
689
AxyI 791
Eco81I 791
StuI 805
BstXI 821
BstXI 827
NcoI 827
BstXI 901
PstI 920
BstXI 939
NaeI 1014
NgoMIV 1014
NaeI 1101
NgoMIV 1101
EgeI 1104
NarI 1104
NaeI 1311
NgoMIV 1311
HincII 1352
PvuII 1398
PvuII 1577
PvuII 1601
Tth111I 1658
StuI 1806
HincII 1964
EcoRI 2135
SphI 2197
2225
PvuII
HincII
SalI
StrI
XhoI
ApaI
Asp718I
KpnI
2261
AseI 2429
PvuII 2481
AseI 2488
AflIII 2659
BspHI 3379
DraI 3416
DraI 3435
AseI 3723
FspI 3772
PvuI 3919
ScaI 4030
DraI 4127
BspHI 4387
''lacZ
kCYP1A1
lacZ'
ColE1ori
Amp-r
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Figure 5.2 (A). Assessment of pFastBac1/Bam-Sal/CYP1A1 plasmid veracity by
diagnostic restriction enzyme digestion. Digestion of pFastBac1/Bam-Sal/CYP1A1
construct by BamHI and SalI (performed as described in ‘Materials and Methods’)
produces two expected fragments of 4738 bp and 1551 bp. Lane 1, 1.0 kb DNA ladder
for sizing linear double-stranded DNA fragments (Invitrogen, catalogue No- 15615-
016); Lane 2, pFastBac1/Bam-Sal/CYP1A1 digested with BamHI, SalI, expected
fragments being 4738 bp and 1551 bp.
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Figure 5.2 (B). The plasmid map of pFastBac1/Bam-Sal/CYP1A1.
5.3.2 CYP1B1 cloning
Cytochrome P450 1B1 (CYP1B1) cDNA was isolated in our laboratory
previously by PCR from a human liver cDNA library (Life Technology, Catalogue No
10422-012). CYP1B1 was isolated with the forward primer (5’- ATGGATCCGC
CACCATGGGC ACCAGCCTCA GCCCGAACG -3’, the BamHI site and the Kozak
sequence are marked with an underline and bold letters respectively), and the reverse
pFastBac1/Bam-Sal/CYP1A1
6289 bps
1000
2000
3000
4000
5000
6000
NaeI 127
NgoMIV 127
BspHI 536
DraI 796
ScaI 893
PvuI 1004
FspI 1151
AseI 1200
DraI 1488
DraI 1507
BspHI 1544
AflIII 2264
BglII 2547
BalI 2707
BstXI 2710
EagI 2768
EcoRV 2823
BsaBI 3012
BglII 3017
Esp3I 3176
Tth111I 3225
AflIII 3246
BsrGI 3410
HincII 3548
BbsI 3750
EagI 3758
SnaBI 3879
AseI 3896
BsaBI 3924
BamHI 4032
AxyI 4134
Eco81I 4134
StuI 4148
BstXI 4164++
NcoI 4170++
BstXI 4282++
NgoMIV 4357++
NarI 4447
NaeI 4654
NgoMIV 4654
HincII 4695
PvuII 4741
PvuII 4920
PvuII 4944
Tth111I 5001
StuI 5149
HincII 5307
EcoRI 5478
SphI 5540
5568
PvuII
HincII
SalI
SacI
SpeI
NotI
EagI
XbaI
PstI
StrI
XhoI
SphI
Asp718I
KpnI
HindIII
ScaI
BsaBI
5673
DraI 5715
MunI 5765
HincII 5776
HpaI 5776
BclI 5914
AseI 6232
f1_ori
Amp-r
ColE1
Tn7R
Gm-r
polHp
kCYP1A1
SV40_polyA
Tn7L
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primer (5’-ATGTCGACTT ATTGGCAAGT TTCCTTGGCT TG -3’, the SalI site is
underlined).
The gene was amplified using the above mentioned primers as described in
‘Materials and Methods’ (Section Number 2.2.2). The PCR product was run on an
agarose gel containing ethidium bromide (0.1 µg/ml) and the DNA fragment of
expected size was isolated and purified using Qiagen gel extraction kit according to the
manufacturer’s protocol. The purified DNA fragment was digested with the restriction
enzymes, BamHI, SalI, and after digestion run again on an agarose gel that contained
ethidium bromide. The digested cDNA fragment was purified using a Qiagen gel
extraction kit. CYP1B1 cDNA was then directionally ligated using T4 DNA ligase into
pBluescript KS+ (digested with BamHI-SalI). The ligation mixture was transformed
into E. coli DH5α competent cells, and colonies containing the correct recombinant 
constructs were identified with restriction analysis. Plasmids were extracted from
positive clones. The experimental methods employed are detailed in ‘Materials and
Methods’ (Section Number 2.2.11). The cDNA sequence was confirmed by DNA
sequencing and its alignment with the reference sequence in the NCBI database. The
resultant plasmid was named pBluKS+/Bam-Sal/CYP1B1 (Figure 5.3).
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Figure 5.3. The plasmid map of pBluKS+/Bam-Sal/CYP1B1.
For subcloning of CYP1B1 into the transfer vector, the CYP1B1 cDNA was
isolated from pBluKS+/Bam-Sal/CYP1B1 using the set of restriction enzymes, BamHI
and SalI. The digested fragment of CYP1B1 was gel purified and used for ligation into
pFastBac1 (cut with BamHI, SalI). The ligation mixture was transformed into E. coli
DH5α competent cells, and transformants were screened with restriction analysis 
(Figure 5.4(A)). The cDNA in the pFastBac1 vector was cloned under the control of
polyhedrin promoter. The resultant recombinant transfer vector was named
pFastBac1/Bam-Sal/CYP1B1 (Figure 5.4(B)).
pBluKS+/Bam-Sal/CYP1B1
4563 bps
1000
2000
3000
4000
NaeI 328
NgoMIV 328
FspI 480
PvuI 500
PvuII 530
653
SacI
BstXI
NotI
EagI
XbaI
SpeI
BamHI
NcoI
699
SmaI 853
ApaI 856
PvuII 970
EagI 1049
NaeI 1051
NgoMIV 1051
NotI 1083
EagI 1084
FspI 1155
XhoI 1196
NarI 1262
BspHI 1311
PstI 1439
ScaI 1443
FspI 1461
EcoRI 1478
SmaI 1553
EagI 1611
NarI 1685
PstI 1715
XhoI 1761
BstEII 1817
BspHI 1984
BstXI 1991
DraI 2246
NcoI 2274
SacI 2279
SalI 2333
XhoI 2339
ApaI 2348
Asp718I 2354
KpnI 2354
AseI 2522
PvuII 2574
AseI 2581
AflIII 2752
BspHI 3472
DraI 3509
DraI 3528
AseI 3816
FspI 3865
PvuI 4012
ScaI 4123
DraI 4220
BspHI 4480
''lacZ
hum-CYP1B1
lacZ'
ColE1ori
Amp-r
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Figure 5.4 (A). Assessment of the pFastBac1/Bam-Sal/CYP1B1 plasmid veracity by
diagnostic restriction enzyme digestion. Digestion of pFastBac1/Bam-Sal/CYP1B1
construct by BamHI, SalI produces two expected fragments of 4738 bp and 1644 bp.
The diagnostic restriction digestion was performed as described in ‘Materials and
Methods’ (Section Number 2.2.4). Lane 1, 1.0 kb DNA ladder for sizing linear double-
stranded DNA fragments (Invitrogen, Catalogue No 15615-016); Lane 2,
pFastBac1/CYP1B1 digested with BamHI, SalI, expected fragments being 4738 bp and
1644 bp.
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pFastBac1/Bam-Sal/CYP1B1
6382 bps
1000
2000
3000
4000
5000
6000
NaeI 127
NgoMIV 127
BspHI 536
DraI 796
ScaI 893
PvuI 1004
FspI 1151
AseI 1200
DraI 1488
DraI 1507
BspHI 1544
AflIII 2264
BglII 2547
BalI 2707
BstXI 2710
EagI 2768
EcoRV 2823
BsaBI 3012
BglII 3017
Esp3I 3176
Tth111I 3225
AflIII 3246
BsrGI 3410
HincII 3548
BbsI 3750
EagI 3758
SnaBI 3879
AseI 3896
BsaBI 3924
BamHI 4032
NcoI 4042
BalI 4132
SmaI 4196
ApaI 4199
BalI 4212
PvuII 4313
EagI 4392
NaeI 4394++
EagI 4427++
XhoI 4539++
BspHI 4654
PstI 4782
ScaI 4786
FspI 4804
EcoRI 4821
SmaI 4896
EagI 4954
EgeI 5028
NarI 5028
PstI 5058
StrI 5104
XhoI 5104
BstEII 5160
HincII 5307
BspHI 5327
BstXI 5334
DraI 5589
NcoI 5617
SacI 5622
5676
HincII
SalI
SacI
SpeI
NotI
EagI
XbaI
PstI
StrI
XhoI
SphI
Asp718I
KpnI
HindIII
ScaI
BsaBI
5766
DraI 5808
MunI 5858
HincII 5869
HpaI 5869
BclI 6007
AseI 6325
f1_ori
Amp-r
ColE1
Tn7R
Gm-r
polHp
hum-CYP1B1
SV40_polyA
Tn7L
Figure 5.4 (B). The plasmid map of pFastBac1/Bam-Sal/CYP1B1.
5.3.3 CYP1A2 cloning
Human cDNA ORF clone for cytochrome P450 1A2 (CYP1A2, Reference ID:
NM_000761) in pCMV6-XL4 vector was procured from Origene (Catalogue No
SC119671). CYP1A2 cDNA was then isolated from the pCMV6-XL4 vector with the
forward primer (5’- ATGGATCCGC CACCATGGCA TTGTCCCAGT CTGTTCCC -
3’, the BamHI site and the Kozak sequence are marked with an underline and bold
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letters, respectively), and the reverse primer (5’-ATCTCGAGTC AGTTGATGGA
GAAGCGCAGC CGCGCC -3’, the XhoI site is underlined).
Figure 5.5 (A). CYP1A2 PCR amplified fragment generated by using CYP1A2 forward
and reverse primers. The PCR and agarose gel electrophoresis was performed as
described in ‘Materials and Methods’. Lane 1, 1.0 kb DNA ladder for sizing linear
double-stranded DNA fragments (Invitrogen, catalogue No- 15615-016); Lane 2, 1615
bp PCR fragment of CYP1A2.
The PCR product was run on an agarose gel (Figure 5.5(A)), containing
ethidium bromide and DNA fragment of expected size (1615 bp) was isolated and
purified using a Qiagen gel extraction kit according to the manufacturer’s protocol. The
purified DNA fragment was digested with the restriction enzymes, BamHI, XhoI and
after digestion run again on an agarose gel that contained ethidium bromide. The
digested DNA fragment was purified using a Qiagen gel extraction kit. CYP1A2 gene
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was then directionally ligated using T4 DNA ligase into pBluescript KS+ (digested with
BamHI-XhoI). The ligation mixture was transformed into E .coli DH5α competent 
cells, and colonies containing the correct recombinant constructs were identified with
restriction analysis (Figure 5.5 (B)). Plasmids were extracted from positive clones. The
experimental methods employed are detailed in ‘Materials and Methods’. The resultant
plasmid was named pBluKS+/Bam-Xho/CYP1A2 (Figure 5.5 (C)).
Figure 5.5 (B). Assessment of the pBluKS+/Bam-Xho/CYP1A2 plasmid veracity by
diagnostic restriction enzyme digestion. Digestion of pBluKS+/Bam-Xho/CYP1A2
construct by BamHI, XhoI produces two expected fragments of 2913 bp and 1615 bp.
The diagnostic restriction enzyme digestion was performed as described in ‘Materials
and Methods’ (Section Number 2.2.4). Lane 1, 1.0 kb DNA ladder for sizing linear
double-stranded DNA fragments (Invitrogen, Catalogue No 15615-016). Lane 2, Clone
#1, pBluescript KS+/CYP1A2 digested with BamHI, XhoI, expected fragments being
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2913 bp and 1615 bp; Lane 3, Clone #2, pBluescript KS+/CYP1A2 digested with
BamHI, XhoI, expected fragments being 2913 bp and 1615 bp.
Figure 5.5 (C). The plasmid map of pBluKS+/Bam-Xho/CYP1A2.
For subcloning of CYP1A2 into the transfer vector, the CYP1A2 gene was
isolated from pBluKS+/Bam-Xho/CYP1A2 using the set of restriction enzymes,
BamHI, XhoI. The digested fragment of CYP1A2 was gel purified and used for ligation
into pFastBac1 (cut with BamHI, XhoI). The ligation mixture was transformed into E.
coli DH5α competent cells, and transformants were screened with restriction enzyme 
analysis (Figure 5.6(A)). The cDNA in the pFastBac1 vector was cloned under the
pBluKS+/Bam-Xho/CYP1A2
4473 bps
1000
2000
3000
4000
NaeI 328
NgoMIV 328
FspI 480
PvuI 500
PvuII 530
653
SacI
BstXI
NotI
EagI
XbaI
SpeI
BamHI
NcoI
699
StuI 794
StuI 811
BstXI 827
BstXI 833
NcoI 833
PstI 926
NaeI 1020
NgoMIV 1020
NaeI 1107
NgoMIV 1107
NarI 1110
BclI 1215
BspHI 1369
PstI 1448
StuI 1461
PstI 1490
Tth111I 1658
PvuII 1790
StuI 1806
BbsI 1919
BstXI 1952
BglII 2100
SalI 2165
AflIII 2215
MunI 2242
XhoI 2249
ApaI 2258
Asp718I 2264
KpnI 2264
AseI 2432
PvuII 2484
AseI 2491
AflIII 2662
BspHI 3382
DraI 3419
DraI 3438
AseI 3726
FspI 3775
PvuI 3922
ScaI 4033
DraI 4130
BspHI 4390
''lacZ
h_CYP1A2
lacZ'
ColE1ori
Amp-r
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control of polyhedrin promoter. The resultant recombinant transfer vector was named
pFastBac1/Bam-Xho/CYP1A2 (Figure 5.6 (B)).
Figure 5.6 (A). Assessment of the pFastBac1/Bam-Xho/CYP1A2 plasmid veracity by
diagnostic restriction enzyme digestion. Digestion of pFastBac1/Bam-Xho/CYP1A2
construct by StuI produces five expected fragments of 5292 bp, 1012 bp, 650 bp, 345 bp
and 17 bp. The 17 bp fragment cannot be seen on the gel as the size of the fragment is
very small. The diagnostic restriction digestion was performed as described in
‘Materials and Methods’ (Section Number 2.2.4). Lane 1, 1.0 kb DNA ladder for sizing
linear double-stranded DNA fragments (NEB, catalogue No- N3232S); Lane 2,
pFastBac1/Bam-Xho/CYP1A2 digested with StuI, expected fragments are 5292 bp,
1012 bp, 650 bp, 345 bp and 17 bp.
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Figure 5.6 (B). The plasmid map of pFastBac1/Bam-Xho/CYP1A2.
5.3.4 CYP2C8 cloning
Cytochrome P450 2C8 (CYP2C8) gene was isolated in our laboratory previously
by PCR from a human liver cDNA library (Life Technology, Catalogue No 10422-012).
CYP2C8 was isolated with the forward primer (5’- CGACTAGTGC CACCATGGAA
CCTTTTGTGG TCCTGGTGCT GTG -3’, the SpeI site and the Kozak sequence are
marked with an underline and bold letters, respectively), and the reverse primer (5’-
pFastBac1/Bam-Xho/CYP1A2
6304 bps
1000
2000
3000
4000
5000
6000
NaeI 127
NgoMIV 127
BspHI 536
DraI 796
ScaI 893
PvuI 1004
FspI 1151
AseI 1200
DraI 1488
DraI 1507
BspHI 1544
AflIII 2264
BglII 2547
BalI 2707
BstXI 2710
EagI 2768
EcoRV 2823
BsaBI 3012
BglII 3017
Esp3I 3176
Tth111I 3225
AflIII 3246
BsrGI 3410
HincII 3548
BbsI 3750
EagI 3758
SnaBI 3879
AseI 3896
BsaBI 3924
BamHI 4032
NcoI 4042
StuI 4137
StuI 4154
BstXI 4170++
NcoI 4176++
NaeI 4363
NgoMIV 4363++
NarI 4453
BclI 4558
BalI 4630
BspHI 4712
PstI 4791
StuI 4804
PstI 4833
HincII 4965
Tth111I 5001
PvuII 5133
StuI 5149++
HincII 5283
BstXI 5295
BalI 5431++
BalI 5458
HincII 5508
SalI 5508
AflIII 5558
MunI 5585
SacI 5604
SpeI 5610
5617
NotI
EagI
XbaI
PstI
StrI
XhoI
SphI
Asp718I
KpnI
HindIII
ScaI
BsaBI
5688 DraI 5730
MunI 5780
HincII 5791
HpaI 5791
BclI 5929
AseI 6247
f1_ori
Amp-r
ColE1
Tn7R
Gm-r
polHp
kCYP1A2
'lacZ'
SV40_polyA
Tn7L
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CCGCTCGAGT CAGACAGGGA TGAAGCAGAT CTGGTATGAG -3’, the XhoI site
is underlined).
The cDNA was further amplified using above mentioned primers as described in
‘Materials and Methods’ (Section Number 2.2.2). The PCR product was run on an
agarose gel containing ethidium bromide and the DNA fragment of expected size was
isolated and purified using a Qiagen gel extraction kit according to the manufacturer’s
protocol. The purified DNA fragment was digested with SpeI, XhoI restriction enzymes
and after digestion run again on an agarose gel that contained ethidium bromide. The
digested DNA fragment was purified using a Qiagen gel extraction kit. The CYP2C8
gene was then directionally ligated using T4 DNA ligase into pBluescript KS+ (cut with
SpeI-XhoI). The ligation mixture was transformed into E. coli DH5α competent cells, 
and colonies containing the correct recombinant constructs were identified with
restriction enzyme analysis. Plasmids were extracted from positive clones. The
experimental methods employed are detailed in ‘Materials and Methods’. The gene
sequence was confirmed by DNA sequencing and its alignment with reference sequence
in the NCBI database. The resultant plasmid was named pBluKS+/Spe-Xho/CYP2C8
(Figure 5.7).
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Figure 5.7. The plasmid map of pBluKS+/Spe-Xho/CYP2C8.
For subcloning of CYP2C8 into the transfer vector, the CYP2C8 gene was
isolated from pBluKS+/Spe-Xho/CYP2C8 using the set of restriction enzymes, SpeI,
XhoI. The digested fragment of CYP2C8 was gel purified and used for ligation into
pFastBac1 (cut with SpeI, XhoI). The ligation mixture was transformed into E. coli
DH5α competent cells, and transformants were screened via restriction enzyme analysis 
(Figure 5.8 (A)). The cDNA in the pFastBac1 vector was cloned under the control of
polyhedrin promoter. The resultant recombinant transfer vector was named
pFastBac1/Spe-Xho/CYP2C8 (Figure 5.8 (B)).
pBluKS+/Spe-Xho/CYP2C8
4392 bps
1000
2000
3000
4000
NaeI 328
NgoMIV 328
FspI 480
PvuI 500
PvuII 530
653
SacI
BstXI
NotI
EagI
XbaI
SpeI
NcoI
693
NcoI 1325
BamHI 1329
HincII 1463 ++
ClaI 1484
BclI 1497
EcoRI 1535
BclI 1675
SphI 1707
Tth111I 1772
BalI 1921 ++
DraI 2083
PstI 2103
BglII 2145
StrI 2168
XhoI 2168
ApaI 2177
Asp718I 2183
KpnI 2183
AseI 2351
PvuII 2403
AseI 2410
AflIII 2581
BspHI 3301
DraI 3338
DraI 3357
AseI 3645
FspI 3694
PvuI 3841
ScaI 3952
DraI 4049
BspHI 4309
''lacZ
h_CYP2C8
lacZ'
ColE1ori
Amp-r
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Figure 5.8 (A). Assessment of the pFastBac1/Spe-Xho/CYP2C8 plasmid veracity by
diagnostic restriction enzyme digestion. All the expected DNA fragments were
observed on the gel. The diagnostic restriction enzyme digestion was performed as
described in ‘Materials and Methods’ (Section Number 2.2.4). Lane 1, 1.0 kb DNA
ladder for sizing linear double-stranded DNA fragments (NEB, catalogue No- N3232S);
Lane 2, pFastBac1/Spe-Xho/CYP2C8 digested with NcoI, expected fragments being
5592 bp and 632 bp; Lane 3, pFastBac1/Spe-Xho/CYP2C8 digested with AflIII,
expected fragments being 5242 bp and 982 bp; Lane 4, 1.0 kb DNA ladder for sizing
linear double-stranded DNA fragments (NEB, Catalogue No N3232S); Lane 5,
pFastBac1/Spe-Xho/CYP2C8 digested with HpaI, expected fragments being 5375 bp
and 849 bp.
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Figure 5.8 (B). The plasmid map of pFastBac1/Spe-Xho/CYP2C8.
5.3.5 CYP2E1 cloning
Cytochrome P450 2E1 (CYP2E1) gene was isolated in our laboratory previously
by PCR from a human liver cDNA library (Life Technology, Catalogue No 10422-012).
CYP2E1 was isolated with the forward primer (5’- GAAGATCTGC CACCATGTCT
GCCCTCGGAG TGACCGTGGC CCT -3’, the BglII site and the Kozak sequence are
marked with an underline and bold letters, respectively), and the reverse primer (5’-
ATCTCGAGTC ATGAGCGGGG AATGACACAG -3’, the XhoI site is underlined).
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Figure 5.9 (A). CYP2E1 PCR amplified fragment generated by using CYP2E1 forward
and reverse primers. The PCR and agarose gel electrophoresis was performed as
described in ‘Materials and Methods’. Lane 1, 1.0 kb DNA ladder for sizing linear
double-stranded DNA fragments (Invitrogen, Catalogue No 15615-016); Lane 2, PCR
fragment of CYP2E1.
The cDNA was amplified using above mentioned primers as described in
‘Materials and Methods’ (Section Number 2.2.2). The PCR product was run on an
agarose gel (Figure 5.9(A)) containing ethidium bromide and the DNA fragment of
expected size was isolated and purified using a Qiagen gel extraction kit according to
the manufacturer’s protocol. The purified DNA fragment was digested with the
restriction enzymes, BglII, XhoI and after digestion run again on an agarose gel that
contained ethidium bromide. The digested DNA fragment was purified using a Qiagen
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gel extraction kit. CYP2E1 cDNA was then directionally ligated using T4 DNA ligase
into pSP73 (digested with BglII-XhoI). The ligation mixture was transform into E. coli
DH5α competent cells and colonies containing the correct recombinant constructs were 
identified with restriction enzyme analysis (Figure 5.9 (B)). Plasmids were extracted
from positive clones. The experimental methods employed are detailed in ‘Materials
and Methods’ (Section Number 2.2.11). The gene sequence was confirmed by DNA
sequencing and its alignment with reference sequence in the NCBI database. The
resultant plasmid was named pSP73/Bgl-Xho/CYP2E1 (Figure 5.9 (C)).
Figure 5.9 (B). Assessment of the pSP73/Bgl-Xho/CYP2E1 plasmid veracity by
diagnostic restriction enzyme digestion. Digestion of pSP73/Bgl-Xho/CYP2E1
construct by BglII, XhoI produces two expected fragments of 2383 bp and 1494 bp. The
diagnostic restriction enzyme digestion was performed as described in ‘Materials and
Methods’ (Section Number 2.2.4). Lane 1, 1.0 kb DNA ladder for sizing linear double-
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stranded DNA fragments (Invitrogen, Catalogue No 15615-016); Lane 2, Clone #1,
pSP73/BglII-XhoI/CYP2E1 digested with BglII, XhoI, expected fragments being 2383
bp and 1494 bp; Lane 3, Clone #2, pSP73/BglII-XhoI/CYP2E1 digested with BglII,
XhoI, expected fragments being 2913 2383 bp and 1494 bp.
Figure 5.9 (C). The plasmid map of pSP73/BglII-XhoI/CYP2E1.
For subcloning of CYP2E1 into the transfer vector, the CYP2E1 gene was
isolated from pSP73/BglII-XhoI/CYP2E1 using the set of restriction enzymes BglII,
XhoI. The digested fragment of CYP2E1 was gel purified and used for ligation into
pFastBac1 (cut with BamHI, SalI which have compatible sticky ends to BglII, XhoI –
pSP73/BglII-XhoI/CYP2E1
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but once the vector is ligated to the gene insert, the gene cannot be re-isolated from the
resultant plasmid). The ligation mixture was transformed into E. coli DH5α competent 
cells, and transformants were screened with restriction analysis (Figure 5.10 (A)). The
cDNA in the pFastBac1 vector was cloned under the control of polyhedrin promoter.
The resultant recombinant transfer vector was named pFastBac1/CYP2E1 (Figure 5.10
(B)).
Figure 5.10 (A). Assessment of the pFastBac1/CYP2E1 plasmid veracity by diagnostic
restriction enzyme digestion. Digestion of pFastBac1/CYP2E1 construct by BamHI-
XbaI produces two expected fragments of 5152 bp and 1080 bp. The diagnostic
restriction enzyme digestion was performed as described in ‘Materials and Methods’
(Section Number 2.2.4). Lane 1, 1.0 kb DNA ladder for sizing linear double-stranded
DNA fragments (Invitrogen, Catalogue No 15615-016); Lane 2, pFastBac1/CYP2E1
digested with BamHI, XbaI, expected fragments being 5152 bp and 1080 bp.
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Figure 5.10 (B). The plasmid map of pFastBac1/CYP2E1.
5.4 Generation of bacmid Constructs and baculoviruses
The recombinant transfer vectors, named pFastBac1/Bam-Sal/CYP1A1,
pFastBac1/Bam-Sal/CYP1B1, pFastBac1/Bam-Xho/CYP1A2, pFastBac1/Spe-
Xho/CYP2C8 and pFastBac1/CYP2E1 were transposed into DH10Bac competent cells.
DH10Bac cells contain a baculovirus shuttle vector (bacmid DNA) and a helper plasmid
which allow generation of a recombinant bacmid by site-specific transposition. The
propagation of recombinant bacmid in E. coli DH10Bac was identified by white colour
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in the presence of a chromogenic substrate-Bluo-gal and the inducer IPTG. The white
colonies were streaked a second time on the Bluo-gal plates and after confirming the
white phenotype, recombinant bacmids were isolated and confirmed by PCR analysis.
PCR was performed using M13 forward primer (5’GTTTTCCCAGTCACGAC 3’) and
gene specific reverse primers (Figure 5.11) or gene specific forward and reverse primers
as indicated.
Figure 5.11. Confirmation of CYP1A1, CYP1A2, CYP1B1, CYP2E1 and CYP2C8 gene
transpositions on to bacmids. All the CYP recombinations on bacmid were confirmed
by PCR which were performed as described in ‘Materials and Methods’ (Section
Number 2.2.16). Lane 1, 1 kb DNA ladder for sizing linear double-stranded DNA
fragments (Invitrogen, Catalogue No 15615-016); Lane 2, CYP1A1 recombinant
bacmid confirmation, PCR was performed using set of M13 forward and gene specific
reverse primers. Expected PCR fragment size for CYP1A1 transposition confirmation
is ~3200 bp; Lane 3, CYP1A2 recombinant bacmid confirmation, PCR was performed
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using set of M13 forward and gene specific reverse primers. Expected PCR fragment
size for CYP1A2 transposition confirmation is ~3200 bp; Lane 4, 1 kb DNA ladder for
sizing linear double-stranded DNA fragments (Invitrogen, Catalogue No 15615-016);
Lane 5, CYP1B1 recombinant bacmid confirmation, PCR was performed using gene
specific forward and reverse primers. Expected PCR fragment size for CYP1B1
transposition confirmation is 1644 bp; Lane 6, 1 kb DNA ladder for sizing linear
double-stranded DNA fragments (Invitrogen, Catalogue No 15615-016); Lane 7,
CYP2E1 recombinant bacmid confirmation, PCR was performed using a set of M13
forward and gene specific reverse primers. Expected PCR fragment size for CYP2E1
transposition confirmation is ~3200 bp; Lane 8, CYP2C8 recombinant bacmid
confirmation, PCR was performed using a set of M13 forward and gene specific reverse
primers. Expected PCR fragment size for CYP2C8 transposition confirmation is ~3200
bp.
In order to generate baculoviruses, Sf9 cells were transfected with recombinant
bacmids as described in ‘Materials and Methods’ (Section Number 2.3.7). Hereafter,
CYP baculovirus is referred to as BV-CYP. The baculoviruses produced in Sf9 cells by
initial transfections were subjected to two more rounds of amplification by infecting the
cells with baculoviruses for 96 h. The baculovirus titration was performed using plaque
assay and titres of the baculovirus stocks were determined. The experimental methods
employed are detailed in ‘Materials and Methods’.
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5.5 Expression of CYP1A1, CYP1B1, CYP1A2, CYP2C8 and
CYP2E1 in Sf9 cells
Following amplification and titration of recombinant baculoviruses, Sf9 cells
were infected with CYP baculoviruses in separate experiments. The cells were
incubated in a 27°C humidified incubator. To compensate for low endogenous levels of
haem in insect cells, haemin (2 µg/ ml) and δ-amino levulinic acid (100µM) were added 
24 h post-infection to the cells. Cells were harvested 63 h post-infection and the
microsomes were prepared. The experimental methods employed are detailed in
‘Materials and Methods’.
The presence of the individual CYPs in different microsomes was confirmed by
Coomassie staining. Microsomes (20 µg of microsomal proteins/ lane) were separated
on 10% sodium dodecyl sulfate-polyacrylamide gel and protein bands were visualised
by staining with Coomassie G-250 followed by several de-staining steps as described in
‘Materials and Methods’ (Section Number 2.4.5). Commassie staining of microsomal
protein fractions prepared from recombinant baculovirus infected insect cells detected
CYP1A1, CYP1B1, CYP1A2, CYP2C8 and CYP2E1 protein bands (Figure 5.12 (A)
and (B)). The size of the protein bands was consistent with the molecular weights
predicted from the cDNA sequences.
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Figure 5.12 (A). SDS-PAGE gel analysis of CYP1A1, CYP2E1 and CYP2C8 proteins.
20 µg of microsomal fractions of the proteins expressed in Sf9 cells were loaded per
lane on 10% SDS-PAGE. Gels were stained with Coomassie blue G-250 as described
in ‘Materials and Methods’ (Section Number 2.4.5). Lane 1; protein marker (Santa
Cruz Biotechnology, Catalogue No sc-2361); Lane 2, CYP1A1; Lane 3, CYP2E1;
Lane 4, negative control (proteins from cells infected with baculovirus encoding no
foreign gene) ; Lane 5, protein marker ( Santa Cruz Biotechnology, catalogue No: sc-
2361). Lane 6, negative control (proteins from cells infected with baculovirus encoding
no foreign gene); Lane 7, CYP2C8.
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Figure 5.12 (B). SDS-PAGE gel analysis of CYP1B1 and CYP1A2 proteins. 20 µg of
microsomal fractions of the proteins expressed in Sf9 cells were loaded per lane on 10%
SDS-PAGE. Gels were stained with Coomassie blue G-250 as described in ‘Materials
and Methods’ (Section Number 2.4.5). Lane 1, protein marker (Bio-Rad, Catalogue No
161-0375); Lane 2, negative control (proteins from cells infected with baculovirus
encoding no foreign gene); Lane 3, CYP1A2; Lane 4, protein marker (Santa Cruz
Biotechnology, catalogue No: sc-2361); Lane 5, CYP1B1; Lane 6, negative control
(proteins from cells infected with baculovirus encoding no foreign gene).
5.6 Co-expression of CYPs with the CPRs in Sf9 cells
As presented in Chapters 3 and 4, ΔhRD does not anchor on to the microsomal 
membranes – therefore, it was not pursued further. CYP1B1, CYP1A2 and CYP2E1
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were studied in the context of three different CPR species viz. hRD, ΔhRDM and yRD, 
whereas CYP1A1 and CYP2C8 were studied only in the context of ΔhRDM.  In the 
human liver microsomes, CYP levels are found to be exceeding the levels of NADPH
cytochrome P450 reductase by a 10:1 to 20:1 ratio (Estabrook et al 1971). In line with
this, while co-infecting Sf9 cells with BV-CYP and BV-CPR, multiplicity of infection
(MOI) for BV-CPR was kept 10 times less (1 x 10-1 pfu/cell) than that for CYPs (1
pfu/cell). Cytochrome b5 is known to augment CYP2C8 and CYP2E1 catalytic activity.
For the co-expression of the third protein (cytochrome b5) with CYP2C8 and CYP2E1,
the MOI of BV-cyt-b5 was kept at 0.1 pfu/ cell. To compensate for low endogenous
levels of haem in insect cells, haemin (2 µg/ ml) and δ-amino levulinic acid (100µM) 
were added 24 hour post-infection. Cells were harvested after 63 h and the microsomes
were prepared. The experimental methods employed are detailed in ‘Materials and
Methods’.  Western blot and Coomassie staining experiments for hRD, ΔhRDM and 
yRD were presented in Chapter 3 and Coomassie staining for cytochrome b5 was
presented in Chapter 4.
After co-expression with CPRs, Western blotting was performed for CYP1A2
and CYP2E1 microsomes. For Western blotting, the microsomes prepared from the
baculovirus infected Sf9 cells were separated on 10% sodium dodecyl sulfate-
polyacrylamide gel (1.5 µg microsomal protein/ lane). The proteins were transferred to
Immobilon-P membrane (Millipore) by semi-dry transfer method. The membrane was
blocked overnight at 4ºC with 5% non-fat dry milk in PBS. The blot for CYP1A2 was
probed with goat anti-rat CYP1A1 polyclonal antibody (BD-Gentest, Catalogue No
458124) at a 1:2500 dilution followed by exposure to donkey anti-goat HRP-conjugated
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secondary antibody (Santa Cruz Biotechnology, Catalogue No sc-2304) at a 1:7500
dilution. The blot for CYP2E1 was probed with goat anti-rat CYP2E1 polyclonal
antibody (BD-Gentest, Catalogue No 458216) at a 1:2500 dilution followed by
exposure to donkey anti-goat HRP-conjugated secondary antibody (Santa Cruz
Biotechnology, Catalogue No sc-2304) at a 1:7500 dilution. The blots were incubated
with luminal, a chemiluminescent substrate, for short period of time.
Chemiluminescence was captured (Figure 5.13 (A) and (B)) on Gel Doc™, Bio-Rad.
Human CYP protein bands reacted with the corresponding antibodies in Western blot
analysis. The protein band intensities were measured by densitometry using ‘Quantity
One’ software from Bio-Rad.
Figure 5.13 (A). Immunoblot analyses of CYP1A2 co-expressed with different CPR
species in Sf9 insect cells. Sf9 cells were infected with CYP and CPR baculoviruses at
an MOI of 1 pfu/cell and 0.1 pfu/cell, respectively. Microsomes were prepared 63 h
post-infection.  1.5 μg of microsomal fractions were loaded per lane on 10% SDS-
PAGE and immunoblotting was performed as described in ‘Materials and Methods’
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(Section Number 2.4.6). The numbers below the bands show band intensities in
arbitrary units. Lane 1, negative control (proteins from cells infected with baculovirus
encoding no foreign gene); Lane 2, CYP1A2 expressed alone; Lane 3, CYP1A2 co-
expressed with hRD;  Lane 4, CYP1A2 co-expressed with ΔhRDM;  Lane 5, CYP1A2 
co-expressed with yRD.
Figure 5.13 (B). Immunoblot analyses of CYP2E1 co-expressed with different CPR
species in Sf9 insect cells. Sf9 cells were infected with CYP and CPR baculoviruses at
an MOI of 1 pfu/cell and 0.1 pfu/cell, respectively. Microsomes were prepared 63 h
post-infection. 1.5 μg of microsomal fractions were loaded per lane on 10% SDS-PAGE 
and immunoblotting was performed as described in ‘Materials and Methods’ (Section
Number 2.4.6). The numbers below the bands show band intensities in arbitrary units.
Lane 1, negative control (proteins from cells infected with baculovirus encoding no
foreign gene); Lane 2, CYP2E1 co-expressed with cytochrome b5; Lane 3, CYP2E1
co-expressed with cytochrome b5 and hRD; Lane 4, CYP2E1 co-expressed with
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cytochrome b5 and ΔhRDM;  Lane 5, CYP2E1 co-expressed with cytochrome b5 and
yRD.
5.7 CYP amounts and their catalytic activities supported by
   hRD, ΔhRDM and yRD 
The insect cells were infected with CYP (BV-CYP1B1, BV-CYP1A2 and BV-
CYP2E1) recombinant baculoviruses alone (MOI: 1.0 pfu/cell) and also co-infected
with hRD or ΔhRDM or yRD baculoviruses (MOI: 0.1 pfu/cell).  CYP1A1 and 
CYP2C8 were studied only with one CPR, i.e. ΔhRDM.  In case of CYP2C8 and 
CYP2E1, cells were also co-infected with a third baculovirus, BV-cyt-b5 (MOI: 0.1).
Haemin (2 µg/ ml) and δ-amino levulinic acid (100µM) were added 24 h post-infection 
to compensate for low endogenous levels of haem. Microsomes were prepared 63-h
post-infection and the protein concentrations were determined by a modified Bradford
method (Bradford 1976). The microsomes were diluted to a protein concentration of 1
mg/ml with 100 mM potassium phosphate buffer (pH 7.4), 20% (vol/vol) glycerol.
Then a few grains of sodium dithionite were added and a baseline recorded on a dual
wavelength spectrophotometer (Shimadzu UV-2401PC). CYP holoprotein contents
were spectrophotometrically measured as reduced carbon monoxide (CO) difference
spectra (Omura and Sato 1964) using 91 mM-1 cm -1 as the extinction coefficient. The
experimental methods have been described in detail in ‘Materials and Methods’.
Carbon monoxide difference spectra of CYPs expressed on their own are presented in
Figure 5.14.
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Figure 5.14. Reduced carbon monoxide difference spectra of CYPs. Sf9 cells were
infected with CYP baculoviruses at an MOI of 1 pfu/ cell. 63 h post-infection, the cells
were harvested and microsomes were prepared. CYP content was measured by reduced
carbon monoxide difference spectra as described in ‘Materials and Methods’ (Section
Number 2.4.3). (A) CYP1A1 CO-difference spectrum, (B) CYP1B1 CO-difference
spectrum, (C) CYP1A2 CO-difference spectrum, (D) CYP2C8 CO-difference spectrum
and (E) CYP2E1 CO-difference spectrum.
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5.7.1   CYP1B1 interactions with hRD, ΔhRDM and yRD 
CYP1B1 was expressed with and without the CPRs, microsomes were prepared
and CYP contents were measured by carbon monoxide difference spectroscopy as
described above. Table 5.1 shows specific contents of CYP1B1 when expressed with
and without the CPRs.
Table 5.1. CYP1B1 content in microsomal samples, determined by reduced CO-
difference spectroscopy. Sf9 cells were co-infected with CYP and CPR baculoviruses
at an MOI of 1 and 0.1 pfu/ cell respectively. Microsomes were prepared 63 h post-
infection as described in ‘Materials and Methods’ (Section Number 2.4.1). Data are
presented as mean values ± STDEV.
Microsomes specific content of CYP1B1
(pmole/mg protein)
CYP1B1
CYP1B1+ hRD
CYP1B1+ ΔhRDM 
CYP1B1+ yRD
1287.56 ± 96.3
630.94 ± 52.9
940.91 ± 66.2
644.10 ± 61.7
The results, indicating that co-expression of CYPs with CPRs results in decrease
in spectrally active CYP levels (holoprotein levels), are in agreement with what we
observed in Chapters 3 and 4,. CYP content is highest when expressed without CPR.
However, in microsomes which co-express CPRs, it is observed that CYP1B1 content is
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higher when it is co-expressed with ΔhRDM in comparison to the CYP content obtained 
after co-expression with hRD or yRD (see Table 5.1). This implies that the destruction
of CYP1B1 holoprotein by ΔhRDM is far less than that caused by hRD and yRD.  In 
Chapter 3, experimental evidence has been presented that correlates the destruction of
CYPs with reactive oxygen species that are induced by CPRs.
The catalytic activities of CYP1B1 co-expressed with CPRs were measured
using the ethoxyresorufin-O-deethylase (EROD) assay (Klotz et al. 1984). CYP1B1
converts 7-ethoxyresorufin (7-ER) to resorufin in the presence of NADPH and oxygen
and the assay is well known as the EROD assay. The amount of resorufin produced is
measured fluorometrically and it reflects the level of 7-ethoxyresorufin o-deethylase
activities. Both, CYP1B1 and CYP1A1 can catalyse deethylation of the substrate 7-
ethoxyresorufin (7-ER) to form the product resorufin, which exhibits fluorescence at
excitation wavelength of 530 nm and emission wavelength of 590 nm.
The production of the metabolite resorufin, by deethylation of the fluorogenic
substrate 7-ethoxyresorufin was measured for 30 min. The assay was performed as
described before (Klotz et al. 1984). The reaction kinetics was carried out at 37ºC in a
reaction volume of 100 µl/well in 96-well black plates with transparent flat bottom
(Fisher, Catalogue No FB86083). The assay mixture contained 100 mM Potassium
phosphate buffer pH 7.4, containing 5 µM 7-ethoxyresorufin , 1.5 pmole CYP1B1 and
the NADPH regenerating system (1.3 mM NADP+, 3.3 mM G6P, 3.3 mM MgCl2,
0.4U/ml G6PDH). Resorufin formation was measured fluorometrically on the Biotek
266
y = 117.65x - 6.847
R² = 1
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
500000
0 1000 2000 3000 4000 5000
R
F
U
Resorufin conc. (pmol)
Resorufin Standard Curve
Synegy HT plate reader (excitation wavelength of 528/20 nm and emission wavelength
of 590/20 nm). Changes in fluorescence were recorded for 30 min as relative
fluorescence units (RFU).
The metabolite of 7-ER, resorufin, was used to generate a standard curve – it
was prepared using a range of concentrations of resorufin (1.82, 5.5, 16.5, 49.4, 148.1,
444.4, 1333.3 and 4000 pmole/100 µl reaction volume). The end-point assays were
performed in 96-well black plates. The fluorescent values (RFU) were recorded on the
Biotek Synegy HT plate reader using an excitation wavelength of 528/20 nm and
emission wavelength of 590/20 nm. The standard curve was plotted (Figure 5.15 (A))
and resorufin concentrations in test samples (Figure 5.15 (A)) were measured using the
equation from the standard curve.
Figure 5.15 (A). The resorufin standard curve. The curve was prepared as described in
Section 5.7.1.
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Figure 5.15 (B). Kinetic analysis of CYP1B1 catalytic activities in the EROD assay.
Sf9 cells were co-infected with CYP1B1 and the CPR baculoviruses at an MOI of 1 and
0.1 pfu/ cell, respectively. The catalytic activities of CYP1B1 were measured in
microsomes prepared at 63h post-infection. EROD assay was performed as described in
Section 5.7.1.
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Table 5.2. CYP1B1 enzyme reaction rates in co-expressed microsomes. Sf9 cells were
co-infected with CYP1B1 and the CPR baculoviruses at an MOI of 1 and 0.1 pfu/ cell,
respectively. The reaction rates were measured in microsomes prepared at 63h post-
infection. EROD assay was performed as described in Section 5.7.1.
Microsomes CYP1B1 reaction rates
(pmole resorufin formed/ min/ pmole of CYP1B1)
CYP1B1
CYP1B1+hRD
CYP1B1+ΔhRDM 
CYP1B1+yRD
0.4292
1.9462
2.1176
0.7897
NADPH-cytochrome P450 reductase activities of human and yeast CPRs in
CYP1B1 co-expressed microsomes were measured by the reduction of the tetrazolium
salt, MTT, as described in ‘Materials and Methods’ (Section Number 2.4.7). In CYP
and CPR co-expressed microsomes, reduction potential of yRD was similar to that of
hRD (Table 5.2), which means yRD can reduce MTT as efficiently as hRD. This
observation is in line with similar levels of decrease in CYP1B1 holoprotein content in
the presence of either yRD or hRD (Table 5.1). Both the CPRs probably cause
oxidative damage to microsomal proteins which results in decrease in holoprotein
levels.  Reduction potential of ΔhRDM towards MTT is comparatively lower than hRD 
and yRD.
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Table 5.3. NADPH cytochrome P450 reductase activities exhibited by hRD, ΔhRDM 
and yRD in CYP1B1 co-expressed microsomes. Sf9 cells were co-infected with
CYP1B1 baculoviruses (MOI 1.0 pfu/cell) and CPR baculoviruses (MOI 0.1 pfu/cell)
and microsomes were prepared 63 h post-infection. Reductase activity was measured
by using MTT as described in Materials and Methods (Section Number 2.4.7). The
moles of MTT reduced per minute per mg of protein were calculated.
CPR Species Reductase activity
(nmole MTT reduced/min/mg protein)
CYP1B1
CYP1B1+ hRD
CYP1B1+ ΔhRDM 
CYP1B1+ yRD
14.5 ± 3.2
250.6 ± 47.1
173.1 ± 31.0
260.5 ± 39.3
As observed in Figure 5.15 (B) and Table 5.2, hRD and ΔhRDM supported 
CYP1B1 catalytic activity far better than yRD. However NADPH cytochrome P450
reductase activity of yRD as measured by the MTT assay (Table 5.2) is high. This
observation again indicates that reduction potential of yRD towards MTT is not directly
proportional to its ability to couple with a CYP. To highlight the ability of CPRs to
support CYP1B1 activity, their coupling efficiency with CYP1B1 was calculated by
using the following formula,
Coupling efficiency = CYP1B1 activity in EROD assay∕ CPR activity in MTT assay  
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As the coupling efficiency of ΔhRDM was highest among the three CPRs, percentage 
relative coupling efficiency for hRD and yRD was calculated in comparison with
ΔhRDM, considering ΔhRDM activity as 100% (Table 5.4).  The percent coupling 
efficiency values show that ΔhRDM couples better with CYP1B1 than its native form, 
hRD, and yeast reductase, yRD.  The lower level of ROS induction by ΔhRDM (as 
depicted in Figures 3.22 and 3.23 in Chapter 3) correlates to its higher coupling
efficiency. ROS induced by CPRs is responsible for a decrease in CYP holoproein
content and possibly it is also responsible for uncoupling of CYP catalytic activity (as
observed in the CYP enzyme assays).
Table 5.4. Percent relative coupling efficiency of hRD, ΔhRDM and yRD with 
CYP1B1. CYP1B1 activity in the EROD assay and CPR activity measured in the MTT
assay were used for the calculations. CYP1B1 activity was divided by CPR activity and
percent relative coupling efficiency was measured.
Microsome samples % Relative coupling efficiency
CYP1B1+ ΔhRDM 
CYP1B1+ hRD
CYP1B1+ yRD
100
63.49
24.78
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5.7.2   CYP1A2 interactions with hRD, ΔhRDM and yRD 
CYP1A2 was expressed with and without the CPRs, microsomes were prepared
and CYP1A2 holoprotein contents were measured by carbon monoxide difference
spectroscopy as described in Section 5.7. Table 5.5 shows specific contents of CYP1A2
when expressed with and without CPRs.
Table 5.5. CYP1A2 specific content in microsomal samples, determined by reduced
CO-difference spectroscopy. Sf9 cells were co-infected with CYP and CPR
baculoviruses at an MOI of 1 and 0.1 pfu/ cell, respectively. Microsomes were prepared
63 h post-infection as described in ‘Materials and Methods’ (Section Number 2.4.1).
Data are presented as mean values ± STDEV.
Microsomes Specific content of CYP1A2
(pmole/mg protein)
CYP1A2
CYP1A2+ hRD
CYP1A2+ ΔhRDM 
CYP1A2+ yRD
1577.66 ± 88.3
644.41 ± 54.0
1162.21 ± 75.1
369.05 ± 31.5
Like the other CYPs studied, CYP1A2 holoprotein content was highest when it
was expressed alone and the CYP holoprotein content was lower when CYP1A2 was
co-expressed with the CPRs. However decrease in holoprotein content in yRD co-
expressed microsomes was four fold, which indicates that yRD is extremely destructive
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to CYP1A2 on insect cell microsomes. In comparison with hRD, genetically modified
CPR, ΔhRDM, seems to yield substantially higher amounts of CYP1A2 holoprotein.  
The CYP1A2 content in hRD co-expressed microsomes was 2.5 fold lower than in the
microsomes which contained only CYP1A2. Decrease in CYP1A2 holoprotein content
by hRD and yRD is highest among all the CYPs that we studied which indicates that
CYP-CPR interactions vary depending on the CYP isoform.
In order to compare the ability of different CPR species to transfer electrons to
CYP1A2, enzyme assays were performed using the fluorogenic substrate, 3-cyano-7-
ethoxycoumarin (CEC). CEC is metabolized mainly by CYP2C19 and CYP1A2 to a
fluorescent product 3-cyano-7-hydroxycoumarin (CHC). However, CEC is also
metabolized by CYP2D6, though not specific to the enzyme. The reactions were
carried out in a reaction volume of 100 μl/ well in 96-well black plates with transparent 
flat bottom (Fisher Scientific, Catalogue No FB85083) at 37°C in 100 mM potassium
phosphate buffer pH 7.4, containing 3 μM CEC, 1.0 pmole CYP1A2 and the NADPH 
regenerating system (1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl2,
0.4U/ml glucose-6-phosphate dehydrogenase). The fluorescent values were recorded on
the Biotek Synegy HT plate reader using an excitation wavelength of 400 nm (20 nm)
and emission wavelength of 460 nm (40 nm). Changes in fluorescence were measured
as relative fluorescence units (RFU). Kinetic progression of reactions was measured for
30 min (Figure 5.16 (B) and Table 5.6). Standard curve was plotted and CHC
concentrations in test samples were measured using the equation from the standard
curve. The standard curve is shown in Figure 5.16 (A).
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y = 57.589x + 61.687
R² = 0.9943
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The standard curve of CHC was prepared using a range of concentrations of
CHC (0, 39.1, 78.1, 156.3, 312.5, 625, 1250 pmole/ ml). The assays for generation of
the standard curve were performed in 96-well black plates. The fluorescent values
(RFU) were recorded on the Biotek Synegy HT plate reader using an excitation
wavelength of 400 nm (20 nm) and emission wavelength of 460 nm (40 nm).
Figure 5.16 (A). CHC standard curve. The curve was prepared as described in Section
5.7.2.
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Figure 5.16 (B). Kinetic analysis of CYP1A2 catalytic activities using CEC as a
substrate. Sf9 cells were co-infected with CYP1A2 and the CPR baculoviruses at an
MOI of 1 and 0.1 pfu/ cell, respectively. The catalytic activities of CYP1A2 were
measured in microsomes prepared at 63h post-infection. The enzyme assay was
performed as described in Section 5.7.2.
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Table 5.6. CYP1A2 enzyme reaction rates in co-expressed microsomes. Sf9 cells were
co-infected with CYP1A2 and the CPR baculoviruses at an MOI of 1 and 0.1 pfu/ cell,
respectively. The reaction rates were measured in microsomes prepared at 63h post-
infection. CEC assay was performed as described in Section 5.7.2.
Microsomes CYP1A2 reaction rates
(pmole CHC formed/ min/ pmole of CYP1A2)
CYP1A2
CYP1A2+hRD
CYP1A2+ΔhRDM 
CYP1A2+yRD
0.194
3.590
4.510
2.246
In order to find out the reductase activities of CPRs in co-expressed microsomes,
reductase assays were performed as described in ‘Materials and Methods’ (Section
Number 2.4.7) using MTT as a substrate. Reductase activities of hRD and yRD were
comparable and reductase activity of ΔhRDM was lower than that of hRD or yRD 
(Table 5.7). However as seen in CO binding difference spectra, co-expression with the
stronger CPRs, hRD and yRD, yield very low CYP1A2 holoprotein. Once again
amongst all the three CPRs studied, co-expression with ΔhRDM appears to yield 
highest content of CYP1A2 holoprotein. Albeit the levels of CYP1A2 holoprotein
change (Table 5.5), apoprotein levels of CYP1A2 remain unchanged (Figure 5.13 (A)).
The observation that CPRs cause destruction to CYP holoprotein levels without
changing apoprotein levels seems to be common to all the CYPs that we studied. This
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finding again emphasises that CPRs do not modulate CYP expression levels but are
responsible for CYP holoprotein destruction by means of reactive oxygen species.
Table 5.7. NADPH cytochrome P450 reductase activities exhibited by hRD, ΔhRDM 
and yRD in CYP1A2 co-expressed microsomes. Sf9 cells were co-infected with
CYP1A2 baculoviruses (MOI 1.0 pfu/cell) and CPR baculoviruses (MOI 0.1 pfu/cell)
and microsomes were prepared 63 h post-infection. Reductase activity was measured
using MTT as described in ‘Materials and Methods’ (Section Number 2.4.7). The
moles of MTT reduced per minute per mg of protein were calculated.
CPR Species Reductase activity
(nmole MTT reduced/min/mg protein)
CYP1A2
CYP1A2+ hRD
CYP1A2+ ΔhRDM 
CYP1A2+ yRD
10.6 ± 2.1
238.1 ± 19.7
100.9 ± 12.0
201.8 ± 23.5
It is noticeable from the Figure 5.16 (B) and Table 5.6 that ΔhRDM is more 
efficient than hRD and yRD in terms of its ability to support CYP1A2 catalytic activity
or couple with the CYP. To compare the abilities of the CPRs to support CYP1A2
activity, their coupling efficiencies with CYP1A2 were calculated by using the
following formula,
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Coupling efficiency = CYP1A2 activity in CEC assay∕ CPR activity in MTT assay  
As the coupling efficiency of ΔhRDM was highest among the three CPRs, percentage 
relative coupling efficiency for hRD and yRD was calculated in comparison with
ΔhRDM, considering ΔhRDM activity as 100% (Table 5.8).  Though coupling 
efficiency of yRD appears to be close to hRD, it is extremely destructive to the
CYP1A2 holoprotein resulting in very low levels of spectrally active CYP1A2.
Table 5.8. Percent relative coupling efficiency of hRD, ΔhRDM and yRD with 
CYP1A2. CYP1A2 activity in the CEC assay and CPR activity measured in the MTT
assay were used for the calculations. CYP1A2 activity was divided by CPR activity and
percent relative coupling efficiency was measured.
Microsome samples % Relative coupling efficiency
CYP1A2+ ΔhRDM 
CYP1A2+ hRD
CYP1A2+ yRD
100
33.73
24.9
5.7.3   CYP2E1 interactions with hRD, ΔhRDM and yRD 
CYP2E1 and cytochrome b5 were expressed with and without the CPRs,
microsomes were prepared and CYP2E1 holoprotein contents were measured by carbon
monoxide difference spectroscopy as described in Section 5.7. Table 5.9 shows specific
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contents of CYP2E1 when expressed with and without CPRs. It was observed that like
other CYPs, CYP2E1 holoprotein levels change when co-expressed with the CPRs.
However CYP1E1 apoprotein levels as measured by densitometry from the immunoblot
(Figure 5.13 (B)) do not change regardless of co-expression with hRD, or ΔhRDM or 
yRD. These results confirm that CPRs do not regulate the CYP expression at the
transcription level but are responsible for decrease in spectrally active enzyme i.e.
holoprotein.
Table 5.9. CYP2E1 specific content in microsome samples, determined by reduced CO-
difference spectroscopy. Sf9 cells were co-infected with CYP and CPR baculoviruses
at an MOI of 1 and 0.1 pfu/ cell respectively. Microsomes were prepared 63 h post-
infection as described in Materials and Methods (Section Number 2.4.1). Data are
presented as mean values ± STDEV.
Microsomes Specific content of CYP2E1
(pmole/mg protein)
CYP2E1+ b5
CYP2E1+ b5 + hRD
CYP2E1+ b5 + ΔhRDM 
CYP2E1+ b5 + yRD
1009.16
471.88
583.33
453.49
Kinetic studies with CYP2E1 microsomes (i.e. measurement of activities) were
performed using Vivid® fluorogenic substrate EOMCC (3-cyano-7-(ethoxymethoxy)
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coumarin) as per the standard Invitrogen Screening Kit protocol (Marks et al; 2002,
2003). EOMCC is demethylated by human CYP2E1 as well as CYP2D6 to the
fluorescent product 3-cyano-7-hydroxycoumarin (CHC). The reactions were carried out
in a reaction volume of 100 μl/ well in 96-well black plates (Fisher Scientific, Catalogue 
No FB85083) at 37ºC in 100mM potassium phosphate buffer pH 8.0, containing 10 μM 
EOMCC, 2.5 pmole CYP2E1 and the NADPH regenerating system (1.3 mM NADP+,
3.3 mM glucose-6-phosphate, 3.3 mM MgCl2, 0.4U/ml glucose-6-phosphate
dehydrogenase). The fluorescent values were recorded on the Biotek Synegy HT plate
reader using an excitation wavelength of 400 nm (20 nm) and emission wavelength of
460 nm (40 nm). Changes in fluorescence were measured as relative fluorescence units
(RFU). Kinetic progression of reactions was measured for 30 min (Figure 5.17 (B) and
Table 5.10). Concentrations of product formed were determined using CHC as a
standard.
The standard curve of CHC was prepared using a range of concentrations of
CHC (0, 39.1, 78.1, 156.3, 312.5, 625, 1250 pmole/ ml). The assay for the standard was
performed in 96-well black plates. The fluorescent values (RFU) were recorded on the
Biotek Synegy HT plate reader using an excitation wavelength of 400 nm (20 nm) and
emission wavelength of 460 nm (40 nm). Standard curve was plotted and CHC
concentrations in test samples were measured using the equation from the standard
curve. The standard curve is shown in Figure 5.17 (A).
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Figure 5.17 (A). CHC standard curve. The curve was prepared as described in Section
5.7.3
Figure 5.17 (B). Kinetic analysis of CYP2E1 catalytic activities using EOMCC as a
substrate. Sf9 cells were co-infected with CYP2E1, CPR and cytochrome b5
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baculoviruses at an MOI of 1, 0.1 and 0.1 pfu/ cell, respectively. The catalytic activities
of CYP2E1 were measured in microsomes prepared at 63h post-infection. The enzyme
assay was performed as described in Section 5.7.3.
Table 5.10. CYP2E1 enzyme reaction rates in co-expressed microsomes. Sf9 cells
were co-infected with CYP2E1, the CPR and b5 baculoviruses at an MOI of 1, 0.1 and
0.1 pfu/ cell, respectively. The reaction rates were measured in microsomes prepared at
63h post-infection. EOMCC assay was performed as described in Section 5.7.3.
Microsomes CYP2E1 reaction rates
(pmole CHC formed/ min/ pmole of CYP2E1)
CYP2E1+ b5
CYP2E1+ b5 + hRD
CYP2E1+ b5 + ΔhRDM 
CYP2E1+ b5 + yRD
0.1581
0.5671
0.4149
0.3077
Reductase activities of CPRs in CYP2E1 co-expressed microsomes were
analysed using reductase assay as described in ‘Materials and Methods’ (Section
Number 2.4.7) using MTT as a substrate. Reductase activity of hRD and yRD was
comparable and reductase activity of ΔhRDM was lower than that of hRD and yRD 
(Table 5.11).
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Table 5.11. NADPH cytochrome P450 reductase activities exhibited by hRD, ΔhRDM 
and yRD in CYP2E1 co-expressed microsomes. Sf9 cells were co-infected with
CYP2E1 baculoviruses (MOI 1.0 pfu/cell), CPR baculoviruses (MOI 0.1 pfu/cell) and
b5 baculoviruses (MOI 0.1 pfu/cell), and microsomes were prepared 63 h post-infection.
Reductase activity was measured by using MTT as described in ‘Materials and
Methods’ (Section Number 2.4.7). The moles of MTT reduced per minute per mg of
protein were calculated.
CPR Species Reductase activity
(nmole MTT reduced/min/mg protein)
CYP2E1+ b5
CYP2E1+ b5+ hRD
CYP2E1+ b5+ ΔhRDM 
CYP2E1+ b5+ yRD
26.5 ± 3.8
217.7 ± 19.3
169.9 ± 17.1
276.1 ± 45.5
The coupling efficiency was calculated. The percent relative coupling efficiency
of CPRs with CYP2E1 was calculated in comparison with ΔhRDM (Table 5.12). 
Surprisingly hRD and ΔhRDM couple equally well with CYP2E1 and coupling 
efficiency of yRD with CYP2E1 seems to be better than that with CYP1B1 and
CYP1A2. The findings show that interaction of any particular CPR with CYP is
dependent on the CYP isoform.
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Table 5.12. Percent relative coupling efficiency of hRD, ΔhRDM and yRD with 
CYP2E1. CYP2E1 activity in the EOMCC assay and CPR activity measured in the
MTT assay were used for the calculations. CYP2E1 activity was divided by CPR
activity and percent relative coupling efficiency was measured.
Microsome samples % Relative coupling efficiency
CYP2E1+ b5+ ΔhRDM 
CYP2E1+ b5+ hRD
CYP2E1+ b5+ yRD
100
106.65
45.64
5.7.4   CYP1A1 co-expression with ΔhRDM 
CYP1A1 and CYP2C8 were co-expressed only with ΔhRDM as described in 
Section 5.7. The catalytic activity of CYP1A1 was measured using ethoxyresorufin-O-
deethylase (EROD) assay (Klotz et al. 1984). The amount of resorufin produced was
measured fluorometrically which reflects the level of 7-ethoxyresorufin o-deethylase
activities.
The assay was performed as described before (Klotz et al. 1984). The reaction
kinetics was carried out at 37ºC in a reaction volume of 100 µl/well in 96-well black
plates with transparent flat bottom (Fisher, Cat. No. FB86083). The assay mixture
contained 100 mM Potassium phosphate buffer pH 7.4, containing 5µM 7-
ethoxyresorufin , 1.5 pmole CYP1A1 and the NADPH regenerating system (1.3 mM
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NADP+, 3.3 mM G6P, 3.3 mM MgCl2, 0.4U/ml G6PDH). Resorufin formation was
measured fluorometrically on the Biotek Synegy HT plate reader (excitation wavelength
of 528/20 nm and emission wavelength of 590/20 nm). Changes in fluorescence were
recorded for 30 min as relative fluorescence units (RFU). Standard curve shown in
Figure 5.15 (A) was used to calculate resorufin concentrations in test samples.
CYP1A1 was successfully co-expressed with ΔhRDM as a catalytically active enzyme. 
Figure 5.18. Kinetic analysis of CYP1A1 catalytic activity in EROD assay. Sf9 cells
were co-infected with CYP1A1 and CPR baculoviruses at an MOI of 1 and 0.1 pfu/ cell,
respectively. The catalytic activity of CYP1A1 was measured in microsomes prepared
at 63h post-infection. The enzyme assay was performed as described above. The
reaction rate observed was 1.608 pmole resorufin formed/ min/ pmole of CYP1A1.
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5.7.5   CYP2C8 co-expression with ΔhRDM 
Dibenzylfluorescein (DBF) dealkylation activities in the microsomal fractions
prepared from the Sf9 cells co-infected with CYP2C8+b5+ΔhRDM baculoviruses at an 
MOI of 1, 0.1 and 0.1 pfu/cell respectively for 63 h were determined. DBF is
dealkylated by CYP2C and CYP3A to form the product, fluorescein. The production of
the metabolite, fluorescein from the substrate DBF (BD-Gentest, Catalogue No 451755)
was measured for 30 min at 37ºC. The reactions were carried out at 37ºC in a reaction
volume of 0.1ml/well in 96-well black plates. The assay mixture contained 100mM
Potassium phosphate buffer pH 8.0, containing 1 µM DBOMF , 4.0 pmole CYP2C8 and
the NADPH regenerating system (1.3 mM NADP+, 3.3 mM G6P, 3.3 mM MgCl2,
0.4U/ml G6PDH). Fluorescein formation was measured fluorometrically on the Biotek
Synegy HT plate reader (excitation wavelength of 485/20 nm and emission wavelength
of 528/20 nm). Changes in fluorescence were recorded for 30 min as relative
fluorescence units (RFU). Metabolite of DBF, fluorescein was used to generate a
standard curve (Chapter 4, Figure 4.10 (B)). Fluorescein formed per ml of the reaction
over a period of 30 min in test samples (Figure 5.19) was calculated using the standard
curve.  CYP2C8 was successfully co-expressed with ΔhRDM as a catalytically active 
enzyme.
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Figure 5.19. Kinetic analysis of CYP2C8 catalytic activity using DBF as a substrate.
Sf9 cells were co-infected with CYP2C8, ΔhRDM and b5 baculoviruses at an MOI of 1.
0.1 and 0.1 pfu/ cell, respectively. The catalytic activities of CYP2C8 were measured in
microsomes prepared at 63h post-infection. The enzyme assay was performed as
described above. The reaction rate observed was 0.047 pmole fluorescein formed/ min/
pmole of CYP2C8.
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5.8 Conclusion
It has been reported that P450 enzymes and the accessory proteins (NADPH-
P450 reductase and cytochrome b5) interact with each other with different affinities
(Shimada et. al, 2005). The objective of studying individual CYPs for their interactions
with the CPRs was to elucidate whether we observe any differences in the affinities.
However in our project, in order to study these affinities, we have taken an approach of
studying coupling between CYP and CPR, where the enzyme catalytic activities are
taken into account.  We studied the CPRs, viz. hRD, ∆hRDM and yRD, in context of 
three more CYPs – CYP1B1, CYP1A2 and CYP2E1. We also studied CYP1A1 and
CYP2C8, though only in the context of ∆hRDM.  In the case of CYP2C8 and CYP2E1, 
apart from a CPR, a third protein cytochrome b5 was also co-expressed. Cytochrome b5
is known to augment CYP2C8 and CYP2E1 mediated monooxygenase reactions
(Porter, 2002). In conclusion, we summarise the findings of Chapter 5 as follows,
 The five human cytochrome P450 enzymes CYP1A1, CYP1A2, CYP1B1,
CYP2C8 and CYP2E1 were cloned into the transfer vector pFastBac1,
recombinant bacmids were made and baculoviruses for the CYPs were generated
successfully.
 The five CYPs were expressed alone and also co-expressed with the CPRs and
where necessary with a third protein cytochrome b5. The CYPs were expressed
as catalytically active enzymes by means of co-infection with multiple
recombinant baculoviruses. Multiple baculoviruses can be used to express a
productive monooxygenase system in insect cells.
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 It was observed through Western blot densitometry and CO-binding difference
spectra that CPRs destroy the CYP holoproteins without altering CYP
apoprotein levels. This would indicate that CPRs do not modulate CYP
expression at the transcriptional level but are responsible for destruction of CYP
holoprotein which is a result of ROS induction by CPRs. The experimental
evidence for ROS generation by CPRs has been presented in Chapters 3 and 4.
 The enzyme assays for CYPs and CPRs were set up and used for studying the
CYP-CPR interactions.  ΔhRDM was identified as the most efficient CPR, 
amongst hRD, ΔhRDM and yRD, in terms of its ability to cause less damage to 
CYP holoprotein and to support CYP catalytic activities more efficiently with
the exception of CYP2E1 where hRD was found to be the best in terms of
supporting the enzyme activity.
 In co-expressed microsomes, reduction potential of yRD in MTT assay is similar
to hRD or sometimes better, but yRD does not support CYP activity very well,
which indicates that its reduction potential towards MTT is not directly
proportional to its ability to support CYP catalytic activities.
 The coupling efficiency of yRD with the CYPs was found to be inferior to
∆hRDM and hRD which indicates that use of yRD for human CYP expressions 
particularly in the ‘insect cell expression system’ may not be physiologically
feasible.  As coupling efficiency of the genetically engineered molecule ∆hRDM 
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was higher than hRD and yRD, relative coupling efficiencies for hRD and yRD
were calculated assuming ∆hRDM coupling efficiency as 100%.  The coupling 
efficiencies of CYP1B1, CYP1A2 and CYP2E1 with hRD, ∆hRDM and yRD 
are summarised below in the Table 5.13.
Table 5.13. Percent relative coupling efficiencies of hRD, ΔhRDM and yRD with 
CYP1B1, CYP1A2 and CYP2E1.
CYP/ CPR ∆hRDM 
coupling efficiency
hRD yRD
CYP1B1 100% 63.49 24.78
CYP1A2 100% 33.73 24.9
CYP2E1 100% 106.65 45.64
 The full length NADPH cytochrome P450 reductase, hRD, coupled as
efficiently as ΔhRDM with CYP2E1; hRD and yRD were specifically very 
destructive to CYP1A2 as compare to other CYPs, which proves that different
CPRs have different affinities towards the CYP isoforms.
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Chapter 6 Cytochrome P450 inhibition – using known selective
inhibitors to profiling of the natural product
Plumbagin, a naphthoquinone
6.1 Introduction
Evaluation of specific cytochrome P450 enzyme inhibition by a drug candidate
is crucially important as co-administration of drugs may result in one or both inhibiting
the other’s metabolism, a concept known as ‘pharmacokinetic drug–drug
interactions’(Li, 1997). This may alter plasma levels and potentially cause adverse drug
reactions or toxicity; therefore, cytochrome P450 inhibition studies are vital for
predicting drug-drug interactions (DDI).
DDI remains an important aspect of clinical practice and new drug discovery
process. The antifungal agent ketoconazole, a potent inhibitor of CYP3A4, can interact
with drugs that are potential substrates of CYP3A4. One example of this is the
interaction between the inhibitor ketoconazole and the substrate terfenadine. Co-
administration of ketoconazole and terfenadine leads to increased plasma levels of
terfenadine, resulting in cardiotoxicity. The interaction between terfenadine and
ketoconazole is known as an inhibitory drug–drug interaction, where one drug
(ketoconazole) inhibits the metabolism of another drug (terfenadine), leading to a higher
than intended plasma level (Li, 2005). The major clinical consequence of inhibitory
DDI is undesired drug toxicity (Miller et al. 2000).
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In drug metabolism or CYP inhibition studies, usually cDNA-expressed
microsomes that contain only one specific human CYP isoform are used as an in vitro
system. Of the human P450 enzymes, a relatively small subset of the CYPs (CYP1A2,
CYP2D6, CYP2C9, CYP2C19, CYP3A4 and CYP2E1) appears to be the most
commonly responsible for metabolism of drugs and associated drug-drug interactions
(Spatzenegger and Jaeger 1995). More recently, some other human P450 enzymes,
such as CYP3A5, CYP2B6, and CYP2C8, have come to the fore because they have
been implicated in the metabolism of a number of marketed drugs and physiologically
important endogenous molecules (O'Donnell et al. 2006).
There is some degree of similarity among the CYP enzyme structures.
However, that structural similarity of enzymes cannot be used to predict which isoforms
will be responsible for a drug's metabolism. In view of that, the pharmaceutical
industry has found it highly desirable to develop high-throughput screening assays on
the basis of cDNA-expressed microsomes that contain only one specific human P450
isoform.
Cytochrome P450 inhibition is measured via CYP enzyme assays in the
presence of a range of concentrations of a test compound and enzyme activity is
compared to the vehicle control. A compound concentration responsible for 50%
inhibition of the enzyme activity (IC50) is then calculated. Wide-scale determination of
IC50s of potential drug candidates from mechanism-based data, using in vitro systems,
allows dramatic reduction in the number of in vivo studies that were previously
required.
292
In this chapter, we present results from inhibition studies with the CYP
isozymes, CYP1A1, CYP1A2, CYP1B1, CYP2D6 and CYP3A4. The CYP inhibition
experiments were performed using our own CYP enzymes so as to find out if there are
any differences in the catalytic properties of the electron donor partner hRD and its
variant ΔhRDM with respect to activation of the CYPs.  The primary objective of our 
inhibition studies was to determine whether the genetically engineered variant of the full
length NADPH cytochrome P450 reductase (ΔhRDM) results in any change in 
quantitative inhibition of the CYPs that are activated by the native human CPR (hRD) –
in other words, whether inhibition data from these two systems (one supported by hRD
and other by ΔhRDM) is different from each other.  In order to do so, we compared 
different CYP–ΔhRDM complexes with CYPs whose activities were supported by hRD 
in inhibition studies.
Known selective inhibitors, α-naphthoflavone (for CYP1A1 and CYP1B1;
Shimada et al. 1998), furafylline (for CYP1A2; Tassaneeyakul et al. 1994), quinidine
(for CYP2D6; Von Bahr et al. 1980) and ketoconazole (for CYP3A4; Olkkola et al.
1994) have been used for the comparative inhibition studies.
Apart from the above mentioned reference standards, the natural
naphthoquinone plumbagin, was analysed for its ability to inhibit CYP1A1, CYP1A2,
CYP1B1, CYP2D6 and CYP3A4. Plumbagin is isolated from the roots of plumbago
zeylannica (Chitrak) and has been used in Indian ayurvedic medicine for thousands of
years (Iyengar and Pendse 1966). The compound has potential antiproliferative activity
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against several tumour types (Acharya et al. 2008) and it also has anti-microbial activity
(Farr et al. 1985). At De Montfort University, we have been involved in investigating
anti-proliferative activity of different natural compounds. In our experiments,
plumbagin proved to be quite efficacious and that was the reason why we chose to
investigate its CYP inhibition profile. As described earlier, assessment of the in vitro
CYP inhibition potential of plumbagin may have important implications for predicting
the likelihood of plumbagin’s interactions with other marketed anticancer agents.
6.2 IC50 Determination
The IC50 determination methodology was adapted from protocols obtained from
BD Biosciences with some modifications. The assays were performed in 96-well black
microtitre plates with transparent flat bottom (Fisher, Catalogue No FB86083). The
template for plate set up is shown in Figure 6.1. The row designations are A through H
and the column designations are 1 through 12. The assays were performed in duplicate
rows of 12 wells. The test compound was added to the wells in column one and serially
diluted 3-fold to the wells in column 8. Wells in columns 9 and 10 were control wells
which contained no test compound (therefore no inhibition, that is full signal, was
detected). The wells in columns 11 and 12 were blanks. To the blank wells stop
solution was added prior to the addition of CYP enzymes and their respective
substrates. The only signal detected in blanks was background noise. Rows A/B and
C/D were replicates. The assay was conducted in a final volume of 200 µl per well.
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Figure 6.1. 96-well microtitre plate set up for IC50 determination in CYP inhibition
assays.
6.3  CYP1A1 inhibition by α-naphthoflavone and plumbagin 
The CYP1A1 microsomes co-expressed with hRD and ΔhRDM were subjected 
to inhibition studies. The protein expressions and microsome preparations were
performed as described in Chapter 5. CYP1A1 inhibition by reference standard (i.e. the
known inhibitor), α-naphthoflavone, and the test compound, plumbagin, was performed 
using the end point EROD assay. EROD assay is described in Chapter 5. In the assay
plate, into the wells in column 1, 144 µl and into the wells in columns 2 to 12, 100 µl of
the NADPH regenerating system was added (1.3 mM NADP+, 3.3 mM G6P, 3.3 mM
MgCl2, 0.4U/ml G6PDH).  6 µl of the α-naphthoflavone stock (50 µM prepared in 
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acetonitrile) was added to A1 and B1 wells. 6 µl of the plumbagin stock (500 µM
prepared in acetonitrile) was added to C1 and D1 wells. 50 µl of the solutions from the
wells in column 1 to the wells in columns 2 through 8 were serially diluted using a
multichannel pipette. In order to minimize the potential carry over, pipette tips were
changed during every step of the serial dilution. The extra 50 µl solution in the wells in
column 8 was removed and discarded. The plate was covered with a lid and placed in a
37°C incubator for 10 min to pre-warm the solution and the plate. Then to the wells in
columns 1 through 10, 100 µl of the enzyme/substrate mix was added to the final
concentration of 5 µM 7-ethoxyresorufin and 1.5 pmole CYP1A1 in 100 mM potassium
phosphate buffer pH 7.4. The lid of the plate was replaced and the plate was incubated
at 37°C for 15 min. At the end of the incubation period, the reaction was stopped by
dispensing 75 µl of the STOP solution to each well (80% acetonitrile and 20% 0.5 M
Tris base). To the blank wells in column 11 and 12, STOP solution was added prior to
initiation of the reaction. At the end, 100 µl of the enzyme/substrate mix was added to
the wells in columns 11 and 12. The plate was then scanned on the Biotek Synegy HT
plate reader for measuring relative fluorescence units (RFU) at excitation wavelength of
528/20 nm and emission wavelength of 590/20 nm. The averages of replicates were
used for calculating the percentage (%) inhibition of CYP1A1 at every concentration of
α-naphthoflavone and plumbagin that was tested.  The % inhibition was calculated 
using the RFU values obtained in control wells with the help of the formula,
% Inhibition = 100 -
Test - Blank
Control - Blank
X 100
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The percentage inhibition calculated for each concentration of the compounds was then
used for calculating IC50 value using the formula,
IC50 =
50 % - low percentage
high percentage - low percentage
X (high concentration – low concentration)
+ low concentration
where, low percentage is percent inhibition less than 50% and high percentage is
percent inhibition greater than 50%. High and low concentrations are respective
concentrations of the compounds at which the high percentage and low percentage
inhibition is observed.
Table 6.1 Alpha-naphthoflavone and plumbagin IC50 values in assays that monitor the
inhibition of CYP1A1+hRD and CYP1A1+ΔhRDM.  Data are presented as mean values 
± STDEV of duplicates of single experiment.
Microsome samples α-Naphthoflavone IC50 (µM) Plumbagin IC50 (µM)
CYP1A1+hRD 0.0703 ± 0.008 5.88149 ± 0.683
CYP1A1+ΔhRDM                0.06 ± 0.005              5.3194 ± 0.81 
Results depicted in Table 6.1 show that there are no significant differences in
IC50 values of the two compounds when tested with CYP1A1+ hRD and CYP1A1+
ΔhRDM (P >0.05).  Moreover the dose-dependent responses to the inhibition of 
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CYP1A1, when separately co-expressed with hRD or with ΔhRDM, by α-
naphthoflavone are very similar (Figure 6.2). This is true for plumbagin too (Figure
6.3). These comparative inhibition studies, using CYP1A1+hRD and
CYP1A1+ΔhRDM, do not show any significant difference in IC50 values or dose-
response profiles of the two compounds. The results indicate that the novel, genetically
engineered ΔhRDM does not at all alter the nature of the active site of the CYP1A1 – if 
it did, IC50 values and the dose-response curves would have been noticeably different.
Therefore, we would like to suggest that CYP microsomes that use ΔhRDM as the 
electron donor protein can be confidently used for drug metabolism studies
Figure 6.2.  The CYP1A1 inhibition by α-naphthoflavone at various concentrations. 
Inhibition studies were performed as described in Section 6.3. Each value represents
the mean of individual determinations.
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Figure 6.3. The CYP1A1 inhibition by plumbagin at various concentrations. Inhibition
studies were performed as described in Section 6.3. Each value represents the mean of
individual determinations.
6.4  CYP1B1 inhibition by α-naphthoflavone and plumbagin 
The CYP1B1 microsomes that co-express hRD and ΔhRDM were subjected to 
inhibition studies.  CYP1B1 inhibition by the reference standard, α-naphthoflavone, and 
test compound, plumbagin, was performed using the end point EROD assay. The
inhibition assay was performed as described in Section 6.3 except that CYP1B1
microsomes were used in the place of CYP1A1.
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Table 6.2. Alpha-naphthoflavone and plumbagin IC50 values in assays that monitor the
inhibition of CYP1B1+hRD and CYP1B1+ΔhRDM.  Data are presented as mean values 
± STDEV of duplicates of single experiment.
Microsome samples α-Naphthoflavone IC50 (nM) Plumbagin IC50 (µM)
CYP1B1+hRD 0.780 ± 0.092 2.3543 ± 0.155
CYP1B1+ΔhRDM                  0.811 ± 0.068               2.4038 ± 0.17 
As shown in Table 6.2 there are no significant differences in the IC50 values for
the CYP1B1+ hRD and CYP1B1+ ΔhRDM (P >0.05).  The CYP1B1 inhibition by α-
naphthoflavone and plumbagin in CYP1B1+hRD and CYP1B1+ΔhRDM samples was 
dose dependent (Figure 6.4 and Figure 6.5). The comparative inhibition studies using
CYP1B1+hRD and CYP1B1+ΔhRDM did not show any significant difference in the 
IC50 or dose-response values of the two compounds.
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Figure 6.4.  The CYP1B1 inhibition by α-Naphthoflavone at various concentrations. 
Inhibition studies were performed as described in Section 6.4. Each value represents
the mean of individual determinations.
Figure 6.5. The CYP1B1 inhibition by plumbagin at various concentrations. Inhibition
studies were performed as described in Section 6.4. Each value represents the mean of
individual determinations.
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6.5 CYP1A2 inhibition by furafylline and plumbagin
The CYP1A2 microsomes co-expressed with hRD and ΔhRDM were subjected 
to inhibition studies. CYP1A2 inhibition by the reference standard, furafylline, and test
compound, plumbagin, was performed using CEC assay. CYP1A2 expression in Sf9
cells, microsome preparation and assay using CEC as a substrate is described in Chapter
5. In the assay plate, into the wells in column 1, 144 µl and into the wells in columns 2
to 12, 100 µl of the NADPH regenerating system was added (1.3 mM NADP+, 3.3 mM
G6P, 3.3 mM MgCl2, 0.4U/ml G6PDH). 6 µl of the furafylline stock (5 mM prepared
in acetonitrile) was added to A1 and B1 wells. 6 µl of the plumbagin stock (500 µM
prepared in acetonitrile) was added to C1 and D1 wells. 50 µl of the solutions from the
wells in column 1 to the wells in columns 2 through 8 were serially diluted using a
multichannel pipette. In order to minimize the potential carry over, pipette tips were
changed during every step of the serial dilution. The extra 50 µl solution in the wells in
column 8 was removed and discarded. The plate was covered with a lid and placed in a
37°C incubator for 10 min to pre-warm the solution and the plate. Then to the wells in
columns 1 through 10, 100 µl of the enzyme/substrate mix was added to the final
concentration of 50 µM CEC and 1.0 pmole CYP1A2 in 100 mM potassium phosphate
buffer pH 7.4. The lid of the plate was replaced and the plate was incubated at 37°C for
15 min. At the end of the incubation period, the reaction was stopped by dispensing 75
µl of the STOP solution to each well (80% acetonitrile and 20% 0.5 M Tris base). To
the blank wells in column 11 and 12, STOP solution was added prior to initiation of the
reaction. At the end, 100 µl of the enzyme/substrate mix was added to the wells in
columns 11 and 12. The plate was then scanned on the Biotek Synegy HT plate reader
for measuring relative fluorescence units (RFU) at excitation wavelength of 409/20 nm
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and emission wavelength of 460/20 nm. The averages of replicates were used for
calculating the % inhibition of CYP1A2 at every concentration of furafylline and
plumbagin. The percent inhibition was calculated in comparison with control using the
formula,
% Inhibition = 100 -
Test - Blank
Control - Blank
X 100
The percent inhibition calculated for each concentration of the compounds was then
used for calculating IC50 value using the formula,
IC50 =
50 % - low percentage
high percentage - low percentage
X (high concentration – low concentration)
+ low concentration
where low percentage is percent inhibition less than 50% and high percentage is percent
inhibition greater than 50%. High and low concentrations are respective concentrations
of the compounds at which the high percentage and low percentage inhibition is
observed.
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Table 6.3. Furafylline and plumbagin IC50 values in CYP1A2+hRD and
CYP1A2+ΔhRDM inhibition assays.  Data are presented as mean values ± STDEV of 
duplicates of single experiment.
Microsome samples Furafylline IC50 (µM) Plumbagin IC50 (µM)
CYP1A2+hRD 1.5217 ± 0.235 1.2975 ± 0.302
CYP1A2+ΔhRDM            1.6809 ± 0.269            1.4256 ± 0.277 
As shown in Table 6.3, there are no significant differences in IC50 values for the
CYP1A2+ hRD and CYP1A2+ ΔhRDM (P >0.05).  The CYP1A2 inhibition by 
furafylline and plumbagin in CYP1A2+hRD and CYP1A2+ΔhRDM samples was dose 
dependent (Figure 6.6 and Figure 6.7). The comparative inhibition studies using
CYP1A2+hRD and CYP1A2+ΔhRDM did not show significant difference in IC50 or
dose-response values of the compounds.
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Figure 6.6. The CYP1A2 inhibition by furafylline at various concentrations. Inhibition
studies were performed as described in Section 6.5. Each value represents the mean of
individual determinations.
Figure 6.7. The CYP1A2 inhibition by plumbagin at various concentrations. Inhibition
studies were performed as described in Section 6.5. Each value represents the mean of
individual determinations.
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6.6 CYP2D6 inhibition by quinidine and plumbagin
The CYP2D6 microsomes, co-expressed with hRD and ΔhRDM, were subjected 
to inhibition studies. CYP2D6 inhibition by the reference standard, quinidine, and test
compound, plumbagin, was performed using AMMC assay. CYP2D6 expression,
microsome preparation and assay using AMMC as a substrate are described in Chapter
3. In the assay plate, into the wells in column 1, 144 µl and into the wells in columns 2
to 12, 100 µl of the NADPH regenerating system was added (1.3 mM NADP+, 3.3 mM
G6P, 3.3 mM MgCl2, 0.4U/ml G6PDH). 6 µl of the quinidine stock (25 µM prepared in
acetonitrile) was added to A1 and B1 wells. 6 µl of the plumbagin stock (500 µM
prepared in acetonitrile) was added to C1 and D1 wells. 50 µl of the solutions from the
wells in column 1 to the wells in columns 2 through 8 were serially diluted using a
multichannel pipette. In order to minimize the potential carry over, pipette tips were
changed during every step of the serial dilution. The extra 50 µl solution in the wells in
column 8 was removed and discarded. The plate was covered with a lid and placed in
37°C incubator for 10 min to pre-warm the solution and the plate. Then to the wells in
columns 1 through 10, 100 µl of the enzyme/substrate mix was added to the final
concentration of 1.5 µM AMMC and 1.5 pmole CYP2D6 in 100 mM Potassium
phosphate buffer pH 8. The lid of the plate was replaced and the plate was incubated at
37°C for 30 min. At the end of the incubation period, the reaction was stopped by
dispensing 75 µl of the STOP solution to each well (80% acetonitrile and 20% 0.5 M
Tris base). To the blank wells in column 11 and 12, STOP solution was added prior to
initiation of the reaction. At the end 100 µl of the enzyme/substrate mix was added to
the wells in columns 11 and 12. The plate was then scanned on the Biotek Synegy HT
plate reader for measuring relative fluorescence units (RFU) at excitation wavelength of
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390/20 nm and emission wavelength of 460/40 nm. The averages of replicates were
used for calculating the % inhibition of CYP2D6 at every concentration of quinidine
and plumbagin. The percent inhibition was calculated in comparison with control using
the formula,
% Inhibition = 100 -
Test - Blank
Control - Blank
X 100
The percent inhibition calculated for each concentration of the compounds was then
used for calculating IC50 value using the formula,
IC50 =
50 % - low percentage
high percentage - low percentage
X (high concentration – low concentration)
+ low concentration
where, low percentage is percent inhibition less than 50% and high percentage is
percent inhibition greater than 50%. High and low concentrations are respective
concentrations of the compounds at which the high percentage and low percentage
inhibition is observed.
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Table 6.4. Quinidine and plumbagin IC50 values in CYP2D6+hRD and
CYP2D6+ΔhRDM inhibition assays.  Data are presented as mean values ± STDEV of 
duplicates of single experiment.
Microsome samples Quinidine IC50 (µM) Plumbagin IC50 (µM)
CYP2D6+ hRD 0.0132 ± 0.002 2.4599 ± 0.241
CYP2D6+ ΔhRDM             0.0111 ± 0.002             2.2508 ± 0.305 
As shown in Table 6.4, there are no significant differences in IC50 values for the
CYP2D6+ hRD and CYP2D6+ ΔhRDM (P >0.05).  The CYP2D6 inhibition by 
Quinidine and plumbagin in CYP2D6+hRD and CYP2D6+ΔhRDM samples was dose 
dependent (Figure 6.8 and Figure 6.9). The comparative inhibition studies using
CYP2D6+hRD and CYP2D6+ΔhRDM did not show significant difference in IC50 or
dose-response values of the compounds.
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Figure 6.8. The CYP2D6 inhibition by quinidine at various concentrations. Inhibition
studies were performed as described in Section 6.6. Each value represents the mean of
individual determinations.
Figure 6.9. The CYP2D6 inhibition by plumbagin at various concentrations. Inhibition
studies were performed as described in Section 6.6. Each value represents the mean of
individual determinations.
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6.7 CYP3A4 inhibition by ketoconazole and plumbagin
The CYP3A4 microsomes, co-expressed with hRD and ΔhRDM, were subjected 
to inhibition studies. CYP3A4 inhibition by the reference standard, ketoconazole, and
test compound, plumbagin, was performed using DBOMF assay. CYP3A4 expression
in Sf9 cells, microsome preparation and assay using DBOMF as a substrate are
described in Chapter 4. In the assay plate, into the wells in column-1, 144 µl and into
the wells in columns 2 to 12, 100 µl of the NADPH regenerating system was added (1.3
mM NADP+, 3.3 mM G6P, 3.3 mM MgCl2, 0.4U/ml G6PDH). 6 µl of the
ketoconazole stock (250 µM prepared in acetonitrile) was added to A1 and B1 wells. 6
µl of the plumbagin stock (500 µM prepared in acetonitrile) was added to C1 and D1
wells. 50 µl of the solutions from the wells in column 1 to the wells in columns 2
through 8 were serially diluted using a multichannel pipette. In order to minimize the
potential carry over, pipette tips were changed during every step of the serial dilution.
The extra 50 µl solution in the wells in column 8 was removed and discarded. The plate
was covered with a lid and placed in 37°C incubator for 10 min to prewarm the solution
and the plate. Then to the wells in columns 1 through 10, 100 µl of the
enzyme/substrate mix was added to the final concentration of 10 µM DBOMF and 1.0
pmole CYP3A4 in 100 mM Potassium phosphate buffer pH 8.0. The lid of the plate
was replaced and the plate was incubated at 37°C for 10 min. At the end of the
incubation period, the reaction was stopped by dispensing 75 µl of the STOP solution to
each well (80% acetonitrile and 20% 0.5 M Tris base). To the blank wells in column 11
and 12, STOP solution was added prior to initiation of the reaction. At the end 100 µl
of the enzyme/substrate mix was added to the wells in columns 11 and 12. The plate
was then scanned on the Biotek Synegy HT plate reader for measuring relative
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fluorescence units (RFU) at excitation wavelength of 485/20 nm and emission
wavelength of 528/20 nm. The averages of replicates were used for calculating the %
inhibition of CYP3A4 at every concentration of ketoconazole and plumbagin. The
percent inhibition was calculated in comparison with control using the formula,
% Inhibition = 100 -
Test - Blank
Control - Blank
X 100
The percent inhibition calculated for each concentration of the compounds was then
used for calculating IC50 value using the formula,
IC50 =
50 % - low percentage
high percentage - low percentage
X (high concentration – low concentration)
+ low concentration
where low percentage is percent inhibition less than 50% and high percentage is percent
inhibition greater than 50%. High and low concentrations are respective concentrations
of the compounds at which the high percentage and low percentage inhibition is
observed.
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Table 6.5. Ketoconazole and plumbagin IC50 values in CYP3A4+b5+hRD and
CYP3A4+b5+ΔhRDM inhibition assays.  Data are presented as mean values ± STDEV 
of duplicates of single experiment.
Microsome samples Ketoconazole IC50 (µM) Plumbagin IC50 (µM)
CYP3A4+b5+ hRD 0.0017 ± 0.0002 5.8971 ± 0.711
CYP3A4+b5+ ΔhRDM 0.0019 ± 0.0002 5.536 ± 0.403 
As shown in Table 6.5 there are no significant differences in IC50 values for the
CYP3A4+b5+hRD and CYP3A4+b5+ΔhRDM (P >0.05).  The CYP3A4 inhibition by 
ketoconazole and plumbagin in CYP3A4+b5+hRD and CYP3A4+b5+ΔhRDM samples 
was dose dependent (Figure 6.10 and Figure 6.11). The comparative inhibition studies
using CYP3A4+b5+hRD and CYP3A4+b5+ΔhRDM did not show significant difference 
in IC50 or dose-response values of the compounds.
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Figure 6.10. The CYP3A4 inhibition by ketoconazole at various concentrations.
Inhibition studies were performed as described in Section 6.7. Each value represents
the mean of individual determinations.
Figure 6.11. The CYP3A4 inhibition by plumbagin at various concentrations.
Inhibition studies were performed as described in Section 6.7. Each value represents
the mean of individual determinations.
313
6.8 Conclusion
The CYP inhibition assays were successfully set up and performed for CYP1A1,
CYP1A2, CYP1B1, CYP2D6 and CYP3A4 enzymes. The mean IC50 values found for
the known inhibitors, α-naphthoflavone, furafylline, quinidine and ketoconazole were 
consistent with that reported previously (Crespi et al. 1997).
As presented in previous Chapters, we have identified ΔhRDM as a relatively 
superior CPR with respect to its ability to cause less damage to the CYPs and its ability
to couple with the CYPs. However, it was important to study its behaviour and directly
compare it with the human native CPR in the most important aspect of drug
metabolism, namely experiments related to CYP inhibition studies. From the results
obtained from the comparative CYP inhibition experiments, we did not observe any
significant differences in the IC50 values of the compounds for inhibition of CYPs
activated by hRD and ΔhRDM.  The CYP inhibition by reference standards in hRD as 
well as ΔhRDM co-expressed CYP samples was dose dependent.  The inhibition studies 
demonstrated that even though ΔhRDM is a genetically engineered novel form of 
human CPR, it does not alter the quantification of CYP inhibition by the chemical
compounds. This comprehensive in vitro assessment of ΔhRDM has provided evidence 
in support of its use as an effective electron donor protein.
Apart from the reference standards, we analysed the natural naphthoquinone
plumbagin for its ability and specificity to inhibit the CYPs. Plumbagin also inhibited
all the CYP reactions in a dose dependent manner. Plumbagin IC50 values in hRD and
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ΔhRDM co-expressed CYP samples were not significantly different.  Interestingly 
however, we found that plumbagin has higher affinity towards CYP1A2 over other
CYPs that we studied (Table 6.6). It inhibits CYP1A2 as potently as does the reference
standard, furafylline.
Table 6.6 Plumbagin IC50 values in hRD and ΔhRDM supported CYPs.  Data are 
presented as mean values ± STDEV of duplicates of single experiment.
Microsome samples Plumbagin IC50 (µM)
CYP1A1+hRD 5.88149 ± 0.683
CYP1A1+ΔhRDM 5.3194 ± 0.81 
CYP1B1+hRD 2.3543 ± 0.155
CYP1B1+ΔhRDM 2.4038 ± 0.17 
CYP1A2+hRD 1.2975 ± 0.302
CYP1A2+ΔhRDM 1.4256 ± 0.277 
CYP2D6+hRD 2.4599 ± 0.241
CYP2D6+ΔhRDM 2.2508 ± 0.305 
CYP3A4+b5+ hRD 5.8971 ± 0.711
CYP3A4+b5+ ΔhRDM                                5.536 ± 0.403 
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CYP1A2 activates PAHs, nitrosamines, aflatoxin B1, and especially aryl amines
into forms that can bind to DNA, produce mutations and cause cancer (Aoyama et al.
1990; Shimada et al. 1996; Macé et al. 1997; Hammons et al. 1997; Hecht 1998). It has
also been shown previously that CYP1A2 function is strongly induced by tobacco
smoke (Tantcheva-Poor et al. 1999; Kalow and Tang 1991) and some herbal dietary
supplements (Ryu and Chung 2003). The ability of plumbagin to inhibit CYP1A2
suggests that it may possess chemopreventive properties. These preliminary findings
with plumbagin need further in-depth studies in the future.
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Chapter 7 Discussion
The aim of this thesis was to devise an insect cell expression system that
would allow improvement of the levels and activities of the drug metabolising
cytochrome P450 enzymes (CYPs) and contribute to the understandings of CYP-CPR
interactions.
Previously, it has been reported that the catalytic activity of a particular CYP is
determined not only by the abundance of the CYP, but also by the amount of CPR
(Crespi and Miller 1999). Although CPR’s abundance is essential for CYP activity,
paradoxically some results indicate that CPR is directly or indirectly involved in the
degradation of CYP holoprotein (Pederson and Aust 1975; Guengerich 1978; Trakshel
et al. 1986). It also appears that coupling of CYP to CPR is very crucial for CYP
catalytic activity. However some CYPs, such as CYP2E1, have shown a high degree of
uncoupling (Wang et al. 1996). Literature data have shown that CPR is absolutely
essential for CYP catalytic activity, however at the same time CPR is detrimental for the
expression of CYPs (Ding et al. 1997). My research addressed this paradox to some
extent by designing a genetically engineered variant of the human CPR which is less
toxic and couples well with CYPs than the human native CPR. In addition, use of a
high-activity CPR from yeast in my studies allowed us to improve our understanding on
CYP-CPR interactions.
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In this study it was important to investigate the effect of various CPRs on the
expression and enzyme activities of CYP holoenzymes in a well defined eukaryotic
model system. Expression of CYPs in the baculovirus expression system provides the
unique advantage of being able to co-infect with two or more recombinant
baculoviruses. This would allow the CYP to CPR ratio to be changed by altering the
MOI for each virus (Tamura 1992). In line with this, we thought that the baculovirus
expression system would be ideal to study CYP-CPR interactions for my studies.
We aimed to find a set of experimental conditions that would be less destructive
to CYPs and which would yield higher CYP activity. I have cloned, expressed and
studied the seven CYPs, CYP3A4, CYP2E1, CYP2D6, CYP1A2, CYP1A1, CYP1B1
and CYP2C8 in conjunction with different CPR species (the native human CPR,
variants of human CPR and the yeast CPR) and b5 (where necessary). The findings of
the experiments performed are discussed in the following sections.
7.1 Cloning, expression, localisation and enzymatic
activities of the CPRs
With the exception of some plants, a single CPR of a particular eukaryotic
species interacts with all other CYP enzymes of the same species (Benveniste 1991).
Since improving the understanding by which CPR interacts with various CYPs was an
important goal of this thesis, we initially cloned and expressed native human CPR
(hRD), its variants (ΔhRD and ΔhRDM) and yeast CPR (yRD) in Sf9 insect cells. 
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Previously it has been found that the proteolytic cleavage of 56 N-terminal
amino acids from human CPR results in loss of the ability of the CPR to interact and
transfer electrons to CYPs (Bonina et al. 2005) which confirms the importance of the N-
terminal sequence for catalysis. In this study we have demonstrated that the NH2-
terminal 24-amino acid truncated version of hRD, viz. ΔhRD does not anchor on the 
microsomal membranes.  However interestingly, the other variant, ΔhRDM which also 
lacks the N-terminal 24-amino acids but contains an extra 17-amino acid sequence
(SSEQKLISEEDLNGSRL) linked to ΔhRD’s COOH (C)-terminus has the ability to 
adhere once again to microsomal membranes like the native CPR (Figure 3.16). This
C-terminal 17-amino acid sequence includes a 12-amino acid motif (EQKLISEEDLN)
which is often referred to as the c-myc tag and belongs to an exposed epitope in the
oncogenic protein c-myc (Evan et al. 1985). We reasoned that by deleting an N-
terminal domain and introducing an unusual peptide fragment at the C-terminus, we
may have grossly altered the membrane-binding topology of the engineered molecule,
ΔhRDM.  It is possible that the C-terminal tag is the source of the ΔhRDM’s ability to 
anchor on to the microsomal membranes. The c-myc tag is generally used as an epitope
tag for immune-detection of novel proteins and can be added to either the N-terminus or
C-terminus of a known protein coding sequence. Some previous studies have shown
that an epitope tag may or may not affect a target protein activity or its folding and
topology (Sells and Chernoff 1995; Jarvik and Telmer 1998; Chavand et al. 2001).
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In the beginning of this study, apart from human CPRs, we also cloned and
expressed yeast NADPH cytochrome P450 reductase in insect cells. As human CPR
functions extremely poorly in yeast (unpublished results from our lab), it has rarely
been used in the published literature for expression of human CYPs in yeast. However,
although yeast CPR has been successfully used for heterologous expression of human
CYPs in yeast, it has never been used for expression studies in any other eukaryotic cell
system. We therefore decided to explore the interactions of yeast CPR with human
CYPs in insect cell microsomes (ER membranes).
Reductase assays on hRD, ΔhRD, ΔhRDM and yRD using the artificial 
substrate, MTT, revealed that the CPRs when expressed alone have different reduction
potentials towards MTT (Table 3.1). Reductase activity of yRD was highest amongst
all the CPRs.  ΔhRD reductase activity on microsomes was equal to the negative control 
(i.e. cells which do not contain any recombinant gene).  This was expected as the ΔhRD 
product does not anchor to (at least not present in) the microsomal membranes as
revealed by Coomassie staining and Western blotting (see Section 3.5). Our
experiments have consistently failed to show any reductase activity of ΔhRD in the 
MTT assay even in the soluble cytosolic fraction of the cell lysate.  It may be that ΔhRD 
is highly unstable in the cytosol of insect cells possibly where it is subjected to
spontaneous digestion by intracellular proteases. However, interestingly the genetically
engineered molecule, ΔhRDM, was found to be catalytically active towards reduction of 
the artificial substrate, MTT. Therefore, we were extremely keen to assess whether
ΔhRDM was catalytically active towards its physiological substrate, CYP.  The 
reduction potential of ΔhRDM was significantly lower than that of hRD and yRD.  
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Before we could study interactions of these CPRs via co-expression with various
CYPs, we opted to optimise CYP expression in insect cells using CYP2D6 as a model –
CYP2D6 being an important CYP isozyme in drug metabolism studies. The
optimisation of CYP expression is discussed in the following section.
7.2 Optimisation of CYP expression
In order to find out the optimal multiplicity of infection of CYP and CPR
baculoviruses (MOI) for producing spectrally active CYP, we infected Sf9 cells with
BV-2D6 using a range of MOIs (from 1 x 10-1 pfu/cell to 4 pfu/cell). The spectral
analysis of all the microsomes was typical of P450 proteins. However it was observed
that infection with the lowest MOI of 0.1 pfu/cell resulted in a major peak at 450 nm
and a very small peak at 420 nm (Figure 3.19). The peak at 420 nm is an indication of
spectrally inactive CYP. A clear indication of the best MOI for CYP infection (i.e. the
MOI which produces the highest level of CYPs) was obtained. Increasing the CYP
MOI above this level was associated with an increase in the peak at 420 nm. These
results suggest that using higher MOIs of BV-2D6 result in a gradual increase in the
formation of inactive CYP2D6. This is possibly a result of misfolding of the over-
expressed protein. It could be inferred that optimal expression of spectrally active CYP
depends on accumulation of properly folded CYP2D6 protein in the microsomal
membranes which can be achieved by infecting the insect cells with a lower MOI. It
also implies that high levels of spectrally active CYP can not be simply produced by
gradually increasing the initial MOI.
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7.3 Co-expression of CYP2D6 with the CPRs and their
interactions
In parallel to the results from MTT assays, in co-expressed microsomes the
reductase activity of yRD was the highest amongst all the CPRs followed by hRD and
ΔhRDM (Table 3.4).  ΔhRD reductase activity was equal to negative control which was 
expected as it only corroborated the results obtained with MTT. This strongly
suggested that the ΔhRD product may not anchor to microsomal membranes.  
Interestingly however, it was observed that the strongest CPR, yRD, resulted in the
lowest yield of spectrally active CYP2D6 in microsomes which co-express CYP2D6
and yRD. The second strongest CPR, hRD, also resulted in a lower yield of spectrally
active CYP2D6.  Amongst all the CPRs studied, ΔhRDM which has the lowest 
reduction potential towards the artificial substrate MTT appeared to yield the highest
content of spectrally active CYP2D6 (Table 3.2).
All the CPRs studied did decrease the spectrally active CYP holoenzyme
produced in co-expression studies (Table 3.2 & Figure 3.21). Intriguingly though, the
immunologically detectable apoprotein levels were found to be unaffected by co-
expression of different CPRs (Table 3.3). The detrimental effect of the CPRs on
CYP2D6 holoprotein was of dissimilar magnitude and it depended on the CPR that was
co-expressed. We were then able to show the possible cause of CYP2D6 holoprotein
destruction by CPRs. The reactive oxygen species (ROS) assays indicated that the
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reason behind this destruction is likely to be oxidative damage triggered by CPRs
(Figure 3.23 & 3.24). This data demonstrate that CPRs do not modulate CYP
expression at the gene transcriptional or protein translational levels but reduce CYP
holoenzyme levels by means of oxidative damage.
LC/MS analysis using dextromethorphan as a substrate showed that in
comparison to hRD co-expressed CYP2D6, the hRDM co-expressed CYP2D6 had
increased enzyme activity as seen by increased Vmax and thereby overall efficiency of
catalysis (Table 3.8). No significant changes were observed in the Km values stating
that the affinity of the substrate towards CYP2D6 holoenzyme has not changed but the
higher coupling efficiency of ΔhRDM has resulted in an increased Vmax thereby 
quadrupling of the efficiency of catalysis.
CYP2D6 enzyme activities supported by per unit of CPRs were calculated in
terms of coupling efficiency. Based on the CYP2D6 fluorometric enzyme assays
(Figure 3.25(B), 3.26(B) & 3.27), percentage relative coupling efficiency (Figure 3.28)
and efficiency of catalysis (Table 3.8), it can be concluded that the ΔhRDM, which has 
the weakest reduction potential, surprisingly provides the best CYP2D6 reaction rates in
comparison with the two wild-type CPRs – hRD and yRD.  We found that ΔhRDM not 
only coupled far better to CYP2D6 than the native human CPR (hRD) but also yields
higher levels of CYP2D6 with far less destruction of the CYP. Despite the strong
reduction potential towards MTT, yRD does not couple equally effectively with
CYP2D6. This means that the ability of a CPR to reduce an artificial substrate is not
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directly proportional to its ability to reduce the physiological substrate. CYP2D6
activity measured in the CPR co-expressed microsomes indicated that the strength of
the reductase does not determine CYP activity – it is the ability of CPR to couple with
CYP which is crucial.
Since ΔhRDM shows clear superiority over the two reductases hRD and yRD 
(being less destructive to the CYP2D6 holoprotein and having better reaction rates), we
thought of increasing the ΔhRDM amounts during co-expression with CYP2D6.   By 
doubling the MOI of BV-ΔhRDM during co-expression, substantial increase in rates of 
reaction were observed (Figure 3.29). A similar experiment was performed with
CYP2D6 and hRD and again an increase in the reaction rates were observed (Figure
3.30).  However, even though doubling of MOIs of both BV-ΔhRDM and BV-hRD 
improved the enzyme reaction rates, this was traded off against a sharp decrease in the
amount of spectrally active CYP2D6 (Table 3.9). This experiment allowed us to
understand that controlling CPR expression levels is important for achieving a balance
between amounts of spectrally active enzyme and its catalytic activity. It was also
noted from this particular experiment that the spectrally active CYP2D6 at 5:1 ratio of
CYP2D6 : ΔhRDM was more that 100% higher than the CYP2D6 obtained when the 
CYP2D6 : hRD ratio was 5:1 (Table 3.9).  Thus, ΔhRDM clearly provides room for 
further improvement.
Based on the results obtained, Chapter 3 clearly illustrates that peak enzymatic
activity cannot simply be obtained by increasing the MOI of a CPR baculovirus or by
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using a CPR which has very strong reduction potential. Coupling efficiency of a CPR is
extremely important to achieve the best enzymatic activity of the CYP. In conclusion
ΔhRDM, a genetically engineered variant of human CPR, offers advantages of high-
level expression of CYP2D6 with better reaction rates.  ΔhRDM also offers an 
improvement in the ratio of spectrally active CYP2D6 to spectrally inactive CYP2D6.
7.4 Interaction of CYP3A4 with the CPRs
Our results in Chapter 3 indicated that the yeast CPR, yRD, can act as an
alternative electron donor to the human CPR, hRD, for the general activation of human
CYPs. We wanted to explore if the results obtained from the co-expression studies of
yRD and CYP2D6, which express optimal activity in the absence of cytochrome b5, are
applicable in the context of another CYP where the presence of cytochrome b5 is
essential. We chose CYP3A4, which is also widely used for drug metabolism studies,
for these studies.
We therefore co-expressed the yeast CPR and human CYP3A4 enzymes in
insect cells along with cytochrome b5 in Chapter 4. We have also co-expressed
different human CPRs (hRD, ΔhRD and ΔhRDM) with human CYP3A4 at optimal 
MOIs and have compared our results with experiments that allow co-expression of the
yeast CPR (yRD) and CYP3A4 using similar MOIs. All co-expression studies were
performed in the presence of human cytochrome b5.
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Literature data have shown the reduction in human CYP levels when co-
expressed with a CPR in baculovirus expression systems (Chen et. al. 1997; Wang et.
al. 1996; Paine et. al. 1996). Our results are in agreement with these reports. We have
linked this effect to the increased production of hydroxyl radicals in Chapter 3 (Figure
3.23 & 3.24). Like CYP2D6, CYP3A4 holoenzyme levels also changed with different
magnitudes depending on which reductase species was used for co-expression with
CYP3A4 (Table 4.1). Co-expression of yRD and hRD resulted in lower CYP3A4
holoenzyme content than when ΔhRDM was co-expressed. 
In CYP3A4 co-expressed microsomes, yRD enzyme activity towards its
artificial substrate MTT was higher than hRD and ΔhRDM (Table 4.4).  However 
CYP3A4 catalytic activity towards de-alkylation of DBOMF in yRD co-expressed
microsomes was extremely poor in comparison to hRD or ΔhRDM co-expressed 
microsomes (Figure 4.11). The CYP3A4 activity in the presence of cytochrome b5 and
yeast CPR was nearly as low as the activities observed in the microsomes that co-
express only CYP3A4 and b5. It should be noted that reaction rates of yRD supported
CYP2D6 enzyme activities are much better, as presented in Chapter 3 (Figure 3.25(B),
3.26(B) & 3.27). This observation indicates that yRD does not support CYP3A4
activity as effectively as it supports CYP2D6 activity on insect cell microsomes.
To determine whether the oxidative damage to CYP3A4 by yRD is accelerated
by co-expressing the third protein cytochrome b5, reactive oxygen species (ROS) in
cells infected with CPR and cytochrome b5 baculoviruses were measured. Our results
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from the H2DCFDA assay showed that both yRD and hRD induce higher amounts of
reactive oxygen species than ΔhRDM.  However, co-expression of b5 with CPRs did not
noticeably alter the ROS levels induced by CPRs in insect cells (Table 4.6).
In spite of similar amounts of CYP3A4 holoprotein content in microsomes co-
expressing yRD and hRD (Table 4.1), CYP3A4 catalytic activity in the presence of
yRD is unusually poor as compared to CYP3A4 activity in the presence of hRD and
ΔhRDM (Figure 4.11).  We do not know the reason for this; however it is very likely 
that oxidative damage is not the complete reason for the poor CYP3A4 catalytic activity
in the presence of yRD. It is possible that the specific intracellular environment in
insect cells may not support the interaction of yRD with human CYP3A4 in the
presence of human cytochrome b5. This may suggest the importance for a CYP and the
CPR to have correct spatial orientation of their redox centres for effective electron
transfer. Recently, protein crystal structure of yeast CPR has been solved which reveals
that it has a second FMN binding site at the interface of the two connecting FMN
binding domains. The two FMN binding domains have different accessibilities to the
bulk solvent and different amino acid environments (Lamb et al 2006). Electrostatic
forces have been shown experimentally to limit accessibility of electron transfer sites on
CPR for its charged redox partners (Voznesensky and Schenkman 1994). One could
speculate that the human cytochrome b5, bound to CYP3A4, plays a major role in
hindering the transfer of electrons from the yeast CPR, yRD, to the CYP3A4 active site
on insect cell microsomes.
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In conclusion, our findings in Chapter 4 demonstrate that (1) yRD perceptibly
lacks the ability to support human CYP3A4 catalytic activity on insect cell ER
membranes, in the presence of cytochrome b5, (2) Co-expression of cytochrome b5 did
not seem to play any role in increasing or decreasing the ROS induced by CPRs, (3) in
comparison with yRD, human reductases hRD and ΔhRDM are probably the better 
redox partners for a human CYP which demands cytochrome b5 for manifestation of
optimal activity – this could be due to the inability of CYP3A4 and yRD to form a
mutually correct spatial orientation in the intracellular endoplasmic reticular
environment afforded by insect cells and (4) once again the variant of hRD enzyme,
ΔhRDM, appears to be far superior to the wild-type hRD in terms of its ability to couple 
with CYP3A4 and to produce higher amounts of a spectrally-active, catalytically-useful
CYP enzyme.
7.5 Interaction of CYP1A1, CYP1B1, CYP1A2, CYP2C8 and
CYP2E1 with the CPRs
Previously it was found that electrostatic forces play an important role in the
interactions between electron transfer proteins and in many cases these pairing
interactions are responsible for the complex formation; in contrast, repulsion between
the charged residues of two proteins may interfere with protein-protein complex
formation (Voznesensky and Schenkman 1992). The different distribution of charges
on CPR binding sites may cause different CYPs to have different affinities for CPR
(Voznesensky and Schenkman 1994). Recently it has been shown in protein binding
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assays that CYPs and the accessory proteins (CPR and cytochrome b5) interact with
each other with different affinities (Shimada et. al. 2005).
In Chapter 5, we have examined the interactions of the CPRs with several other
CYP isoforms from different sub-families. In order to study these affinities, we have
taken an approach of studying coupling between CYP and CPR, where the enzyme
catalytic activities are taken into account.  We studied the CPRs, viz. hRD, ∆hRDM and 
yRD, in the context of three more CYPs – CYP1B1, CYP1A2 and CYP2E1. We also
studied CYP1A1 and CYP2C8, though only in the context of ∆hRDM.  In the case of 
CYP2C8 and CYP2E1, apart from a CPR, a third protein cytochrome b5 was also co-
expressed. Cytochrome b5 is known to augment CYP2C8 and CYP2E1 mediated
monooxygenase reactions (Porter, 2002).
Based on Western blot densitometry (Figure 5.13 (A) & (B)) and CYP
holoenzyme content (Table 5.5 & 5.9), it was again observed that CPRs destroy
CYP1A2 and CYP2E1 holoproteins without altering the CYP apoprotein levels. This
would indicate that CPRs generically do not modulate CYP expression at the
transcriptional or translational level but are responsible for the destruction of CYP
holoprotein which is a result of ROS induction by CPRs.
In the co-expressed microsomes, reduction potential of yRD in the MTT assay
was higher than hRD or sometimes similar, but yRD did not support CYP activity as
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efficiently as the human CPR.  ΔhRDM was identified as the most effective CPR, 
amongst hRD, ΔhRDM and yRD, as it caused less damage to CYP holoprotein and 
supported CYP catalytic activities more efficiently.
The coupling efficiency of yRD with the CYPs was found to be inferior to
∆hRDM and hRD which indicates that use of yRD for human CYP expressions, 
particularly in the ‘insect cell expression system’, may not be physiologically feasible.
While comparing coupling efficiency of yRD with various CYPs, it was observed that it
couples relatively better with CYP2E1 and CYP2D6 in comparison to other CYPs that
we studied (Table 7.1).  The genetically engineered molecule ∆hRDM coupled more 
efficiently with the CYPs than hRD and yRD.  As coupling efficiency of ∆hRDM was 
higher than hRD and yRD, relative coupling efficiencies for hRD and yRD were
calculated assuming ∆hRDM coupling efficiency as 100%.  The coupling efficiencies of 
CYP2D6, CYP3A4, CYP1B1, CYP1A2 and CYP2E1 with hRD, ∆hRDM and yRD are 
summarised in the table below.
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Table 7.1 Percent relative coupling efficiencies of hRD, ΔhRDM and yRD with 
CYP2D6, CYP3A4, CYP1B1, CYP1A2 and CYP2E1.
CYP/ CPR ∆hRDM 
coupling efficiency
hRD yRD
CYP2D6 100 55.6 44.89
CYP3A4 100 65.31 29.17
CYP1B1 100 63.49 24.78
CYP1A2 100 33.73 24.9
CYP2E1 100 106.65 45.64
The above results suggest that different CPRs have different affinities towards
the different CYP isoforms which could account for the variations on the charges on
CYP and CPR binding sites and spatial orientation of their redox centres.
7.6 Cytochrome P450 inhibition
We identified ΔhRDM as a relatively superior CPR with respect to its abilities to 
(1) cause less damage to the CYPs and (2) overall couple better with the CYPs.
However, it was important to study its allosteric behaviour and directly compare it with
the human native CPR in the most important aspect of drug metabolism, namely
experiments related to CYP inhibition studies. The CYP inhibition assays were
successfully set up and performed for CYP1A1, CYP1A2, CYP1B1, CYP2D6 and
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CYP3A4 enzymes in order to determine whether there are any differences in the
catalytic properties of the electron donor partner hRD and its variant ΔhRDM with 
respect to activation of the CYPs. The mean IC50 values found for the known inhibitors,
α-naphthoflavone, furafylline, quinidine and ketoconazole were consistent with that 
reported previously (Crespi et al. 1997).
From the results obtained from the comparative CYP inhibition experiments, we
did not observe any significant differences in the IC50 values of the compounds for
inhibition of CYPs activated by hRD and ΔhRDM.  The CYP inhibition by reference 
standards in hRD as well as ΔhRDM co-expressed CYP samples was dose dependent.  
The inhibition studies demonstrated that even though ΔhRDM is a genetically 
engineered novel form of human CPR, it does not alter the quantification of CYP
inhibition by the chemical compounds. This comprehensive in vitro assessment of
ΔhRDM has provided evidence in support of its use as an effective electron donor 
protein for CYPs.
Apart from the reference standards, we analysed the natural naphthoquinone,
plumbagin, for its ability and specificity to inhibit the CYPs. Plumbagin also inhibited
all the CYP reactions in dose dependent manner. Plumbagin IC50 values in hRD and
ΔhRDM co-expressed CYP samples were not significantly different.  Interestingly 
however, we found that plumbagin has higher affinity towards CYP1A2 inhibition over
other CYPs that we studied (Table 6.6). It inhibits CYP1A2 as potently as does the
reference standard, furafylline.
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Previously, it has been shown that CYP1A2 function is strongly induced by
tobacco smoke (Tantcheva-Poor et al. 1999; Kalow and Tang 1991) and some herbal
dietary supplements (Ryu and Chung 2003). Furthermore CYP1A2 has been implicated
in activation of PAHs, nitrosamines, aflatoxin B1, and especially aryl amines into forms
that can bind to DNA, produce mutations and cause cancer (Aoyama et. al. 1990;
Shimada et. al. 1996; Macé et. al. 1997; Hammons et. al. 1997; Hecht 1998). In line
with this, the ability of plumbagin to inhibit CYP1A2 suggests that it may possess
anticancer chemopreventive properties. These preliminary findings with plumbagin
warrant further studies to elucidate its in vivo role in CYP1A2 inhibition.
7.7 Summary
In summary, we have devised a functionally active CYP expression system
which uses a genetically engineered human CPR, ΔhRDM.  The system provides some 
unique advantages over the CYP expression system that uses human native CPR, hRD,
as the electron donor protein.  Use of ΔhRDM as electron donor to CYPs allowed us to 
achieve our goal of improving CYP expression levels and in the coupling of CYPs with
a CPR. The key findings of the thesis are summarised below.
 Truncation of a 24-amino acid charged region at NH2-terminal end of
hRD, prevents association of the resultant molecule, ΔhRD, to 
microsomal membranes.  ΔhRDM which also lacks the N-terminal 24-
amino acids but contains an extra 17-amino acid sequence
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(SSEQKLISEEDLNGSRL) linked to ΔhRD’s C-terminus has the ability 
to adhere once again to microsomal membranes.
 Co-expression of all the CPRs with the CYPs resulted in reduction of
CYP holoprotein without altering the apoprotein levels. The detrimental
effect of the CPRs on CYP holoprotein was of different magnitudes
depending on the CPR that was co-expressed.
 CPRs do not modulate the CYP expression at the gene transcriptional or
protein translational levels but are responsible for reduction in CYP
holoenzyme levels by means of oxidative damage. Co-expression of
cytochrome b5 does not seem to play any role in increasing or decreasing
the oxidative damage caused by CPRs.
 The ability of a CPR to reduce an artificial substrate is not directly
proportional to its ability to reduce the physiological substrate. The
strength of the reductase does not determine CYP activity – it is the
ability of CPR to couple with CYP which is crucial.
 Different CPRs have different affinities towards the different CYP
isoforms which could account for the variations on the charges on CYP
and CPR binding sites and spatial orientation of their redox centres.
 ΔhRDM, a genetically engineered variant of human CPR offers 
advantages of high-level expression of CYP with better reaction rates.
ΔhRDM also offers an improvement in the ratio of spectrally active 
CYP2D6 to spectrally inactive CYP2D6.
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 The inhibition studies demonstrate that even though ΔhRDM is a 
genetically engineered form of human CPR, it does not alter the
quantification of CYP inhibition by chemical compounds. It implies that
the allosteric interactions, which modulate enzyme active site
conformations, of ΔhRDM and hRD with a particular CYP are similar. 
 This comprehensive in vitro assessment of ΔhRDM has provided 
evidence in support of its use as an effective electron donor protein for
CYPs.
7.8 Prospects for the future
In this project we have identified ΔhRDM as a relatively superior electron donor 
protein to the CYPs. However for reasons that are poorly understood any particular
CPR has different affinities to different CYPs. Crystal structure of the FMN binding
domain of human CPR has been solved which indicates that the FMN domain has an
unusual surface charge distribution, leading to a very strong dipole, which may be
involved in docking a CYP into place for electron transfer (Zhao et al. 1999). This
surface is thought to be the most suitable for electron transfer from CPR. Site-directed
mutagenesis studies have revealed that different parts of the FMN domain are involved
in CYP and cytochrome c binding (Shen and Kasper 1995) – besides MTT, cytochrome
c is another artificial electron transfer substrate for CPRs. Studies with cytochrome b5
also indicate that its binding site on CPR is distinct from that of CYP (Nadler and
Strobel 1991). It may be that every individual CYP isozyme has a slightly different
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interaction with CPR. Extensive site-directed mutagenesis studies in FMN domain of
CPR might throw more light on whether different amino acid residues of this domain
are involved in interaction with individual CYPs. In addition site-directed mutagenesis
studies are also needed on ΔhRDM to understand which amino acid residues are exactly 
responsible for giving this molecule the ability to anchor on to the ER membranes.
These further studies may help us to define a human CPR with even better properties
than ΔhRDM.   
336
Chapter 8 References
Acharya, B.R., Bhattacharyya, B. and Chakrabarti, G. (2008) The natural
naphthoquinone plumbagin exhibits antiproliferative activity and disrupts the
microtubule network through tubulin binding. Biochemistry, 47(30), pp. 7838-
7845.
Anderson, D., Harris, R., Polayes, D., Ciccarone, V., Donahue, R., Gerard, G., and
Jessee, J. (1996) Rapid generation of recombinant baculoviruses and expression of
foreign genes using the Bac-To-Bac® baculovirus expression system. Focus, 17,
pp. 53-58.
Anttila, S., Hietanen, E., Vainio, H., Camus, A.M., Gelboin, H.V., Park, S.S., Heikkilä,
L., Karjalainen, A. and Bartsch, H. (1991) Smoking and peripheral type of cancer
are related to high levels of pulmonary cytochrome P450IA in lung cancer
patients. Int J Cancer, 47(5), pp. 681-685.
Aoyama, T., Yamano, S., Guzelian, P.S., Gelboin, H.V. and Gonzalez, F.J. (1990) Five
of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450
metabolically activate aflatoxin B1. Proc Natl Acad Sci, 87 (12), pp. 4790-4793.
Atkins, A.L. (1999) Preparation of yeast cells for confocal microscopy, In Paddock,
S.W (ed) Confocal Microscopy: methods and protocols. Methods in Mol Biol,
122, pp. 131-140.
Ayres, M.D., Howard, S. C., Kuzio, J., Lopez Ferber, M. and Possee, R. D. (1994) The
complete DNA sequence of Autographa californica nuclear polyhedrosis virus.
Virology, 202 (2), pp. 586–605.
Backes, W.L. and Kelley, R.W. (2003) Organization of multiple cytochrome P450s with
NADPH-cytochrome P450 reductase in membranes. Pharmacol Ther, 98(2), pp.
221-33.
Bardsley, J.S. (1994) Establishment of human tissue banks. Hum Exp Toxicol, 13 (6),
pp. 435-437.
337
Barnes, H.J., Arlotto, M. P. and Waterman, M. R. (1991) Expression and enzymatic
activity of recombinant cytochrome P450 17α-hydroxylase in Escherichia coli.
Proc Natl Acad Sci, 88, pp. 5597-5601.
Battula, N., Sagara, J. and Gelboin, H.V. (1987) Expression of P1-450 and P3-450 DNA
Coding Sequences as Enzymatically Active Cytochromes P-450 in Mammalian
Cells. Proc. Natl. Acad. Sci. 84(12), pp. 4073-4077.
Beaune, P. (1993) [Human cytochromes P450. Applications in pharmacology].
Therapie, 48 (6), pp. 521-526.
Benveniste, I., Lesot, A., Hasenfratz, M.P., Kochs, G. and Durst, F. (1991) Multiple
forms of NADPH-cytochrome P450 reductase in higher plants. Biochem Biophys
Res Commun, 177 (1), pp. 105-112.
Bertz, R.J. and Granneman, G.R. (1997) Use of in vitro and in vivo data to estimate the
likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet, 32(3),
pp. 210-258.
Blanck, J., Smettan, G., Ristau, O., Ingelman-Sundberg, M. and Ruckpaul, K. (1984)
Mechanism of rate control of the NADPH dependent reduction of cytochrome P-
450 by lipids in reconstituted phospholipid vesicles. Eur J Biochem, 144 (3), pp.
509-513.
Bondza-Kibangou, P., Millot, C., Dufer, J. and Millot, J.M. (2004) Modifications of
cellular autofluorescence emission spectra under oxidative stress induced by 1
alpha,25dihydroxyvitamin D(3) and its analog EB1089. Technol Cancer Res
Treat, 3 (4), pp. 383-391.
Bonina, T.A., Gilep, A.A., Estabrook, R.W. and Usanov, S.A. (2005) Engineering of
proteolytically stable NADPH-cytochrome P450 reductase. Biochemistry, 70 (3),
pp. 357-365.
Bowen, W.P., Carey, J.E., Miah, A., McMurray, H.F., Munday, P.W., James, R.S.,
Coleman, R.A. and Brown, A.M. (2000) Measurement of cytochrome P450 gene
338
induction in human hepatocytes using quantitative real-time reverse transcriptase-
polymerase chain reaction. Drug Metab Dispos, 28(7), pp. 781-8.
Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem,
72, pp. 248-254.
Brian, W.R., Sari, M.A., Iwasaki, M., Shimada, T., Kaminsky, L.S. and Guengerich,
F,P. (1990) Catalytic activities of human liver cytochrome P-450 IIIA4 expressed
in Saccharomyces cerevisiae. Biochemistry, 29(51), pp. 11280-11292.
Capdevila, J.H., Falck, J.R. and Harris, R.C. (2000) Cytochrome P450 and arachidonic
acid bioactivation. Molecular and functional properties of the arachidonate
monooxygenase. J Lipid Res, 41(2), pp. 163-81.
Chang, T.K., Yu, L., Maurel, P. and Waxman, D.J. (1997) Enhanced cyclophosphamide
and ifosfamide activation in primary human hepatocyte cultures: response to
cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer
Res, 57(10), pp. 1946-54.
Chauret, N., Dobbs, B., Lackman, R.L., Bateman, K., Nicoll-Griffith, D.A., Stresser,
D.M., Ackermann, J.M., Turner, S.D., Miller, V.P. and Crespi, C.L. (2001) The
use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-
methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver
microsomes. Drug Metab Dispos, 29 (9), pp. 1196-1200.
Chavand, O., Spilsbury, K. and Rakoczy, P.E. (2001) Addition of a c-myc epitope tag
within the VEGF protein does not affect in vitro biological activity. Biochem Cell
Biol, 79(1), pp. 107-112.
Chen, L., Buters, J.T., Hardwick, J.P., Tamura, S., Penman, B.W., Gonzalez, F.J. and
Crespi, C.L. (1997) Coexpression of Cytochrome P4502A6 and Human NADPH-
P450 Oxidoreductase in the Baculovirus System. Drug Metab Dispos, 25 (4), pp.
399-405.
339
Chen, Z. and Banerjee, R. (1998) Purification of Soluble Cytochrome b5 as a
Component of the Reductive Activation of Porcine Methionine Synthase. J Biol
Chem, 273 (40), 26248-26255.
Crespi, C.L. and Miller, V.P. (1999) The use of heterologously expressed drug
metabolizing enzymes-state of the art and prospects for the future. Pharmacol
Ther, 84 (2), pp. 121-131.
Crespi, C.L., Miller, V.P. and Penman, B.W. (1997) Microtiter plate assays for
inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem,
248(1), pp. 188-90.
Crespi, C.L., Penman, B.W., Leakey, J.A., Arlotto, M.P., Stark, A., Parkinson, A.,
Turner, T., Steimel, D.T., Rudo, K., Davies, R.L. et al. (1990) Human cytochrome
P450IIA3: cDNA sequence role of the enzyme in the metabolic of promutagens
comparison to nitrosamine activation by human cytochrome P450IIE1.
Carcinogenesis, 11 (8), pp. 1293-1300.
Dai, Y., Rashba-Step, J. and Cederbaum, A.L. (1993) Stable expression of human
cytochrome P4502E1 in HepG2 cells: characterization of catalytic activities and
production of reactive oxygen intermediates. Biochemistry, 32 (27), pp. 6928-
6937.
Danielson, P.B. (2002) The cytochrome P450 superfamily: biochemistry, evolution and
drug metabolism in humans. Curr Drug Metab, 3 (6), pp. 561-597.
Deeni, Y.Y., Paine, M.J., Ayrton, A.D., Clarke, S.E., Chenery, R. and Wof, C.R. (2001)
Expression, purification, and biochemical characterization of a human cytochrome
P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein. Arch
Biochem biophys, 396 (1), pp. 16-24.
Ding, S., Yao, D., Burchell, B., Wolf, C.R. and Friedberg, T. (1997) High Levels of
Recombinant CYP3A4 Expression in Chinese Hamster Ovary Cells Are
Modulated by Coexpressed Human P450 Reductase and Hemin Supplementation.
Arch of Biochem and Biophys, 348(2), pp. 403-410(8).
340
Doehmer, J., Dogra, S., Friedberg, T., Monier, S., Adesnik, M., Glatt, H. and Oesch, F.
(1988) Stable Expression of Rat Cytochrome P-450IIB1 cDNA in Chinese
Hamster Cells (V79) and Metabolic Activation of Aflatoxin B1. Proc Natl Acad
Sci, 85(16), pp. 5769-5773.
Dong, J. and Porter, T.D. (1996) Coexpression of Mammalian Cytochrome P450 and
Reductase in Escherichia coli. Arch Biochem Biophys, 327 (2), pp. 254-259.
Edwards, R.J., Adams, D.A., Watts, P.S., Davies, D.S. and Boobis, A.R. (1998)
Development of a comprehensive panel of antibodies against the major xenobiotic
metabolising forms of cytochrome P450 in humans. Biochem Pharmacol, 56(3),
pp. 377-87.
Ellis, S.W., Ching, M.S., Watson, P.F., Henderson, C.J., Simula, A.P., Lennard, M.S.,
Tucker, G.T. and Woods, H.F. (1992) Catalytic activities of human debrisoquine
4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Biochem
Pharmacol, 44 (4), pp. 617-620.
Enoch, H.G. and Strittmatter, P. (1979) Cytochrome b5 reduction by NADPH-
cytochrome P-450 reductase. J Biol Chem, 254, pp. 8976-8981.
Estabrook, R.W. (2003) A passion for P450s (rememberances of the early history of
research on cytochrome P450). Drug Metab Dispos, 31 (12), pp. 1461-1473.
Estabrook, R.W., Franklin, M.R., Cohen, B., Shigamatzu, A. and Hildebrandt, A.G.
(1971) Biochemical and genetic factors influencing drug metabolism. Influence of
hepatic microsomal mixed function oxidation reactions on cellular metabolic
control. Metabolism, 20(2), pp. 187-199.
Eugster, H.P. and Sengstag, C. (1993) Saccharomyces cerevisiae: an alternative source
for human microsomal liver enzymes and its use in drug interaction studies.
Toxicology, 82 (1-3), pp. 61-73.
Evan, G.I., Lewis, G.K., ramsay, G. and Bishop, J.M. (1985) Isolation of monoclonal
antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol, 5
(12), pp.3610-3616.
341
Farr, S.B., Natvig, D.O. and Kogoma, T. (1985) Toxicity and mutagenicity of
plumbagin and the induction of a possible new DNA repair pathway in
Escherichia coli. J Bacteriol, 164(3), pp. 1309-1316.
French, J.S., Guengerich, F.P. and Coon, M.J. (1980) Interactions of cytochrome P450,
NADPH-cytochrome P-450 reductase, phospholipid, and substrate in the
reconstituted liver microsomal enzyme system. J Biol Chem, 255 (9), pp. 4112-
4119.
Fukushima, H., Takeda, T., Sasaki, N., Watanabe, T. and Nozawa, Y. (1984) Isolation
of detergent-solubilized NADPH-cytochrome c reductase from Tetrahymena
microsomes, with regard to thermoadaptive regulation of fatty acyl-CoA
desaturase activity. Comparative Biochemistry and Physiology Part B:
Biochemistry and Molecular Biology, 78 (4), pp. 855-858.
Ged, C., Rouillon, J.M., Pichard, L., Combalbert, J., Bressot, N., Bories, P., Michel, H.,
Beaune, P. and Maurel, P. (1989) The increase in urinary excretion of 6 beta-
hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br
J Clin Pharmacol, 28(4), pp. 373-387.
Gonzalez, F.J. (1992) Human cytochromes P450: problems and prospects. Trends
Pharmacol Sci, 13 (9), pp. 346-352.
Gonzalez, F.J. and Korzekwa, K.R. (1995) Cytochromes P450 expression systems.
Annu Rev Pharmacol Toxicol, 35, pp. 369-390.
Gonzalez, F.J., Kimura, S., Tamura, S. and Gelboin, H.V. (1991) Expression of
mammalian cytochrome P450 using baculovirus Methods. Enzymol, 206, pp. 93-
99.
Graham, S.E. and Peterson, J.A. (1999) How similar are P450s and what can their
differences teach us? Arch Biochem Biophys, 369 (1), pp. 24-29.
Groves, J. (1995) Models and Mechanism of Cytochrome P450 Action. Cytochrome
P450: Structure, Mechanism, and Biochemistry, 3rd ed., pp. 1-48.
342
Guengerich, F.P. (1978) Destruction of heme and hemoproteins mediated by liver
microsomal reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-
450 reductase. Biochemistry, 17(17), pp. 3633-3639.
Guengerich, F.P. (1995) Influence of nutrients and other dietary materials on
cytochrome P-450 enzymes. Am J Clin Nutr, 61(3 Suppl), pp. 651S-658S.
Guengerich, F.P. (1999) Cytochrome P-450 3A4: regulation and role in drug
metabolism. Annu Rev Pharmacol Toxicol, 39, pp. 1-17.
Guengerich, F.P. and Shimada, T. (1991) Oxidation of toxic and carcinogenic chemicals
by human cytochrome P-450 enzymes. Chem Res Toxicol, 4(4), pp. 391-407.
Hakkola, J., Pasanen, M., Pelkonen, O., Hukkanen, J., Evisalmi, S., Anttila, S., Rane,
A., Mäntylä, M., Purkunen, R., Saarikoski, S., Tooming, M. and Raunio, H.
(1997) Expression of CYP1B1 in human adult and fetal tissues and differential
inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta
and cultured cells. Carcinogenesis, 18(2), pp. 391-397.
Hammons, G.J., Milton, D., Stepps, K., Guengerich, F.P., Tukey, R.H. and Kadlubar,
F.F. Metabolism of carcinogenic heterocyclic and aromatic amines by
recombinant human cytochrome P450 enzymes. Carcinogenesis, 18(4), pp. 851-
854.
Hanahan, D. (1983) Studies on transformation of Escherichia coli with plasmids. J Mol
Biol, 166 (4), pp. 557-580.
Hannermann, F., Bichet, A., Ewen, K. M. and Bernhardt, R. (2007) Cytochrome P450
systems--biological variations of electron transport chains. Biochim Biophys
Acta, 1770 (3), pp. 330-344.
Harris, R. and Polayes, D. (1997) A new baculovirus expression vector for the
simultaneous expression of two heterologous proteins in the same insect cell.
Focus, 19. pp. 6-8.
Haugen, D.A., Armes, L.G., Yasunobu, K.T. and Coon, M.J. (1997) Amino-terminal
sequence of phenobarbital-inducible cytochrome P-450 from rabbit liver
343
microsomes: similarity to hydrophobic amino-terminal segments of preproteins.
Biochem Biophys Res Commun, 77(3), pp. 967-973.
Hayashi, K., Sakaki, T., Kominami, S., Inouye, K. and Yabusaki, Y. (2000)
Coexpression of genetically engineered fused enzyme between yeast NADPH-
P450 reductase and human cytochrome P450 3A4 and human cytochrome b5 in
yeast. Arch Biochem Biophys, 381 (1), pp. 164-170.
Hecht, S.S. (1997) Approaches to cancer prevention based on an understanding of N-
nitrosamine carcinogenesis. Proc Soc Exp Biol Med, 216(2), pp. 181-191.
Hecht, S.S. (1999) DNA adduct formation from tobacco-specific N-nitrosamines. Mutat
Res, 424(1-2), pp. 127-142.
Hildebrandt, A. and Estabrook, R.W. (1971) Evidence for the participation of
cytochrome b 5 in hepatic microsomal mixed-function oxidation reactions. Arch
Biochem Biophys, 143 (1), pp. 66-79.
Holloway, P.W. and Katz, J.T. (1975) Effect of cytochrome b5 on the size, density, and
permeability of phosphatidylcholine vesicles. J Biol Chem, 250 (23), pp. 9002-
9007.
Holmans, P.L., Shet, M.S., Martin-Wixtrom, C.A., Fisher, C.W. and Estabrook, R.W.
(1994) The high-level expression in Escherichia coli of the membrane-bound form
of human and rat cytochrome b5 and studies on their mechanism of function.
Arch Biochem Biophys, 312(2), pp. 554-65.
Horecker, B.L. (1950) Triphosphopyridine nucleotide-cytochrome c reductase in liver. J
Biol Chem, 183, pp. 593-605.
Imaoka, S., Yamada, T., Hiroi, T., Hayashi, K., Sakaki, T., Yabusaki, Y. and Funae, Y.
(1996) Multiple forms of human P450 expressed in Saccharomyces cerevisiae.
Systematic characterization and comparison with those of the rat. Biochem
Pharmacol, 51(8), pp. 1041-1050.
Iwata, H., Fujita, K., Kushida, H., Suzuki, A., Konno, Y., Nakamura, K., Fujino, A. and
Kamataki, T. (1998) High Catalytic Activity of Human Cytochrome P450 Co-
344
expressed with Human NADPH-Cytochrome P450 Reductase in Escherichia coli.
Biochem Pharmacol, 55 (8), pp. 1315-1325.
Iyanagi, T. and Mason, H.S. (1973) Some properties of hepatic reduced nicotinamide
adenine dinucleotide phosphate-cytochrome c reductase. Biochemistry, 12 (12),
pp. 2297-2308.
Iyanagi, T., Anan, F.K., Imai, Y. and Mason, H.S. (1978) Studies on the microsomal
mixed function oxidase system: redox properties of detergent-solubilized
NADPH-cytochrome P-450 reductase. Biochemistry, 17 (11), pp. 2224-2230.
Iyengar, M.A. and Pendse, G.S. (1966) Plumbago zeylanica L. (Chitrak). A
gastrointestinal flora normaliser. Planta Med, 14(3), pp. 337-351.
Jarvik, J.W. and Telmer, C.A. (1998) Epitope tagging. Ann Rev Genet, 32, pp. 601-618.
Kalow, W. and Tang, B.K. (1991) Caffeine as a metabolic probe: exploration of the
enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther, 49(1), pp.
44-48.
Kaminsky, L.S., Dunbar, D.A., Wang, P.P., Beaune, P., Larrey, D., Guengerich, F.P.,
Schnellmann, R.G. and Sipes, I.G. (1984) Human hepatic cytochrome P-450
composition as probed by in vitro microsomal metabolism of warfarin. Drug
Metab Dispos, 12 (4), 470-477.
Kapucuoglu, N., Coban, T., Raunio, H., Pelkonen, O., Edwards, R.J., Boobis, A.R. and
Iscan, M. (2003) Expression of CYP3A4 in human breast tumour and non-tumour
tissues. Cancer Lett, 202(1), pp. 17-23.
Klingenberg, M. (1958) Pigments of rat liver microsomes. Arch Biochem Biophys, 75
(2), pp. 376-386.
Klotz, A.V., Stegeman, J.J. and Walsh, C. (1984) An alternative 7-ethoxyresorufin O-
deethylase activity assay: a continuous visible spectrophotometric method for
measurement of cytochrome P-450 monooxygenase activity. Anal Biochem,
140(1), pp. 138-145.
345
Kocarek, T.A., Schuetz, E.G., Strom, S.C., Fisher, R.A. and Guzelian PS. (1995)
Comparative analysis of cytochrome P4503A induction in primary cultures of rat,
rabbit, and human hepatocytes. Drug Metab Dispos, 23(3), pp. 415-421.
Kolars, J.C., Schmiedlin-Ren, P., Schuetz, J.D., Fang, C. and Watkins, P.B. (1992)
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel
enterocytes. J Clin Invest, 90(5), pp. 1871-1878.
Lamb, D.C., Kim, Y., Yermalitskaya, L.V., Yermalitsky, V.N., Lepesheva, G.I., Kelly,
S.L., Waterman, M.R. and Podust, L.M. (2006) A second FMN binding site in
yeast NADPH-cytochrome P450 reductase suggests a mechanism of electron
transfer by diflavin reductases. Structure, 14(1), pp. 51-61.
Landi, M.T., Sinha, R., Lang, N.P. and Kadlubar, F.F. (1999) Human cytochrome
P4501A2. IARC Sci Publ, 148, pp. 173-95.
Lee, C.A., Kadwell, S. H., Kost, T. A. and Serabjitsingh, C. J. (1995) CYP3A4
expressed by insect cells infected with a recombinant baculovirus containing both
CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar
to human liver microsomal CYP3A4. Arch Biochem Biophys, 319 (1), pp. 157-
167.
Li, A.P. (2001) Screening for human ADME/Tox drug properties in drug discovery.
Drug Discov Today, 6(7), pp. 357-366.
Li, A.P., ed. (1997) Advances in Pharmacology: Pharmacokinetic Drug–Drug
Interactions (Vol. 43), Academic Press.
Lieber, C.S. (1997) Cytochrome P-4502E1: its physiological and pathological role.
Physiol Rev, 77(2), pp. 517-544.
Lu, A.Y. and Coon, M.J. (1968) Role of hemoprotein P-450 in fatty acid omega-
hydroxylation in a soluble enzyme system from liver microsomes. J Biol Chem,
243 (6), pp. 1331-1332.
346
Lu, A.Y., Junk, K.W. and Coon, M.J. (1969) Resolution of the cytochrome P-450-
containing omega-hydroxylation system of liver microsomes into three
components. J Biol Chem, 244 (13), pp. 3714-3721.
Luckow, V. (1991) Cloning and expression of heterologous genes in insect cells with
baculovirus vectors. Prokop, A., Bajpai, R. K. and Ho, C. S. (Eds.). In:
Recombinant DNA technology and applications, McGraw-Hill, Inc., pp. 97−104. 
Luckow, V.A., Lee, S. C., Barry, G. F. and Olins, P. O. (1993) Efficient generation of
infectious recombinant baculoviruses by site-specific transposon-mediated
insertion of foreign genes into a baculovirus genome propagated in Escherichia
coli. J Virol, 67 98), pp. 4566-4579.
Macé, K., Aguilar, F., Wang, J.S., Vautravers, P., Gómez-Lechón, M., Gonzalez, F.J.,
Groopman, J., Harris, C.C. and Pfeifer, A.M. (1997) Aflatoxin B1-induced DNA
adduct formation and p53 mutations in CYP450-expressing human liver cell lines.
Carcinogenesis, 18(7), 1291-1297.
Marks, B.D,, Goossens, T.A,, Braun, H.A,, Ozers, M.S,, Smith, R.W., Lebakken, C. and
Trubetskoy, O.V. (2003) High-throughput screening assays for CYP2B6
metabolism and inhibition using fluorogenic Vivid® substrates. AAPS PharmSci,
5, pp. E18.
Marks, B.D., Smith, R.W., Braun, H.A., Goossens, H.A., Christenson, M., Ozers, M.S.,
Lebakken, C.S. and Trubetskoy, O.V., (2002) A high throughput screening assay
to screen for CYP2E1metabolism and inhibition using a fluorogenic Vivid® P450
substrate. Assay Drug Dev Technol, 1, pp. 73-81.
Masters, C. J. (1998) On the role of the peroxisome in the metabolism of drugs and
xenobiotics. Biochemical Pharmacology, 56 (6), pp. 667-673.
Mauk, M.R. and Mauk, A.G. (1982) Interaction between cytochrome b5 and human
methemoglobin. Biochemistry, 21 (19), 4730-4734.
347
Miller, V.P., Stresser, D.M., Blanchard, A.P., Turner, S. and Crespi, C.L. (2000)
Fluorometric high-throughput screening for inhibitors of cytochrome P450. Ann
N Y Acad Sci, 919, pp. 26-32.
Mokashi, V., Li, L. and Porter, T.D. (2003) Cytochrome b5 reductase and cytochrome
b5 support the CYP2E1-mediated activation of nitrosamines in a recombinant
Ames test. Arch Biochem Biophys, 412 (1), pp. 147-152.
Morel, F., Beaune, P.H., Ratanasavanh, D., Flinois, J.P., Yang, C.S., Guengerich, F.P,
and Guillouzo A. (1990) Expression of cytochrome P-450 enzymes in cultured
human hepatocytes. Eur J Biochem, 191(2), pp. 437-444.
Mullis, K., Faloona, F., Scharf, S., Saiki, R., Horn, G. and Erlich, H. (1986) Specific
enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold
Spring Harb Symp Quant Biol, 51 (1), pp. 263-273.
Murray, G.I., Taylor, M.C., McFadyen, M.C., McKay, J.A., Greenlee, W.F., Burke,
M.D. and Melvin, W.T. (1997) Tumor-specific expression of cytochrome P450
CYP1B1. Cancer Res, 57(14), pp. 3026-3031.
Nadler, S.G. and Strobel, H.W. (1991) Identification and characterization of an
NADPH-cytochrome P450 reductase derived peptide involved in binding to
cytochrome P450. Arch Biochem Biophys, 290(2), pp. 277-284.
Nakajima, M., Fujiki, Y., Kyo, S., Kanaya, T., Nakamura, M., Maida, Y., Tanaka, M.,
Inoue, M. And Yokoi, T. (2005) Pharmacokinetics of paclitaxel in ovarian cancer
patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin
Pharmacol, 45 (6), pp. 674-682.
Narimatsu, S., Takatsu, N., Yamano, S., Inoue, Y., Hanioka, N., Kiryu, K., Naito, S.,
Gonzalez, F.J. and Yamamoto, S. (2006) The effect of dimethyl sulfoxide on the
function of cytochrome P450 2D6 in HepG2 cells upon the co-expression with
NADPH-cytochrome P450 reductase. Chem Biol Interact, 159 (1), pp. 47-57.
Nebert, D.W. and McKinnon, R.A. (1994) Cytochrome P450: evolution and functional
diversity. Prog Liver Dis, 12, pp. 63-97.
348
Nebert, D.W., Adesnik, M., Coon, M.J., Estabrook R.W., Gonzalez, F.J., Guengerich,
F.P., Gunsalus, I.C., Johnson, E.F., Kemper, B. and Levin, W. et al. (1987) The
P450 gene superfamily: recommended nomenclature. DNA, 6 (1), pp. 1-11.
Nebert, D.W., McKinnon, R.A. and Puga, A. (1996) Human drug-metabolizing enzyme
polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol, 15(4), 273-
280.
Nebert, D.W., Nelson, D.R., Adesnik, M., Coon, M.J., Estabrook R.W., Gonzalez, F.J.,
Guengerich, F.P., Gunsalus, I.C., Johnson, E.F. and Kemper, B. et al. (1989) The
P450 superfamily: updated listing of all genes and recommended nomenclature
for the chromosomal loci. DNA, 8 (1), pp. 1-13.
Nebert, D.W., Nelson, D.R., Coon, M.J., Estabrook R.W., Feyereisen, R., Fujii-
Kuriyama, Y., Gonzalez, F.J., Guengerich, F.P., Gunsalus, I.C., Johnson, E.F. et
al. (1991) The P450 superfamily: update on new sequences, gene mapping, and
recommended nomenclature. DNA Cell Biol, 10 (1), pp. 1-14.
Nelson, D.R. (1999) Cytochrome P450 and the individuality of species. Arch Biochem
Biophys, 369(1), pp. 1-10.
Nelson, D.R., Kamataki, T., Waxman, D.J., Guengerich, F.P., Estabrook, R.W.,
Feyereisen, R., Gonzalez, F.J., Coon, M.J., Gunsalus, I.C., Gotoh O. et al. (1993)
The P450 superfamily: update on new sequences, gene mapping, accession
numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol, 12
(1), pp. 1-51.
Nelson, D.R., Koymans, L., Kamataki, T., Stegeman, J.J., Feyereisen, R., Waxman,
D.J., Waterman, M.R., Gotoh, O., Coon, M.J., Estabrook, R.W., Gunsalus, I.C.
and Nebert, D.W. (1996) P450 superfamily: update on new sequences, gene
mapping, accession numbers and nomenclature. Pharmacogenetics, 6 (1), pp. 1-
42.
Noshiro, M., Harada, N. and Omura, T. (1979) Immunochemical study on the
participation of cytochrome b5 in drug oxidation reactions of mouse liver
microsomes. Biochem Biophys Res Commun, 91 (1), pp. 207-213.
349
O'Donnell, C.J., Grime, K., Courtney, P., Slee, D. and Riley, R.J. (2007) The
development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and
a preliminary assessment of utility in a drug discovery setting. Drug Metab
Dispos, 35(3), pp. 381-385.
Olkkola, K.T., Backman, J.T. and Neuvonen, P.J. (1994) Midazolam should be avoided
in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin
Pharmacol Ther, 55(5), pp. 481-485.
Omiecinski, C.J., Remmel, R.P. and Hosagrahara, V.P. (1999) Concise review of the
cytochrome P450s and their roles in toxicology. Toxicol Sci, 48 (2), pp. 151-156.
Omura, T. and Sato, R. (1964) The carbon monoxide-binding pigment of liver
microsomes. I. Evidence for its hemoprotein nature. J Biol Chem, 239, pp. 2370-
2378.
Paine, M.J., Gilham, D., Roberts, G.C. and Wolf, C.R. (1996) Functional high level
expression of cytochrome P450 CYP2D6 using baculoviral expression systems.
Arch Biochem Biophys, 328(1), pp. 143-150.
Parkinson, A. (1996) Biotransformation of Xenobiotics. Casarette and Daull's
Toxicology: the basic science of poisons, 5th ed., pp. 113-186.
Pederson, T.C. and Aust, S.D. (1975) The mechanism of liver microsomal lipid
peroxidation. Biochim Biophys Acta, 385(2), pp. 232-241.
Pelkonen, O., Mäenpää, J., Taavitsainen, P., Rautio, A. and Raunio, H. (1998)
Inhibition and induction of human cytochrome P450 (CYP) enzymes.
Xenobiotica, 28(12), pp. 1203-1253.
Perrot, N., Nalpas, B., Yang, C.S. and Beaune, P.H. (1989) Modulation of cytochrome
P450 isozymes in human liver, by ethanol and drug intake. Eur J Clin Invest,
19(6), pp. 549-555.
350
Peyronneau, M.A., Renaud, J.P., Truan, G., Urban, P., Pompon, D. and Mansuy, D.
(1992) Optimization of yeast-expressed human liver cytochrome P-450 3A4
catalytic activities by coexpressing NADPH-cytochrome P-450 and cytochrome
b5. Eur J Biochem, 207 (1), pp. 109-116.
Phillips, A.H. and Langdon, R.G. (1962) Hepatic triphosphopyridine nucleotide
cytochrome c reductase: isolation, characterization, and kinetic studies. J Biol
Chem, 237, pp. 2652-2660.
Pichard, L., Fabre, I., Daujat, M., Domergue, J., Joyeux, H. and Maurel, P. (1992)
Effect of corticosteroids on the expression of cytochromes P450 and on
cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol
Pharmacol, 41(6), pp. 1047-1055.
Polayes, D., Harris, R., Anderson, D. and Ciccarone, V. (1996) New naculovirus
expression vectors for the purification of recombinant proteins from insect cells.
Focus, 18, pp. 10-13.
Porter, T.D. (2002) The roles of cytochrome b5 in cytochrome P450 reactions. J
Biochem Mol Toxicol, 16 (6), pp. 311-316.
Poulos, T.L., Finzel, B.C. and Howard, A.J. (1986) Crystal structure of substrate-free
Pseudomonas putida cytochrome P-450. Biochemistry, 25 (18), pp. 5314-5322.
Pritchard, M.P., Glancey, M.J., Blake, J.A., Gilham, D.E., Burchell, B., Wolf, C.R. and
Friedberg, T. (1998) Functional co-expression of CYP2D6 and human NADPH-
cytochrome P450 reductase in Escherichia coli. Pharmacogenetics, 8 (1), 33-42.
Raunio, H., Husgafvel-Pursiainen, K., Anttila, S., Hietanen, E., Hirvonen, A. and
Pelkonen, O. (1995) Diagnosis of polymorphisms in carcinogen-activating and
inactivating enzymes and cancer susceptibility--a review. Gene, 159(1), pp. 113-
121.
Renaud, J.P., Cullin, C., Pompon, D., Beaune, P. and Mansuy, D. (1990) Expression of
human liver cytochrome P450 IIIA4 in yeast. A functional model for the hepatic
enzyme. Eur J Biochem, 194(3), pp. 889-896.
351
Rendic, S. and DiCarlo, F.J. (1997) Human cytochrome P450 enzymes: a status report
summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab
Rev, 29 (1-2), pp. 413-580.
Richardson, T.H., Griffin, K.J., Jung, F., Raucy, J.L. and Johnson, E.F. (1997) Targeted
antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an
inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys, 338(2),
pp. 157-64.
Rodríguez-Antona, C., Jover, R., Gómez-Lechón, M.J. and Castell, J.V. (2000)
Quantitative RT-PCR measurement of human cytochrome P-450s: application to
drug induction studies. Arch Biochem Biophys, 376(1), pp. 109-116.
Ronis, M.J., Badger, T.M., Shema, S.J., Roberson, P.K. and Shaikh, F. (1996)
Reproductive toxicity and growth effects in rats exposed to lead at different
periods during development. Toxicol Appl Pharmacol, 136(2), pp. 361-371.
Ryu, S.D. and Chung, W.G. (2003) Induction of the procarcinogen-activating CYP1A2
by a herbal dietary supplement in rats and humans. Food Chem Toxicol, 41(6),
pp. 861-866.
Savas, U. and Jefcoate, C.R. (1994) Dual regulation of cytochrome P450EF expression
via the aryl hydrocarbon receptor and protein stabilization in C3H/10T1/2 cells.
Mol Pharmacol, 45(6), pp. 1153-1159.
Schägger, H. and von Jagow, G. (1987) Tricine-sodium dodecyl sulfate-polyacrylamide
gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa.
Anal Biochem, 166 (2), pp. 368-379.
Schenkman, J.B. and Jansson, I. (2003) The many roles of cytochrome b5. Pharmacol
Ther, 97 (2), pp. 139-152.
Schmidt, J.V. and Bradfield, C.A. (1996) Ah receptor signaling pathways. Annu Rev
Cell Dev Biol, 12, pp. 55-89.
Schuetz, E.G., Schuetz, J.D., Strom, S.C., Thompson, M.T., Fisher, R.A., Molowa,
D.T., Li, D. and Guzelian, P.S. (1993) Regulation of human liver cytochromes P-
352
450 in family 3A in primary and continuous culture of human hepatocytes.
Hepatology, 18(5), pp. 1254-1262.
Schwarz, D., Kisselev, P., Honeck, H., Cascorbi, I., Schunck, W.H. and Roots, I. (2001)
Co-expression of human cytochrome P4501A1 (CYP1A1) variants and human
NADPH-cytochrome P450 reductase in the baculovirus/insect cell system.
Xenobiotica, 31(6), pp. 345-356.
Sells, M.A. and Chernoff, J. (1995) Epitope-tag vectors for eukaryotic protein
production. Gene, 152, pp. 187-189.
Shen, A.L. and Kasper, C.B. (1995) Role of acidic residues in the interaction of
NADPH-cytochrome P450 oxidoreductase with cytochrome P450 and
cytochrome c. J Biol Chem, 270 946), pp. 27475- 27480.
Shephard, E.A., Phillips, I.R. Santisteban, I., West, L.F., Palmer, C.N., Ashworth, A.
and Povey, S. (1989) Isolation of a cytochrome P-450 reductase cDNA clone and
localization of the corresponding gene to chromosome 7q11.2. Ann Hum Genet,
53 (4), pp. 291-301.
Shet, M.S., Fisher, C.W., Arlotto, M.P., Shackleton, C.H., Holmans, P.L., Martin-
Wixtrom, C.A., Saeki, Y. and Estabrook, R.W. (1994) Purification and enzymatic
properties of a recombinant fusion protein expressed in Escherichia coli
containing the domains of bovine P450 17A and rat NADPH-P450 reductase.
Arch Biochem Biophys, 311(2), pp. 402-417.
Shimada, T. and Guengerich, F.P. (1985) Participation of a rat liver cytochrome P-450
induced by pregnenolone 16 alpha-carbonitrile and other compounds in the 4-
hydroxylation of mephenytoin. Mol Pharmacol, 28 (2), pp. 215-219.
Shimada, T., Hayes, C.L., Yamazaki, H., Amin, S., Hecht, S.S., Guengerich, F.P. and
Sutter, T.R. (1996) Activation of chemically diverse procarcinogens by human
cytochrome P-450 1B1. Cancer Res, 56(13), pp. 2979-2984.
353
Shimada, T., Mernaugh, R.L. and Guengerich, F.P. (2005) Interactions of mammalian
cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b(5)
enzymes. Arch Biochem Biophys, 435 (1), pp. 207-216.
Shimada, T., Misono, K.S. and Guengerich, F.P. (1986) Human liver microsomal
cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic
polymorphism in oxidative drug metabolism. Purification and characterization of
two similar forms involved in the reaction. J Biol Chem, 261 (2), pp. 909-921.
Shimada, T., Yamazaki, H., Foroozesh, M., Hopkins, N.E., Alworth, W.L. and
Guengerich, F.P. (1998) Selectivity of polycyclic inhibitors for human
cytochrome P450s 1A1, 1A2, and 1B1. Chem Res Toxicol, 11(9), pp. 1048-1056.
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. And Guengerich, F.P. (1994)
Interindividual variations in human liver cytochrome P-450 enzymes involved in
the oxidation of drugs, carcinogens and toxic chemicals: studies with liver
microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther, 270 (1),
pp. 414-423.
Shou, M., Lin, Y., Lu, P., Tang, C., Mei, Q., Cui, D., Tang, W., Ngui, J.S., Lin, C.C.,
Singh, R., Wong, B.K., Yergey, J.A., Lin, J.H., Pearson, P.G., Baillie, T.A.,
Rodrigues, A.D. and Rushmore, T.H. (2001) Enzyme kinetics of cytochrome
P450- mediated reactions. Curr Drug Metab, 2 (1), pp. 17-36.
Simmons, D.L., Lalley, P.A. and Kasper, C.B. (1985) Chromosomal assignments of
genes coding for components of the mixed-function oxidase system in mice.
Genetic localization of the cytochrome P-450PCN and P-450PB gene families and
the nadph-cytochrome P-450 oxidoreductase and epoxide hydratase genes. J Biol
Chem, 260 (1), pp. 515-521.
Song, B.J., Veech, R.L. and Saenger, P. (1990) Cytochrome P450IIE1 is elevated in
lymphocytes from poorly controlled insulin-dependent diabetics. J Clin
Endocrinol Metab, 71(4), pp. 1036-1040.
Spatzenegger, M. and Jaeger, W. (1995) Clinical importance of hepatic cytochrome
P450 in drug metabolism. Drug Metab Rev, 27 (3), pp. 397-417.
354
Strittmatter, P. (1967) Methods Enzymol, 10, pp. 561-565.
Strittmatter, P. and Velick, S.F. (1956) The isolation and properties of microsomal
cytochrome. J Biol Chem, 221(1), pp. 253-264.
Summers, M.D. and Smith, G.E. (1987) A Manual of Methods for Baculovirus Vectors
and Insect Cell Culture Procedures. Texas Agricultural Experiment Station,
Bulletin No. 1555.
Sutter, T.R. and Loper, J.C. (1989) Disruption of the Saccharomyces cerevisiae gene for
NADPH cytochrome P450 reductase causes increased sensitivity to ketoconazole.
Biochem Biophys Res Commun, 160 (3), pp. 1257-1266.
Sutter, T.R., Tang, Y.M., Hayes, C.L., Wo, Y.Y., Jabs, E.W., Li, X., Yin, H., Cody,
C.W. and Greenlee, W.F. (1994) Complete cDNA sequence of a human dioxin-
inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps
to chromosome 2. J Biol Chem, 269(18), pp. 13092-13099.
Szczesna-skorupa, E., Chen, C.D., Liu, H. and Kemper, B. (2004) Gene expression
changes associated with the endoplasmic reticulum stress response induced by
microsomal cytochrome p450 overproduction. J Biol Chem, 279 (14), pp. 13953-
13961.
Takesue, S. and Omura T. (1970) Purification and Properties of NADH-cytochrome b5
Reductase Solubilized by Lysosomes from Rat Liver Microsomes. J Biochem, 67,
pp. 267-276.
Tamura, S., Korzekwa, K.R., Kimura, S., Gelboin, H.V. and Gonzalez, F.J. (1992)
Baculovirus-mediated expression and functional characterization of human
NADPH-P450 oxidoreductase. Arch Biochem Biophys, 293 (2), pp. 219-223.
Tang, Y.M., Chen, G.F., Thompson, P.A., Lin, D.X., Lang, N.P. and Kadlubar, F.F.
(1999) Development of an antipeptide antibody that binds to the C-terminal
region of human CYP1B1. Drug Metab Dispos, 27(2), pp. 274-280.
355
Tantcheva-Poór, I., Zaigler, M., Rietbrock, S. and Fuhr, U. (1999) Estimation of
cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-
based caffeine test. Pharmacogenetics, 9(2), pp. 131-144.
Tassaneeyakul, W., Birkett, D.J., Veronese, M.E., McManus, M.E., Tukey, R.H. and
Miners, J.O. (1994) Direct characterization of the selectivity of furafylline as an
inhibitor of human cytochromes P450 1A1 and 1A2. Pharmacogenetics, 4(5), pp.
281-284.
Trakshel, G.M., Kutty, R.K. and Maines, M.D. (1986) Cadmium-mediated inhibition of
testicular heme oxygenase activity: the role of NADPH-cytochrome c (P-450)
reductase. Arch Biochem Biophys, 251(1), pp. 175-187.
Truan, G., Cullin, C., Reisdorf, P., Urban, P. and Pompon, D. (1993) Enhanced in vivo
monooxygenase activities of mammalian P450s in engineered yeast cells
producing high levels of NADPH-P450 reductase and human cytochrome b5.
Gene, 125 (1), pp. 49-55.
Vergeres, G. and Waskell, L. (1995) Cytochrome b5, its functions, structure and
membrane topology. Biochimie, 77 (7-8), pp. 604-20.
Vermillion, J.L., Ballou, D.P., Massey, V. and Coon, M.J. (1981) Separate roles for
FMN and FAD in catalysis by liver microsomal NADPH-cytochrome P-450
reductase. J Biol Chem, 256 (1), pp. 266-277.
Voice, M.W., Zhang, Y., Wof, C.R., Burchell, B. and Friedberg, T. (1999) Effects of
human cytochrome b5 on CYP3A4 activity and stability in vivo. Arch Biochem
Biophys, 366 (1), pp. 116-124.
Von Bahr, C., Glaumann, H., Gudas, J. and Kaplowitz, N. (1980) Inhibition of hepatic
metabolism of azathioprine by furosemide in human liver in vitro. Biochem
Pharmacol, 29(10), pp. 1439-1441.
Voznesensky, A.I. and Schenkman, J.B. ( 1994) Quantitative analyses of electrostatic
interactions between NADPH-cytochrome P450 reductase and cytochrome P450
enzymes. J Biol Chem, 269 (22), pp. 15724-15731.
356
Voznesensky, A.I. and Schenkman, J.B. (1992) The cytochrome P450 2B4-NADPH
cytochrome P450 reductase electron transfer complex is not formed by charge-
pairing. J Biol Chem, 267(21), pp. 14669-14676.
Walsky, R.L. and Obach, R.S. (2004) Validated assay for human cytochrome P450
activities. Drug Metab Dispos, 32, pp. 647-660.
Wang, M.H., Patten, C.J., Yang, G.Y., Paranawithana, S.R., Tan, Y. and yang, C.S.
(1996) Expression and coupling of human cytochrome P450 2E1 and NADPH-
cytochrome P450 oxidoreductase in dual expression and co-infection systems
with baculovirus in insect cells. Arch Biochem Biophys, 334 (2), pp. 380-388.
Watanabe, M. (1998) Polymorphic CYP genes and disease predisposition--what have
the studies shown so far? Toxicol Lett, 102-103, pp. 167-171.
Werck-Reichhart, D. and Feyereisen, R. (2000) Cytochrome P450: a success story.
Genome Biol, 1 (6), pp. 3000.1- 3000.9.
Weyer, U. and Possee, R.D. (1991) A baculovirus dual expression vector derived from
the Autographa californica nuclear polyhedrosis virus polyhedrin and p10
promoters: co-expression of two influenza virus genes in insect cells. J Gen Virol,
72(12), pp. 2967–2974.
White, R.E., Sligar, S.G. and Coon, M.J. (1980) Evidence for a homolytic mechanism
of peroxide oxygen-oxygen bond cleavage during substrate hydroxylation by
cytochrome P-450. J Biol Chem, 255 (23), pp. 11108-11111.
Wiliams, C.H. and Kamin, H. (1962) Microsomal triphosphopyridine nucleotide-
cytochrome c reductase of liver. J Biol Chem, 237, pp 587-595.
Willey, J.C., Coy, E.L., Frampton, M.W., Torres, A., Apostolakos, M.J., Hoehn, G.,
Schuermann, W.H., Thilly, W.G., Olson, D.E., Hammersley, J.R., Crespi, C.L.
and Utell, M.J. (1997) Quantitative RT-PCR measurement of cytochromes p450
1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase
expression in lung cells of smokers and nonsmokers. Am J Respir Cell Mol Biol,
17(1), pp. 114-124.
357
Wolf, C.R., Seilman, S., Oesch, F., Mayer, R.T. and Burke, M.D. (1986) Multiple forms
of cytochrome P-450 related to forms induced marginally by phenobarbital.
Differences in structure and in the metabolism of alkoxyresorufins. Biochem J,
240 (1), pp. 27-33
Yabusaki, Y. (1995) Artificial P450/reductase fusion enzymes: what can we learn from
their structures? Biochimie, 77 (7-8), pp. 594-603.
Yamamoto, T., Suzuki, A. and Kohno, Y. (2003) High-throughput screening to estimate
single or multiple enzymes involved in drug metabolism: microtitre plate assay
using a combination of recombinant CYP2D6 and human liver microsomes.
Xenobiotica, 33 (8), pp. 823-839.
Yamano, S., Aoyama, T., McBride, O.W., Hardwick, J.P., Gelboin, H.V. and Gonzalez,
F.J. (1989) Human NADPH-P450 oxidoreductase: complementary DNA cloning,
sequence and vaccinia virus-mediated expression and localization of the CYPOR
gene to chromosome 7. Mol Pharmacol, 36 (1), pp. 83-88.
Yamazaki, H., Inui, Y., Wrighton, S.A., Guengerich, F.P, and Shimada T. (1995)
Procarcinogen activation by cytochrome P450 3A4 and 3A5 expressed in
Escherichia coli and by human liver microsomes. Carcinogenesis, 16(9), pp.
2167-2170.
Yamazaki, H., Nakamura, M., Komatsu, T., Ohyama, K., Hatanaka, N., Asahi, S.,
Shimada, N., Guengerich, F.P., Shimada, T., Nakajima, M. and Yokoi, T. (2002)
Roles of NADPH-P450 reductase and Apo- and Holo-cytochrome b5 on
xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s
expressed in mambranes of Escherichia coli. Protein Expr Purif, 24 (3), pp. 329-
337.
Yasukochi, Y. and Masters B.S.S. (1976) Some properties of a detergent solubilized
NADPH-cytochrome c (cytochrome P450) reductase purified by bispecific
affinity chromatography. J Biol Chem, 251,pp. 5337-5344.
Yim, S.K., Yun, C.H., Ahn, T., Jung, H.C. and Pan, J.G. (2005) A continuous
spectrophotometric assay for NADPH-cytochrome P450 reductase activity using
358
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. J Biochem Mol
Biol, 38 (3), pp. 366-369.
Yin, O.Q., Tomlinson, B., Chow, A.H., Waye, M.M. and Chow, M.S. (2004)
Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-
dose effect and intrasubject variability. J Clin Pharmacol, 44 (6), pp. 582-589.
Zevin, S. and Benowitz, N.L. (1999) Drug interactions with tobacco smoking. An
update. Clin Pharmacokinet, 36(6), pp. 425-438.
Zhao, Q., Modi, S., Smith, G., Paine, M., McDonagh, P.D., Wolf, C.R., Tew, D., Lian,
L.Y., Roberts, G.C. and Driessen, H.P. (1999) Crystal structure of the FMN-
binding domain of human cytochrome P450 reductase at 1.93 A resolution.
Protein Sci, 8(2), pp. 298-306.
Zhou, S.F., Di, Y.M., Chanm E., Du, Y.M., Chow, V.D., Xue, C.C., Lai, X., Wang,
J.C., Li, C.G., Tian, M, and Duan, W. (2008) Clinical pharmacogenetics and
potential application in personalized medicine. Curr Drug Metab, 9(8), pp. 738-
784.
